T-bet compositions and methods of use thereof

ABSTRACT

Isolated nucleic acid molecules encoding T-bet, and isolated T-bet polypeptides, are provided. The invention further provides antisense nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals carrying a T-bet transgene. The invention further provides T-bet fusion proteins and anti-T-bet antibodies. Methods of using the T-bet compositions of the invention are also disclosed, including methods for detecting T-bet expression and/or activity in a biological sample, methods of modulating T-bet expression and/or activity in a cell, and methods for identifying agents that modulate the expression and/or activity of T-bet.

RELATED APPLICATIONS

[0001] This application is continuation-in-part application of U.S. application Ser. No. 10/008,264, filed on Dec. 3, 2001 (pending), which is a continuation-in-part application of PCT/US00/15345, filed on Jun. 1, 2000 (pending), published pursuant to PCT Article 21, in English, which claims priority to U.S. Provisional Application Serial No. 06/137,085, filed Jun. 2, 1999, the entire contents of each of these applications is incorporated herein by this reference.

GOVERNMENT FUNDING

[0002] Work described herein was supported, at least in part, under grants AI/AG 37833, AI 39646, AI 36535, AR 6-2227, TGAI 07290 awarded by the National Institutes of Health. The U.S. government therefore may have certain rights in this invention.

BACKGROUND OF THE INVENTION

[0003] Cells of the immune system alter patterns of gene expression in response to extracellular and intracellular signals. A group of polypeptides, designated cytokines or lymphokines, which affect a range of biological activities in several cell types, are among the most important of these signals. While many cell types in the immune system secrete cytokines, the T helper (Th) lymphocyte is the major source of these polypeptides. More than a decade ago it was discovered that Th cells differentiate into two distinct subsets, Th1 and Th2, upon T cell receptor engagement, defined both by their distinct functional abilities and by unique cytokine profiles (Paul and Seder, 1994, Cell 76, 241-251; Mosmann and Coffman, 1989, Annu. Rev. Immunol. 7, 145-173; Mosmann et al., 1986, J. Immunol. 136, 2348-2357; Snapper and Paul, 1987, Science 236, 944-947). Th1 cells mediate delayed type hypersensitivity responses and macrophage activation while Th2 cells provide help to B cells and are critical in the allergic response (Mosmann and Coffman, 1989, Annu. Rev. Immunol. 7, 145-173; Paul and Seder, 1994, Cell 76, 241-251; Arthur and Mason, 1986, J. Exp. Med. 163, 774-786; Paliard et al., 1988, J. Immunol. 141, 849-855; Finkelman et al, 1988, J. Immunol. 141, 2335-2341). The evidence that Th1 cells directed cell-mediated immunity while Th2 cells contributed to humoral responses fit nicely with the observations that an organism tends to mount either a cell-mediated or humoral response, but not both, in response to pathogens. These functional differences between the Th subsets can be explained most easily by the activities of the cytokines themselves. IFN-γ is the “signature” cytokine of Th1 cells although Th1 cells also produce IL-2, TNF and LT. The corresponding “signature” cytokine for Th2 cells is IL-4. Th2 cells also secrete IL-5, IL-6, IL-9, IL-10 and IL-13.

[0004] Upon encountering antigen, the naive CD4+ T helper precursor (Thp) cell enacts a genetic program that ultimately sends it down a Th1 or Th2 lineage. While it is clear that polarization can be achieved by manipulating the antigen and costimulatory signals i.e. the “strength of signal” received by the Thp (Constant and Bottomly, 1997. Annu. Rev. Immunol. 15, 297-322), the most potent inducers of effector Th cells are undoubtedly the cytokines themselves. IL-4 promotes Th2 differentiation and simultaneously blocks Th1 development, an effect that is mediated via the Stat6 signaling pathway. Thus, mice that lack IL-4 or Stat6, fail to develop Th2 cells (Kopf et al., 1993, Nature 362, 245-248; Kuhn et al., 1991, Science 254, 707-710; Kaplan et al., 1996, Immunity 4, 313-319; Shimoda et al., 1996, Nature 380, 630-633; Takeda et al., 1996, Nature 380, 627-630). In contrast, IL-12, IL-18 and IFN-γ are the cytokines critical for the development of Th1 cells (Hsieh et al., 1993, Science 260, 547-549; Okamura et al., 1995, nature 378, 88-91; Gu et al., 1997, Science 275, 206-209; Meraz et al., 1996, Cell 84, 431-442; Magram et al., 1996, Immunity 4, 471-481). IFN-γ acting via the Stat1 pathway (Meraz et al., 1996, Cell 84, 431-442), and IL-12, acting via the Stat-4 signaling pathway (Jacobson et al., 1995, J. Exp. Med. 181, 1755-1762) together promote the differentiation of Th1 cells and block commitment to the Th2 lineage (Szabo et al., 1995, Immunity 2, 665-675; Szabo et al., 1997, J. Exp. Med. 185: 817-824). Mice deficient in IL-12 or Stat4 do not have Th1 cells (Magram et al., 1996, Immunity 4, 471-481; Takeda et al., 1996, Nature 380, 627-630; Shimoda et al., 1996, Nature 380, 630-633). Another important Th1-inducing cytokine is IL-18, whose receptor is related to the IL-1 receptor family (Cerretti et al., 1992, Science 256, 97-100). Mice lacking IL-18 have defective in vivo Th1 responses (Takeda et al., 1998, Immunity 8, 383-390) and both IL-12 and IL-18 regulate IFN-γ expression (Barbulescu et al., 1998, Eur. J. Immunol. 27, 1098-1107; Robinson et al., 1997, Immunity 7, 571-581; Ahn et al., 1997, J. Immunol. 159, 2125-2131). The cytokines themselves, then, form a positive and negative feedback system that drives Th polarization (Powrie and Coffman, 1993, Immunol. Today 14, 270-274; Scott, 1991, J. Immunol. 147, 3149; Maggi et al., 1992, J. Immunol. 148, 2142; Parronchi et al., 1992, J. Immunol. 149, 2977; Fargeas et al., 1992, Eur. J. Immunol. 149, 2977; Manetti et al., 1993, J. Exp. Med. 177, 1199; Trinchieri, 1993, Immunol. Today 14, 335-338; Macatonia et al., 1993, Immunol. 5, 1119; Seder et al., 1993, Proc. Natl. Acad. Sci. USA 90, 10188-10192; Wu et al., 1993, J. Immunol. 151, 1938; Hsieh et al., 1993, Science 260, 547-549) (reviewed in (Seder and Paul, 1994, In Annual Review of Immunology, Vol. 12, 635-673; Paul and Seder, 1994, Cell 76, 241-251; O'Garra, 1998, Immunity 8, 275-283).

[0005] Over the last few years, significant progress has been made in identifying the transcription factors that control the transition of a Thp to a Th2 cell as evidenced by the capacity of such factors to drive IL-4 production reviewed in (Glimcher and Singh, 1999 Cell 96, 13-23; Szabo et al., 1997, Current Opinions in Immunology 9, 776-781). The provision of three distinct proteins, the c-Maf proto-oncogene, the transcription factor Nuclear Factor of Activated T cells (NFAT), and a novel nuclear antigen, NFAT-Interacting Protein 45 kD (NIP45), have been shown to confer on a non-T cell the ability to produce endogenous IL-4 (Hodge et al., 1996, Science 274, 1903-1905; Ho et al., 1998, J. Exp. Med. 188:1859-1866). These factors and others such as GATA-3 (Zheng and Flavell, 1997, Cell 89, 587-596) and Stat6 clearly can drive the production of IL-4, and therefore the development of Th2 cells, both in vitro and in vivo.

[0006] In contrast, little is known about the molecular basis of Th1 differentiation. For example, the only known transcription factors whose absence results in a failure to generate Th1 cells are Stat4 (Thierfelder et al., 1996, Nature 382, 171-174; Kaplan et al., 1996, Nature 382, 174-177) and IRF-1(Lohoff et al., 1997, Immunity:681-689; Taki et al., 1997, Immunity 6:673-679), neither of which is Th1-specific. The Ets family member ERM which is induced by IL-12 in a Stat4-dependent manner has recently been reported to be Th1-specific but it does not affect the production of Th1 cytokines (Ouyang et al, 1999, Proc. Natl. Acad. Sci. 96:3888). The absence of Th1 cells in Stat4 deficient mice is secondary to the failure of IL-12 to drive the Th1 program while the lack of Th1 cells in IRF-1 deficient mice is likely due to its direct effect in controlling transcription of the IL-12 gene (Lohoff et al., 1997, Immunity 6: 681-689; Taki et al, 1997, Immunity 6:673-679). However, some of the signaling pathways upstream of such putative Th1-specific regulatory factors are beginning to be elucidated. The p38 kinase is one such signaling molecule as demonstrated by the ability of constitutively activated MAP kinase kinase 6 (MKK6) to boost IFN-γ production. Conversely, overexpression of a dominant negative p38 MAP kinase or targeted disruption of Jnk2 or Jnk1 reduces Th1 responses (Rincón et al., 1998, EMBO J. 17, 2817-2829; Yang et al, 1998, Immunity 9, 575-585; Dong et al., 1998, Science 282, 2092-2095). The JNK signaling pathway might affect Th development by a direct effect on the transcription of the IFN-γ gene, but this has not been shown. For example, the ATF-2 and AP-1 transcription factors are both substrates of JNK kinases and these factors as well as NFκB and Stat4 proteins are known to bind to sites in the IFN-γ promoter (Zhang et al, 1998, Immunol. 161, 6105-6112; Ye et al., 1996, Mol. Cell. Biol. 16:4744; Barbulescu et al., 1997, Eur. J. Immunol. 27, 1098-1107; Sica et al., 1997, J. Biol. Chem. 272, 30412-30420). The production of IFN-γ is, however, normal in mice lacking ATF-2. Because cytokines are critical in the development of Th1 and Th2 cells and, thereby, in determining whether an immune response will be primarily cellular or humoral, compositions and methods for modulating the production of Th1 and/or Th2 cytokines would be of tremendous benefit in modulating the immune response.

SUMMARY OF THE INVENTION

[0007] This invention is based, at least in part, on the discovery of novel compositions which act to promote the Th1 phenotype in naïve T helper precursor cells (Thp), both by initiating Th1 cell genetic programs and by repressing the opposing programs in Th2 cells. In particular, this invention provides isolated nucleic acid molecules encoding T-bet and isolated T-bet protein. T-bet (T box expressed in T cells) is a new member of the T box family of transcription factors whose founding member is the brachyury gene. T-bet is constitutively expressed selectively in thymocytes and Th1 cells. T-bet is the first Th1 specific transcription factor that can transactivate the interferon-γ gene, induce interferon-γ production in retrovirally transduced primary T cells and redirect polarized Th2 cells into the Th1 pathway. T-bet also controls IFN-γ production in CD8+ T cells, as well as in cells of the innate immune system, e.g., NK cells and dendritic cells. The invention also provides methods of using these novel T-bet compositions.

[0008] One aspect of the invention pertains to isolated nucleic acid molecules comprising a nucleotide sequence encoding a T-bet polypeptide. In one embodiment, the nucleic acid molecule encodes the polypeptide shown in SEQ ID NO:2 or SEQ ID NO:4. In another embodiment, the nucleic acid molecule comprises the nucleotide sequence shown in SEQ ID NO:1, SEQ ID NO;5 or SEQ ID NO:3. In other embodiments, the nucleic acid molecule has at least 70% nucleotide identity with at least about 700 contiguous nucleotides of SEQ ID NO:1; at least 70% nucleotide identity with at least about 500 contiguous nucleotides of SEQ ID NO:3; at least 90% nucleotide identity with at least about 700 contiguous nucleotides of SEQ ID NO:1; or at least 90% nucleotide identity with at least about 500 contiguous nucleotides of SEQ ID NO:3.

[0009] In another aspect, the invention pertains to a isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide that modulates IFN-γ production in a cell, wherein the nucleotide sequence hybridizes to the complement of the nucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:3 in 6× SSC at 45° C., followed by one or more washes in 0.2× SSC, 0.1% SDS at 50-65° C. In a particular embodiment, the nucleic acid molecule comprises a nucleotide sequence that hybridizes under conditions of 6× SSC at 45° C., followed by one or more washes in 0.2× SSC, 0.1% SDS at 50-65° C. to at least nucleotides 138-327 of SEQ ID NO:1, or a complement thereof, wherein the nucleotide sequence detects a nucleotide sequence encoding a T-bet polypeptide.

[0010] The invention also pertains to an isolated nucleic acid molecule which is antisense to the coding strand of the nucleic acid comprising a nucleotide sequence encoding a T-bet polypeptide. The invention further pertains to an isolated nucleic acid molecule comprising a nucleotide sequence complementary to mRNA transcribed from a gene encoding a T-bet polypeptide as well as an isolated nucleic acid molecule comprising a nucleotide sequence from a gene encoding a T-bet polypeptide, wherein the nucleotide sequence is not translated. In certain embodiments, these nucleic acid molecules have a nucleotide sequence between, for example, 20-30 or 22-25, nucleotides in length. The nucleic acid molecules of the invention may be double stranded or single stranded. The invention also pertains to vectors comprising a nucleotide sequence encoding a T-bet polypeptide, a vector comprising a nucleotide sequence encoding a T-bet polypeptide, e.g., an expression vector, and a host cell containing the vector.

[0011] The invention further pertains to a method for producing a T-bet polypeptide comprising culturing a host cell with a vector comprising a nucleotide sequence encoding a T-bet polypeptide in a suitable medium until a T-bet polypeptide is produced. The method further comprises the step of isolating the T-bet polypeptide from the medium or the host cell.

[0012] In another aspect, the invention pertains to isolated T-bet polypeptides. In one embodiment, the T-bet polypeptide comprises the amino acid sequence encoded by the nucleic acid sequence of SEQ ID NO:1 or SEQ ID NO:3, or the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO:4. In another embodiment, the T-bet polypeptide comprises at least 70% amino acid identity with the polypeptide shown in SEQ ID NO:2 or SEQ ID NO: 4 and binds to DNA. In yet another embodiment, the T-bet polypeptide has at least 90% amino acid identity with the polypeptide shown in SEQ ID NO:2. The invention also pertains to a fusion polypeptide comprising a T-bet polypeptide operatively linked to a polypeptide other than T-bet. In one embodiment, the polypeptide other than T-bet is the repressor domain of the Drosophila engrailed polypeptide.

[0013] The invention further pertains to antibodies that specifically bind at least one mammalian T-bet polypeptide. In a preferred embodiment, the antibody specifically binds human T-bet polypeptide. In another embodiment, the antibody specifically binds both human and mouse T-bet polypeptide. The antibody can be polyclonal or monoclonal. The antibody may also be coupled to a detectable substance. Methods of producing antibodies are also encompassed by the invention. For example, a method of producing an antibody that specifically binds to T-bet comprising, immunizing an animal with a T-bet polypeptide, or antigenic fragment thereof, such that antibodies are produced by B cells of the animal; isolating B cells of the animal; and fusing the B cells with myeloma cells to form immortal, hybridoma cells that secrete human monoclonal antibodies which specifically bind to T-bet, can be performed. The subject in these methods can be a non-human transgenic animal having a genome comprising a human heavy chain transgene and a human light chain transgene. In one embodiment, the method includes a T-bet polypeptide, or a fragment thereof, which comprises at least 8 amino acid residues of the amino acid sequence shown in SEQ ID NO: 2 or 4. The invention also pertains to intrabodies, e.g., an intrabody that specifically binds at least one mammalian T-bet polypeptide, e.g., an intrabody that specifically binds human T-bet polypeptide.

[0014] In yet another aspect, the invention pertains to a composition comprising an agent that modulates T-bet and a pharmaceutically acceptable carrier. The agent may be an agonist of T-bet or an antagonist of T-bet. The agent can modulate the expression and/or activity of T-bet and an antigen, e.g., the agent can increase the expression and/or activity of T-bet or the agent decreases the expression and/or activity of T-bet. The agent can also be a DNA molecule encoding a T-bet polypeptide; a T-bet polypeptide; or a DNA molecule encoding a dominant negative T-bet polypeptide. In one embodiment, the invention pertains to a method for treating a condition or a disorder that would benefit from modulation of the expression and/or activity of T-bet in a subject comprising administering the immunomodulatory compositions desribed above. The disorder to be treated may be an autoimmune disorder.

[0015] In a further aspect, the invention pertains to a nonhuman transgenic animal, e.g., a mouse, that contains cells carrying a transgene encoding a T-bet polypeptide. The nonhuman animal may comprise in its genome an exogenous DNA molecule that functionally disrupts a T-bet gene of the non-human animal, wherein the animal exhibits a phenotype characterized by decreased IFN-γ production, relative to a wild-type animal.

[0016] The invention also pertains to a recombinant cell comprising an exogenous T-bet molecule or a portion thereof, and a reporter gene operably linked to a regulatory region responsive to T-bet such that upon activation of T-bet, transcription of the reporter gene occurs. The invention further pertains to a recombinant cell comprising a gene encoding an ecdysone receptor, an exogenous gene encoding a T-bet expression plasmid operatively linked to the ecdysone gene, and a reporter gene operatively linked to an IFN-γ promoter.

[0017] The invention also pertains to a method for detecting the presence of T-bet in a biological sample comprising contacting the biological sample with an agent capable of detecting an indicator of T-bet activity or expression such that the presence of T-bet is detected in the biological sample. The invention further pertains to a method for modulating expression in a cell of a gene whose transcription is regulated by T-bet, comprising contacting the cell with an agent that modulates the expression or activity of T-bet such that expression of the gene is altered. In one embodiment, the expression of T-bet is selectively modulated. In other embodiments, the agent increases the expression and/or activity of T-bet or decreases the expression and/or activity of T-bet. The step of contacting can occur in vivo or in vitro. The cell may be a T cell, e.g., a lamina propria T cell, a CD8+ cell, and a CD4+ cell, a B cell, a dendritic cell, or NK cell. In one embodiment the cell is a mammalian cell, e.g., a a human cell. In another embodiment, the gene is a cytokine gene, e.g., IL-2, IFN-γ, IL-4, IL-5, TNFα, TGF-β, LT(lymphotoxin), and IL-10. In yet another embodiment, the gene is a cytokine receptor gene

[0018] The invention further pertains to a method for modulating the effects of at least one external influence on a cell, wherein the external influence modulates T-bet expression and/or activity, the method comprising contacting a cell with an agent that modulates T-bet expression and/or activity in the cell such that T-bet mediated effects of at least one external influence is modulated. In one embodiment, the at least one external influence is a cytokine. In another embodiment, the cell is present in a subject suffering from a disorder that would benefit from modulation of T-bet expression and/or activity. In other embodiments, the external influence is a cytokine the agent increases the expression and/or activity of T-bet or the external influence is a cytokine the agent decreases the expression and/or activity of T-bet. The cell may be a T cell, e.g., a lamina propria T cell, a CD8+ cell, and a CD4+ cell, a B cell, a dendritic cell, or NK cell. In one embodiment the cell is a mammalian cell, e.g., a a human cell. In another embodiment, the gene is a cytokine gene, e.g., IL-2, IFN-γ, IL-4, IL-5, TNFα, TGF-β, LT(lymphotoxin), and IL-10. In yet another embodiment, the gene is a cytokine receptor gene. In certain embodiments the agent directly modulates T-bet expression and/or activity. In other embodiments, the agent indirectly modulates T-bet expression and/or activity.

[0019] In other aspects, the invention relates to a method of modulating the expression and/or activity of T-bet, comprising contacting a cell with an agent that modulates TGF-β-mediated signaling. In one embodiment, the TGF-β-mediated signaling can be increased and T-bet expression and/or activity decreased. In another embodiment, the TGF-β-mediated signaling is decreased and T-bet expression and/or activity is increased The method can be performed in a subject that would benefit from reduced IFN-γ production by cells of the innate and/or adaptive immune system.

[0020] The invention also pertains to a method of modulating the expression and/or activity of T-bet, comprising contacting a cell with an agent that modulates STAT1-mediated signaling. In one embodiment, STAT1-mediated signaling is increased and T-bet expression and/or activity is increased. In another embodiment, STAT1mediated signaling is decreased and T-bet expression and/or activity is decreased. The method can be performed in a subject that would benefit from increased IFN-γ production by cells of the innate and/or adaptive immune system.

[0021] The invention further pertains to a method of modulating the interaction between T-bet and a molecule with which T bet interacts comprising contacting a cell with an agent that modulates T-bet expression and/or activity such that the interaction between T-bet and a Molecule with which T-bet interacts is modulated. The molecule with which T-bet interacts can be selected from the group consisting of: a T-bet responsive DNA element, a cytokine promoter, and a Tec kinase. The method can be performed in a subject that would benefit from modulation of IFN-γ production by cells of the innate and/or adaptive immune system.

[0022] In yet another aspect, the invention pertains to a method for reducing the level of expression of genes which are activated by extracellular influences which induce T-bet mediated intracellular signaling in a cell, the method comprising contacting a cell with an agent that reduces T-bet activity in the cell such that expression of the genes is reduced. The cell may be a T cell, e.g., a lamina propria T cell, a CD8+ cell, and a CD4+ cell, a B cell, a dendritic cell, or NK cell. In one embodiment the cell is a mammalian cell, e.g., a a human cell. In another embodiment, the gene is a cytokine gene, e.g., IL-2, IFN-γ, IL-4, IL-5, TNFα, TGF-β, LT(lymphotoxin), and IL-10. In yet another embodiment, the gene is a cytokine gene, e.g., IFN-γ.

[0023] In another aspect, the invention relates to a method for increasing the level of expression of genes which are activated by extracellular influences which induce T-bet mediated intracellular signaling in a cell, the method comprising contacting a cell with an agent that increases T-bet activity in the cell such that expression of the genes is increased. The cell may be a T cell, e.g., a lamina propria T cell, a CD8+ cell, and a CD4+ cell, a B cell, a dendritic cell, or NK cell. In one embodiment the cell is a mammalian cell, e.g., a a human cell. In another embodiment, the gene is a cytokine gene, e.g., IL-2, IFN-γ, IL-4, IL-5, TNFα, TGF-β, LT(lymphotoxin), and IL-10. In yet another embodiment, the gene is a cytokine gene, e.g., IFN-γ.

[0024] The invention also pertains to a method for modulating T-bet expression and/or activity in a cell comprising contacting the cell with an agent that modulates T-bet expression and/or activity such that T-bet expression and/or activity in the cell is modulated. The agent can increase or decrease the activity of T-bet or increase or decrease the expression of T-bet.

[0025] The invention also pertains to a method for modulating the production of at least one cytokine by a cell comprising contacting the cell with an agent that modulates T-bet expression and/or activity such that cytokine production in the cell is modulated. The cell may be selected from the group consisting of: a T cell, a B cell, an NK cell, and a dendritic cell. The at least one cytokine can be a Th1 cytokine, e.g., The method IFN-γ. The at least one cytokine may also be a Th2 cytokine. In one embodiment, the method results in altered pattern of cytokines produced by the cell.

[0026] The invention further pertains to a method of modulating an immune response in a subject comprising administering an agent that modulates T-bet to the subject such that the immune response is modulated. Immune responses that can be modulated include, a humoral immune response and a cellular immune response.

[0027] In another aspect, the invention pertains to a method of modulating IFN-γ production by a cell comprising contacting a cell with an agent that modulates T-bet expression and/or activity such that IFN-γ production is modulated. The cell may be a T cell, e.g., a lamina propria T cell, a CD8+ cell, and a CD4+ cell, a B cell, a dendritic cell, or NK cell. In one embodiment the cell is a mammalian cell, e.g., a a human cell. In certain embodiment, the the expression and/or activity of T-bet is increased, thereby increasing the production of IFN-γ. In other embodiments, the expression and/or activity of T-bet is decreased, thereby decreasing the production of IFN-γ.

[0028] The invention further pertains to a method of modulating signaling via the Jak1/STAT-1 pathway in a cell comprising contacting a cell with an agent that modulates T-bet expression and/or activity such that signaling via the Jak1/STAT-1 pathway is modulated. In another aspect, the invention pertains to a method of modulating the IgG class switching in a cell comprising contacting a cell with an agent that modulates T-bet expression and/or activity such IgG Class Switching is modulated. In yet another aspect, the invention pertains to a method of modulating B lymphocyte function comprising contacting a cell with an agent that modulates T-bet expression and/or activity such B lymphocyte function is modulated.

[0029] In a further apsect, the invention pertains to a method of modulating TGF-β-mediated signaling in a cell comprising contacting a cell with an agent that modulates the activity or expression of T-bet such that TGF-β-mediated signaling is modulated. In one embodiment, the activity or expression of T-bet is decreased in the cell and TGF-β-mediated signaling is increased. In another embodiment, the activity or expression of T-bet is increased in the cell and TGF-β-mediated signaling is decreased.

[0030] The invention also pertains to a method of modulating the generation of CD8+ effector memory cells comprising contacting a CD8+ T cell with an agent that modulates the expression and/or activity of T-bet to thereby modulate the production of CD8+ effector memory cells. In one embodiment, the expression and/or activity of T-bet is increased, thereby increasing the generation of CD8 effector memory cells. In another embodiment, the expression and/or activity of T-bet is decreased, thereby decreasing the generation of CD8 effector memory cells. The invention further pertains to a method of treating a disorder that would benefit from modulation of a CD8+ T cell response comprising contacting a CD8+ T cell with an agent that modulates the expression and/or activity of T-bet to thereby treat a disorder that would benefit from modulation of a CD8+ T cell response. In one embodiment, the expression and/or activity of T-bet is increased, thereby increasing the activity of CD8 cells. In another embodiment, the expression and/or activity of T-bet is decreased, thereby decreasing the activity of CD8+ cells. The disorder to be treated may be a viral infection, e.g., cancer. The invention further pertains to a method of modulating the production of IL-10 in a CD8+ cell comprising contacting a CD8+ T cell with an agent that modulates the expression and/or activity of T-bet to thereby modulate the production of IL-10 in a CD8+ T cell. In certain embodiments, the expression and/or activity of T-bet is increased, thereby decreasing the production of IL-10. In other embodiments, the expression and/or activity of T-bet is decreased, thereby increasing the production of IL-10.

[0031] In another aspect, the invention pertains to a method of modulating the cytolytic activity of a CD8+ cell comprising contacting a CD8+ T cell with an agent that modulates the expression and/or activity of T-bet to thereby modulate the cytolytic activity of a CD8+ cell. The invention also pertains to a method of modulating the production of IFN-γ in an NK cell comprising contacting an NK cell with an agent that modulates the expression and/or activity of T-bet to thereby modulate the production of IFN-γ in an NK cell. In one embodiment, the expression and/or activity of T-bet is increased, thereby increasing the production of IFN-γ. In another embodiment, the expression and/or activity of T-bet is decreased, thereby decreasing the production of IFN-γ.

[0032] The invention also pertains to a method of modulating the generation of NK cells comprising contacting an NK cell with an agent that modulates the expression and/or activity of T-bet to thereby modulate the cytolytic activity of an NK cell. In one embodiment, the expression and/or activity of T-bet is increased, thereby increasing the generation of NK cells. In another embodiment, the expression and/or activity of T-bet is decreased, thereby decreasing the generation of NK cells. The invention also pertains to a method of modulating NK cell cytolytic activity comprising contacting an NK cell with an agent that modulates the expression and/or activity of T-bet to thereby modulate NK cell cytolytic activity. In one embodiment, the agent increases the expression and/or activity of T-bet and NK cell cytolytic activity is increased. In another embodiment, the agent decreases the expression and/or activity of T-bet and NK cell activity is decreased. In a certain embodiment, the expression of granzyme b is decreased. In another embodiment, the agent decreases the expression of perforin

[0033] In another aspect, the invention pertains to a a method of modulating the production of IFN-γ in a dendritic cell comprising contacting an NK cell with an agent that modulates the expression and/or activity of T-bet to thereby modulate the production of IFN-γ in a dendritic cell. In certain embodiments, the expression and/or activity of T-bet is increased, thereby increasing the production of IFN-γ. In other embodiments, the expression and/or activity of T-bet is decreased, thereby decreasing the production of IFN-γ.

[0034] The invention also pertains to a method of modulating the production of IFN-γ at the site of antigen presentation to a naive T cell in vivo, comprising administering an agent that modulates the expression and/or activity of T-bet to a subject to thereby modulate the production of IFN-γ at the site of antigen presentation to a naive T cell. In one embodiment, the method further comprises administering an antigen to the subject.

[0035] The invention also pertains to a method of modulating the induction of tolerance in peripheral T cells, comprising administering an agent that modulates the expression and/or activity of T-bet to a subject to thereby modulate the induction of tolerance in peripheral T cells. In one embodiment, the number or percentage of Tr cells in the subject is modulated. In another embodiment, the activity or expression of T-bet is increased and peripheral tolerance is increased. In yet other embodiments, the activity or expression of T-bet is decreased and peripheral tolerance is decreased.

[0036] In yet another aspect, the invention pertains to a method of treating or preventing a disorder that would benefit from treatment with an agent that modulates the expression and/or activity of T-bet comprising administering to a subject with said disorder an agent that modulates the expression and/or activity of T-bet. The invention also pertains to a method of treating or preventing a disorder that would benefit from treatment with an agent that modulates the expression of T-bet comprising administering to a subject with said disorder an agent that modulates the expression of T-bet. The disorders of the invention include autoimmune diseases as described herein and known in the art. The autoimmune diseases can be mediated by Th2 cells. In particular embodiments, the autoimmunce diseases are Crohn's disease, multiple sclerosis, ulcerative colitis or rheumatod arthritis. In one embodiment, a disorder that can be treated is asthma.

[0037] The invention also pertains to a method of treating or preventing an infectious disease that would benefit from treatment with an agent that modulates the expression and/or activity of T-bet comprising administering to a subject with said infectious disease an agent that modulates the expression and/or activity of T-bet. The infectious disease may be caused by a bacterium or by a virus.

[0038] The invention further pertains to a method of treating multiple sclerosis comprising administering an agent that reduces the expression and/or activity of T-bet to a subject such that multiple sclerosis is treated and a method of treating rheumatoid arthritis comprising administering an agent that reduces the expression and/or activity of T-bet to a subject such that rheumatoid arthritis is treated.

[0039] The invention also pertains to a a method for identifying a compound that modulates the expression and/or activity of a T-bet polypeptide, comprising providing an indicator composition that comprises a T-bet polypeptide; contacting the indicator composition with a test compound; and determining the effect of the test compound on the expression and/or activity of the T-bet polypeptide in the indicator composition to thereby identify a compound that modulates the expression and/or activity of a T-bet polypeptide. The indicator composition may comprise a T-bet polypeptide and a DNA molecule to which the T-bet polypeptide binds; and the effect of the test compound on the expression and/or activity of the T-bet polypeptide is determined by evaluating the binding of the T-bet polypeptide to the DNA molecule in the presence and absence of the test compound. The indicator composition may also be a cell comprising a T-bet polypeptide and a reporter gene responsive to the T-bet polypeptide; and the effect of the test compound on the expression and/or activity of the T-bet polypeptide is determined by evaluating the expression of the reporter gene in the presence and absence of the test compound. The method may further comprise determining the effect of the test compound on an immune response to thereby identify a compound that modulates an immune response. In one embodiment, the expression and/or activity of T-bet is enhanced. On another embodiment, the expression and/or activity of T-bet is inhibited.

[0040] The activity of T-bet may be IFN-γ production or transcription of IgG2a. The test compound may be selected from the group comprised of: a T-bet nucleic acid molecule, a T-bet peptide, a small molecule T-bet agonist and a small molecule T-bet antagonist; an intracellular antibody, a nucleic acid molecule that is antisense to a T-bet molecule, a dominant negative T-bet molecule, a small molecule T-bet agonist and a small molecule T-bet antagonist. The cell may be selected from the group consisting of: a T cell, a B cell, and a macrophage. In one embodiment, the indicator composition is a cell that expresses T-bet polypeptide. In another embodiment, the cell has been engineered to express the T-bet polypeptide by introducing into the cell an expression vector encoding the T-bet polypeptide. In another embodiment, the indicator composition is a cell free composition. In yet another embodiment, the indicator composition is a cell that expresses a T-bet polypeptide and a target molecule, and the ability of the test compound to modulate the interaction of the T-bet polypeptide with a target molecule is monitored.

[0041] In another aspect, the invention pertains to a method of identifying a compound that modulates a signal transduction pathway involving T-bet comprising: a) contacting cells deficient in T-bet with a test compound; and b) determining the effect of the test compound on an expression and/or activity of T-bet, the test compound being identified as a modulator of the expression and/or activity of a signal transduction pathway involving T-bet based on the ability of the test compound to modulate a signal transduction pathway involving T-bet in the cells deficient in T-bet. In one embodiment, the cells deficient in T-bet are in a non-human T-bet deficient animal and the cells are contacted with the test compound by administering the test compound to the non-human T-bet deficient animal.

[0042] The invention also relates to a method of identifying compounds useful in modulating TGF-β-mediated signaling comprising, a) providing an indicator composition comprising T-bet polypeptide; b) contacting the indicator composition with each member of a library of test compounds; c) selecting from the library of test compounds a compound of interest that modulates the expression and/or activity of T-bet polypeptide to thereby identify a compound that modulates TGF-β-mediated signaling. T-bet activity is measured by measuring cytokine production, measuring the expression of Smad7, by measuring TGF-β-mediated signaling, wherein the amount of TGF-β is measured.

[0043] The invention also relates to a method of identifying compounds useful in modulating the Jak1/STAT-1 pathway comprising, a) providing an indicator composition comprising T-bet polypeptide; b) contacting the indicator composition with each member of a library of test compounds; c) selecting from the library of test compounds a compound of interest that modulates the expression and/or activity of T-bet polypeptide to thereby identify a compound that modulates the Jak1/STAT-1 pathway.

[0044] The invention also encompasses a method of identifying compounds useful in modulating T cell lineage commitment comprising, a) providing an indicator composition comprising T-bet polypeptide; b) contacting the indicator composition with each member of a library of test compounds; c) selecting from the library of test compounds a compound of interest that modulates the activity or expression of T-bet polypeptide to thereby identify a compound that modulates T cell lineage commitment. In one embodiment, commitment of T cells to Th1 lineage is measured. In another embodiment, commitment of T cells to Th2 lineage is measured. In yet another embodiment, the compound increases commitment of T cells to Th1 lineage. In another embodiment, the compound decreases commitment of T cells to Th2 lineage. In another embodiment, the compound increases commitment of T cells to Th2 lineage. In yet another embodiment, the compound decreases commitment of T cells to Th1 lineage. In certain embodiments, the the activity of T-bet is measured by measuring cytokine production, e.g., a cytokine selected from the group consisting of IL-2, IFNγ, IL-4, IL-5, TNFα, TGF-β, LT(lymphotoxin), and IL-10. The indicator composition can be a cell that expresses T-bet polypeptide. In one embodiment, the cell is committed to a T cell lineage. In another embodiment, the cell is not yet committed to a T cell lineage.

[0045] In another aspect, the invention relates to a method of identifying compounds useful in modulating the production of at least one cytokine comprising, a) providing an indicator composition comprising T-bet polypeptide; b) contacting the indicator composition with each member of a library of test compounds; c) selecting from the library of test compounds a compound of interest that modulates the expression and/or activity of T-bet polypeptide to thereby identify a compound that modulates the production of at least one cytokine. In one embodiment, the production of at least one cytokine is measured. In another embodiment, the production of more than one cytokine is measured. In another embodiment, the pattern of cytokines produced is measured. The cell may be selected from the group consisting of: a T cell, a B cell, and an NK cell.

[0046] The invention also relates to a method of identifying compounds useful in modulating the production of IFN-γ comprising, a) providing an indicator composition comprising T-bet polypeptide; b) contacting the indicator composition with each member of a library of test compounds; c) selecting from the library of test compounds a compound of interest that modulates the expression and/or activity of T-bet polypeptide to thereby identify a compound that modulates the production of IFN-γ. The indicator composition can be a cell that expresses T-bet polypeptide. The cell can be selected from the group consisting of: a T cell, a B cell, and an NK cell. The cell can be engineered to express the T-bet polypeptide by introducing into the cell an expression vector encoding the T-bet polypeptide. The indicator composition can be a cell free composition. The indicator composition can be a cell that expresses a T-bet polypeptide and a target molecule, and the ability of the test compound to modulate the interaction of the T-bet polypeptide with a target molecule is monitored. In one embodiment, the indicator composition comprises an indicator cell, wherein the indicator cell comprises a T-bet polypeptide and a reporter gene responsive to the T-bet polypeptide. In another embodiment, the indicator cell contains: a recombinant expression vector encoding the T-bet polypeptide; and a vector comprising a T-bet responsive regulatory element operatively linked a reporter gene; and said method comprises: a) contacting the indicator cell with a test compound; b) determining the level of expression of the reporter gene in the indicator cell in the presence of the test compound; and c) comparing the level of expression of the reporter gene in the indicator cell in the presence of the test compound with the level of expression of the reporter gene in the indicator cell in the absence of the test compound to thereby select a compound of interest that modulates the expression and/or activity of T-bet polypeptide.

[0047] The invention also relates to a method of identifying a compound that modulates the production of IFN-γ comprising: a) contacting cells deficient in T-bet with a test compound; and b) determining the effect of the test compound on the production of IFN-γ the test compound being identified as a modulator of the production of IFN-γ based on the ability of the test compound to modulate the production of IFN-γ in the cells deficient in T-bet. The invention also relates to a method of identifying compounds useful in modulating IFN-γ production comprising, a) providing an indicator composition comprising T-bet polypeptide; b) contacting the indicator composition with each member of a library of test compounds; c) selecting from the library of test compounds a compound of interest that modulates the interaction between T-bet and a Tec kinase to thereby identify compounds useful in modulating IFN-γ production.

[0048] The invention further relates to a method of identifying compounds useful in modulating IL-4 production comprising, a) providing an indicator composition comprising T-bet polypeptide; b) contacting the indicator composition with each member of a library of test compounds; c) selecting from the library of test compounds a compound of interest that modulates the interaction between T-bet and a Tec kinase to thereby identify compounds useful in modulating IL-4 production.

[0049] The invention further relates to a method of identifying compounds useful in modulating IgG class switching comprising, a) providing an indicator composition comprising T-bet polypeptide; b) contacting the indicator composition with each member of a library of test compounds; c) selecting from the library of test compounds a compound of interest that modulates the expression and/or activity of T-bet polypeptide; and d) determining the effect of the compound of interest on IgG class switching to thereby identify a compound that modulates the production of IgG class switching. In one embodiment, the activity of T-bet is measured by measuring IgG2a production. The T-bet activity can also be measured by measuring IgG1 production or by measuring IgE production.

[0050] In another aspect, the invention relates to a method of identifying compounds useful in modulating B lymphocyte function comprising, a) providing an indicator composition comprising T-bet polypeptide; b) contacting the indicator composition with each member of a library of test compounds; c) selecting from the library of test compounds a compound of interest that modulates the expression and/or activity of T-bet polypeptide; and d) determining the effect of the compound of interest on B lymphocyte function to thereby identify a compound that modulates B lymphocyte function. The activity of T-bet is measured by measuring, for example, cytokine production or the production of pathogenic autoantibodies

[0051] In yet another apsect, the invention pertains to a method of identifying compounds useful in modulating an autoimmune disease comprising, a) providing an indicator composition comprising T-bet polypeptide; b) contacting the indicator composition with each member of a library of test compounds; c) selecting from the library of test compounds a compound of interest that modulates the expression and/or activity of T-bet polypeptide to thereby identify a compound that modulates an autoimmune disease.

[0052] The invention further pertains to a method for modulating the expression and/or activity of T-bet comprising contacting a cell with an agent that modulates a post-translational modification of T-bet such that the expression and/or activity of T-bet is modulated. The post-translational modification is selected from, for example, phosphorylation, glycosylation and ubiquitination.

[0053] In another aspect, the invention pertains to a method of diagnosing a subject for a disorder associated with aberrant immune cell activation comprising: detecting expression of T-bet in immune cells of a subject suspected of having said disorder; comparing expression of T-bet in immune cells of said subject to a control that is not associated with aberrant immune cell activation; and diagnosing the subject for a disorder based on a change in expression of T-bet in immune cells of the subject as compared to the control. The disorder can be, for example, an autoimmune disease as described herein or known in the art.

BRIEF DESCRIPTION OF THE DRAWINGS

[0054]FIG. 1A shows a nucleotide sequence alignment of murine and human T-bet. The alignment was prepared using the ALIGN program. FIG. 1B shows an amino acid sequence alignment of murine and human T-bet prepared using the Lipman Pearson protein alignment program. The T-box sequence is shown in bold. Tyrosine phosphorylation sites are underlined. The nuclear localization site is marked with arrows.

[0055] FIGS. 2A-B show that T-bet binds to and transactivates consensus T-box sites with functionally important domains that map to both 5′ and 3′ regions.

[0056]FIG. 3A shows that T-bet is preferentially expressed in double negative thymocytes. Panel B shows that in a survey of Th clones, T-bet expression is restricted to Th1 cells. Panel C shows western blot analysis of T-bet. Panel D shows FACS analysis of T-bet expression.

[0057] FIGS. 4A-B show that T-bet expression correlates with IFN-γ induction in NK and B cells.

[0058]FIG. 5 shows that T-bet transactivates the IFN-γ gene in Th cells.

[0059]FIG. 6 shows that retroviral gene transduction of T-bet reduces increases IFN-γ production and represses IL-2 production.

[0060]FIG. 7 shows that T-bet activates IFN-γ and represses IL-2 production in primary T cells.

[0061]FIG. 8 shows that T-bet induces IFN-γ and inhibits IL-4 production in developing Th2 cells.

[0062]FIG. 9 shows that T-bet redirects polarized Th2 cells into the Th1 pathway. Th-skewing was carried out as above and retroviral infections were performed on day 9 of culture

[0063]FIG. 10 shows that T-bet redirects polarized Tc2 cells into the Tc1 pathway. CD8+ T cells were purified by MoFlo and cultured under Th2 skewing conditions as above and retroviral transductions performed on day 8 of culture.

[0064]FIG. 11 shows that T-bet is tyrosine phosphorylated.

[0065]FIG. 12 shows the activity of a T-bet dominant negative mutant.

[0066]FIG. 13 shows that treatment of activated T-cell enriched LPMCs with TGF-β but not IL-4 suppressed T-bet expression suggesting a reciprocal relationship between TGF-β and T-bet.

[0067]FIG. 14 shows that mice lacking T-bet are resistant to EAE development.

[0068]FIG. 15 shows that mice lacking T-bet had a mean clinical score of less than 0.5 and were protected from EAE.

[0069]FIG. 16 shows that the percentage of CD4⁺ cells staining positive for IFN-γ was 33% in 2D2 MOG×T-bet^(+/+) animals and 3% in 2D2 MOG×T-bet^(−/−) animals.

[0070]FIG. 17 shows a substantial decrease (approximately two thirds reduction) in numbers of CD8 cells in the absence of T-bet as evidenced by the reduction in CD8⁺, CD44Hi, CD62Lhi, CD69Hi and Ly6CHi cells.

[0071]FIG. 18 shows that T-bet is required for IFN-γ production in CD8+ cells.

[0072]FIG. 19 shows that T-bet regulates the production of IFN-γ in NK cells.

[0073]FIG. 20 shows that the generation of NK cells is also impaired in the absence of T-bet.

[0074]FIG. 21 shows diminished spontaneous tumor cell lysis in T-bet^(−/−) NK cells.

[0075]FIG. 22 shows that expression of lytic genes was impaired in the absence of T-bet.

[0076] FIGS. 23 A-C show the normal development and activation of murine dendritic cells in mice lacking T-bet.

[0077]FIG. 24 shows low levels of T-bet expression in unstimulated DCs and a rapid up-regulation of T-bet transcript levels after treatment with IFN-γ.

[0078]FIG. 25 shows that T-bet is essential for optimal production of IFN-γ by dendritic cells.

[0079]FIG. 26 shows the conserved structure of Tec family members.

[0080]FIG. 27 shows the predicted tyrosine phosphorylation sites of human T-bet.

[0081]FIG. 28 shows the modified forms of T-bet that were made and used as substrates in in vitro kinase assays.

[0082]FIG. 29 shows that both ITK and Rlk phosphorylated N-terminal and C-terminal but not DNA-binding regions of T-bet in in vitro kinase assays.

[0083]FIG. 30 shows that although T-bet is present in T cells from ITK knock out animals, tyrosine phosphorylation of the molecule is reduced. In contrast, T-bet was hyperphosphorylated in Rlk knockout T cells

[0084]FIG. 31 shows that T_(R) cells are increased in the absence of T-bet.

[0085]FIG. 32 shows that IFN-γ regulates T-bet expression in a self-reinforcing feedback mechanism between IFN-γ and T-bet.

[0086]FIG. 33 shows that T-bet expression was markedly reduced in STAT1 and IFN-γ R1 deficient T cells yet STAT4 deficient cells exhibited T-bet levels comparable to wildtype controls.

[0087]FIG. 34 shows reduced IFN-γ expression in T-bet and STAT1, but not STAT4 deficient CD4+ T cells.

[0088]FIG. 35A-B shows reduced IFN-γ expression in T-bet, STAT1 and STAT4 deficient Th1 cells.

[0089]FIG. 36 shows that CD8 cells that lack T-bet produce substantially increased levels of IL-10 and IL-2.

DETAILED DESCRIPTION OF THE INVENTION

[0090] This invention pertains to T-bet compositions, such as isolated nucleic acid molecules encoding T-bet and isolated T-bet proteins, as well as methods of use therefore. The expression and/or activity of T-bet can be modulated using the instant invention. As discussed in more detail below, T-bet is an important intracellular transducer or mediator of a variety of extracellular signals. T-bet is a transcription factor that operates in different cell types to transduce extracellular signals into specific patterns of gene expression. In particular, it has now been demonstrated that T-bet has a central role in cytokine gene expression. Different cell types and different genes respond to T-bet, which serves to modulate a variety of cellular responses. T-bet also controls expression of several genes, expression of these genes and others similarly affected can be modulated (e.g., enhanced or reduced) by controlling the expression and/or activity of T-bet.

[0091] Using the instant invention, the expression of a gene responsive to T-bet can be positively or negatively regulated to provide for increased or decreased production, respectively, of the protein whose expression is modulated by T-bet. Furthermore, genes which do not, in their naturally-occurring form, have T-bet recognition sequences can be placed under the control of T-bet by inserting a T-bet binding site in an appropriate position using techniques known in the art. In addition, extracellular signals transduced via T-bet can be modulated, e.g., by contacting a cell with an agent that modulates the expression and/or activity of T-bet such that the T-bet mediated effects of such extracellular influences are modulated. Thus, T-bet expression and/or activity can be controlled to modulate signaling via a signal transduction pathway in which T-bet is involved.

[0092] So that the invention may be more readily understood, certain terms are first defined.

[0093] As used herein, the term “modulated” with respect to T-bet includes changing the expression, activity or function of T-bet in such a manner that it differs from the naturally-occurring expression, function or activity of T-bet under the same conditions.

[0094] For example, the expression, function or activity can be greater or less than that of naturally occurring T-bet, e.g., owing to a change in binding specificity, etc. As used herein, the various forms of the term “modulate” include stimulation (e.g., increasing or upregulating a particular response or activity) and inhibition (e.g., decreasing or downregulating a particular response or activity).

[0095] As used herein, the term “T-bet molecules” includes T-bet nucleic acid molecules that share structural features with the nucleic acid molecules shown in SEQ ID NOs: 1 and 3 and T-bet proteins that share the distinguishing structural and functional features of the T-bet proteins shown in SEQ ID NOs 2 and 4. The T-bet proteins are members of the T-box family of proteins and share some amino acid sequence homology to Brachyury, Tbx1-6, T-brain-1 (Tbr-1). T-box proteins comprise a T box domain which binds to DNA at a T box binding site. Further structural and functional features of T-bet proteins are provided below.

[0096] As used herein, the term “nucleic acid molecule” is intended to include DNA molecules (e.g., cDNA or genomic DNA) and RNA molecules (e.g., mRNA). The nucleic acid molecule may be single-stranded or double-stranded, but preferably is double-stranded DNA.

[0097] An used herein, an “isolated nucleic acid molecule” refers to a nucleic acid molecule that is free of gene sequences which naturally flank the nucleic acid in the genomic DNA of the organism from which the nucleic acid is derived (i.e., genetic sequences that are located adjacent to the gene for the isolated nucleic molecule in the genomic DNA of the organism from which the nucleic acid is derived). For example, in various embodiments, an isolated T-bet nucleic acid molecule typically contains less than about 10 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived, and more preferably contains less than about 5, kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of naturally flanking nucleotide sequences. An “isolated” T-bet nucleic acid molecule may, however, be linked to other nucleotide sequences that do not normally flank the T-bet sequences in genomic DNA (e.g., the T-bet nucleotide sequences may be linked to vector sequences). In certain preferred embodiments, an “isolated” nucleic acid molecule, such as a cDNA molecule, also may be free of other cellular material. However, it is not necessary for the T-bet nucleic acid molecule to be free of other cellular material to be considered “isolated” (e.g., a T-bet DNA molecule separated from other mammalian DNA and inserted into a bacterial cell would still be considered to be “isolated”).

[0098] As used herein, the term “hybridizes under high stringency conditions” is intended to describe conditions for hybridization and washing under which nucleotide sequences having substantial homology (e.g., typically greater than 70% homology) to each other remain stably hybridized to each other. A preferred, non-limiting example of high stringency conditions are hybridization in a hybridization buffer that contains 6× sodium chloride/ sodium citrate (SSC) at a temperature of about 45° C. for several hours to overnight, followed by one or more washes in a washing buffer containing 0.2× SSC, 0.1% SDS at a temperature of about 50-65° C.

[0099] The term “percent (%) identity” as used in the context of nucleotide and amino acid sequences (e.g., when one amino acid sequence is said to be X% identical to another amino acid sequence) refers to the percentage of identical residues shared between the two sequences, when optimally aligned. To determine the percent identity of two nucleotide or amino acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps may be introduced in one sequence for optimal alignment with the other sequence). The residues at corresponding positions are then compared and when a position in one sequence is occupied by the same residue as the corresponding position in the other sequence, then the molecules are identical at that position. The percent identity between two sequences, therefore, is a function of the number of identical positions shared by two sequences (i.e., % identity=# of identical positions/total # of positions×100).

[0100] Computer algorithms known in the art can be used to optimally align and compare two nucleotide or amino acid sequences to define the percent identity between the two sequences. A preferred, non-limiting example of a mathematical algorithm utilized for the comparison of two sequences is the algorithm of Karlin and Altschul (1990) Proc. Natl. Acad. Sci. USA 87:2264-68, modified as in Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-77. Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul, et al. (1990) J. Mol. Biol. 215:403-10. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al., (1997) Nucleic Acids Research 25(17):3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. See http://www.ncbi.nlm.nih.gov. For example, the nucleotide sequences of the invention were blasted using the default Blastn matrix 1-3 with gap penalties set at: existance 5 and extension 2. The amino acid sequences of the invention were blasted using the default settings: the Blosum62 matrix with gap penalties set at existance 11 and extension 1.

[0101] Another preferred, non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller, CABIOS (1989). Such an algorithm is incorporated into the ALIGN program (version 2.0) which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used. If multiple programs are used to compare sequences, the program that provides optimal alignment (i.e., the highest percent identity between the two sequences) is used for comparison purposes.

[0102] As used herein, a “naturally-occurring” nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein).

[0103] As used herein, an “antisense” nucleic acid comprises a nucleotide sequence which is complementary to a “sense” nucleic acid encoding a protein, e.g., complementary to the coding strand of a double-stranded cDNA molecule, complementary to an mRNA sequence or complementary to the coding strand of a gene. Accordingly, an antisense nucleic acid can hydrogen bond to a sense nucleic acid.

[0104] As used herein, the term “coding region” refers to regions of a nucleotide sequence comprising codons which are translated into amino acid residues, whereas the term “noncoding region” refers to regions of a nucleotide sequence that are not translated into amino acids (e.g., 5′ and 3′ untranslated regions).

[0105] As used herein, the term “vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a “plasmid”, which refers to a circular double stranded DNA loop into which additional DNA segments may be ligated. Another type of vector is a viral vector, wherein additional DNA segments may be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as “recombinant expression vectors” or simply “expression vectors”. In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, “plasmid” and “vector” may be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

[0106] As used herein, the term “host cell” is intended to refer to a cell into which a nucleic acid of the invention, such as a recombinant expression vector of the invention, has been introduced. The terms “host cell” and “recombinant host cell” are used interchangeably herein. It should be understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

[0107] As used herein, a “transgenic animal” refers to a non-human animal, preferably a mammal, more preferably a mouse, in which one or more of the cells of the animal includes a “transgene”. The term “transgene” refers to exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal, for example directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal.

[0108] As used herein, a “homologous recombinant animal” refers to a type of transgenic non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, e.g., an embryonic cell of the animal, prior to development of the animal.

[0109] As used herein, an “isolated protein” refers to a protein that is substantially free of other proteins, cellular material and culture medium when isolated from cells or produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized.

[0110] As used herein, the term “antibody” is intended to include immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site which specifically binds (immunoreacts with) an antigen, such as Fab and F(ab′)₂ fragments. The terms “monoclonal antibodies” and “monoclonal antibody composition”, as used herein, refer to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope of an antigen, whereas the term “polyclonal antibodies” and “polyclonal antibody composition” refer to a population of antibody molecules that contain multiple species of antigen binding sites capable of interacting with a particular antigen. A monoclonal antibody compositions thus typically display a single binding affinity for a particular antigen with which it immunoreacts.

[0111] As used here, the term “intrabodies” refers to intracellularly expressed antibody constructs, usually single-chain Fv (scFv) antibodies, directed against a target inside a cell, e.g. an intracellular protein such as T -bet.

[0112] As used herein, the term “autoimmune disease” refers to disorders or conditions in a subject wherein the immune system attacks the body's own cells, causing tissue destruction. Autoimmune diseases include general autoimmune diseases, i.e., in which the autoimmune reaction takes place simultaneously in a number of tissues, or organ specific autoimmune diseases, i.e., in which the autoimmune reaction targets a single organ. Examples of autoimmune diseases that can be diagnosed, prevented or treated by the methods and compositions of the present invention include, but are not limited to, diabetes mellitus, rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, psoriatic arthritis, multiple sclerosis, myasthenia gravis, systemic lupus erythematosis, autoimmune thyroiditis, atopic dermatitis and eczematous dermatitis, psoriasis, Sjögren's Syndrome, alopecia areata, allergic responses due to arthropod bite reactions, Crohn's disease, aphthous ulcer, iritis, conjunctivitis, keratoconjunctivitis, ulcerative colitis, allergic asthma, cutaneous lupus erythematosus, scleroderma, vaginitis, proctitis, compound eruptions, leprosy reversal reactions, erythema nodosum leprosum, autoimmune uveitis, allergic encephalomyelitis, acute necrotizing hemorrhagic encephalopathy, idiopathic bilateral progressive sensorineural hearing loss, aplastic anemia, pure red cell anemia, idiopathic thrombocytopenia, polychondritis, Wegner's granulomatosis, chronic active hepatitis, Stevens-Johnson syndrome, idiopathic sprue, lichen planus, Crohn's disease, Graves ophthalmopathy, sarcoidosis, primary biliary cirrhosis, uveitis posterior, experimental allergic encephalomyelitis (EAE), and interstitial lung fibrosis, and secondary diseases caused as a result of autoimmune diseases.

[0113] As used herein, the term “T cell” (i.e., T lymphocyte) is intended to include all cells within the T cell lineage, including thymocytes, immature T cells, mature T cells and the like, from a mammal (e.g., human or mouse).

[0114] As used herein, the term “immune response” includes T cell mediated and/or B cell mediated immune. Exemplary immune responses include T cell responses, e.g., cytokine production, and cellular cytotoxicity. In addition, the term immune response includes antibody production (humoral responses) and activation of cells of the innate immune system, e.g.,cytokine responsive cells such as macrophages.

[0115] As used herein, the term “T helper type 1 response” refers to a response that is characterized by the production of one or more cytokines selected from IFN-γ, IL-2, TNF, and lymphtoxin (LT) and other cytokines produced preferentially or exclusively by Th1 cells rather than by Th2 cells.

[0116] As used herein, a “T helper type 2 response” (Th2 response) refers to a response by CD4⁺ T cells that is characterized by the production of one or more cytokines selected from IL-4, IL-5, IL-6 and IL-10, and that is associated with efficient B cell “help” provided by the Th2 cells (e.g., enhanced IgG1 and/or IgE production).

[0117] As used herein, the term “a cytokine that regulates development of a Th2 response” is intended to include cytokines that have an effect on the initiation and/or progression of a Th2 response, in particular, cytokines that promote the development of a Th2 response, e.g., IL-4, IL-5 and IL-10.

[0118] As used herein the term “innate immune system” includes natural or native immune mechanisms, i.e., mechanisms that exist before infection, are capable of rapid responses to microbes, and react in essentially the same way to repeated infections.

[0119] As used herein, the term “adaptive immune system” or “specific immune system” includes immune mechanisms that are stimulated by exposure of infectious agents and increase in magnitude and defensive capabilities with each successive exposure to a particular microbe.

[0120] The term “agent” or “compound” or “test compound” includes reagents or test agents which are employed in the methods or assays or present in the compositions of the invention. The term “agent” or “compound” or “test compound” includes compounds that have not previously been identified as, or recognized to be, a modulator of T-bet expression or activity. In one embodiment, more than one compound, e.g., a plurality of compounds, can be tested at the same time in a screening assay for their ability to modulate expression and/or activity of T-bet or a molecule acting upstream or downstream of T-bet in a signal transduction pathway. The term “library of test compounds” refers to a panel comprising a multiplicity of test compounds.

[0121] In one embodiment, the term “agent” or “compound” or “test compound” excludes naturally occurring compounds such as cytokines. In another embodiment, the term agent excludes antibodies which bind to naturally occurring cytokines. In another embodiment, the term “agent” excludes antibodies that bind to cytokine receptors. In yet another embodiment, the term “agent” excludes those agents that transduce signals via the T cell receptor, e.g., antigen in the context of an MHC molecule or antibody to a component of the T cell receptor complex. In one embodiment, the agent or test compound is a compound that directly interacts with T-bet or directly interacts with a molecule with which T-bet interacts (e.g., a compound that inhibits or stimulates the interaction between T-bet and a T-bet target molecule, e.g., DNA or another protein). In another embodiment, the compound is one that indirectly modulates T-bet expression and/or activity, e.g., by modulating the activity of a molecule that is upstream or downstream of T-bet in a signal transduction pathway involving T-bet. Such compounds can be identified using screening assays that select for such compounds, as described in detail below.

[0122] The term “small molecule” is a term of the art and includes molecules that are less than about 1000 molecular weight or less than about 500 molecular weight. In one embodiment, small molecules do not exclusively comprise peptide bonds. In another embodiment, small molecules are not oligomeric. Exemplary small molecule compounds which can be screened for activity include, but are not limited to, peptides, peptidomimetics, nucleic acids, carbohydrates, small organic molecules (e.g., polyketides) (Cane et al. 1998. Science 282:63), and natural product extract libraries. In another embodiment, the compounds are small, organic non-peptidic compounds. In a further embodiment, a small molecule is not biosynthetic.

[0123] As used herein, the term “a modulator of T-bet” includes a modulator of T-bet expression, processing, post-translational modification, or activity. The term includes agents, for example a compound or compounds which modulates transcription of a T-bet gene, processing of a T-bet mRNA, translation of T-bet mRNA, post-translational modification of a T-bet protein (e.g., glycosylation, ubiquitinization or phosphorylation) or activity of a T-bet protein. A “modulator of T-bet activity” includes compounds that directly or indirectly modulate T-bet activity. For example, an indirect modulator of T-bet activity may modulate a signal transduction pathway that includes T-bet. Examples of modulators that directly modulate T-bet activity include antisense nucleic acid molecules that bind to T-bet mRNA or genomic DNA, intracellular antibodies that bind to T-bet intracellularly and modulate (i.e., inhibit) T-bet activity, T-bet peptides that inhibit the interaction of T-bet with a target molecule and expression vectors encoding T-bet that allow for increased expression of T-bet activity in a cell, dominant negative forms of T-bet, as well as chemical compounds that act to specifically modulate the activity of T-bet.

[0124] As used herein an “agonist” of the T-bet proteins can retain substantially the same, or a subset, of the biological activities of the naturally occurring form of a T-bet protein. An “antagonist” of a T-bet protein can inhibit one or more of the activities of the naturally occurring form of the T-bet protein by, for example, competitively modulating a cellular activity of a T-bet protein.

[0125] As used interchangeably herein, “T-bet activity,” “biological activity of T-bet” or “functional activity T-bet,” include an activity exerted by T-bet protein on a T-bet responsive cell or tissue, e.g., a T cell, dendritic cells, NK cells, or on a T-bet target molecule, e.g., a nucleic acid molecule or protein target molecule, as determined in vivo, or in vitro, according to standard techniques. In one embodiment, T-bet activity is a direct activity, such as an association with a T-bet-target molecule. Alternatively, a T-bet activity is an indirect activity, such as a downstream biological event mediated by interaction of the T-bet protein with a T-bet target molecule. The biological activities of T-bet are described herein and include, but are not limited to: modulation of IFN-γ production in cells of the innate and adaptive immune system, modulation of T cell lineage commitment, modulation of the production of cytokines, modulation of TGF-β mediated signaling, modulation of the Jak1/STAT-1 pathway, modulation of IgG class switching, modulation of B lymphocyte function, and modulation of disorders that would benefit from modulation of T-bet, e.g., autoimmune diseases, multiple sclerosis or rheumatoid arthritis, infection, e.g., with a virus or a bacterium, asthma, and other disorders or unwanted conditions in which Th1 or Th2 cytokines are implicated, e.g., inflammation. These findings provide for the use of T-bet (and other molecules in the pathways in which T-bet is involved) as drug targets and as targets for therapeutic intervention in various diseases, disorders or conditions. The invention yet further provides immunomodulatory compositions, such as vaccines, comprising agents which modulate T-bet activity.

[0126] As used herein, the term “target molecule” or “binding partner” is a molecule with which T-bet binds or interacts in nature, and which interaction results in a biological response. The target molecule can be a protein or a nucleic acid molecule. Exemplary target molecules of the invention include proteins in the same signaling pathway as the T-bet protein, e.g., proteins which may function upstream (including both stimulators and inhibitors of activity) or downstream of the T-bet protein in a pathway involving for example, modulation of T cell lineage commitment, modulating the production of cytokines, modulating TGF-β mediated signaling, modulating the Jak1/STAT-1 pathway, modulating IgG class switching, modulating B lymphocyte function, and modulating an autoimmune disease. Exemplary T-bet target molecules include tyrosine kinases s, e.g., a Tec kinase such as ITK or rlk or DNA sequences with which T-bet interacts to modulate gene transcription.

[0127] As used herein, the term “gene whose transcription is regulated by T-bet”, includes genes having a regulatory region regulated by T-bet. Such genes can be positively or negatively regulated by T-bet. The term also includes genes which are indirectly modulated by T-bet, i.e., are modulated as the result of the activation of a signaling pathway in which T-bet is involved. Exemplary genes regulated by T-bet include, for example, the cytokine genes, e.g., IL-2, IFN-γ, IL-4, IL-5, TNFα, TGF-β, LT(lymphotoxin), and IL-10.

[0128] As used herein, the term “signal transduction pathway” includes the means by which a cell converts an extracellular influence or signal (e.g., a signal transduced by a receptor on the surface of a cell, such as a cytokine receptor or an antigen receptor) into a cellular response (e.g., modulation of gene transcription). Exemplary signal transduction pathways include the JAK1/STAT-1 pathway (Leonard, W. 2001. Int. J. Hematol. 73:271) and the TGF-β pathway (Attisano and Wrana. 2002. Science. 296:1646) A “signal transduction pathway involving T-bet” is one in which T-bet is a signaling molecule which relays signals.

[0129] As used herein, the term “contacting” (i.e., contacting a cell e.g. a cell, with a compound) includes incubating the compound and the cell together in vitro (e.g., adding the compound to cells in culture) as well as administering the compound to a subject such that the compound and cells of the subject are contacted in vivo. The term “contacting” does not include exposure of cells to a T-bet modulator that may occur naturally in a subject (i.e., exposure that may occur as a result of a natural physiological process).

[0130] As used herein, the term “dominant negative T-bet protein” includes T-bet molecules (e.g., portions or variants thereof) that compete with native (i.e., naturally occurring wild-type) T-bet molecules, but which do not have T-bet activity. Such molecules effectively decrease T-bet activity in a cell. As used herein, “dominant negative T-bet protein” refers to a modified form of T-bet which is a potent inhibitor of T-bet activity.

[0131] As used herein, the term “indicator composition” refers to a composition that includes a protein of interest (e.g., T-bet), for example, a cell that naturally expresses the protein, a cell that has been engineered to express the protein by introducing an expression vector encoding the protein into the cell, or a cell free composition that contains the protein (e.g., purified naturally-occurring protein or recombinantly-engineered protein).

[0132] As used herein, the term “cell” includes prokaryotic and eukaryotic cells. In one embodiment, a cell of the invention is a bacterial cell. In another embodiment, a cell of the invention is a fungal cell, such as a yeast cell. In another embodiment, a cell of the invention is a vertebrate cell, e.g., an avian or mammalian cell. In a preferred embodiment, a cell of the invention is a murine or human cell.

[0133] As used herein, the term “dendritic cell” refers to a type of antigen-presenting cells which are particularly active in stimulating T cells. Dendritic cells can be obtained by culturing bone-marrow cells in the presence of GM-CSF and selecting those cells that express MHC class II molecules and CD11c. Dendritic cells can also express CD11b⁺, DEC-205⁺, CD8-alpha⁺.

[0134] As used herein, the term “site of antigen presentation to a naive T cell” includes those sites within lymphoid tissues where naive CD4 T cells first come into contact with antigen, e.g., as presented by interdigitating dendritic cells during an in vivo primary immune response.

[0135] As used herein, the term “CD8+ effector memory cell” refers to CD8 T cells responsible for maintaining long term immunity against a particular pathogen. CD8 effector/memory cells are CD8+, CD44 High, CD62 High, CD69 High, and Ly6C High.

[0136] As used herein, the term “cytolytic activity” refers to ability of a cell, e.g., a CD8+ cell or an NK cell, to lyse target cells. Such cytolytic activity can be measured using standard techniques, e.g., by radioactively labeling the target cells.

[0137] As used herein, the term “T_(R) cell” refers to CD25 expressing CD4+ T cells (Treg) that function as suppressors of self-specific T cell responses. TR cells are responsible for maintenance of tolerance in peripheral T cells.

[0138] As used herein, the term “peripheral T cells” refers to mature single positive T cells that leave the thymus and enter the peripheral circulation. As used herein, the term “Tec kinase” refers to a family of tyrosine kinases of which ITK and Rlk/Txk (rlk) are the predominant family members. Tec kinases are expressed in T cells, and are involved in T cell antigen receptor mediated activation of T cells. The Tec family of protein tyrosine kinases play an important role in signaling through antigen-receptors such as the TCR, BCR and Fcε receptor. Members of the Tec kinase family of tyrosine kinases include, for example, Tec, Btk, Itk, Rlk and Bmx.

[0139] As used herein, the term “tolerance” refers to unresponsiveness to T cell-receptor-mediated signal by a T cell. Such T cell-mediated signals include, e.g., antigen in the context of MHC molecules or foreign MHC molecules.

[0140] As used herein, the term “lineage commitment” refers to the program that initiates T cell lineage development from a precursor cell, e.g., a Thp cell, into a fully differentiated effector cell of a specific lineage, e.g., into a T cell that secretes a specific profile of cytokines upon receptor-mediated stimulation, such as a Th1 or a Th2 cell.

[0141] As used herein, the term “engineered” (as in an engineered cell) refers to a cell into which a nucleic acid molecule encoding the T-bet protein has been introduced.

[0142] As used herein, the term “cell free composition” refers to an isolated composition, which does not contain intact cells. Examples of cell free compositions include cell extracts and compositions containing isolated proteins.

[0143] As used herein, the term “reporter gene” refers to any gene that expresses a detectable gene product, e.g., RNA or protein. Preferred reporter genes are those that are readily detectable. The reporter gene may also be included in a construct in the form of a fusion gene with a gene that includes desired transcriptional regulatory sequences or exhibits other desirable properties. Examples of reporter genes include, but are not limited to CAT (chloramphenicol acetyl transferase) (Alton and Vapnek (1979), Nature 282: 864-869) luciferase, and other enzyme detection systems, such as beta-galactosidase; firefly luciferase (deWet et al. (1987), Mol. Cell. Biol. 7:725-737); bacterial luciferase (Engebrecht and Silverman (1984), PNAS 1: 4154-4158; Baldwin et al. (1984), Biochemistry 23: 3663-3667); alkaline phosphatase (Toh et al. (1989) Eur. J. Biochem. 182: 231-238, Hall et al. (1983) J. Mol. Appl. Gen. 2: 101), human placental secreted alkaline phosphatase (Cullen and Malim (1992) Methods in Enzymol. 216:362-368) and green fluorescent protein (U.S. Pat. No. 5,491,084; WO 96/23898).

[0144] As used herein, the term “T-bet-responsive element” refers to a DNA sequence that is directly or indirectly regulated by the activity of T-bet (whereby activity of T-bet can be monitored, for example, via transcription of the reporter genes).

[0145] As used herein, the term “cells deficient in T-bet” is intended to include cells of a subject that are naturally deficient in T-bet, as wells as cells of a non-human T-bet deficient animal, e.g., a mouse, that have been altered such that they are deficient in T-bet. The term “cells deficient in T-bet” is also intended to include cells isolated from a non-human T-bet deficient animal or a subject that are cultured in vitro.

[0146] As used herein, the term “non-human T-bet deficient animal” refers to a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, e.g., an embryonic cell of the animal, prior to development of the animal, such that the endogenous T-bet gene is altered, thereby leading to either no production of T-bet or production of a mutant form of T-bet having deficient T-bet activity. Preferably, the activity of T-bet is entirely blocked, although partial inhibition of T-bet activity in the animal is also encompassed. The term “non-human T-bet deficient animal” is also intended to encompass chimeric animals (e.g., mice) produced using a blastocyst complementation system, such as the RAG-2 blastocyst complementation system, in which a particular organ or organs (e.g., the lymphoid organs) arise from embryonic stem (ES) cells with homozygous mutations of the T-bet gene.

[0147] There is a known and definite correspondence between the amino acid sequence of a particular protein and the nucleotide sequences that can code for the protein, as defined by the genetic code (shown below). Likewise, there is a known and definite correspondence between the nucleotide sequence of a particular nucleic acid molecule and the amino acid sequence encoded by that nucleic acid molecule, as defined by the genetic code. GENETIC CODE Alanine (Ala, A) GCA, GCC, GCG, GCT Arginine (Arg, R) AGA, ACG, CGA, CGC, CGG, CGT Asparagine (Asn, N) AAC, AAT Aspartic acid (Asp,D) GAC, GAT Cysteine (Cys, C) TGC, TGT Glutamic acid (Glu,E) GAA, GAG Glutamine (Gln, Q) CAA, CAG Glycine (Gly, G) GGA, GGC, GGG, GGT Histidine (His, H) CAC, CAT Isoleucine (Ile, I) ATA, ATC, ATT Leucine (Leu, L) CTA, CTC, CTG, CTT, TTA, TTG Lysine (Lys, K) AAA, AAG Methionine (Met, M) ATG Phenylalanine (Phe,F) TTC, TTT Proline (Pro, P) CCA, CCC, CCG, CCT Serine (Ser, S) AGC, AGT, TCA, TCC, TCG, TCT Threonine (Thr, T) ACA, ACC, ACG, ACT Tryptophan (Trp, W) TGG Tyrosine (Tyr, Y) TAC, TAT Valine (Val, V) GTA, GTC, GTG, GTT Termination signal TAA, TAG, TGA (end)

[0148] An important and well known feature of the genetic code is its redundancy, whereby, for most of the amino acids used to make proteins, more than one coding nucleotide triplet may be employed (illustrated above). Therefore, a number of different nucleotide sequences may code for a given amino acid sequence. Such nucleotide sequences are considered functionally equivalent since they result in the production of the same amino acid sequence in all organisms (although certain organisms may translate some sequences more efficiently than they do others). Moreover, occasionally, a methylated variant of a purine or pyrimidine may be found in a given nucleotide sequence. Such methylations do not affect the coding relationship between the trinucleotide codon and the corresponding amino acid.

[0149] In view of the foregoing, the nucleotide sequence of a DNA or RNA molecule coding for a T-bet protein of the invention (or any portion thereof) can be use to derive the T-bet amino acid sequence, using the genetic code to translate the DNA or RNA molecule into an amino acid sequence. Likewise, for any T-bet-amino acid sequence, corresponding nucleotide sequences that can encode the T-bet protein can be deduced from the genetic code (which, because of its redundancy, will produce multiple nucleic acid sequences for any given amino acid sequence). Thus, description and/or disclosure herein of a T-bet nucleotide sequence should be considered to also include description and/or disclosure of the amino acid sequence encoded by the nucleotide sequence. Similarly, description and/or disclosure of a T-bet amino acid sequence herein should be considered to also include description and/or disclosure of all possible nucleotide sequences that can encode the amino acid sequence.

[0150] Brachyury or T is the founding member of a family of transcription factors that share a 200 amino acid DNA-binding domain called the T-box (reviewed in Smith, 1997; Papaioannou, 1997; Meisler, 1997). The Brachyury (Greek for ‘short tail’) mutation was first described in 1927 in heterozygous mutant animals who had a short, slightly kinked tail (Herrmann et al., 1990). The amino-terminal half (amino acids 1-229) of the Brachyury T-box protein contains a conserved domain known as the T box which has been shown to exhibit sequence-specific DNA-binding activity (Kispert, A. & Herrmann, B. G. 1993. EMBO J. 12:3211; Papapetrou, C., et al. 1997. FEBS Lett. 409:201; Kispert, A., et al. 1995. EMBO J. 14:4763). The C-terminal half contains two pairs of transactivation and repression domains. The similarity of sequence between the T box region in orthologous species can be as high as 99% and is around 40-70% between non-orthologous genes. The T-box domain has recently been co-crystallized with DNA and demonstrates a novel sequence-specific DNA recognition architecture in which the protein contacts DNA in both the major and minor grooves (Müller, C. W. & Herrmann, B. G. 1997. Nature 389, 884).

[0151] A yeast one hybrid approach was used to identify Th-1 specific transcription factors. Yeast cells were made to express an IL-2 promoter-reporter gene construct and were transformed with a cDNA library made from an anti-CD3 activated Th1 cell clone. Inspection of the IL-2 promoter reveals an excellent T-box binding site at −240 to −220 just 5′ of the NFkB site. As described in the appended examples, T-bet was isolated in a yeast one hybrid screening assay based on its ability to bind to the IL-2 promoter.

[0152] The nucleotide sequence encoding murine T-bet is shown in SEQ ID NO:3. Murine T-bet is a 530 amino acid protein with a 190 amino acid T-box domain located at residues 136-326. The amino acid sequence of murine T-bet is shown in SEQ ID NO:4. After the murine T-bet sequence was cloned as described herein, it was possible to compile the sequence of the human ortholog of T-bet from nucleic acid fragments which were not previously known to encode any known protein. The nucleotide sequence of human T-bet is shown in SEQ ID NO:1. Human T-bet is a 535 amino acid protein with a 190 amino acid T-box domain located at residues 138-327. The human T-bet gene maps to chromosome 17. The nucleotide and amino acid sequences of two members (human and mouse) of the T-bet family of proteins are shown in FIG. 1 and SEQ ID Nos: 1-4.

[0153] The T-bet proteins of the invention have homology to T-box proteins. There are now eight T-box genes in the mouse not including Brachyury. These include Tbx1-6, T-brain-1 (Tbr-1) and now, T-bet, each with a distinct and usually complex expression pattern. T-brain-1 expression, for example is largely restricted to distinct domains within the cerebral cortex (Bulfone, A., et al. 1995. Neuron 15, 63. T-bet is most similar in sequence to Tbr-1. Outside of the T-box, the T-bet proteins of the invention bear no similarity to other T-box proteins.

[0154] T-bet is T-box protein expressed only in T cells and is most similar in sequence to Tbr-1. Other species also express Brachyury-like genes. Such vertebrate species include Xenopus, zebrafish, chick and humans (Rao, 1994; Horb and Thomsen, 1997; Conlon et al., 1996; Ryan et al., 1996; Schulte-Merker et al., 1994; Edwards et al., 1996; Morrison et al., 1996; Law et al., 1995; Cambell et al., 1998) as well as more distant species such as amphioxus, ascidians, echinoderms, Caenorhabditis elegans, Drosophila and other insects (Holland et al., 1995). These genes are conserved both in sequence and in expression pattern.

[0155] T-bet is unique in that it is the only T-box protein to be tyrosine phosphorylated. There are three predicted tyrosine phosphorylation sites at Tyr 76, Tyr 119, and Tyr 531 of human T-bet and one at Tyr 525 of murine T-bet. A nuclear localization sequence is also present at amino acids 498-501 of human T-bet and 493-496 of murine T-bet. Mapping experiments locate two transactivation domains, one 5′ and one 3′ of the T-box domain. The data shown herein demonstrate that T-bet binds to a consensus T-box site (defined by target site selection in vitro as 5′-GGGAATTTCACACCTAGGTGTGAAATTCCC-3′) and to the human IL-2 promoter, the murine IL-2 promoter, the human IFN-γ intron III, and two binding sites in the murine IFN-γ proximal promoter. (Szabo et al. 2000. Cell 100:655-669). T-bet is expressed only in the thymus and in the peripheral lymphoid system. In the periphery, T-bet is expressed only in Th1 cells where it is induced both in response to TcR stimulation and to IL-12. In the thymus levels of T-bet are highest in DN and Rag2−/−thymocytes.

[0156] These data demonstrate that the selective expression of T-bet, a novel T-box family member, accounts for tissue-specific IFN-γ expression. T-bet is expressed only in Th1 and not in Th2 cells and is induced in the former upon transmission of signals through the T cell receptor.

[0157] In addition, T-bet is a potent transactivator of the IFN-γ gene. The expression of T-bet correlates with IFN-γ expression in cells of the adaptive and innate immune system including: Th1 cells, B cells, NK cells, and dendritic cells. T-bet is responsible for the genetic program that initiates Th1 lineage development from naïve Thp cells and acts both by initiating Th1 genetic programs and by repressing the opposing programs in Th2 cells.

[0158] Various aspects of the invention are described in further detail in the following subsections:

[0159] I. Isolated Nucleic Acid Molecules

[0160] One aspect of the invention pertains to isolated nucleic acid molecules that encode T-bet. In a preferred embodiment, the nucleic acid molecule of the invention comprises the nucleotide sequence shown in SEQ ID NO:1 or SEQ ID NO:3. In another embodiment, a nucleic acid molecule of the invention comprises at least about 700 contiguous nucleotides of SEQ ID NO:1 or at least about 500 contiguous nucleotides of SEQ ID NO:3. In a preferred embodiment, a nucleic acid molecule of the invention comprises at least about 800, at least about 1000, at east about 1200, at least about 1400 or at least about 1600 contiguous nucleotides of SEQ ID NO:1. In another preferred embodiment, a nucleic acid molecule of the invention comprises at least about 600, at least about 800, at least about 1000, at least about 1200, or at least about 1400 contiguous nucleotides of SEQ ID NO:3.

[0161] In other embodiments, the nucleic acid molecule has at least 70% identity, more preferably 80% identity, and even more preferably 90% identity with a nucleic acid molecule comprising: at least about 700, at least about 800, at least about 1000, at east about 1200, at least about 1400 or at least about 1600 contiguous nucleotides of SEQ ID NO:1. In other embodiments, the nucleic acid molecule has at least 70% identity, more preferably 80% identity, and even more preferably 90% nucleotide identity with a nucleic acid molecule comprising: at least about 600, at least about 800, at least about 1000, at least about 1200, or at least about 1400 contiguous nucleotides of SEQ ID NO:3.

[0162] Nucleic acid molecules that differ from SEQ ID NO: 1 or 3 due to degeneracy of the genetic code, and thus encode the same T-bet protein as that encoded by SEQ ID NO: 1 and 3, are encompassed by the invention. Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino acid sequence shown in SEQ ID NO: 2 or SEQ ID NO:4.

[0163] In addition, nucleic acid molecules encoding T-bet proteins can be isolated from other sources using standard molecular biology techniques and the sequence information provided herein. For example, a T-bet DNA can be isolated from a human genomic DNA library using all or portion of SEQ ID NO: 1 or 3 as a hybridization probe and standard hybridization techniques (e.g., as described in Sambrook, J., et al. Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1989). Moreover, a nucleic acid molecule encompassing all or a portion of a T-bet gene can be isolated by the polymerase chain reaction using oligonucleotide primers designed based upon the sequence of SEQ ID NO: 1 or 3. For example, mRNA can be isolated from cells (e.g., by the guanidinium-thiocyanate extraction procedure of Chirgwin et al. (1979) Biochemistry 18: 5294-5299) and cDNA can be prepared using reverse transcriptase (e.g., Moloney MLV reverse transcriptase, available from Gibco/BRL, Bethesda, Md.; or AMV reverse transcriptase, available from Seikagaku America, Inc., St. Petersburg, Fla.). Synthetic oligonucleotide primers for PCR amplification can be designed based upon the nucleotide sequence shown in SEQ ID NO: 1 or 3. A nucleic acid of the invention can be amplified using cDNA or, alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to a T-bet nucleotide sequence can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.

[0164] In addition to the T-bet nucleotide sequence shown in SEQ ID NO: 1 and 3, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to minor changes in the nucleotide or amino acid sequences of T-bet may exist within a population. Such genetic polymorphism in the T-bet gene may exist among individuals within a population due to natural allelic variation. Such natural allelic variations can typically result in 1-2% variance in the nucleotide sequence of the a gene. Any and all such nucleotide variations and resulting amino acid polymorphisms in T-bet that are the result of natural allelic variation and that do not alter the functional activity of T-bet are intended to be within the scope of the invention.

[0165] Nucleic acid molecules corresponding to natural allelic variants of the T-bet DNAs of the invention can be isolated based on their homology to the T-bet nucleic acid molecules disclosed herein using the human DNA, or a portion thereof, as a hybridization probe according to standard hybridization techniques under high stringency hybridization conditions. Exemplary high stringency conditions include hybridization in a hybridization buffer that contains 6× sodium chloride/sodium citrate (SSC) at a temperature of about 45° C. for several hours to overnight, followed by one or more washes in a washing buffer containing 0.2× SSC, 0.1% SDS at a temperature of about 50-65° C. Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention hybridizes under high stringency conditions to a second nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1 or 3. Preferably, an isolated nucleic acid molecule of the invention that hybridizes under high stringency conditions to the sequence of SEQ ID NO: of SEQ ID NO:1 or 3. In one embodiment, such a nucleic acid molecule is at least about 700, 800, 900, 1000, 1200, 1300, 1400, 1500, or 1600 nucleotides in length. In another embodiment, such a nucleic acid molecule and comprises at least about 700, 800, 900, 1000, 1200, 1300, 1400, 1500, or 1600 contiguous nucleotides of SEQ ID NO: 1 or at least about 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, or 1500 contiguous nucleotides of SEQ ID NO: 3. Preferably, an isolated nucleic acid molecule corresponds to a naturally-occurring allelic variant of a T-bet nucleic acid molecule.

[0166] In addition to naturally-occurring allelic variants of the T-bet sequence that may exist in the population, the skilled artisan will further appreciate that minor changes may be introduced by mutation into the nucleotide sequence of SEQ ID NO: 1 or 3, thereby leading to changes in the amino acid sequence of the encoded protein, without altering the functional activity of the T-bet protein. For example, nucleotide substitutions leading to amino acid substitutions at “non-essential” amino acid residues may be made in the sequence of SEQ ID NO: 1 or 3. A “non-essential” amino acid residue is a residue that can be altered from the wild-type sequence of T-bet (e.g., the sequence of SEQ ID NO: 1 or 3) without altering the functional activity of T-bet, such as its ability to interact with DNA or its ability to enhance transcription from an IFN-γ promoter, whereas an “essential” amino acid residue is required for functional activity.

[0167] Accordingly, another aspect of the invention pertains to nucleic acid molecules encoding T-bet proteins that contain changes in amino acid residues that are not essential for T-bet activity. Such T-bet proteins differ in amino acid sequence from SEQ ID NO: 2 or 4 yet retain T-bet activity. An isolated nucleic acid molecule encoding a non-natural variant of a T-bet protein can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NO: 1 or 3 such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein. Mutations can be introduced into SEQ ID NO: 1 or 3 by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more non-essential amino acid residues. A “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art, including basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a nonessential amino acid residue in T-bet is preferably replaced with another amino acid residue from the same side chain family.

[0168] Alternatively, in another embodiment, mutations can be introduced randomly along all or part of the T-bet coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for their ability to bind to DNA and/or activate transcription, to identify mutants that retain functional activity. Following mutagenesis, the encoded T-bet mutant protein can be expressed recombinantly in a host cell and the functional activity of the mutant protein can be determined using assays available in the art for assessing T-bet activity (e.g., by measuring the ability of the protein to bind to a T-box binding element present in DNA or by measuring the ability of the protein to modulate a Th1 or Th2 phenotype in a T cell.

[0169] Another aspect of the invention pertains to isolated nucleic acid molecules that are antisense to the coding strand of a T-bet mRNA or gene. An antisense nucleic acid of the invention can be complementary to an entire T-bet coding strand, or to only a portion thereof. In one embodiment, an antisense nucleic acid molecule is antisense to a coding region of the coding strand of a nucleotide sequence encoding T-bet that is unique to the T-bet family of proteins or which is unique to a T-bet sequence from a particular species. In another embodiment, the antisense nucleic acid molecule is antisense to a noncoding region of the coding strand of a nucleotide sequence encoding T-bet that is unique to T-bet family of proteins or which is unique to a T-bet sequence from a particular species. In preferred embodiments, an antisense molecule of the invention comprises at least about 700 contiguous nucleotides of the noncoding strand of SEQ ID NO: 1, more preferably at least 800, 1000, 1200, 1400, or 1600 contiguous nucleotides of the noncoding strand of SEQ ID NO: 1 or at least about 500 contiguous nucleotides of the noncoding strand of SEQ ID NO: 3, more preferably at least 600, 800, 1000, 1200, or 1400 contiguous nucleotides of the noncoding strand of SEQ ID NO: 3.

[0170] Given the coding strand sequences encoding T-bet disclosed herein (e.g., SEQ ID NOs: 1 and 3, antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick base pairing. The antisense nucleic acid molecule may be complementary to the entire coding region of T-bet mRNA, or alternatively can be an oligonucleotide which is antisense to only a portion of the coding or noncoding region of T-bet mRNA. For example, the antisense oligonucleotide may be complementary to the region surrounding the translation start site of T-bet mRNA. An antisense oligonucleotide can be, for example, about 15, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

[0171] In another embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. A ribozyme having specificity for a T-bet-encoding nucleic acid can be designed based upon the nucleotide sequence of a T-bet gene disclosed herein. For example, a derivative of a Tetrahymena L-19 IVS RNA can be constructed in which the base sequence of the active site is complementary to the base sequence to be cleaved in a T-bet-encoding mRNA. See for example Cech et al. U.S. Pat. No. 4,987,071; and Cech et al. U.S. Pat. No. 5,116,742. Alternatively, T-bet mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See for example Bartel, D. and Szostak, J. W. (1993) Science 261: 1411-1418.

[0172] In another embodiment, RNAi can be used to inhibit T-bet expression. RNA interference (RNAi is a post-transcriptional, targeted gene-silencing technique that uses double-stranded RNA (dsRNA) to degrade messenger RNA (mRNA) containing the same sequence as the dsRNA (Sharp, P. A. and Zamore, P. D. 287, 2431-2432 (2000); Zamore, P. D., et al. Cell 101, 25-33 (2000). Tuschl, T. et al. Genes Dev. 13, 3191-3197 (1999)). The process occurs when an endogenous ribonuclease cleaves the longer dsRNA into shorter, 21- or 22-nucleotide-long RNAs, termed small interfering RNAs or siRNAs. The smaller RNA segments then mediate the degradation of the target mRNA.

[0173] The antisense RNA strand of RNAi can be antisense to at least a portion of the coding region of T-bet or to at least a portion of the 5′ or 3′ untranslated region of the T-bet gene. In one embodiment, siRNA duplexes are composed of 21-nt sense and 21-nt antisense strands, paired in a manner to have a 2-nt 3′ overhang. In one embodiment, siRNA sequences with TT in the overhang. The target region can be, e.g., 50 to 100 nt downstream of the start codon, 3′-UTRs may also be targeted. In one embodiment, a 23-nt sequence motif AA(N19)TT (N, any nucleotide) can be searched for and hits with between about 30-70% G/C-content can be selected. If no suitable sequences are found, the search is extended using the motif NA(N21). SiRNAs are preferably chemically synthesized using appropriately protected ribonucleoside phosphoramidites and a conventional DNA/RNA synthesizer. SiRNAs are also available commercially from, e.g., Dharmacon, Xeragon Inc, Proligo, and Ambion. In one embodiment one or more of the chemistries described above for use in antisense RNA can be employed.

[0174] Yet another aspect of the invention pertains to isolated nucleic acid molecules encoding T-bet fusion proteins. Such nucleic acid molecules, comprising at least a first nucleotide sequence encoding a T-bet protein, polypeptide or peptide operatively linked to a second nucleotide sequence encoding a non-T-bet protein, polypeptide or peptide, can be prepared by standard recombinant DNA techniques. T-bet fusion proteins are described in further detail below in subsection III.

[0175] II. Recombinant Expression Vectors and Host Cells

[0176] Another aspect of the invention pertains to vectors, preferably recombinant expression vectors, containing a nucleic acid encoding T-bet (or a portion thereof). The expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operatively linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, “operably linked” is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence (e.g., in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell). The term “regulatory sequence” includes promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel; Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990). Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cell and those which direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector may depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., T-bet proteins, mutant forms of T-bet proteins, T-bet fusion proteins and the like).

[0177] The recombinant expression vectors of the invention can be designed for expression of T-bet protein in prokaryotic or eukaryotic cells. For example, T-bet can be expressed in bacterial cells such as E. coli, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990). Alternatively, the recombinant expression vector may be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.

[0178] Expression of proteins in prokaryotes is most often carried out in E. coli with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors can serve one or more purposes: 1) to increase expression of recombinant protein; 2) to increase the solubility of the recombinant protein; 3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification; 4) to provide an epitope tag to aid in detection and/or purification of the protein; and/or 5) to provide a marker to aid in detection of the protein (e.g., a color marker using β-galactosidase fusions). Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc.; Smith, D. B. and Johnson, K. S. (1988) Gene 67:31-40), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein. Recombinant proteins also can be expressed in eukaryotic cells as fusion proteins for the same purposes discussed above.

[0179] Examples of suitable inducible non-fusion E. coli expression vectors include pTrc (Amann et al., (1988) Gene 69:301-315) and pET 1d (Studier et al., Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990) 60-89). Target gene expression from the pTrc vector relies on host RNA polymerase transcription from a hybrid trp-lac fusion promoter. Target gene expression from the pET 11d vector relies on transcription from a T7 gn10-lac fusion promoter mediated by a coexpressed viral RNA polymerase (T7 gn1). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident λ prophage harboring a T7 gn1 gene under the transcriptional control of the lacUV 5 promoter.

[0180] One strategy to maximize recombinant protein expression in E. coli is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, S., Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990) 119-128). Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in E. coli (Wada et al., (1992) Nuc. Acids Res. 20:2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

[0181] In another embodiment, the T-bet expression vector is a yeast expression vector. Examples of vectors for expression in yeast S. cerivisae include pYepSec1 (Baldari. et al., (1987) EMBO J. 6:229-234), pMFa (Kurjan and Herskowitz, (1982) Cell 30:933-943), pJRY88 (Schultz et al., (1987) Gene 54:113-123), and pYES2 (Invitrogen Corporation, San Diego, Calif.).

[0182] Alternatively, T-bet can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., Sf9 cells) include the pAc series (Smith et al., (1983) Mol. Cell Biol. 3:2156-2165) and the pVL series (Lucklow, V. A., and Summers, M. D., (1989) Virology 170:31-39).

[0183] In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pMex-NeoI, pCDM8 (Seed, B., (1987) Nature 329:840) and pMT2PC (Kaufman et al. (1987), EMBO J. 6:187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40.

[0184] In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include lymphoid-specific promoters (Calame and Eaton (1988) Adv. Immunol. 43:235-275), in particular promoters of T cell receptors (Winoto and Baltimore (1989) EMBO J. 8:729-733) and immunoglobulins (Banerji et al. (1983) Cell 33:729-740; Queen and Baltimore (1983) Cell 33:741-748), the albumin promoter (liver-specific; Pinkert et al. (1987) Genes Dev. 1:268-277), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle (1989) Proc. Natl. Acad. Sci. USA 86:5473-5477), pancreas-specific promoters (Edlund et al. (1985) Science 230:912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, for example the murine hox promoters (Kessel and Gruss (1990) Science 249:374-379) and the α-fetoprotein promoter (Campes and Tilghman (1989) Genes Dev. 3:537-546).

[0185] Moreover, inducible regulatory systems for use in mammalian cells are known in the art, for example systems in which gene expression is regulated by heavy metal ions (see e.g., Mayo et al. (1982) Cell 29:99-108; Brinster et al. (1982) Nature 296:39-42; Searle et al. (1985) Mol. Cell. Biol. 5:1480-1489), heat shock (see e.g., Nouer et al. (1991) in Heat Shock Response, e.d. Nouer, L., CRC, Boca Raton, Fla., pp167-220), hormones (see e.g., Lee et al. (1981) Nature 294:228-232; Hynes et al. (1981) Proc. Natl. Acad. Sci. USA 78:2038-2042; Klock et al. (1987) Nature 329:734-736; Israel & Kaufman (1989) Nucl. Acids Res. 17:2589-2604; and PCT Publication No. WO 93/23431), FK506-related molecules (see e.g., PCT Publication No. WO 94/18317) or tetracyclines (Gossen, M. and Bujard, H. (1992) Proc. Natl. Acad. Sci. USA 89:5547-5551; Gossen, M. et al. (1995) Science 268:1766-1769; PCT Publication No. WO 94/29442; and PCT Publication No. WO 96/01313). Accordingly, in another embodiment, the invention provides a recombinant expression vector in which T-bet DNA is operatively linked to an inducible eukaryotic promoter, thereby allowing for inducible expression of T-bet protein in eukaryotic cells.

[0186] The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively linked to a regulatory sequence in a manner which allows for expression (by transcription of the DNA molecule) of an RNA molecule which is antisense to T-bet mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen which direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see Weintraub, H. et al., Antisense RNA as a molecular tool for genetic analysis, Reviews—Trends in Genetics, Vol. 1(1) 1986.

[0187] Another aspect of the invention pertains to recombinant host cells into which a vector, preferably a recombinant expression vector, of the invention has been introduced. A host cell may be any prokaryotic or eukaryotic cell. For example, T-bet protein may be expressed in bacterial cells such as E. coli, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art. Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms “transformation” and “transfection” are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook et al. (Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory press (1989)), and other laboratory manuals.

[0188] For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Preferred selectable markers include those which confer resistance to compounds, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker may be introduced into a host cell on the same vector as that encoding T-bet or may be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by compound selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die).

[0189] A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (i.e., express) T-bet protein. Accordingly, the invention further provides methods for producing T-bet protein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding T-bet has been introduced) in a suitable medium until T-bet is produced. In another embodiment, the method further comprises isolating T-bet from the medium or the host cell. In its native form the T-bet protein is an intracellular protein and, accordingly, recombinant T-bet protein can be expressed intracellularly in a recombinant host cell and then isolated from the host cell, e.g., by lysing the host cell and recovering the recombinant T-bet protein from the lysate. Alternatively, recombinant T-bet protein can be prepared as a extracellular protein by operatively linking a heterologous signal sequence to the amino-terminus of the protein such that the protein is secreted from the host cells. In this case, recombinant T-bet protein can be recovered from the culture medium in which the cells are cultured.

[0190] Certain host cells of the invention can also be used to produce nonhuman transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which T-bet-coding sequences have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous T-bet sequences have been introduced into their genome or homologous recombinant animals in which endogenous T-bet sequences have been altered. Such animals are useful for studying the function and/or activity of T-bet and for identifying and/or evaluating modulators of T-bet activity. Accordingly, another aspect of the invention pertains to nonhuman transgenic animals which contain cells carrying a transgene encoding a T-bet protein or a portion of a T-bet protein. In a subembodiment, of the transgenic animals of the invention, the transgene alters an endogenous gene encoding an endogenous T-bet protein (e.g., homologous recombinant animals in which the endogenous T-bet gene has been functionally disrupted or “knocked out”, or the nucleotide sequence of the endogenous T-bet gene has been mutated or the transcriptional regulatory region of the endogenous T-bet gene has been altered).

[0191] A transgenic animal of the invention can be created by introducing T-bet-encoding nucleic acid into the male pronuclei of a fertilized oocyte, e.g., by microinjection, and allowing the oocyte to develop in a pseudopregnant female foster animal. The T-bet nucleotide sequence of SEQ ID NO: 1 or 3 can be introduced as a transgene into the genome of a non-human animal. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably linked to the T-bet transgene to direct expression of T-bet protein to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Pat. Nos. 4,736,866 and 4,870,009, both by Leder et al., U.S. Pat. No. 4,873,191 by Wagner et al. and in Hogan, B., Manipulating the Mouse Embryo, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986). Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the T-bet transgene in its genome and/or expression of T-bet mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene encoding T-bet can further be bred to other transgenic animals carrying other transgenes.

[0192] To create a homologous recombinant animal, a vector is prepared which contains at least a portion of a T-bet gene into which a deletion, addition or substitution has been introduced to thereby alter, e.g., functionally disrupt, the endogenous T-bet gene. In one embodiment, a homologous recombination vector is designed such that, upon homologous recombination, the endogenous T-bet gene is functionally disrupted (i.e., no longer encodes a functional protein; also referred to as a “knock out” vector). Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous T-bet gene replaced by the T-bet gene. In the homologous recombination vector, the altered portion of the T-bet gene is flanked at its 5′ and 3′ ends by additional nucleic acid of the T-bet gene to allow for homologous recombination to occur between the exogenous T-bet gene carried by the vector and an endogenous T-bet gene in an embryonic stem cell. The additional flanking T-bet nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5′ and 3′ ends) are included in the vector (see e.g., Thomas, K. R. and Capecchi, M. R. (1987) Cell 51:503 for a description of homologous recombination vectors). The vector is introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced T-bet gene has homologously recombined with the endogenous T-bet gene are selected (see e.g., Li, E. et al. (1992) Cell 69:915). The selected cells are then injected into a blastocyst of an animal (e.g., a mouse) to form aggregation chimeras (see e.g., Bradley, A. in Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, E. J. Robertson, ed. (IRL, Oxford, 1987) pp. 113-152). A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley, A. (1991) Current Opinion in Biotechnology 2:823-829 and in PCT International Publication Nos.: WO 90/11354 by Le Mouellec et al.; WO 91/01140 by Smithies et al.; WO 92/0968 by Zijlstra et al.; and WO 93/04169 by Berns et al.

[0193] In addition to the foregoing, the skilled artisan will appreciate that other approaches known in the art for homologous recombination can be applied to the instant invention. Enzyme-assisted site-specific integration systems are known in the art and can be applied to integrate a DNA molecule at a predetermined location in a second target DNA molecule. Examples of such enzyme-assisted integration systems include the Cre recombinase-lox target system (e.g., as described in Baubonis, W. and Sauer, B. (1993) Nucl. Acids Res. 21:2025-2029; and Fukushige, S. and Sauer, B. (1992) Proc. Natl. Acad. Sci. USA 89:7905-7909) and the FLP recombinase-FRT target system (e.g., as described in Dang, D. T. and Perrimon, N. (1992) Dev. Genet. 13:367-375; and Fiering, S. et al. (1993) Proc. Natl. Acad. Sci. USA 90:8469-8473). Tetracycline-regulated inducible homologous recombination systems, such as described in PCT Publication No. WO 94/29442 and PCT Publication No. WO 96/01313, also can be used.

[0194] In another embodiment, transgenic animals can be made in which T-bet is expressed in all T cells, e.g., using the CD4 enhancer (Zheng, W-P. & Flavell, R. A. 1997. Cell 89, 587). Recent work suggests the CD2 enhancer can also be used. In fact, it is more powerful in achieving high level expression in T cells, expression is not variegated and transgene expression is copy number-dependent (Zhumabekov, T., et al. 1995. J. Immunol. Meth. 185, 133; Sharp, L. L., et al. 1997. Immunity 7, 609). Mice with high level expression of T-bet RNA (using the human growth hormone intron as a probe to distinguish transgene driven T-bet RNA from endogenous T-bet) can be identified by screening adequate numbers of founders.

[0195] In another approach, a dominant repressor transgenic can be created. For example, a dominant-repressor T-bet can be made by using the proximal lck enhancer (Alberola-IIa, J., et al. 1996 J. Exp. Med. 184, 9) driving a fusion of T-bet and engrailed can be made (Taylor, D., 1996. Genes Dev. 10, 2732; Li, J., Thurm, H., et al. 1997. Proc. Natl. Acad. Sci. USA 94, 10885). This construct specifically represses T-bet transactivation of a multimerized T-bet reporter and does not affect NFAT-dependent reporter transactivation.

[0196] Alternatively, null mutations can be generated by targeted mutagenesis in ES cells (Ranger, A. M., et al. 1998. Nature 392, 186; Hodge, M. R., et al. 1996. Immunity 4:1., 144; Grusby, M. J., et al. 1991. Science 253, 1417; Reimold, A. M., et al. 1996. Nature 379: 262; Kaplan, M. H., 1996. Immunity:313; Kaplan, M. H., et al. 1996. Nature 382, 174; Smiley, S. T., et al. 1997. Science 275, 977). For example using techniques which are known in the art, a genomic T-bet clone can be isolated from a genomic library, the intron-exon organization delineated, and a targeting construct in the cre-lox vector (see discussion below) created which should delete the first exon and 450 bp of upstream promoter sequence. This construct can be electroporated into an ES cell line, and double compound resistant (e.g., neomycin, gancyclovir) clones identified by Southern blot analysis. Clones bearing homologous recombinant events in the T-bet locus can then be identified and injected into blastocysts obtained from day 3.5 BALB/c pregnant mice. Chimeric mice can then be produced and mated to wildtype BALB/c mice to generate germline transmission of the disrupted T-bet gene.

[0197] In another embodiment, implantation into RAG2-deficient blastocysts (Chen, J., et al. 1993. Proc. Natl. Acad. Sci. USA 90, 4528) or the cre-lox inducible deletion approach can be used to develop mice that are lacking T-bet only in the immune system. For example, the targeting construct can be made in the cre-lox vector. The blastocyst complementation system has been used to study NFATc, an embryonic lethal phenotype (Ranger, A. M., et al. 1998. Immunity 8:125). This approach requires disrupting the T-bet gene on both chromosomes in ES cells, which can be accomplished, e.g., by using a mutant neomycin gene and raising the concentration of G418 in the ES cultures, as described (Chen, J., 1993. Proc. Natl. Acad. Sci. USA 90;4528) or by flanking the neo gene with cre-lox sites. To disrupt the second allele, the neomycin gene can be deleted by transfecting the ES clone with the cre recombinase, and then the ES clone can be retransfected with the same targeting construct to select clones with T-bet deletions on both alleles. A third transfection with cre-recombinase yields the desired doubly-deficient ES cells. Such doubly targeted ES cells are then implanted into RAG2 blastocysts and the lymphoid organs of the chimeric mice thus generated will be entirely colonized by the transferred ES cells. This allows assessment of the effect of the absence of T-bet on cells of the lymphoid system without affecting other organ systems where the absence of T-bet might cause lethality.

[0198] The conditional ablation approach employing the cre-lox system can also be used. Briefly, a targeting construct is generated in which lox recombination sequences are placed in intronic regions flanking the exons to be deleted. This construct is then transfected into ES cells and mutant mice are generated as above. The resulting mutant mice are then mated to mice transgenic for the cre recombinase driven by an inducible promoter. When cre is expressed, it induces recombination between the introduced lox sites in the T-bet gene, thus effectively disrupting gene function. The key feature of this approach is that gene disruption can be induced in the adult animal at will by activating the cre recombinase.

[0199] A tissue-specific promoter can be used to avoid abnormalities in organs outside the immune system. The cre-expressing transgene may be driven by an inducible promoter. Several inducible systems are now being used in cre-lox recombination strategies, the most common being the tetracycline and ecdysone systems. A tissue-specific inducible promoter can be used if there is embryonic lethality in the T-bet null mouse.

[0200] An alternative approach is to generate a transgenic mouse harboring a regulated T-bet gene (for example using the tetracycline off promoter; e.g., St-Onge, et al. 1996. Nuc. Acid Res. 24, 3875-3877) and then breed this transgenic to the T-bet deficient mouse. This approach permits creation of mice with normal T-bet function; tetracycline can be administered to adult animals to induce disruption of T-bet function in peripheral T cells, and then the effect of T-bet deficiency can be examined over time. Repeated cycles of provision and then removal of compound (tetracycline) permits turning the T-bet gene on and off at will.

[0201] III. Isolated T-Bet Proteins and Anti-T-Bet Antibodies

[0202] Another aspect of the invention pertains to isolated T-bet proteins. Preferably, the T-bet protein comprises the amino acid sequence encoded by SEQ ID NO:1 or 3. In another preferred embodiment, the protein comprises the amino acid sequence of SEQ ID NO: 2 or 4. In other embodiments, the protein has at least 60% amino acid identity, more preferably 70% amino acid identity, more preferably 80%, and even more preferably, 90% or 95% amino acid identity with the amino acid sequence shown in SEQ ID NO: 2 or 4.

[0203] In other embodiments, the invention provides isolated portions of the T-bet protein. For example, the invention further encompasses an amino-terminal portion of T-bet that includes a T-box domain. In various embodiments, this amino terminal portion encompasses at least amino acids 138-327 of human T-bet or at least amino acids 137-326 of mouse T-bet. Another isolated portion of T-bet provided by the invention is a portion encompassing a tyrosine phosphorylation site. This portion comprises at least about 20, at least about 50, at least about 100, or at least about 200 amino acids of T-bet and includes at least amino acids Tyr 76, Tyr 119, and/or Tyr 531 of human T-bet or amino acids Tyr 525 of murine T-bet. Yet another isolated portion of T-bet provided herein is a portion encompassing a nuclear localization sequence shown in amino acids 498-501 of human T-bet or 493-496 of murine T-bet.

[0204] T-bet proteins of the invention are preferably produced by recombinant DNA techniques. For example, a nucleic acid molecule encoding the protein is cloned into an expression vector (as described above), the expression vector is introduced into a host cell (as described above) and the T-bet protein is expressed in the host cell. The T-bet protein can then be isolated from the cells by an appropriate purification scheme using standard protein purification techniques. Alternative to recombinant expression, a T-bet polypeptide can be synthesized chemically using standard peptide synthesis techniques. Moreover, native T-bet protein can be isolated from cells (e.g., from T cells), for example by immunoprecipitation using an anti-T-bet antibody.

[0205] The present invention also pertains to variants of the T-bet proteins which function as either T-bet agonists (mimetics) or as T-bet antagonists. Variants of the T-bet proteins can be generated by mutagenesis, e.g., discrete point mutation or truncation of a T-bet protein. Thus, specific biological effects can be elicited by treatment with a variant of limited function. In one embodiment, treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurring form of the T-bet protein. In one embodiment, the invention pertains to derivatives of T-bet which may be formed by modifying at least one amino acid residue of T-bet by oxidation, reduction, or other derivatization processes known in the art.

[0206] In one embodiment, variants of a T-bet protein which function as either T-bet agonists (mimetics) or as T-bet antagonists can be identified by screening combinatorial libraries of mutants, e.g., truncation mutants, of a T-bet protein for T-bet protein agonist or antagonist activity. In one embodiment, a variegated library of T-bet variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of T-bet variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential T-bet sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display) containing the set of T-bet sequences therein. There are a variety of methods which can be used to produce libraries of potential T-bet variants from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential T-bet sequences. Methods for synthesizing degenerate oligonucleotides are known in the art (see, e.g., Narang, S. A., 1983, Tetrahedron 39:3; Itakura et al., 1984, Annu. Rev. Biochem. 53:323; Itakura et al., 1984, Science 198:1056; Ike et al., 1983, Nucleic Acid Res. 11:477).

[0207] In addition, libraries of fragments of a T-bet protein coding sequence can be used to generate a variegated population of T-bet fragments for screening and subsequent selection of variants of a T-bet protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of a T-bet coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA which can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, an expression library can be derived which encodes N-terminal, C-terminal and internal fragments of various sizes of the T-bet protein.

[0208] Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of T-bet proteins. The most widely used techniques, which are amenable to high through-put analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a new technique which enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify T-bet variants (Arkin and Yourvan, 1992, Proc. Natl. Acad. Sci. USA 89:7811-7815; Delgrave et al., 1993, Protein Engineering 6(3):327-331).

[0209] The invention also provides T-bet fusion proteins. As used herein, a T-bet “fusion protein” comprises a T-bet polypeptide operatively linked to a polypeptide other than T-bet. A “T-bet polypeptide” refers to a polypeptide having an amino acid sequence corresponding to T-bet protein, or a peptide fragment thereof which is unique to T-bet protein whereas a “polypeptide other than T-bet” refers to a polypeptide having an amino acid sequence corresponding to another protein. Within the fusion protein, the term “operatively linked” is intended to indicate that the T-bet polypeptide and the other polypeptide are fused in-frame to each other. The other polypeptide may be fused to the N-terminus or C-terminus of the T-bet polypeptide. For example, in one embodiment, the fusion protein is a GST-T-bet fusion protein in which the T-bet sequences are fused to the C-terminus of the GST sequences. In another embodiment, the fusion protein is a T-bet-HA fusion protein in which the T-bet nucleotide sequence is inserted in a vector such as pCEP4-HA vector (Herrscher, R. F. et al. (1995) Genes Dev. 9:3067-3082) such that the T-bet sequences are fused in frame to an influenza hemagglutinin epitope tag. Such fusion proteins can facilitate the purification of recombinant T-bet.

[0210] Preferably, a T-bet fusion protein of the invention is produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, for example employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, for example, Current Protocols in Molecular Biology, eds. Ausubel et al. John Wiley & Sons: 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide or an HA epitope tag). A T-bet-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the T-bet protein.

[0211] An isolated T-bet protein, or fragment thereof, can be used as an immunogen to generate antibodies that bind specifically to T-bet using standard techniques for polyclonal and monoclonal antibody preparation. The T-bet protein can be used to generate antibodies. For example, polyclonal antisera, can be produced in rabbits using full-length recombinant bacterially produced T-bet as the immunogen. This same immunogen can be used to produce mAb by immunizing mice and removing spleen cells from the immunized mice. Spleen cells from mice mounting an immune response to T-bet can be fused to myeloma cells, e.g., SP2/O-Ag14 myeloma. As described in the appended examples, this methods were used to make polyclonal and monoclonal antibodies which bind to T-bet. In one embodiment, the antibodies can be produced in an animal that does not express T-bet, such as a T-bet knock-out animal. In another embodiment, the antibodies can be generated in a non-human animal having a specific genetic background, e.g., as achieved by backcrossing.

[0212] Alternatively, an antigenic peptide fragment of T-bet can be used as the immunogen. An antigenic peptide fragment of T-bet typically comprises at least 8 amino acid residues of the amino acid sequence shown in SEQ ID NO: 2 or 4 and encompasses an epitope of T-bet such that an antibody raised against the peptide forms a specific immune complex with T-bet. Preferably, the antigenic peptide comprises at least 10 amino acid residues, more preferably at least 15 amino acid residues, even more preferably at least 20 amino acid residues, and most preferably at least 30 amino acid residues. Preferred epitopes encompassed by the antigenic peptide are regions of T-bet that are located on the surface of the protein, e.g., hydrophilic regions, and that are unique to T-bet. In one embodiment such epitopes can be specific for T-bet proteins from one species, such as mouse or human (i.e., an antigenic peptide that spans a region of T-bet that is not conserved across species is used as immunogen; such non conserved residues can be determined using an alignment such as that provided herein). A standard hydrophobicity analysis of the T-bet protein can be performed to identify hydrophilic regions.

[0213] A T-bet immunogen typically is used to prepare antibodies by immunizing a suitable subject, (e.g., rabbit, goat, mouse or other mammal) with the immunogen. An appropriate immunogenic preparation can contain, for examples, recombinantly expressed T-bet protein or a chemically synthesized T-bet peptide. The preparation can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or similar immunostimulatory agent. Immunization of a suitable subject with an immunogenic T-bet preparation induces a polyclonal anti-T-bet antibody response.

[0214] Accordingly, another aspect of the invention pertains to anti-T-bet antibodies. Polyclonal anti-T-bet antibodies can be prepared as described above by immunizing a suitable subject with a T-bet immunogen. The anti-T-bet antibody titer in the immunized subject can be monitored over time by standard techniques, such as with an enzyme linked immunosorbent assay (ELISA) using immobilized T-bet. If desired, the antibody molecules directed against T-bet can be isolated from the mammal (e.g., from the blood) and further purified by well known techniques, such as protein A chromatography to obtain the IgG fraction. At an appropriate time after immunization, e.g., when the anti-T-bet antibody titers are highest, antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies by standard techniques, such as the hybridoma technique originally described by Kohler and Milstein (1975, Nature 256:495-497) (see also, Brown et al. (1981) J. Immunol 127:539-46; Brown et al. (1980) J Biol Chem 255:4980-83; Yeh et al. (1976) PNAS 76:2927-31; and Yeh et al. (1982) Int. J. Cancer 29:269-75), the more recent human B cell hybridoma technique (Kozbor et al. (1983) Immunol Today 4:72), the EBV-hybridoma technique (Cole et al. (1985), Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96) or trioma techniques. The technology for producing monoclonal antibody hybridomas is well known (see generally R. H. Kenneth, in Monoclonal Antibodies: A New Dimension In Biological Analyses, Plenum Publishing Corp., New York, N.Y. (1980); E. A. Lerner (1981) Yale J. Biol. Med., 54:387-402; M. L. Gefter et al. (1977) Somatic Cell Genet., 3:231-36). Briefly, an immortal cell line (typically a myeloma) is fused to lymphocytes (typically splenocytes) from a mammal immunized with a T-bet immunogen as described above, and the culture supernatants of the resulting hybridoma cells are screened to identify a hybridoma producing a monoclonal antibody that binds specifically to T-bet.

[0215] Any of the many well known protocols used for fusing lymphocytes and immortalized cell lines can be applied for the purpose of generating an anti-T-bet monoclonal antibody (see, e.g., G. Galfre et al. (1977) Nature 266:55052; Gefter et al. Somatic Cell Genet., cited supra; Lerner, Yale J. Biol. Med., cited supra; Kenneth, Monoclonal Antibodies, cited supra). Moreover, the ordinary skilled worker will appreciate that there are many variations of such methods which also would be useful. Typically, the immortal cell line (e.g., a myeloma cell line) is derived from the same mammalian species as the lymphocytes. For example, murine hybridomas can be made by fusing lymphocytes from a mouse immunized with an immunogenic preparation of the present invention with an immortalized mouse cell line. Preferred immortal cell lines are mouse myeloma cell lines that are sensitive to culture medium containing hypoxanthine, aminopterin and thymidine (“HAT medium”). Any of a number of myeloma cell lines may be used as a fusion partner according to standard techniques, e.g., the P3-NS1/1-Ag4-1, P3-x63-Ag8.653 or Sp2/O-Ag14 myeloma lines. These myeloma lines are available from the American Type Culture Collection (ATCC), Rockville, Md. Typically, HAT-sensitive mouse myeloma cells are fused to mouse splenocytes using polyethylene glycol (“PEG”). Hybridoma cells resulting from the fusion are then selected using HAT medium, which kills unfused and unproductively fused myeloma cells (unfused splenocytes die after several days because they are not transformed). Hybridoma cells producing a monoclonal antibody of the invention are detected by screening the hybridoma culture supernatants for antibodies that bind T-bet, e.g., using a standard ELISA assay.

[0216] Using such methods several antibodies to T-bet have been generated. Both monoclonal and polyclonal antibodies were generated against full-length recombinant bacterially produced T-bet protein. The 3D10 antibody is of the IgG subtype and the 4B10 antibody was produced by fusion of mouse spleen cells to the SP2/0-Ag14 myeloma and is of the IgG subtype. The 39D antibody recognizes both human and murine T-bet.

[0217] Alternative to preparing monoclonal antibody-secreting hybridomas, a monoclonal anti-T-bet antibody can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (e.g., an antibody phage display library) with T-bet to thereby isolate immunoglobulin library members that bind T-bet. Kits for generating and screening phage display libraries are commercially available (e.g., the Pharmacia Recombinant Phage Antibody System, Catalog No. 27-9400-01; and the Stratagene SurfZAP™ Phage Display Kit, Catalog No. 240612). Additionally, examples of methods and reagents particularly amenable for use in generating and screening antibody display library can be found in, for example, Ladner et al. U.S. Pat. No. 5,223,409; Kang et al. International Publication No. WO 92/18619; Dower et al. International Publication No. WO 91/17271; Winter et al. International Publication WO 92/20791; Markland et al. International Publication No. WO 92/15679; Breitling et al. International Publication WO 93/01288; McCafferty et al. International Publication No. WO 92/01047; Garrard et al. International Publication No. WO 92/09690; Ladner et al. International Publication No. WO 90/02809; Fuchs et al. (1991) Bio/Technology 9:1370-1372; Hay et al. (1992) Hum Antibod Hybridomas 3:81-85; Huse et al. (1989) Science 246:1275-1281; Griffiths et al. (1993) EMBO J 12:725-734; Hawkins et al. (1992) J Mol Biol 226:889-896; Clarkson et al. (1991) Nature 352:624-628; Gram et al. (1992) PNAS 89:3576-3580; Garrad et al. (1991) Bio/Technology 9:1373-1377; Hoogenboom et al. (1991) Nuc Acid Res 19:4133-4137; Barbas et al. (1991) PNAS 88:7978-7982; and McCafferty et al. Nature (1990) 348:552-554.

[0218] Additionally, recombinant anti-T-bet antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in Robinson et al. International Patent Publication PCT/US86/02269; Akira, et al. European Patent Application 184,187; Taniguchi, M., European Patent Application 171,496; Morrison et al. European Patent Application 173,494; Neuberger et al. PCT Application WO 86/01533; Cabilly et al. U.S. Pat. No. 4,816,567; Cabilly et al. European Patent Application 125,023; Better et al. (1988) Science 240:1041-1043; Liu et al. (1987) PNAS 84:3439-3443; Liu et al. (1987) J. Immunol. 139:3521-3526; Sun et al. (1987) PNAS 84:214-218; Nishimura et al. (1987) Canc. Res. 47:999-1005; Wood et al. (1985) Nature 314:446-449; and Shaw et al. (1988) J. Natl Cancer Inst. 80:1553-1559); Morrison, S. L. (1985) Science 229:1202-1207; Oi et al. (1986) BioTechniques 4:214; Winter U.S. Pat. No. 5,225,539; Jones et al. (1986) Nature 321:552-525; Verhoeyan et al. (1988) Science 239:1534; and Beidler et al. (1988) J. Immunol. 141:4053-4060.

[0219] In another embodiment, fully human antibodies can be made using techniques that are known in the art. For example, fully human antibodies against a specific antigen can be prepared by administering the antigen to a transgenic animal which has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled. Exemplary techniques that can be used to make antibodies are described in U.S. Pat. Nos. 6,150,584; 6,458,592; 6,420,140. Other techniques are known in the art.

[0220] An anti-T-bet antibody (e.g., monoclonal antibody) can be used to isolate T-bet by standard techniques, such as affinity chromatography or immunoprecipitation. An anti-T-bet antibody can facilitate the purification of natural T-bet from cells and of recombinantly produced T-bet expressed in host cells. Moreover, an anti-T-bet antibody can be used to detect T-bet protein (e.g., in a cellular lysate or cell supernatant). Detection may be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance. Accordingly, in one embodiment, an anti-T-bet antibody of the invention is labeled with a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; and examples of suitable radioactive material include ¹²⁵I, ¹³¹I, ³⁵S or ³H.

[0221] Yet another aspect of the invention pertains to anti-T-bet antibodies that are obtainable by a process comprising:

[0222] (a) immunizing an animal with an immunogenic T-bet protein, or an immunogenic portion thereof unique to T-bet protein; and

[0223] (b) isolating from the animal antibodies that specifically bind to a T-bet protein.

[0224] Methods for immunization and recovery of the specific anti-T-bet antibodies are described further above.

[0225] In yet another aspect, the invention pertains to T-bet intrabodies. Intrabodies are intracellularly expressed antibody constructs, usually single-chain Fv (scFv) antibodies directed against a target inside a cell, e.g. an intracellular protein such as T-bet (Graus-Porta, D. et al. (1995) Mol. Cell Biol. 15(l):182-91). For example, an intrabody (e.g., and scFv) can contain the variable region of the heavy and the light chain, linked by a flexible linker and expressed from a single gene. The variable domains of the heavy and the light chain contain the complementarity determining regions (CDRs) of the parent antibody, i.e., the main antigen binding domains, which determine the specificity of the scFvs. The scFv gene can be transferred into cells, where scFv protein expression can modulate the properties of its target, e.g., T-bet. Accordingly, in one embodiment, the invention provides a method for using such T-bet intrabodies to prevent T-bet activity in cells, for example, in an in vivo or ex vivo approach, for which the cells are modified to express such intrabodies. In a particular embodiment, the T-bet intrabodies of the invention can be used to directly inhibit T-bet activity. In another embodiment, the T-bet intrabodies can be used to inhibit the interaction of T-bet and a protein with which T-bet interacts. Thus, the T-bet intrabodies of the invention are useful in modulating signaling pathways in which T-bet is involved.

[0226] The T-bet intrabodies can be prepared using techniques known in the art. For example, phage display technology can be used to isolate scFvs from libraries (Lowman, H B et al. (1991) Biochemistry 30(10): 832-8). To select scFvs binding to a particular antigen, the scFvs are fused to a coat protein, typically pIII ((g3p) of filamentous M13 phage. An scFv on the phage that binds an immobilized antigen is enriched during consecutive cycles of binding, elution and amplification. In another example, ribosome display can used to prepare T-bet intrabodies (Hanes, J. et al. (1997) Proc. Natl. Acad. Sci. 94(1): 937-44). Ribosome display is an in vitro method that links the peptide directly to the genetic information (mRNA). An scFv CDNA library is expressed in vitro using a transcription translation system. The translated ScFvs are stalled to the ribosome linked to the encoding mRNA. The scFv is then bound to the immobilized antigen and unspecific ribosome complexes are removed by extensive washes. The remaining complexes are eluted and the RNA is isolated, reverse transcribed to cDNA and subsequently re-amplified by PCR. In yet another example, a Protein Fragment Complementation Assay (PCA) can be used to prepare T-bet intrabodies of the invention (Pelletier, J N et al. (1998) Proc. Natl. Acad. Sci. 95(12): 141-6.) This is a cellular selection procedure based on the complementation of a mutant dihydrofolate reductase (DHFR) in E. coli by the mouse protein (mDHFR). The murine DHFR is dissected into two pairs, which are expressed as fusion proteins with potentially interacting peptides. The interaction of the fusion proteins restores the enzymatic activity of mDHFR, and thus bacterial proliferation. Only a specific interaction of antibody and antigen allows the functional complementation of DHFR which makes the system amenable for the selection of scFvs (Mossner, E. et al. (2001) J Mol. Biol. 308: 115-22).

[0227] IV. Pharmaceutical Compositions

[0228] T-bet modulators of the invention (e.g., T-bet inhibitory or stimulatory agents, including T-bet nucleic acid molecules, proteins, antibodies, or compounds described herein or identified as modulators of T-bet activity) can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the modulatory agent and a pharmaceutically acceptable carrier. As used herein the term “pharmaceutically acceptable carrier” is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

[0229] A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. For example, solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

[0230] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

[0231] Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

[0232] Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

[0233] In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.

[0234] In one embodiment, compositions comprising T-bet modulating agents can comprise a second agent which is useful in modulating a cellular response affected by T-bet For example, in one embodiment, an agent which downmodulates T-bet activity may be administered in combination with a second agent that downmodulates a cellular immune response. Such agents may be administered as part of the same pharmaceutical composition as the T-bet modulating agent or may be formulated for separate administration.

[0235] V. Methods of the Invention

[0236] Diagnostic Assays/Prognostic Assays

[0237] Another aspect of the invention pertains to methods of using the various T-bet compositions of the invention. For example, the invention provides a method for detecting the presence of T-bet activity in a biological sample. The method involves contacting the biological sample with an agent capable of detecting T-bet activity, such as T-bet protein or T-bet mRNA, such that the presence of T-bet activity is detected in the biological sample.

[0238] A preferred agent for detecting T-bet mRNA is a labeled nucleic acid probe capable of specifically hybridizing to T-bet mRNA. The nucleic acid probe can be, for example, the T-bet DNA of SEQ ID NO: 1 or 3, such as an oligonucleotide of at least about 500, 600, 800, 900, 1000, 1200, 1400, or 1600 nucleotides in length and which specifically hybridizes under stringent conditions to T-bet mRNA.

[0239] A preferred agent for detecting T-bet protein is a labeled antibody capable of binding to T-bet protein. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab′)₂) can be used. The term “labeled”, with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin. The term “biological sample” is intended to include tissues, cells and biological fluids. For example, techniques for detection of T-bet mRNA include Northern hybridizations and in situ hybridizations. Techniques for detection of T-bet protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence.

[0240] Such assays are useful in detecting syndromes characterized by developmental defects. For example, mutations in the human T-box genes TBX5 and TBX3 (orthologs of mouse Tbx5 and Tbx3) are responsible for the autosomal dominant genetic diseases Holt-Oram syndrome and ulnar-mammary syndrome respectively (Bamshad, M., et al. 1997. Nature Genetics 16: 311; Basson, C. T., et al. 1997. Nature Genetics 15:30; Li, Q. Y., et al. 1997. Nature Genetics 15: 21; Spranger, S., et al. 1997. J. Med. Genet. 3:978). These syndromes are characterized by developmental defects and might have been predicted by the patterns of expression of Tbx5 and Tbx3 respectively. Holt-Oram syndrome affects the heart and upper limbs while ulnar-mammary syndrome affects limb, apocrine gland, tooth and genital development. Both syndromes are characterized by developmental defects and might have been predicted by the patterns of expression of Tbx5 and Tbx3 respectively. The mutations in these patients involve only one allele of the T-box gene—thus it has been postulated that haploinsufficiency of Tbx3 and Tbx 5 cause these two diseases. Recently it has been demonstrated that provision of Tbx4 and Tbx5 to developing chick embryos controls limb bud identity (Rodriguez-Esteban et al., 1999; Takeuchi et al., 1999). These discoveries emphasize the critical importance of this family in vertebrate development.

[0241] In addition, the existence of T gene homologs in many species provides strong evidence for its function as a transcription factor that regulates a set of as yet unknown target genes involved in mesoderm development. The recent prominence of the T-box family arises from its clear importance in diverse developmental processes, exemplified most dramatically by the T-box mutations in human disease. The generation of mature T cells from thymocyte stem cells and of differentiated Th cells from naive precursors can also be viewed as tightly regulated developmental processes. This discovery that T-bet is responsible for the development of the Th1 lineage demonstrates an important role for this newest T-box family member in the lymphoid system.

[0242] Screening Methods

[0243] The invention further provides methods for identifying compounds that modulate the expression of T-bet (the amount of T-bet in a cell) and/or activity of a T-bet polypeptide (the ability of T-bet to propagate signals in a cell that are brought about as the result of extracellular influences on the cell. For example, the invention provides a method for identifying a compound that modulates the activity of a T-bet polypeptide, comprising

[0244] providing an indicator composition that comprises a T-bet polypeptide;

[0245] contacting the indicator composition with a test compound; and

[0246] determining the effect of the test compound on the activity of the T-bet polypeptide in the indicator composition to thereby identify a compound that modulates the activity of a T-bet polypeptide.

[0247] The activity of a T-bet molecule can be detected in a variety of ways. T-bet is a transcription factor and, therefore, has the ability to bind to DNA and to regulate expression of genes, e.g., cytokine genes as taught in the Examples. Accordingly, specific embodiments of the screening methods of the invention exploit the ability of T-bet polypeptides to bind to DNA; (e.g., IL-2 or IFN-γ promoter); to regulate gene expression (e.g., regulate expression of a Th1-associated cytokine gene, e.g., by repressing the IL-2 gene, transactivating the IFN-γ gene or to regulate the expression of a Th2-associated cytokine gene, e.g., by repressing the IL-4 gene or the IL-10 gene, or to regulate the expression of other genes, (e.g., TGF-β or Toll-like receptor genes, such as TLR6)). In other embodiments, the ability of T-bet to modulate other cellular responses can be measured, for example, as is shown herein, T-bet regulates, inter alia: immunoglobulin class switching; the generation of CD8 effector/memory cells, peripheral tolerance (e.g., by regulating the number of Tr cells present); drives naïve CD4+ cells towards a Th1 cytokine secretion profile, and/or redirects polarized Th2 cells into the Th1 pathway. Accordingly, any of these or other such effects of T-bet on cells can be used as readouts in screening for compounds that modulate the expression and/or activity of T-bet.

[0248] In a preferred embodiment of the screening assays of the invention, the indicator composition comprises an indicator cell, wherein said indicator cell comprises: (i) the a T-bet polypeptide and (ii) a reporter gene responsive to the T-bet polypeptide. Preferably, the indicator cell contains:

[0249] i) a recombinant expression vector encoding the T-bet; and

[0250] ii) a vector comprising regulatory sequences of a Th1-associated cytokine gene operatively linked a reporter gene; and said method comprising:

[0251] a) contacting the indicator cell with a test compound;

[0252] b) determining the level of expression of the reporter gene in the indicator cell in the presence of the test compound; and

[0253] c) comparing the level of expression of the reporter gene in the indicator cell in the presence of the test compound with the level of expression of the reporter gene in the indicator cell in the absence of the test compound to thereby identify a compound that modulates the expression and/or activity of T-bet.

[0254] In another preferred embodiment, the indicator composition comprises a preparation of: (i) a T-bet polypeptide and (ii) a DNA molecule to which the T-bet binds, and

[0255] said method comprising:

[0256] a) contacting the indicator composition with a test compound;

[0257] b) determining the degree of interaction of the T-bet polypeptide and the DNA molecule in the presence of the test compound; and

[0258] c) comparing the degree of interaction of the T-bet and the DNA molecule in the presence of the test compound with the degree of interaction of the T-bet polypeptide and the DNA molecule in the absence of the test compound to thereby identify a compound that modulates the expression and/or activity of T-bet.

[0259] Preferably, the DNA molecule to which T-bet binds comprises a T-box binding sequence. Such sequences are known in the art, see, e.g., (Szabo et al. 2000. Cell 100:655-669).

[0260] In another preferred embodiment, the method identifies polypeptides that interact with T-bet. In this embodiment,

[0261] the indicator composition is an indicator cell, which indicator cell comprises:

[0262] i) a reporter gene operably linked to a transcriptional regulatory sequence; and

[0263] ii) a first chimeric gene which encodes a first fusion protein, said first fusion protein including T-bet;

[0264] the test compound comprises a library of second chimeric genes, which library encodes second fusion proteins;

[0265] expression of the reporter gene being sensitive to interactions between the first fusion protein, the second fusion protein and the transcriptional regulatory sequence; and

[0266] wherein the effect of the test compound on T-bet in the indicator composition is determined by determining the level of expression of the reporter gene in the indicator cell to thereby identify a test compound comprising a polypeptide that interacts with T-bet.

[0267] In a preferred embodiment, the library of second chimeric genes is prepared from cDNA library from Th2 cells.

[0268] In a preferred embodiment of the screening assays of the invention, once a test compound is identified as modulating the expression and/or activity of T-bet, the effect of the test compound on a cellular response modulated by T-bet is then tested. Accordingly, the screening methods of the invention can further comprise determining the effect of the compound on an immune response to thereby identify a compound that modulates such a cellular response, e.g., a T cell or B cell response. In one embodiment, the effect of the compound on an immune response is determined by determining the effect of the compound on expression of a Th1-associated cytokine gene, such as an interferon-γ gene. As used herein, the term “Th1-associated cytokine” is intended to refer to a cytokine that is produced preferentially or exclusively by Th1 cells rather than by Th2 cells. Examples of Th1-associated cytokines include IFN-γ, IL-2, TNF, and lymphtoxin (LT). In another embodiment, the effect of the compound of interest on an immune response is determined by determining the effect of the compound on development of T helper type 1 (Th1) or T helper type 2 (Th2) cells.

[0269] In one embodiment, the invention provides methods for identifying modulators, i.e., candidate or test compounds or agents (e.g., enzymes, peptides, peptidomimetics, small molecules, ribozymes, or T-bet antisense molecules) which bind to T-bet polypeptides; have a stimulatory or inhibitory effect on T-bet expression; T-bet processing; T-bet post-translational modification (e.g., glycosylation, ubiquitinization, or phosphorylation); or T-bet activity; or have a stimulatory or inhibitory effect on the expression, processing or activity of a T-bet target molecule.

[0270] The indicator composition can be a cell that expresses the T-bet polypeptide, for example, a cell that naturally expresses or, more preferably, a cell that has been engineered to express the polypeptide by introducing into the cell an expression vector encoding the polypeptide. Alternatively, the indicator composition can be a cell-free composition that includes the polypeptide (e.g., a cell extract from a T-bet expressing cell or a composition that includes purified T-bet polypeptide, either natural or recombinant).

[0271] Compounds identified using the assays described herein may be useful for treating disorders associated with aberrant T-bet expression, processing, post-translational modification, or activity, e.g., modulation of T cell lineage commitment, modulating the production of cytokines, modulating TGF-β mediated signaling, modulating the Jak1/STAT-1 pathway, modulating IgG class switching and modulating B lymphocyte function.

[0272] Conditions that may benefit from modulation of T-bet include autoimmune disorders including: diabetes mellitus, rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, psoriatic arthritis, multiple sclerosis, myasthenia gravis, systemic lupus erythematosis, autoimmune thyroiditis, atopic dermatitis and eczematous dermatitis, psoriasis, Sjögren's Syndrome, alopecia areata, allergic responses due to arthropod bite reactions, Crohn's disease, aphthous ulcer, iritis, conjunctivitis, keratoconjunctivitis, ulcerative colitis, allergic asthma, cutaneous lupus erythematosus, scleroderma, vaginitis, proctitis, compound eruptions, leprosy reversal reactions, erythema nodosum leprosum, autoimmune uveitis, allergic encephalomyelitis, acute necrotizing hemorrhagic encephalopathy, idiopathic bilateral progressive sensorineural hearing loss, aplastic anemia, pure red cell anemia, idiopathic thrombocytopenia, polychondritis, Wegener's granulomatosis, chronic active hepatitis, Stevens-Johnson syndrome, idiopathic sprue, lichen planus, Crohn's disease, Graves ophthalmopathy, sarcoidosis, primary biliary cirrhosis, uveitis posterior, experimental allergic encephalomyelitis (EAE), and interstitial lung fibrosis

[0273] The subject screening assays can be performed in the presence or absence of other agents. For example, the subject assays can be performed in the presence various agents that modulate the activation state of the cell being screened. For example, in one embodiment, agents that transduce signals via the T cell receptor are included. In another embodiment, a cytokine or an antibody to a cytokine receptor is included.

[0274] In another aspect, the invention pertains to a combination of two or more of the assays described herein. For example, a modulating agent can be identified using a cell-based or a cell-free assay, and the ability of the agent to modulate the expression and/or activity of a T-bet polypeptide can be confirmed in vivo, e.g., in an animal such as an animal model for multiple sclerosis (EAE), rheumatoid arthritis, or infection.

[0275] Moreover, a T-bet modulator identified as described herein (e.g., a dominant negative T-bet molecule, a T-bet nucleic acid or polypeptide molecule, an antisense T-bet nucleic acid molecule, a T-bet-specific antibody, or a small molecule) can be used in an animal model to determine the efficacy, toxicity, or side effects of treatment with such a modulator. Alternatively, a T-bet modulator identified as described herein can be used in an animal model to determine the mechanism of action of such a modulator.

[0276] In another embodiment, it will be understood that similar screening assays can be used to identify compounds that indirectly modulate a T-bet expression and/or activity, e.g., by performing screening assays such as those described above, but employing molecules with which T-bet interacts, i.e., molecules that act either upstream or downstream of T-bet in a signal transduction pathway, such as a Tec kinase.

[0277] Accordingly, as described below, the invention provides a screening assay for identifying compounds that modulate the interaction of T-bet and a T-box binding region (e.g., a cytokine gene regulatory region, such as an IL-2 or IFN-γ gene regulatory region). Assays are known in the art that detect the interaction of a DNA binding protein with a target DNA sequence (e.g., electrophoretic mobility shift assays, DNAse I footprinting assays and the like). By performing such assays in the presence and absence of test compounds, these assays can be used to identify compounds that modulate (e.g., inhibit or enhance) the interaction of the DNA binding protein with its target DNA sequence.

[0278] The cell based and cell free assays of the invention are described in more detail below.

[0279] A. Cell Based Assays

[0280] The indicator compositions of the invention can be a cell that expresses a T-bet polypeptide (or non-T-bet polypeptide such as IFN-γ), for example, a cell that naturally expresses endogenous T-bet or, more preferably, a cell that has been engineered to express an exogenous T-bet polypeptide by introducing into the cell an expression vector encoding the polypeptide. Alternatively, the indicator composition can be a cell-free composition that includes T-bet or a non-T-bet polypeptide such as IFN-γ (e.g., a cell extract from a T-bet-expressing cell or a composition that includes purified T-bet, either natural or recombinant polypeptide).

[0281] Compounds that modulate expression and/or activity of T-bet (or a non-T-bet polypeptide that acts upstream or downstream of T-bet) can be identified using various “read-outs.”

[0282] For example, an indicator cell can be transfected with a T-bet expression vector, incubated in the presence and in the absence of a test compound, and the effect of the compound on the expression of the molecule or on a biological response regulated by T-bet can be determined. The biological activities of T-bet include activities determined in vivo, or in vitro, according to standard techniques. A T-bet activity can be a direct activity, such as an association with a T-bet-target molecule (e.g., a nucleic acid molecule to which T-bet binds such as the transcriptional regulatory region of a cytokine gene) or a polypeptide such as a kinase. Alternatively, a T-bet activity is an indirect activity, such as a cellular signaling activity occurring downstream of the interaction of the T-bet polypeptide with a T-bet target molecule or a biological effect occurring as a result of the signaling cascade triggered by that interaction. For example, biological activities of T-bet described herein include: modulation of T cell lineage commitment, modulating the production of cytokines, modulating TGF-β mediated signaling, modulating the Jak1/STAT-1 pathway, modulating IgG class switching and modulating B lymphocyte function. The various biological activities of T-bet can be measured using techniques that are known in the art. Exemplary techniques are described in more detail in the Examples.

[0283] To determine whether a test compound modulates T-bet expression, in vitro transcriptional assays can be performed. To perform such an assay, the full length promoter and enhancer of T-bet can be operably linked to a reporter gene such as chloramphenicol acetyltransferase (CAT) or luciferase and introduced into host cells.

[0284] As used interchangeably herein, the terms “operably linked” and “operatively linked” are intended to mean that the nucleotide sequence is linked to a regulatory sequence in a manner which allows expression of the nucleotide sequence in a host cell (or by a cell extract). Regulatory sequences are art-recognized and can be selected to direct expression of the desired polypeptide in an appropriate host cell. The term regulatory sequence is intended to include promoters, enhancers, polyadenylation signals and other expression control elements. Such regulatory sequences are known to those skilled in the art and are described in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990). It should be understood that the design of the expression vector may depend on such factors as the choice of the host cell to be transfected and/or the type and/or amount of polypeptide desired to be expressed.

[0285] A variety of reporter genes are known in the art and are suitable for use in the screening assays of the invention. Examples of suitable reporter genes include those which encode chloramphenicol acetyltransferase, beta-galactosidase, alkaline phosphatase or luciferase. Standard methods for measuring the activity of these gene products are known in the art.

[0286] A variety of cell types are suitable for use as indicator cells in the screening assay. Preferably a cell line is used which does not normally express T-bet, such as a Th2 cell clone or a cell from a knock out animal. Nonlymphoid cell lines can also be used as indicator cells, such as the HepG2 hepatoma cell line. Yeast cells also can be used as indicator cells.

[0287] Cells for use in the subject assays include both eukaryotic and prokaryotic cells. For example, in one embodiment, a cell is a bacterial cell. In another embodiment, a cell is a fungal cell, such as a yeast cell. In another embodiment, a cell is a vertebrate cell, e.g., an avian cell or a mammalian cell (e.g., a murine cell, or a human cell).

[0288] In one embodiment, the level of expression of the reporter gene in the indicator cell in the presence of the test compound is higher than the level of expression of the reporter gene in the indicator cell in the absence of the test compound and the test compound is identified as a compound that stimulates the expression of T-bet. In another embodiment, the level of expression of the reporter gene in the indicator cell in the presence of the test compound is lower than the level of expression of the reporter gene in the indicator cell in the absence of the test compound and the test compound is identified as a compound that inhibits the expression of T-bet.

[0289] In one embodiment, the invention provides methods for identifying compounds that modulate cellular responses in which T-bet is involved.

[0290] The ability of a test compound to modulate T-bet binding to a target molecule or to bind to T-bet can also be determined. Determining the ability of the test compound to modulate T-bet binding to a target molecule (e.g., a binding partner) can be accomplished, for example, by coupling the T-bet target molecule with a radioisotope, enzymatic or fluorescent label such that binding of the T-bet target molecule to T-bet can be determined by detecting the labeled T-bet target molecule in a complex. Alternatively, T-bet could be coupled with a radioisotope, enzymatic or fluorescent label to monitor the ability of a test compound to modulate T-bet binding to a T-bet target molecule in a complex. Determining the ability of the test compound to bind T-bet can be accomplished, for example, by coupling the compound with a radioisotope, enzymatic or fluorescent label such that binding of the compound to T-bet can be determined by detecting the labeled T-bet compound in a complex. For example, T-bet targets can be labeled with ¹²⁵I, ³⁵S, ¹⁴C, or ³H, either directly or indirectly, and the radioisotope detected by direct counting of radioemmission or by scintillation counting. Alternatively, compounds can be enzymatically labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product.

[0291] It is also within the scope of this invention to determine the ability of a compound to interact with T-bet without the labeling of any of the interactants. For example, a microphysiometer can be used to detect the interaction of a compound with T-bet without the labeling of either the compound or the T-bet (McConnell, H. M. et al. (1992) Science 257:1906-1912). As used herein, a “microphysiometer” (e.g., Cytosensor) is an analytical instrument that measures the rate at which a cell acidifies its environment using a light-addressable potentiometric sensor (LAPS). Changes in this acidification rate can be used as an indicator of the interaction between a compound and T-bet.

[0292] In another embodiment, a different (i.e., non-T-bet) molecule acting in a pathway involving T-bet that acts upstream or downstream of T-bet can be included in an indicator composition for use in a screening assay. Compounds identified in a screening assay employing such a molecule would also be useful in modulating T-bet activity, albeit indirectly. An exemplary molecule with which T-bet interacts includes the Tec kinases, e.g., ITK or rlk kinase.

[0293] The cells used in the instant assays can be eukaryotic or prokaryotic in origin. For example, in one embodiment, the cell is a bacterial cell. In another embodiment, the cell is a fungal cell, e.g., a yeast cell. In another embodiment, the cell is a vertebrate cell, e.g., an avian or a mammalian cell. In a preferred embodiment, the cell is a human cell.

[0294] The cells of the invention can express endogenous T-bet (or another polypeptide in a signaling pathway involving T-bet) or may be engineered to do so. A cell that has been engineered to express the T-bet polypeptide or a non T-bet polypeptide which acts upstream or downstream of T-bet can be produced by introducing into the cell an expression vector encoding the T-bet polypeptide or a non T-bet polypeptide which acts upstream or downstream of T-bet.

[0295] Recombinant expression vectors that can be used for expression of T-bet polypeptide or a non T-bet polypeptide which acts upstream or downstream of T-bet in the indicator cell are known in the art. In one embodiment, within the expression vector the T-bet-coding sequences are operatively linked to regulatory sequences that allow for inducible or constitutive expression of T-bet in the indicator cell (e.g., viral regulatory sequences, such as a cytomegalovirus promoter/enhancer, can be used). Use of a recombinant expression vector that allows for inducible or constitutive expression of T-bet in the indicator cell is preferred for identification of compounds that enhance or inhibit the activity of T-bet. In an alternative embodiment, within the expression vector the T-bet-coding sequences are operatively linked to regulatory sequences of the endogenous T-bet gene (i.e., the promoter regulatory region derived from the endogenous T-bet gene). Use of a recombinant expression vector in which T-bet expression is controlled by the endogenous regulatory sequences is preferred for identification of compounds that enhance or inhibit the transcriptional expression of T-bet.

[0296] In methods in which a Th1-associated cytokine gene is utilized (e.g., as a reporter gene or as a readout to assess T-bet activity), preferably, the Th1-associated cytokine is interferon-γ or IL-2. As described in the appended examples, T-bet was isolated in a yeast one hybrid screening assay based on its ability to bind to the IL-2 promoter. Accordingly, in one embodiment, a method of the invention utilizes a reporter gene construct containing this region of the proximal IL-2 promoter, most preferably nucleotides −240 to −220 of the IL-2 promoter. Other sequences that can be empolyed include: the consensus T-box site, the human IL-2 promoter, the murine IL-2 promoter, the human IFN-γ intron III, two binding sites in the murine IFN-γ proximal promoter. (Szabo et al. 2000. Cell 100:655-669).

[0297] In one embodiment, an inducible system can be constructed and used in high throughput cell-based screens to identify and characterize target compounds that affect the expression and/or activity of T-bet. The inducible system can be constructed using a cell line that does not normally produce IFN-γ, for example, by using a subclone of the adherent 293T human embryonic kidney cell line that expresses the ecdysone receptor, co-transfected with an ecdysone-driven T-bet expression plasmid, and an IFN-γ promoter luciferase reporter. (Wakita t al. 2001. Biotechniques 31:414; No et al. Proceedings of the National Academy of Sciences USA 93:3346; Graham. 2002 Expert Opin. Biol. Ther. 2:525). Upon treatment with the insect hormone ecdysone, T-bet is expressed, the IFN-γ reporter is activated and luciferase activity is generated. In this system, T-bet confers on the cell line the ability to produce endogenous IFN-γ.

[0298] B. Cell-free Assays

[0299] In another embodiment, the indicator composition is a cell free composition. T-bet or a non-T-bet polypeptide which acts upstream or downstream of T-bet in a pathway involving T-bet expressed by recombinant methods in a host cells or culture medium can be isolated from the host cells, or cell culture medium using standard methods for purifying polypeptides, for example, by ion-exchange chromatography, gel filtration chromatography, ultrafiltration, electrophoresis, and immunoaffinity purification with antibodies specific for T-bet to produce protein that can be used in a cell free composition. Alternatively, an extract of T-bet or non-T-bet expressing cells can be prepared for use as cell-free composition.

[0300] In one embodiment, compounds that specifically modulate T-bet activity are identified based on their ability to modulate the interaction of T-bet with a target molecule to which T-bet binds. The target molecule can be a DNA molecule, e.g., a T-bet-responsive element, such as the regulatory region of a cytokine gene) or a polypeptide molecule, e.g., a Tec kinase. Suitable assays are known in the art that allow for the detection of protein-protein interactions (e.g., immunoprecipitations, fluorescent polarization or energy transfer, two-hybrid assays and the like) or that allow for the detection of interactions between a DNA binding protein with a target DNA sequence (e.g., electrophoretic mobility shift assays, DNAse I footprinting assays and the like). By performing such assays in the presence and absence of test compounds, these assays can be used to identify compounds that modulate (e.g., inhibit or enhance) the interaction of T-bet with a target molecule.

[0301] In one embodiment, the amount of binding of T-bet to the target molecule in the presence of the test compound is greater than the amount of binding of T-bet to the target molecule in the absence of the test compound, in which case the test compound is identified as a compound that enhances binding of T-bet. In another embodiment, the amount of binding of the T-bet to the target molecule in the presence of the test compound is less than the amount of binding of the T-bet to the target molecule in the absence of the test compound, in which case the test compound is identified as a compound that inhibits binding of T-bet.

[0302] Binding of the test compound to the T-bet polypeptide can be determined either directly or indirectly as described above. Determining the ability of the T-bet polypeptide to bind to a test compound can also be accomplished using a technology such as real-time Biomolecular Interaction Analysis (BIA) (Sjolander, S. and Urbaniczky, C. (1991) Anal. Chem. 63:2338-2345; Szabo et al. (1995) Curr. Opin. Struct. Biol. 5:699-705). As used herein, “BIA” is a technology for studying biospecific interactions in real time, without labeling any of the interactants (e.g., BIAcore). Changes in the optical phenomenon of surface plasmon resonance (SPR) can be used as an indication of real-time reactions between biological molecules.

[0303] In the methods of the invention for identifying test compounds that modulate an interaction between T-bet polypeptide and a target molecule, the full-length T-bet polypeptide may be used in the method, or, alternatively, only portions of the T-bet may be used. The degree of interaction between T-bet polypeptides and the target molecule can be determined, for example, by labeling one of the polypeptides with a detectable substance (e.g., a radiolabel), isolating the non-labeled polypeptide and quantitating the amount of detectable substance that has become associated with the non-labeled polypeptide. The assay can be used to identify test compounds that either stimulate or inhibit the interaction between the T-bet protein and a target molecule. A test compound that stimulates the interaction between the T-bet polypeptide and a target molecule is identified based upon its ability to increase the degree of interaction between the T-bet polypeptide and a target molecule as compared to the degree of interaction in the absence of the test compound. A test compound that inhibits the interaction between the T-bet polypeptide and a target molecule is identified based upon its ability to decrease the degree of interaction between the T-bet polypeptide and a target molecule as compared to the degree of interaction in the absence of the compound.

[0304] In more than one embodiment of the above assay methods of the present invention, it may be desirable to immobilize either T-bet or a T-bet target molecule, a kinase, for example, to facilitate separation of complexed from uncomplexed forms of one or both of the polypeptides, or to accommodate automation of the assay. Binding of a test compound to a T-bet polypeptide, or interaction of a T-bet polypeptide with a T-bet target molecule in the presence and absence of a test compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtitre plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided which adds a domain that allows one or both of the polypeptides to be bound to a matrix. For example, glutathione-S-transferase/T-bet fusion proteins or glutathione-S-transferase/target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, Mo.) or glutathione derivatized microtitre plates, which are then combined with the test compound or the test compound and either the non-adsorbed target polypeptide or T-bet polypeptide, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads or microtitre plate wells are washed to remove any unbound components, the matrix is immobilized in the case of beads, and complex formation is determined either directly or indirectly, for example, as described above. Alternatively, the complexes can be dissociated from the matrix, and the level of T-bet binding or activity determined using standard techniques.

[0305] Other techniques for immobilizing polypeptides on matrices can also be used in the screening assays of the invention. For example, either a T-bet polypeptide or a T-bet target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated T-bet polypeptide or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, Ill.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies which are reactive with T-bet polypeptide or target molecules but which do not interfere with binding of the T-bet polypeptide to its target molecule can be derivatized to the wells of the plate, and unbound target or T-bet polypeptide is trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the T-bet polypeptide or target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the T-bet polypeptide or target molecule.

[0306] In yet another aspect of the invention, the T-bet polypeptide or fragments thereof can be used as “bait proteins” in a two-hybrid assay or three-hybrid assay (see, e.g., U.S. Pat. No.5,283,317; Zervos et al. (1993) Cell 72:223-232; Madura et al. (1993) J. Biol. Chem. 268:12046-12054; Bartel et al. (1993) Biotechniques 14:920-924; Iwabuchi et al. (1993) Oncogene 8:1693-1696; and Brent WO94/10300), to identify other polypeptides, which bind to or interact with T-bet (“T-bet-binding proteins” or “T-bet”) and are involved in T-bet activity. Such T-bet-binding proteins are also likely to be involved in the propagation of signals by the T-bet polypeptides or T-bet targets as, for example, downstream elements of a T-bet-mediated signaling pathway. Alternatively, such T-bet-binding polypeptides are likely to be T-bet inhibitors.

[0307] The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for a T-bet polypeptide is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein (“prey” or “sample”) is fused to a gene that codes for the activation domain of the known transcription factor. If the “bait” and the “prey” proteins are able to interact, in vivo, forming a T-bet-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene which encodes the polypeptide which interacts with the T-bet polypeptide.

[0308] In another embodiment, representational difference analysis (RDA) and microchip DNA array analysis to isolate T-bet target genes. For example, differential display or subtraction methods coupled with PCR (RDA; see e.g., Hubank, M. & Schatz, D. G. 1994. Nuc. Acid Res. 22, 5640-5648; Chang, Y., et al. 1994. Science 266, 1865; von Stein, O. D., et al. 1997. Nuc. Acid Res. 25, 2598; Lisitsyn, N. & Wigler, M. 1993. Science 259, 946) employing subtracted or unsubtracted probes or, most recently, DNA microchip array hybridization (Welford et al. 1998. Nucl. Acids. Res. 15:3059) can be used. In performing such assays, a variety of cells can be used, e.g., normal cells, cells engineered to express T-bet, or cells from mice lacking T-bet or overexpressing T-bet (e.g., from a transgenic non-human animal) can be used.

[0309] In yet another embodiment, protcomic approaches to describe T-bet target proteins can be performed. For example, subtractive analysis, analysis of expression patterns, identification of genotypic variations at the protein level and protein identification and detection of post-translational modifications can be performed as described in, e.g., Wang et al. (2002) J. Chromatogr. B. Technol. Biomed Life Sci. 782(1-2): 291-306; Lubman et al. (2002) J. Chromatogr. B. Technol. Biomed Life Sci. 782(1-2): 183-96; and Rai et al. (2002) Arch. Pathol. Lab. Med. 126(12):1518-26.

[0310] C. Assays using T-bet Deficient Cells

[0311] In another embodiment, the invention provides methods for identifying compounds that modulate a biological effect of T-bet using cells deficient in T-bet. As described in the Examples, inhibition of T-bet activity (e.g., by disruption of the T-bet gene) in B cells results in a deficiency of IgG2a production. Thus, cells deficient in T-bet can be used identify agents that modulate a biological response regulated by T-bet by means other than modulating T-bet itself (i.e., compounds that “rescue” the T-bet deficient phenotype). Alternatively, a “conditional knock-out” system, in which the T-bet gene is rendered non-functional in a conditional manner, can be used to create T-bet deficient cells for use in screening assays. For example, a tetracycline-regulated system for conditional disruption of a gene as described in WO 94/29442 and U.S. Pat. No. 5,650,298 can be used to create cells, or T-bet deficient animals from which cells can be isolated, that can be rendered T-bet deficient in a controlled manner through modulation of the tetracycline concentration in contact with the cells. For assays relating to other biological effects of T-bet a similar conditional disruption approach can be used or, alternatively, the RAG-2 deficient blastocyst complementation system can be used to generate mice with lymphoid organs that arise from embryonic stem cells with homozygous mutations of the T-bet gene. T-bet deficient lymphoid cells (e.g., thymic, splenic and/or lymph node cells) or purified T-bet deficient B cells from such animals can be used in screening assays.

[0312] In the screening method, cells deficient in T-bet are contacted with a test compound and a biological response regulated by T-bet is monitored. Modulation of the response in T-bet deficient cells (as compared to an appropriate control such as, for example, untreated cells or cells treated with a control agent) identifies a test compound as a modulator of the T-bet regulated response.

[0313] In one embodiment, the test compound is administered directly to a non-human T-bet deficient animal, preferably a mouse (e.g., a mouse in which the T-bet gene is conditionally disrupted by means described above, or a chimeric mouse in which the lymphoid organs are deficient in T-bet as described above), to identify a test compound that modulates the in vivo responses of cells deficient in T-bet. In another embodiment, cells deficient in T-bet are isolated from the non-human T-bet deficient animal, and contacted with the test compound ex vivo to identify a test compound that modulates a response regulated by T-bet in the cells deficient in T-bet.

[0314] Cells deficient in T-bet can be obtained from a non-human animals created to be deficient in T-bet. Preferred non-human animals include monkeys, dogs, cats, mice, rats, cows, horses, goats and sheep. In preferred embodiments, the T-bet deficient animal is a mouse. Mice deficient in T-bet can be made as described in the Examples. Non-human animals deficient in a particular gene product typically are created by homologous recombination. Briefly, a vector is prepared which contains at least a portion of the T-bet gene into which a deletion, addition or substitution has been introduced to thereby alter, e.g., functionally disrupt, the endogenous T-bet gene. The T-bet gene preferably is a mouse T-bet gene. For example, a mouse T-bet gene can be isolated from a mouse genomic DNA library using the mouse T-bet cDNA as a probe. The mouse T-bet gene then can be used to construct a homologous recombination vector suitable for altering an endogenous T-bet gene in the mouse genome. In a preferred embodiment, the vector is designed such that, upon homologous recombination, the endogenous T-bet gene is functionally disrupted (i.e., no longer encodes a functional polypeptide; also referred to as a “knock out” vector). Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous T-bet gene is mutated or otherwise altered but still encodes functional polypeptide (e.g., the upstream regulatory region can be altered to thereby alter the expression of the endogenous T-bet polypeptide). In the homologous recombination vector, the altered portion of the T-bet gene is flanked at its 5′ and 3′ ends by additional nucleic acid of the T-bet gene to allow for homologous recombination to occur between the exogenous T-bet gene carried by the vector and an endogenous T-bet gene in an embryonic stem cell. The additional flanking T-bet nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5′ and 3′ ends) are included in the vector (see e.g., Thomas, K. R. and Capecchi, M. R. (1987) Cell 51:503 for a description of homologous recombination vectors). The vector is introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced T-bet gene has homologously recombined with the endogenous T-bet gene are selected (see e.g., Li, E. et al. (1992) Cell 69:915). The selected cells are then injected into a blastocyst of an animal (e.g., a mouse) to form aggregation chimeras (see e.g., Bradley, A. in Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, E. J. Robertson, ed. (IRL, Oxford, 1987) pp. 113-152). A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley, A. (1991) Current Opinion in Biotechnology 2:823-829 and in PCT International Publication Nos.: WO 90/11354 by Le Mouellec et al.; WO 91/01140 by Smithies et al.; WO 92/0968 by Zijlstra et al.; and WO 93/04169 by Berns et al.

[0315] In another embodiment, retroviral transduction of donor bone marrow cells from both wild type and T-bet null mice can be performed with the DN or dominant negative constructs to reconstitute irradiated RAG recipients. This will result in the production of mice whose lymphoid cells express only a dominant negative version of T-bet. B cells from these mice can then be tested for compounds that modulate a biological response regulated by T-bet.

[0316] In one embodiment of the screening assay, compounds tested for their ability to modulate a biological response regulated by T-bet are contacted with T-bet deficient cells by administering the test compound to a non-human T-bet deficient animal in vivo and evaluating the effect of the test compound on the response in the animal. The test compound can be administered to a non-human T-bet deficient animal as a pharmaceutical composition. Such compositions typically comprise the test compound and a pharmaceutically acceptable carrier. As used herein the term “pharmaceutically acceptable carrier” is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal compounds, isotonic and absorption delaying compounds, and the like, compatible with pharmaceutical administration. The use of such media and compounds for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or compound is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

[0317] D. Test Compounds

[0318] A variety of test compounds can be evaluated using the screening assays described herein. In certain embodiments, the compounds to be tested can be derived from libraries (i.e., are members of a library of compounds). While the use of libraries of peptides is well established in the art, new techniques have been developed which have allowed the production of mixtures of other compounds, such as benzodiazepines (Bunin et al. (1992). J. Am. Chem. Soc. 114:10987; DeWitt et al. (1993). Proc. Natl. Acad. Sci. USA 90:6909) peptoids (Zuckermann. (1994). J. Med. Chem. 37:2678) oligocarbamates (Cho et al. (1993). Science. 261:1303-), and hydantoins (DeWitt et al. supra). An approach for the synthesis of molecular libraries of small organic molecules with a diversity of 104-105 as been described (Carell et al. (1994). Angew. Chem. Int. Ed. Engl. 33:2059-; Carell et al. (1994) Angew. Chem. Int. Ed. Engl. 33:2061-).

[0319] The compounds of the present invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries, synthetic library methods requiring deconvolution, the ‘one-bead one-compound’ library method, and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam, K. S. (1997) Anticancer Compound Des. 12:145). Other exemplary methods for the synthesis of molecular libraries can be found in the art, for example in: Erb et al. (1994). Proc. Natl. Acad. Sci. USA 91:11422-; Horwell et al. (1996) Immunopharmacology 33:68-; and in Gallop et al. (1994); J. Med. Chem. 37:1233-.

[0320] Libraries of compounds may be presented in solution (e.g., Houghten (1992) Biotechniques 13:412-421), or on beads (Lam (1991) Nature 354:82-84), chips (Fodor (1993) Nature 364:555-556), bacteria (Ladner U.S. Pat. No. 5,223,409), spores (Ladner U.S. Pat. No. '409), plasmids (Cull et al. (1992) Proc Natl Acad Sci USA 89:1865-1869) or on phage (Scott and Smith (1990) Science 249:386-390); (Devlin (1990) Science 249:404-406); (Cwirla et al. (1990) Proc. Natl. Acad. Sci. 87:6378-6382); (Felici (1991) J. Mol. Biol. 222:301-310); In still another embodiment, the combinatorial polypeptides are produced from a cDNA library.

[0321] Exemplary compounds which can be screened for activity include, but are not limited to, peptides, nucleic acids, carbohydrates, small organic molecules, and natural product extract libraries.

[0322] Candidate/test compounds include, for example, 1) peptides such as soluble peptides, including Ig-tailed fusion peptides and members of random peptide libraries (see, e.g., Lam, K. S. et al. (1991) Nature 354:82-84; Houghten, R. et al. (1991) Nature 354:84-86) and combinatorial chemistry-derived molecular libraries made of D- and/or L-configuration amino acids; 2) phosphopeptides (e.g., members of random and partially degenerate, directed phosphopeptide libraries, see, e.g., Songyang, Z. et al. (1993) Cell 72:767-778); 3) antibodies (e.g., polyclonal, monoclonal, humanized, anti-idiotypic, chimeric, and single chain antibodies as well as Fab, F(ab′)₂, Fab expression library fragments, and epitope-binding fragments of antibodies); 4) small organic and inorganic molecules (e.g., molecules obtained from combinatorial and natural product libraries); 5) enzymes (e.g., endoribonucleases, hydrolases, nucleases, proteases, synthatases, isomerases, polymerases, kinases, phosphatases, oxido-reductases and ATPases), and 6) mutant forms or T-bet molecules, e.g., dominant negative mutant forms of the molecules.

[0323] The test compounds of the present invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the ‘one-bead one-compound’ library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam, K. S. (1997) Anticancer Compound Des. 12:145).

[0324] Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt et al. (1993) Proc. Natl. Acad. Sci. U.S.A. 90:6909; Erb et al. (1994) Proc. Natl. Acad. Sci. USA 91:11422; Zuckermann et al. (1994) J. Med. Chem. 37:2678; Cho et al. (1993) Science 261:1303; Carrell et al. (1994) Angew. Chem. Int. Ed. Engl. 33:2059; Carell et al. (1994) Angew. Chem. Int. Ed. Engl. 33:2061; and Gallop et al. (1994) J. Med. Chem. 37:1233.

[0325] Libraries of compounds may be presented in solution (e.g., Houghten (1992) Biotechniques 13:412-421), or on beads (Lam (1991) Nature 354:82-84), chips (Fodor (1993) Nature 364:555-556), bacteria (Ladner U.S. Pat. No. 5,223,409), spores (Ladner U.S. Pat. No. '409), plasmids (Cull et al. (1992) Proc Natl Acad Sci USA 89:1865-1869) or phage (Scott and Smith (1990) Science 249:386-390; Devlin (1990) Science 249:404-406; Cwirla et al. (1990) Proc. Natl. Acad. Sci. 87:6378-6382; Felici (1991) J. Mol. Biol. 222:301-310; Ladner supra.).

[0326] Compounds identified in the subject screening assays can be used in methods of modulating one or more of the biological responses regulated by T-bet. It will be understood that it may be desirable to formulate such compound(s) as pharmaceutical compositions (described supra) prior to contacting them with cells.

[0327] Once a test compound is identified that directly or indirectly modulates T-bet expression and/or activity, by one of the variety of methods described hereinbefore, the selected test compound (or “compound of interest”) can then be further evaluated for its effect on cells, for example by contacting the compound of interest with cells either in vivo (e.g., by administering the compound of interest to a subject) or ex vivo (e.g., by isolating cells from the subject and contacting the isolated cells with the compound of interest or, alternatively, by contacting the compound of interest with a cell line) and determining the effect of the compound of interest on the cells, as compared to an appropriate control (such as untreated cells or cells treated with a control compound, or carrier, that does not modulate the biological response). Compounds of interest can also be identified using structure based drug design using techniques known in the art.

[0328] The instant invention also pertains to compounds identified in the above assays.

[0329] Methods for Modulating Biological Responses Regulated by T-bet

[0330] Yet another aspect of the invention pertains to methods of modulating T-bet expression and/or activity in a cell. The modulatory methods of the invention involve contacting the cell with an agent that modulates T-bet expression and/or activity such that T-bet expression and/or activity in the cell is modulated. In order for T-bet expression and/or activity to be modulated in a cell, the cell is contacted with a modulatory agent in an amount sufficient to modulate the expression and/or activity of T-bet.

[0331] In one embodiment, the modulatory methods of the invention are performed in vitro. In another embodiment, the modulatory methods of the invention are performed in vivo, e.g., in a subject having a disorder or condition that would benefit from modulation of T-bet expression and/or activity.

[0332] The agent may act by modulating the activity of T-bet polypeptide in the cell, (e.g., by contacting a cell with an agent that, e.g., interfers with the binding of T-bet to a molecule with which it interacts, changes the binding specificity of T-bet, or post-translationally modifies T-bet) or the expression of T-bet, (e.g., by modulating transcription of the T-bet gene or translation of the T-bet mRNA).

[0333] Accordingly, the invention features methods for modulating one or more biological responses regulated by T-bet by contacting the cells with a modulator of T-bet expression and/or activity such that the biological response is modulated.

[0334] As described in the appended Examples, T-bet has a variety of biological effects on cells, including modulating amount of T helper-type 2 and/or T helper-type 1 cytokines produced by a cell, modulation of T cell lineage commitment, modulating TGF-β mediated signaling, modulating signaling via the Jak1/STAT-1 pathway, modulating IgG class switching, and modulating B lymphocyte function.

[0335] In another embodiment, a gene whose transcription is modulated by T-bet can be modulated using the methods of the invention. Exemplary genes whose expression is modulated by T-bet include, e.g., IFN-γ, IL-2, IL-4, IL-10, and TGF-β. in another embodiment, a biological response regulated by T-bet can be modulated indirectly by modulating a non-T-bet molecule that acts upstream or downstream of T-bet in a signal transduction pathway involving T-bet. For example, as demonstrated in the instant examples, extracellular influences that modulate T-bet expression and/or activity include TGF-β and IFN-γ. Therefore, agents that modulate TGF-β or IFN-γ or that modulate molecules in a TGF-β or IFN-γ signal transduction pathway can be used to modulate T-bet.

[0336] The subject methods employ agents that modulate T-bet expression, processing, post-translational modification, or activity (or the expression, processing, post-translational modification, or activity of another molecule in a T-bet signaling pathway) such that T-bet is modulated. The subject methods are useful in both clinical and non-clinical settings.

[0337] In one embodiment, the instant methods can be performed in vitro. For example, the production of a commercially valuable polypeptide, e.g., a recombinantly expressed polypeptide, can be increased by stimulating the IFN-γ pathway. In a preferred embodiment, T-bet can be modulated in a cell in vitro and then the treated cells can be administered to a subject.

[0338] The subject invention can also be used to treat various conditions or disorders that would benefit from modulation of T-bet. Exemplary disorders that would benefit from modulation of T-bet expression and/or activity are set forth herein. In one embodiment, the invention provides for modulation of T-bet in vivo, by administering to the subject a therapeutically effective amount of a modulator of T-bet such that a biological effect of T-bet in a subject is modulated. For example, T-bet can be modulated to treat an autoimmune disorder, or an immunodeficiency.

[0339] The term “subject” is intended to include living organisms in which an immune response can be elicited. Preferred subjects are mammals. Particularly preferred subjects are humans. Other examples of subjects include monkeys, dogs, cats, mice, rats cows, horses, goats, sheep as well as other farm and companion animals. Modulation of T-bet expression and/or activity, in humans as well as veterinary applications, provides a means to regulate disorders arising from aberrant T-bet expression and/or activity in various disease states and is encompassed by the present invention.

[0340] Identification of compounds that modulate the biological effects of T-bet by directly or indirectly modulating T-bet expression and/or activity allows for selective manipulation of these biological effects in a variety of clinical situations using the modulatory methods of the invention. For example, the stimulatory methods of the invention (i.e., methods that use a stimulatory agent) can result in increased expression and/or activity of T-bet, which stimulates, e.g., IFN-γ production, IgG class switching and the production of CD8 effector cells and which inhibits, e.g., TGF-β, IL-2, IL-4, and IL-10, and can reduce tolerance (e.g., by reducing the number or percentage of Tr cells). In contrast, the inhibitory methods of the invention (i.e., methods that use an agent that inhibits T-bet) can have the opposite effects.

[0341] Application of the modulatory methods of the invention to the treatment of a disorder may result in cure of the disorder, a decrease in the type or number of symptoms associated with the disorder, either in the long term or short term (i.e., amelioration of the condition) or simply a transient beneficial effect to the subject.

[0342] Application of the immunomodulatory methods of the invention is described in further detail below.

[0343] A. Inhibitory Agents

[0344] According to a modulatory method of the invention, T-bet expression and/or activity is inhibited in a cell by contacting the cell with an inhibitory agent. Inhibitory agents of the invention can be, for example, intracellular binding molecules that act to inhibit the expression and/or activity of T-bet. As used herein, the term “intracellular binding molecule” is intended to include molecules that act intracellularly to inhibit the expression and/or activity of a polypeptide by binding to the polypeptide itself, to a nucleic acid (e.g., an mRNA molecule) that encodes the polypeptide or to a target with which the polypeptide normally interacts (e.g., to a DNA target sequence to which T-bet binds). Examples of intracellular binding molecules, described in further detail below, include antisense T-bet nucleic acid molecules (e.g., to inhibit translation of T-bet mRNA), intracellular anti-T-bet antibodies (e.g., to inhibit the activity of T-bet polypeptide) and dominant negative mutants of the T-bet polypeptide.

[0345] In one embodiment, an inhibitory agent of the invention is an antisense nucleic acid molecule that is complementary to a gene encoding T-bet or to a portion of said gene, or a recombinant expression vector encoding said antisense nucleic acid molecule. The use of antisense nucleic acids to downregulate the expression of a particular polypeptide in a cell is well known in the art (see e.g., Weintraub, H. et al., Antisense RNA as a molecular tool for genetic analysis, Reviews—Trends in Genetics, Vol. 1(1) 1986; Askari, F. K. and McDonnell, W. M. (1996) N. Eng. J. Med. 334:316-318; Bennett, M. R. and Schwartz, S. M. (1995) Circulation 92:1981-1993; Mercola, D. and Cohen, J. S. (1995) Cancer Gene Ther. 2:47-59; Rossi, J. J. (1995) Br. Med. Bull. 51:217-225; Wagner, R. W. (1994) Nature 372:333-335). An antisense nucleic acid molecule comprises a nucleotide sequence that is complementary to the coding strand of another nucleic acid molecule (e.g., an mRNA sequence) and accordingly is capable of hydrogen bonding to the coding strand of the other nucleic acid molecule. Antisense sequences complementary to a sequence of an mRNA can be complementary to a sequence found in the coding region of the mRNA, the 5′ or 3′ untranslated region of the mRNA or a region bridging the coding region and an untranslated region (e.g., at the junction of the 5′ untranslated region and the coding region). Furthermore, an antisense nucleic acid can be complementary in sequence to a regulatory region of the gene encoding the mRNA, for instance a transcription initiation sequence or regulatory element. Preferably, an antisense nucleic acid is designed so as to be complementary to a region preceding or spanning the initiation codon on the coding strand or in the 3′ untranslated region of an mRNA. An antisense nucleic acid for inhibiting the expression of T-bet polypeptide in a cell can be designed based upon the nucleotide sequence encoding the T-bet polypeptide (e.g., SEQ ID NO: 1 or 3), constructed according to the rules of Watson and Crick base pairing.

[0346] An antisense nucleic acid can exist in a variety of different forms. For example, the antisense nucleic acid can be an oligonucleotide that is complementary to only a portion of a T-bet gene. An antisense oligonucleotides can be constructed using chemical synthesis procedures known in the art. An antisense oligonucleotide can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g. phosphorothioate derivatives and acridine substituted nucleotides can be used. To inhibit T-bet expression in cells in culture, one or more antisense oligonucleotides can be added to cells in culture media, typically at about 200 μg oligonucleotide/ml.

[0347] Alternatively, an antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., nucleic acid transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest). Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the expression of the antisense RNA molecule in a cell of interest, for instance promoters and/or enhancers or other regulatory sequences can be chosen which direct constitutive, tissue specific or inducible expression of antisense RNA. For example, for inducible expression of antisense RNA, an inducible eukaryotic regulatory system, such as the Tet system (e.g., as described in Gossen, M. and Bujard, H. (1992) Proc. Natl. Acad. Sci. USA 89:5547-5551; Gossen, M. et al. (1995) Science 268:1766-1769; PCT Publication No. WO 94/29442; and PCT Publication No. WO 96/01313) can be used. The antisense expression vector is prepared as described above for recombinant expression vectors, except that the cDNA (or portion thereof) is cloned into the vector in the antisense orientation. The antisense expression vector can be in the form of, for example, a recombinant plasmid, phagemid or attenuated virus. The antisense expression vector is introduced into cells using a standard transfection technique, as described above for recombinant expression vectors.

[0348] In another embodiment, an antisense nucleic acid for use as an inhibitory agent is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region (for reviews on ribozymes see e.g., Ohkawa, J. et al. (1995) J. Biochem. 118:251-258; Sigurdsson, S. T. and Eckstein, F. (1995) Trends Biotechnol. 13:286-289; Rossi, J. J. (1995) Trends Biotechnol. 13:301-306; Kiehntopf, M. et al. (1995) J. Mol. Med. 73:65-71). A ribozyme having specificity for T-bet mRNA can be designed based upon the nucleotide sequence of the T-bet cDNA. For example, a derivative of a Tetrahymena L-19 IVS RNA can be constructed in which the base sequence of the active site is complementary to the base sequence to be cleaved in a T-bet mRNA. See for example U.S. Pat. Nos. 4,987,071 and 5,116,742, both by Cech et al. Alternatively, T-bet mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See for example Bartel, D. and Szostak, J. W. (1993) Science 261: 1411-1418.

[0349] In another embodiment, RNAi can be used to inhibit T-bet expression. RNA interference (RNAi is a post-transcriptional, targeted gene-silencing technique that uses double-stranded RNA (dsRNA) to degrade messenger RNA (mRNA) containing the same sequence as the dsRNA (Sharp, P. A. and Zamore, P. D. 287, 2431-2432 (2000); Zamore, P. D., et al. Cell 101, 25-33 (2000). Tuschl, T. et al. Genes Dev. 13, 3191-3197 (1999)). The process occurs when an endogenous ribonuclease cleaves the longer dsRNA into shorter, 21- or 22-nucleotide-long RNAs, termed small interfering RNAs or siRNAs. The smaller RNA segments then mediate the degradation of the target mRNA. Kits for synthesis of RNAi are commercially available from, e.g. New England Biolabs and Ambion. In one embodiment one or more of the chemistries described above for use in antisense RNA can be employed.

[0350] Another type of inhibitory agent that can be used to inhibit the expression and/or activity of T-bet in a cell is an intracellular antibody specific for the T-bet polypeptide. The use of intracellular antibodies to inhibit polypeptide function in a cell is known in the art (see e.g., Carlson, J. R. (1988) Mol. Cell. Biol. 8:2638-2646; Biocca, S. et al. (1990) EMBO J. 9:101-108; Werge, T. M. et al. (1990) FEBS Letters 274:193-198; Carlson, J. R. (1993) Proc. Natl. Acad. Sci. USA 90:7427-7428; Marasco, W. A. et al. (1993) Proc. Natl. Acad. Sci. USA 90:7889-7893; Biocca, S. et al. (1994) Bio/Technology 12:396-399; Chen, S-Y. et al. (1994) Human Gene Therapy 5:595-601; Duan, L et al. (1994) Proc. Natl. Acad. Sci. USA 91:5075-5079; Chen, S-Y. et al. (1994) Proc. Natl. Acad. Sci. USA 91:5932-5936; Beerli, R. R. et al. (1994) J. Biol. Chem. 269:23931-23936; Beerli, R. R. et al. (1994) Biochem. Biophys. Res. Commun. 204:666-672; Mhashilkar, A. M. et al. (1995) EMBO J. 14:1542-1551; Richardson, J. H. et al. (1995) Proc. Natl. Acad. Sci. USA 92:3137-3141; PCT Publication No. WO 94/02610 by Marasco et al.; and PCT Publication No. WO 95/03832 by Duan et al.).

[0351] To inhibit polypeptide activity using an intracellular antibody, a recombinant expression vector is prepared which encodes the antibody chains in a form such that, upon introduction of the vector into a cell, the antibody chains are expressed as a functional antibody in an intracellular compartment of the cell. For inhibition of T-bet activity according to the inhibitory methods of the invention, an intracellular antibody that specifically binds the T-bet polypeptide is expressed in the cytoplasm of the cell. To prepare an intracellular antibody expression vector, antibody light and heavy chain cDNAs encoding antibody chains specific for the target protein of interest, e.g., T-bet, are isolated, typically from a hybridoma that secretes a monoclonal antibody specific for the T-bet polypeptide. Hybridomas secreting anti- T-bet monoclonal antibodies, or recombinant anti-T-bet monoclonal antibodies, can be prepared as described above. Monoclonal antibodies specific for T-bet polypeptide have been identified such hybridoma-derived monoclonal antibodies can be used or a recombinant antibody from a combinatorial library can be used), DNAs encoding the light and heavy chains of the monoclonal antibody are isolated by standard molecular biology techniques. For hybridoma derived antibodies, light and heavy chain cDNAs can be obtained, for example, by PCR amplification or cDNA library screening. For recombinant antibodies, such as from a phage display library, cDNA encoding the light and heavy chains can be recovered from the display package (e.g., phage) isolated during the library screening process. Nucleotide sequences of antibody light and heavy chain genes from which PCR primers or cDNA library probes can be prepared are known in the art. For example, many such sequences are disclosed in Kabat, E. A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242 and in the “Vbase” human germline sequence database.

[0352] Once obtained, the antibody light and heavy chain sequences are cloned into a recombinant expression vector using standard methods. To allow for cytoplasmic expression of the light and heavy chains, the nucleotide sequences encoding the hydrophobic leaders of the light and heavy chains are removed. An intracellular antibody expression vector can encode an intracellular antibody in one of several different forms. For example, in one embodiment, the vector encodes full-length antibody light and heavy chains such that a full-length antibody is expressed intracellularly. In another embodiment, the vector encodes a full-length light chain but only the VH/CH1 region of the heavy chain such that a Fab fragment is expressed intracellularly. In the most preferred embodiment, the vector encodes a single chain antibody (scFv) wherein the variable regions of the light and heavy chains are linked by a flexible peptide linker (e.g., (Gly₄Ser)₃) and expressed as a single chain molecule. To inhibit T-bet activity in a cell, the expression vector encoding the anti-T-bet intracellular antibody is introduced into the cell by standard transfection methods, as discussed hereinbefore.

[0353] Yet another form of an inhibitory agent of the invention is an inhibitory form of T-bet, also referred to herein as a dominant negative inhibitor, e.g., a form of T-bet in comprising engrailed sequences as taught in the instant examples. Such a molecule can be introduced into a cell using standard techniques to allow for expression of the altered form of T-bet, in the cell.

[0354] In a preferred embodiment, inhibitory compounds of the invention that reduce the activity and/or expression of T-bet also reduce, for example, the onset or severity of autoimmune diseases such as MS, arthritis, Chrohn's disease and Th1 mediated experimental colitits. The inhibitory compounds of the invention that reduce the activity and/or expression of T-bet also increase, for example, the onset or severity of diseases including, asthma and Th2 mediated colitits.

[0355] In another embodiment, an inhibitory agent of the invention is a small molecule which interacts with the T-bet protein to thereby inhibit the activity of T-bet. Small molecule inhibitors of T-bet can be identified using database searching programs capable of scanning a database of small molecules of known three-dimensional structure for candidates which fit into the target protein site known in the art. Suitable software programs include, for example, CATALYST (Molecular Simulations Inc., San Diego, Calif.), UNITY (Tripos Inc., St Louis, Mo.), FLEXX (Rarey et al., J. Mol. Biol. 261: 470-489 (1996)), CHEM-3DBS (Oxford Molecular Group, Oxford, UK), DOCK (Kuntz et al., J. Mol. Biol 161: 269-288 (1982)), and MACCS-3D (MDL Information Systems Inc., San Leandro, Calif.).

[0356] The molecules found in the search may not necessarily be leads themselves, however, such candidates might act as the framework for further design, providing molecular skeletons to which appropriate atomic replacements can be made. The scaffold, functional groups, linkers and/or monomers may be changed to maximize the electrostatic, hydrogen bonding, and hydrophobic interactions with the target protein. Goodford (Goodford J Med Chem 28:849-857 (1985)) has produced a computer program, GRID, which seeks to determine regions of high affinity for different chemical groups (termed probes) on the molecular surface of the binding site. GRID hence provides a tool for suggesting modifications to known ligands that might enhance binding. A range of factors, including electrostatic interactions, hydrogen bonding, hydrophobic interactions, desolvation effects, conformational strain or mobility, chelation and cooperative interaction and motions of ligand and enzyme, all influence the binding effect and should be taken into account in attempts to design small molecule inhibitors.

[0357] Small molecule inhibitors of T-bet can also be identified using computer-assisted molecular design methods comprising searching for fragments which fit into a binding region subsite and link to a predefined scaffold can be used. The scaffold itself may be identified in such a manner. Programs suitable for the searching of such functional groups and monomers include LUDI (Boehm. J Comp. Aid. Mol. Des. 6:61-78 (1992)), CAVEAT (Bartlett et al. in “Molecular Recognition in Chemical and Biological Problems”, special publication of The Royal Chem. Soc., 78:182-196 (1989)) and MCSS (Miranker et al. Proteins 11: 29-34 (1991)).

[0358] Yet another computer-assisted molecular design method for identifying small molecule inhibitors of the l-bet protein comprises the de novo synthesis of potential inhibitors by algorithmic connection of small molecular fragments that will exhibit the desired structural and electrostatic complementarity with the active binding site of the T-bet protein. The methodology employs a large template set of small molecules with are iteratively pieced together in a model of the T-bet binding site. Programs suitable for this task include GROW (Moon et al. Proteins 11:314-328 (1991)) and SPROUT (Gillet et al. J Comp. Aid. Mol. Des. 7:127 (1993)).

[0359] The suitability of small molecule inhibitor candidates can be determined using an empirical scoring function, which can rank the binding affinities for a set of inhibitors. For an example of such a method see Muegge et al. and references therein (Muegge et al., J Med. Chem. 42:791-804 (1999)). Other modeling techniques can be used in accordance with this invention, for example, those described by Cohen et al. (J. Med. Chem. 33: 883-894 (1994)); Navia et al. (Current Opinions in Structural Biology 2: 202-210 (1992)); Baldwin et al. (J. Med. Chem. 32: 2510-2513 (1989)); Appelt et al. (J. Med. Chem. 34: 1925-1934 (1991)); and Ealick et al. (Proc. Nat. Acad. Sci. USA 88: 11540-11544 (1991)).

[0360] Other inhibitory agents that can be used to inhibit the expression and/or activity of a T-bet polypeptide include chemical compounds that directly inhibit T-bet or compounds that inhibit the interaction between T-bet and target DNA or another polypeptide. Such compounds can be identified using screening assays that select for such compounds, as described in detail above.

[0361] B. Stimulatory Agents

[0362] According to a modulatory method of the invention, T-bet expression and/or activity is stimulated in a cell by contacting the cell with a stimulatory agent. Examples of such stimulatory agents include active T-bet polypeptide and nucleic acid molecules encoding T-bet that are introduced into the cell to increase T-bet expression and/or activity in the cell. A preferred stimulatory agent is a nucleic acid molecule encoding a T-bet polypeptide, wherein the nucleic acid molecule is introduced into the cell in a form suitable for expression of the active T-bet polypeptide in the cell. To express a T-bet polypeptide in a cell, typically a T-bet-encoding DNA is first introduced into a recombinant expression vector using standard molecular biology techniques, as described herein. A T-bet-encoding DNA can be obtained, for example, by amplification using the polymerase chain reaction (PCR), using primers based on the T-bet nucleotide sequence. Following isolation or amplification of T-bet-encoding DNA, the DNA fragment is introduced into an expression vector and transfected into target cells by standard methods, as described herein.

[0363] In one embodiment, stimulatory compounds of the invention include agents that increase the activity and/or expression of T-bet to thereby decrease, for example, the activation of the IL-2 promoter, activation of IL-4 production, activate the production and signaling of TGF-β and the increase of the production of Tr cells. In another embodiment, stimulatory compounds of the invention include agents that increase the activity and/or expression of T-bet to thereby increase, for example, activation of IFN-γ, stimulation of pathogenic autoantibody production, IgG class switching and production of CD8 effector cells.

[0364] In a preferred embodiment, stimulatory compounds of the invention that increase the activity and/or expression of T-bet also increase, for example, the onset or severity of autoimmune diseases such as MS, arthritis, Crohn's disease and Th1 mediated experimental colitits. The stimulatory compounds of the invention that increase the activity and/or expression of T-bet also reduce, for example, the onset or severity of diseases including, asthma and Th2 mediated colitits.

[0365] Other stimulatory agents that can be used to stimulate the activity of a T-bet polypeptide are chemical compounds that stimulate T-bet activity in cells, such as compounds that directly stimulate T-bet polypeptide and compounds that promote the interaction between T-bet and target DNA or other polypeptides. Such compounds can be identified using screening assays that select for such compounds, as described in detail above.

[0366] The modulatory methods of the invention can be performed in vitro (e.g., by culturing the cell with the agent or by introducing the agent into cells in culture) or, alternatively, in vivo (e.g., by administering the agent to a subject or by introducing the agent into cells of a subject, such as by gene therapy). For practicing the modulatory method in vitro, cells can be obtained from a subject by standard methods and incubated (i.e., cultured) in vitro with a modulatory agent of the invention to modulate T-bet expression and/or activity in the cells. For example, peripheral blood mononuclear cells (PBMCs) can be obtained from a subject and isolated by density gradient centrifugation, e.g., with Ficoll/Hypaque. Specific cell populations can be depleted or enriched using standard methods. For example, T cells can be enriched for example, by positive selection using antibodies to T cell surface markers, for example by incubating cells with a specific primary monoclonal antibody (mAb), followed by isolation of cells that bind the mAb using magnetic beads coated with a secondary antibody that binds the primary mAb. Specific cell populations can also be isolated by fluorescence activated cell sorting according to standard methods. If desired, cells treated in vitro with a modulatory agent of the invention can be readministered to the subject. For administration to a subject, it may be preferable to first remove residual agents in the culture from the cells before administering them to the subject. This can be done for example by a Ficoll/Hypaque gradient centrifugation of the cells. For further discussion of ex vivo genetic modification of cells followed by readministration to a subject, see also U.S. Pat. No. 5,399,346 by W. F. Anderson et al. For stimulatory or inhibitory agents that comprise nucleic acids (including recombinant expression vectors encoding T-bet polypeptide, antisense RNA, intracellular antibodies or dominant negative inhibitors), the agents can be introduced into cells of the subject using methods known in the art for introducing nucleic acid (e.g., DNA) into cells in vivo. Examples of such methods encompass both non-viral and viral methods, including:

[0367] Direct Injection: Naked DNA can be introduced into cells in vivo by directly injecting the DNA into the cells (see e.g., Acsadi et al. (1991) Nature 332:815-818; Wolff et al. (1990) Science 247:1465-1468). For example, a delivery apparatus (e.g., a “gene gun”) for injecting DNA into cells in vivo can be used. Such an apparatus is commercially available (e.g., from BioRad).

[0368] Cationic Lipids: Naked DNA can be introduced into cells in vivo by complexing the DNA with cationic lipids or encapsulating the DNA in cationic liposomes. Examples of suitable cationic lipid formulations include N-[-1-(2,3-dioleoyloxy)propyl]N,N,N-triethylammonium chloride (DOTMA) and a 1:1 molar ratio of 1,2-dimyristyloxy-propyl-3-dimethylhydroxyethylammonium bromide (DMRIE) and dioleoyl phosphatidylethanolamine (DOPE) (see e.g., Logan, J. J. et al. (1995) Gene Therapy 2:38-49; San, H. et al. (1993) Human Gene Therapy 4:781-788).

[0369] Receptor-Mediated DNA Uptake: Naked DNA can also be introduced into cells in vivo by complexing the DNA to a cation, such as polylysine, which is coupled to a ligand for a cell-surface receptor (see for example Wu, G. and Wu, C. H. (1988) J. Biol. Chem. 263:14621; Wilson et al. (1992) J. Biol. Chem. 267:963-967; and U.S. Pat. No. 5,166,320). Binding of the DNA-ligand complex to the receptor facilitates uptake of the DNA by receptor-mediated endocytosis. A DNA-ligand complex linked to adenovirus capsids which naturally disrupt endosomes, thereby releasing material into the cytoplasm can be used to avoid degradation of the complex by intracellular lysosomes (see for example Curiel et al. (1991) Proc. Natl. Acad. Sci. USA 88:8850; Cristiano et al. (1993) Proc. Natl. Acad. Sci. USA 90:2122-2126).

[0370] Retroviruses: Defective retroviruses are well characterized for use in gene transfer for gene therapy purposes (for a review see Miller, A. D. (1990) Blood 76:271). A recombinant retrovirus can be constructed having a nucleotide sequences of interest incorporated into the retroviral genome. Additionally, portions of the retroviral genome can be removed to render the retrovirus replication defective. The replication defective retrovirus is then packaged into virions which can be used to infect a target cell through the use of a helper virus by standard techniques. Protocols for producing recombinant retroviruses and for infecting cells in vitro or in vivo with such viruses can be found in Current Protocols in Molecular Biology, Ausubel, F. M. et al. (eds.) Greene Publishing Associates, (1989), Sections 9.10-9.14 and other standard laboratory manuals. Examples of suitable retroviruses include pLJ, pZIP, pWE and pEM which are well known to those skilled in the art. Examples of suitable packaging virus lines include ψ Crip, ψCre, ψ2 and ψAm. Retroviruses have been used to introduce a variety of genes into many different cell types, including epithelial cells, endothelial cells, lymphocytes, myoblasts, hepatocytes, bone marrow cells, in vitro and/or in vivo (see for example Eglitis, et al. (1985) Science 230:1395-1398; Danos and Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:6460-6464; Wilson et al. (1988) Proc. Natl. Acad. Sci. USA 85:3014-3018; Armentano et al. (1990) Proc. Natl. Acad. Sci. USA 87:6141-6145; Huber et al. (1991) Proc. Natl. Acad. Sci. USA 88:8039-8043; Ferry et al. (1991) Proc. Natl. Acad. Sci. USA 88:8377-8381; Chowdhury et al. (1991) Science 254:1802-1805; van Beusechem et al. (1992) Proc. Natl. Acad. Sci. USA 89:7640-7644; Kay et al. (1992) Human Gene Therapy 3:641-647; Dai et al. (1992) Proc. Natl. Acad. Sci. USA 89:10892-10895; Hwu et al. (1993) J. Immunol. 150:4104-4115; U.S. Pat. No. 4,868,116; U.S. Pat. No. 4,980,286; PCT Application WO 89/07136; PCT Application WO 89/02468; PCT Application WO 89/05345; and PCT Application WO 92/07573). Retroviral vectors require target cell division in order for the retroviral genome (and foreign nucleic acid inserted into it) to be integrated into the host genome to stably introduce nucleic acid into the cell. Thus, it may be necessary to stimulate replication of the target cell.

[0371] Adenoviruses: The genome of an adenovirus can be manipulated such that it encodes and expresses a gene product of interest but is inactivated in terms of its ability to replicate in a normal lytic viral life cycle. See for example Berkner et al. (1988) BioTechniques 6:616; Rosenfeld et al. (1991) Science 252:431-434; and Rosenfeld et al. (1992) Cell 68:143-155. Suitable adenoviral vectors derived from the adenovirus strain Ad type 5 dl324 or other strains of adenovirus (e.g., Ad2, Ad3, Ad7 etc.) are well known to those skilled in the art. Recombinant adenoviruses are advantageous in that they do not require dividing cells to be effective gene delivery vehicles and can be used to infect a wide variety of cell types, including airway epithelium (Rosenfeld et al. (1992) cited supra), endothelial cells (Lemarchand et al. (1992) Proc. Natl. Acad. Sci. USA 89:6482-6486), hepatocytes (Herz and Gerard (1993) Proc. Natl. Acad. Sci. USA 90:2812-2816) and muscle cells (Quantin et al. (1992) Proc. Natl. Acad. Sci. USA 89:2581-2584). Additionally, introduced adenoviral DNA (and foreign DNA contained therein) is not integrated into the genome of a host cell but remains episomal, thereby avoiding potential problems that can occur as a result of insertional mutagenesis in situations where introduced DNA becomes integrated into the host genome (e.g., retroviral DNA). Moreover, the carrying capacity of the adenoviral genome for foreign DNA is large (up to 8 kilobases) relative to other gene delivery vectors (Berkner et al. cited supra; Haj-Ahmand and Graham (1986) J. Virol. 57:267). Most replication-defective adenoviral vectors currently in use are deleted for all or parts of the viral E1 and E3 genes but retain as much as 80% of the adenoviral genetic material.

[0372] Adeno-Associated Viruses: Adeno-associated virus (AAV) is a naturally occurring defective virus that requires another virus, such as an adenovirus or a herpes virus, as a helper virus for efficient replication and a productive life cycle. (For a review see Muzyczka et al. Curr. Topics in Micro. and Immunol. (1992) 158:97-129). It is also one of the few viruses that may integrate its DNA into non-dividing cells, and exhibits a high frequency of stable integration (see for example Flotte et al. (1992) Am. J. Respir. Cell. Mol. Biol. 7:349-356; Samulski et al. (1989) J. Virol. 63:3822-3828; and McLaughlin et al. (1989) J. Virol. 62:1963-1973). Vectors containing as little as 300 base pairs of AAV can be packaged and can integrate. Space for exogenous DNA is limited to about 4.5 kb. An AAV vector such as that described in Tratschin et al. (1985) Mol. Cell. Biol. 5:3251-3260 can be used to introduce DNA into cells. A variety of nucleic acids have been introduced into different cell types using AAV vectors (see for example Hermonat et al. (1984) Proc. Natl. Acad. Sci. USA 81:6466-6470; Tratschin et al. (1985) Mol. Cell. Biol. 4:2072-2081; Wondisford et al. (1988) Mol. Endocrinol. 2:32-39; Tratschin et al. (1984) J. Virol. 51:611-619; and Flotte et al. (1993) J. Biol. Chem. 268:3781-3790).

[0373] The efficacy of a particular expression vector system and method of introducing nucleic acid into a cell can be assessed by standard approaches routinely used in the art. For example, DNA introduced into a cell can be detected by a filter hybridization technique (e.g., Southern blotting) and RNA produced by transcription of introduced DNA can be detected, for example, by Northern blotting, RNase protection or reverse transcriptase-polymerase chain reaction (RT-PCR). The gene product can be detected by an appropriate assay, for example by immunological detection of a produced protein, such as with a specific antibody, or by a functional assay to detect a functional activity of the gene product.

[0374] In a preferred embodiment, a retroviral expression vector encoding T-bet is used to express T-bet polypeptide in cells in vivo, to thereby stimulate T-bet polypeptide activity in vivo. Such retroviral vectors can be prepared according to standard methods known in the art (discussed further above).

[0375] A modulatory agent, such as a chemical compound, can be administered to a subject as a pharmaceutical composition. Such compositions typically comprise the modulatory agent and a pharmaceutically acceptable carrier. As used herein the term “pharmaceutically acceptable carrier” is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions. Pharmaceutical compositions can be prepared as described above in subsection IV.

[0376] The identification of T-bet as a key regulator of the development of Th1 cells described herein, and in the repression of the Th2 phenotype, allows for selective manipulation of T cell subsets in a variety of clinical situations using the modulatory methods of the invention. The stimulatory methods of the invention (i.e., methods that use a stimulatory agent to enhance T-bet expression and/or activity) result in production of IFN-γ, with concomitant promotion of a Th1 response and downregulation of both IL-2 and IL-4, thus downmodulating the Th2 response. In contrast, the inhibitory methods of the invention (i.e., methods that use an inhibitory agent to downmodulate T-bet expression and/or activity) inhibit the production of IFN-γ, with concomitant downregulation of a Th1 response and promotion of a Th2 response. Thus, to treat a disease condition wherein a Th1 response is beneficial, a stimulatory method of the invention is selected such that Th1 responses are promoted while downregulating Th2 responses. Alternatively, to treat a disease condition wherein a Th2 response is beneficial, an inhibitory method of the invention is selected such that Th1 responses are downregulated while promoting Th2 responses. Application of the methods of the invention to the treatment of diseases or conditions may result in cure of the condition, a decrease in the type or number of symptoms associated with the condition, either in the long term or short term (i.e., amelioration of the condition) or simply a transient beneficial effect to the subject.

[0377] Numerous diseases or conditions associated with a predominant Th1 or Th2-type response have been identified and would benefit from modulation of the type of response mounted in the individual suffering from the disease condition. Application of the immunomodulatory methods of the invention to such diseases or conditions is described in further detail below.

[0378] A. Allergies

[0379] Allergies are mediated through IgE antibodies whose production is regulated by the activity of Th2 cells and the cytokines produced thereby. In allergic reactions, IL-4 is produced by Th2 cells, which further stimulates production of IgE antibodies and activation of cells that mediate allergic reactions, i.e., mast cells and basophils. IL-4 also plays an important role in eosinophil mediated inflammatory reactions. Accordingly, the stimulatory methods of the invention can be used to inhibit the production of Th2-associated cytokines, and in particular IL-4, in allergic patients as a means to downregulate production of pathogenic IgE antibodies. A stimulatory agent may be directly administered to the subject or cells (e.g., Thp cells or Th2 cells) may be obtained from the subject, contacted with a stimulatory agent ex vivo, and readministered to the subject. Moreover, in certain situations it may be beneficial to coadminister to the subject the allergen together with the stimulatory agent or cells treated with the stimulatory agent to inhibit (e.g., desensitize) the allergen-specific response. The treatment may be further enhanced by administering other Th1-promoting agents, such as the cytokine IL-12 or antibodies to Th2-associated cytokines (e.g., anti-IL-4 antibodies), to the allergic subject in amounts sufficient to further stimulate a Th1-type response.

[0380] B. Cancer

[0381] The expression of Th2-promoting cytokines has been reported to be elevated in cancer patients (see e.g., Yamamura, M., et al (1993) J. Clin. Invest. 91:1005-1010; Pisa, P., et al. (1992) Proc. Natl. Acad. Sci. USA 89:7708-7712) and malignant disease is often associated with a shift from Th1 type responses to Th2 type responses along with a worsening of the course of the disease. Accordingly, the stimulatory methods of the invention can be used to inhibit the production of Th2-associated cytokines in cancer patients, as a means to counteract the Th1 to Th2 shift and thereby promote an ongoing Th1 response in the patients to ameliorate the course of the disease. The stimulatory method can involve either direct administration of an stimulatory agent to a subject with cancer or ex vivo treatment of cells obtained from the subject (e.g., Thp or Th2 cells) with a stimulatory agent followed by readministration of the cells to the subject. The treatment may be further enhanced by administering other Th1-promoting agents, such as the cytokine IL-12 or antibodies to Th2-associated cytokines (e.g., anti-IL-4 antibodies), to the recipient in amounts sufficient to further stimulate a Th1-type response.

[0382] C. Infectious Diseases

[0383] The expression of Th2-promoting cytokines also has been reported to increase during a variety of infectious diseases, including HIV infection, tuberculosis, leishmaniasis, schistosomiasis, filarial nematode infection and intestinal nematode infection (see e.g.; Shearer, G. M. and Clerici, M. (1992) Prog. Chem. Immunol. 54:21-43; Clerici, M and Shearer, G. M. (1993) Immunology Today 14:107-111; Fauci, A. S. (1988) Science 239:617-623; Locksley, R. M. and Scott, P. (1992) Immunoparasitology Today 1:A58-A61; Pearce, E. J., et al. (1991) J. Exp. Med. 173:159-166; Grzych, J-M., et al. (1991) J. Immunol. 141:1322-1327; Kullberg, M. C., et al. (1992) J. Immunol. 148:3264-3270; Bancroft, A. J., et al. (1993) J. Immunol. 150:1395-1402; Pearlman, E., et al. (1993) Infect. Immun. 61:1105-1112; Else, K. J., et al. (1994) J. Exp. Med. 179:347-351) and such infectious diseases are also associated with a Th1 to Th2 shift in the immune response. Accordingly, the stimulatory methods of the invention can be used to inhibit the production of Th2-associated cytokines in subjects with infectious diseases, as a means to counteract the Th1 to Th2 shift and thereby promote an ongoing Th1 response in the patients to ameliorate the course of the infection. The stimulatory method can involve either direct administration of an inhibitory agent to a subject with an infectious disease or ex vivo treatment of cells obtained from the subject (e.g., Thp or Th2 cells) with a stimulatory agent followed by readministration of the cells to the subject. The treatment may be further enhanced by administering other Th1-promoting agents, such as the cytokine IL-12 or antibodies to Th2-associated cytokines (e.g., anti-IL-4 antibodies), to the recipient in amounts sufficient to further stimulate a Th1-type response.

[0384] D. Autoimmune Diseases

[0385] The inhibitory methods of the invention can be used therapeutically in the treatment of autoimmune diseases that are associated with a Th2-type dysfunction. Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue and that promote the production of cytokines and autoantibodies involved in the pathology of the diseases. Modulation of T helper-type responses can have an effect on the course of the autoimmune disease. For example, in experimental allergic encephalomyelitis (EAE), stimulation of a Th2-type response by administration of IL-4 at the time of the induction of the disease diminishes the intensity of the autoimmune disease (Paul, W. E., et al. (1994) Cell 76:241-251). Furthermore, recovery of the animals from the disease has been shown to be associated with an increase in a Th2-type response as evidenced by an increase of Th2-specific cytokines (Koury, S. J., et al. (1992) J. Exp. Med. 176:1355-1364). Moreover, T cells that can suppress EAE secrete Th2-specific cytokines (Chen, C., et al. (1994) Immunity 1:147-154). Since stimulation of a Th2-type response in EAE has a protective effect against the disease, stimulation of a Th2 response in subjects with multiple sclerosis (for which EAE is a model) is likely to be beneficial therapeutically. The inhibitory methods of the invention can be used to effect such a decrease.

[0386] Similarly, stimulation of a Th2-type response in type I diabetes in mice provides a protective effect against the disease. Indeed, treatment of NOD mice with IL-4 (which promotes a Th2 response) prevents or delays onset of type I diabetes that normally develops in these mice (Rapoport, M. J., et al. (1993) J. Exp. Med. 178:87-99). Thus, stimulation of a Th2 response in a subject suffering from or susceptible to diabetes may ameliorate the effects of the disease or inhibit the onset of the disease.

[0387] Yet another autoimmune disease in which stimulation of a Th2-type response may be beneficial is rheumatoid arthritis (RA). Studies have shown that patients with rheumatoid arthritis have predominantly Th1 cells in synovial tissue (Simon, A. K., et al. (1994) Proc. Natl. Acad. Sci. USA 91:8562-8566). By stimulating a Th2 response in a subject with RA, the detrimental Th1 response can be concomitantly downmodulated to thereby ameliorate the effects of the disease.

[0388] Accordingly, the inhibitory methods of the invention can be used to stimulate production of Th2-associated cytokines in subjects suffering from, or susceptible to, an autoimmune disease in which a Th2-type response is beneficial to the course of the disease. The inhibitory method can involve either direct administration of an inhibitory agent to the subject or ex vivo treatment of cells obtained from the subject (e.g., Thp, Th1 cells, B cells, non-lymphoid cells) with an inhibitory agent followed by readministration of the cells to the subject. The treatment may be further enhanced by administering other Th2-promoting agents, such as IL-4 itself or antibodies to Th1-associated cytokines, to the subject in amounts sufficient to further stimulate a Th2-type response.

[0389] In contrast to the autoimmune diseases described above in which a Th2 response is desirable, other autoimmune diseases may be ameliorated by a Th1-type response. Such diseases can be treated using a stimulatory agent of the invention (as described above for cancer and infectious diseases). The treatment may be further enhanced by administrating a Th1-promoting cytokine (e.g., IFN-γ) to the subject in amounts sufficient to further stimulate a Th1-type response.

[0390] The efficacy of agents for treating autoimmune diseases can be tested in the above described animal models of human diseases (e.g., EAE as a model of multiple sclerosis and the NOD mice as a model for diabetes) or other well characterized animal models of human autoimmune diseases. Such animal models include the mrl/lpr/lpr mouse as a model for lupus erythematosus, murine collagen-induced arthritis as a model for rheumatoid arthritis, and murine experimental myasthenia gravis (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 840-856). A modulatory (i.e., stimulatory or inhibitory) agent of the invention is administered to test animals and the course of the disease in the test animals is then monitored by the standard methods for the particular model being used. Effectiveness of the modulatory agent is evidenced by amelioration of the disease condition in animals treated with the agent as compared to untreated animals (or animals treated with a control agent).

[0391] Non-limiting examples of autoimmune diseases, disorders and conditions having an autoimmune component that may be treated according to the invention include diabetes mellitus, arthritis (including rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, psoriatic arthritis), multiple sclerosis, myasthenia gravis, systemic lupus erythematosis, autoimmune thyroiditis, dermatitis (including atopic dermatitis and eczematous dermatitis), psoriasis, Sjögren's Syndrome, including keratoconjunctivitis sicca secondary to Sjögren's Syndrome, alopecia areata, allergic responses due to arthropod bite reactions, Crohn's disease, aphthous ulcer, iritis, conjunctivitis, keratoconjunctivitis, ulcerative colitis, allergic asthma, cutaneous lupus erythematosus, scleroderma, vaginitis, proctitis, compound eruptions, leprosy reversal reactions, erythema nodosum leprosum, autoimmune uveitis, allergic encephalomyelitis, acute necrotizing hemorrhagic encephalopathy, idiopathic bilateral progressive sensorineural hearing loss, aplastic anemia, pure red cell anemia, idiopathic thrombocytopenia, polychondritis, Wegener's granulomatosis, chronic active hepatitis, Stevens-Johnson syndrome, idiopathic sprue, lichen planus, Crohn's disease, Graves ophthalmopathy, sarcoidosis, primary biliary cirrhosis, uveitis posterior, and interstitial lung fibrosis.

[0392] In a particular embodiment, diseases, disorders and conditions that may be treated by the methods of the invention include Crohn's disease and ulcerative colitis, which are the two major forms of inflammatory bowel diseases (IBD) in humans. Cytokines produced by T lymphocytes appear to initiate and perpetuate chronic intestinal inflammation. Crohn's disease is associated with increased production of T helper 1 (Th1) type cytokines such as IFN-γ and TNF. Ulcerative colitis is generally associated with T cells producing large amounts of the Th2 type cytokines and is referred to herein as “Th2-mediated colitis.” “Th1-mediated colitis” refers to a Crohn's disease profile as well as to the Th1 type response which can occur in ulcerative colitis. In Th1-mediated colitis, agents which inhibit the activity of T-bet provide a protective effect. In Th2-mediated colitis, agents which stimulate the activity of T-bet provide a protective effect.

[0393] In another particular embodiment, diseases, disorders and conditions that may be treated by the methods of the invention include asthma, which is a disease of the bronchial tubes, or airways of the lungs, characterized by tightening of these airways. Production of IL-4, IL-5 and IL-13 has been associated with the development of an asthma-like phenotype. Accordingly, agents of the invention which stimulate the activity of T-bet provide a protective effect against asthma.

[0394] E. Transplantation

[0395] While graft rejection or graft acceptance may not be attributable exclusively to the action of a particular T cell subset (i.e., Th1 or Th2 cells) in the graft recipient (for a discussion see Dallman, M. J. (1995) Curr. Opin. Immunol. 7:632-638), numerous studies have implicated a predominant Th2 response in prolonged graft survival or a predominant Th1 response in graft rejection. For example, graft acceptance has been associated with production of a Th2 cytokine pattern and/or graft rejection has been associated with production of a Th1 cytokine pattern (see e.g., Takeuchi, T. et al. (1992) Transplantation 53:1281-1291; Tzakis, A. G. et al. (1994) J. Pediatr. Surg. 29:754-756; Thai, N. L. et al. (1995) Transplantation 59:274-281). Additionally, adoptive transfer of cells having a Th2 cytokine phenotype prolongs skin graft survival (Maeda, H. et al. (1994) Int. Immunol. 6:855-862) and reduces graft-versus-host disease (Fowler, D. H. et al. (1994) Blood 84:3540-3549; Fowler, D. H. et al. (1994) Prog. Clin. Biol. Res. 389:533-540). Still further, administration of IL-4, which promotes Th2 differentiation, prolongs cardiac allograft survival (Levy, A. E. and Alexander, J. W. (1995) Transplantation 60:405-406), whereas administration of IL-12 in combination with anti-IL-10 antibodies, which promotes Th1 differentiation, enhances skin allograft rejection (Gorczynski, R. M. et al. (1995) Transplantation 60:1337-1341).

[0396] Accordingly, the inhibitory methods of the invention can be used to stimulate production of Th2-associated cytokines in transplant recipients to prolong survival of the graft. The inhibitory methods can be used both in solid organ transplantation and in bone marrow transplantation (e.g., to inhibit graft-versus-host disease). The inhibitory method can involve either direct administration of an inhibitory agent to the transplant recipient or ex vivo treatment of cells obtained from the subject (e.g., Thp, Th1 cells, B cells, non-lymphoid cells) with an inhibitory agent followed by readministration of the cells to the subject. The treatment may be further enhanced by administering other Th2-promoting agents, such as IL-4 itself or antibodies to Th1-associated cytokines, to the recipient in amounts sufficient to further inhibit a Th2-type response.

[0397] In addition to the foregoing disease situations, the modulatory methods of the invention also are useful for other purposes. For example, the stimulatory methods of the invention (i.e., methods using a stimulatory agent) can be used to stimulate production of Th1-promoting cytokines (e.g., interferon-γ) in vitro for commercial production of these cytokines (e.g., cells can be contacted with the stimulatory agent in vitro to stimulate interferon-γ production and the interferon-γ can be recovered from the culture supernatant, further purified if necessary, and packaged for commercial use).

[0398] Furthermore, the modulatory methods of the invention can be applied to vaccinations to promote either a Th1 or a Th2 response to an antigen of interest in a subject. That is, the agents of the invention can serve as adjuvants to direct an immune response to a vaccine either to a Th1 response or a Th2 response. For example, to promote an antibody response to an antigen of interest (i.e., for vaccination purposes), the antigen and an inhibitory agent of the invention can be coadministered to a subject to promote a Th2 response to the antigen in the subject, since Th2 responses provide efficient B cell help and promote IgG1 production. Alternatively, to promote a cellular immune response to an antigen of interest, the antigen and a stimulatory agent of the invention can be coadministered to a subject to promote a Th1 response to the antigen in a subject, since Th1 responses favor the development of cell-mediated immune responses (e.g., delayed hypersensitivity responses). The antigen of interest and the modulatory agent can be formulated together into a single pharmaceutical composition or in separate compositions. In a preferred embodiment, the antigen of interest and the modulatory agent are administered simultaneously to the subject. Alternatively, in certain situations it may be desirable to administer the antigen first and then the modulatory agent or vice versa (for example, in the case of an antigen that naturally evokes a Th1 response, it may be beneficial to first administer the antigen alone to stimulate a Th1 response and then administer an inhibitory agent, alone or together with a boost of antigen, to shift the immune response to a Th2 response).

[0399] This invention is further illustrated by the following example, which should not be construed as limiting. The contents of all references, patents and published patent applications cited throughout this application are hereby incorporated by reference. Additionally, all nucleotide and amino acid sequences deposited in public databases referred to herein are also hereby incorporated by reference.

[0400] A nucleic acid molecule comprising a mouse T-bet cDNA cloned into the EcoRI site of the pJG4-5 vector was deposited with the American Type Culture Collection (Manassas, Va.) on Nov. 9, 1999 and assigned Deposit Number PTA-930. A nucleic acid molecule comprising a human T-bet cDNA (prepared from RNA from the human Th1 clone ROT-10) cloned into the PCR 2.1-TOPO vector was deposited with the American Type Culture Collection (Manassas, Va.) on Jan. 28, 2000 and assigned Deposit Number PTA-1339. Both deposits were made under the provisions of the Budapest Treaty.

[0401] V. Kits of the Invention

[0402] Another aspect of the invention pertains to kits for carrying out the screening assays, modulatory methods or diagnostic assays of the invention. For example, a kit for carrying out a screening assay of the invention can include a T-bet-containing indicator composition, means for measuring a readout (e.g., polypeptide secretion) and instructions for using the kit to identify modulators of biological effects of T-bet. In another embodiment, a kit for carrying out a screening assay of the invention comprises T-bet deficient cells, means for measuring the readout and instructions for using the kit to identify modulators of a biological effect of T-bet.

[0403] In another embodiment, the invention provides a kit for carrying out a modulatory method of the invention. The kit can include, for example, a modulatory agent of the invention (e.g., T-bet inhibitory or stimulatory agent) in a suitable carrier and packaged in a suitable container with instructions for use of the modulator to modulate a biological effect of T-bet.

[0404] Another aspect of the invention pertains to a kit for diagnosing a disorder associated with a biological activity of T-bet in a subject. The kit can include a reagent for determining expression of T-bet (e.g., a nucleic acid probe for detecting T-bet mRNA or an antibody for detection of T-bet polypeptide), a control to which the results of the subject are compared, and instructions for using the kit for diagnostic purposes.

[0405] VI. Immunomodulatory Compositions

[0406] Agents that modulate T-bet expression, processing, post-translational modifications, or activity are also appropriate for use in immunomodulatory compositions. Stimulatory or inhibitory agents of the invention can be used to up or down regulate the immune response in a subject. In preferred embodiments, the humoral immune response is regulated.

[0407] T-bet modulating agents can be given alone, or in combination with an antigen to which an enhanced immune response or a reduced immune response is desired.

[0408] In another embodiment, agents which are known adjuvants can be administered with the subject modulating agents. At this time, the only adjuvant widely used in humans has been alum (aluminum phosphate or aluminum hydroxide). Saponin and its purified component Quil A, Freund's complete adjuvant and other adjuvants used in research and veterinary applications have potential use in human vaccines. However, new chemically defined preparations such as muramyl dipeptide, monophosphoryl lipid A, phospholipid conjugates such as those described by Goodman-Snitkoff et al. J. Immunol. 147:410-415 (1991) resorcinols, non-ionic surfactants such as polyoxyethylene oleyl ether and n-hexadecyl polyethylene ether, enzyme inhibitors include pancreatic trypsin inhibitor, diisopropylfluorophosphate (DEP) and trasylol can also be used. In embodiments in which antigen is administered, the antigen can e.g., be encapsulated within a proteoliposome as described by Miller et al., J. Exp. Med. 176:1739-1744 (1992) and incorporated by reference herein, or in lipid vesicles, such as Novasome TM lipid vesicles (Micro Vescular Systems, Inc., Nashua, N.H.), to further enhance immune responses.

[0409] In one embodiment, a nucleic acid molecule encoding a T-bet molecule or portion thereof is administered as a DNA vaccine. This can be done using a plasmid DNA construct which is similar to those used for delivery of reporter or therapeutic genes. Such a construct preferably comprises a bacterial origin of replication that allows amplification of large quantities of the plasmid DNA; a prokaryotic selectable marker gene; a nucleic acid sequence encoding a T-bet polypeptide or portion thereof; eukaryotic transcription regulatory elements to direct gene expression in the host cell; and a polyadenylation sequence to ensure appropriate termination of the expressed mRNA (Davis. 1997. Curr. Opin. Biotechnol. 8:635). Vectors used for DNA immunization may optionally comprise a signal sequence (Michel et al. 1995. Proc. Natl. Acad. Sci USA. 92:5307; Donnelly et al. 1996. J. Infect Dis. 173:314). DNA vaccines can be administered by a variety of means, for example, by injection (e.g., intramuscular, intradermal, or the biolistic injection of DNA-coated gold particles into the epidermis with a gene gun that uses a particle accelerator or a compressed gas to inject the particles into the skin (Haynes et al. 1996. J. Biotechnol. 44:37)). Alternatively, DNA vaccines can be administered by non-invasive means. For example, pure or lipid-formulated DNA can be delivered to the respiratory system or targeted elsewhere, e.g., Peyers patches by oral delivery of DNA (Schubbert. 1997. Proc. Natl. Acad. Sci. USA 94:961). Attenuated microorganisms can be used for delivery to mucosal surfaces. (Sizemore et al. 1995. Science. 270:29)

[0410] In one embodiment, plasmids for DNA vaccination can express T-bet as well as the antigen against which the immune response is desired or can encode modulators of immune responses such as lymphokine genes or costimulatory molecules (Iwasaki et al. 1997. J. Immunol. 158:4591).

[0411] Other means of expressing T-bet, e.g., as described elsewhere herein or known in the art can also be used. For example, in another embodiment, retroviral vectors are also appropriate for expression of T-bet immunomodulatory compositions. Recombinant retroviral vectors allow for integration of a transgene into a host cell genome. To transduce dividing cells, lentiviral vectors can be used as immunomodulatory compositions, and are intended to be encompassed by the present invention. Lentiviruses are complex retroviruses which, based on their higher level of complexity, can integrate into the genome of nonproliferating cells and modulate their life cycles, as in the course of latent infection. These viruses include HIV-1, HIV-2, SIV, FIV and EIV. Like other retroviruses, lentiviruses possess gag, pol and env genes which are flanked by two long terminal repeat (LTR) sequences. Each of these genes encodes multiple polypeptides, initially expressed as one precursor polyprotein. The gag gene encodes the internal structural (matrix capsid and nucleocapsid) polypeptides. The pol gene encodes the RNA-directed DNA polymerase (reverse transcriptase, integrase and protease). The env gene encodes viral envelope glycoproteins and additionally contains a cis-acting element (RRE) responsible for nuclear export of viral RNA. The 5′ and 3′ LTRs serve to promote transcription and polyadenylation of the virion RNAs and contains all other cis-acting sequences necessary for viral replication. Adjacent to the 5′ LTR are sequences necessary for reverse transcription of the genome (the tRNA primer binding site) and for efficient encapsidation of viral RNA into particles (the Psi site). If the sequences necessary for encapsidation (or packaging of retroviral RNA into infectious virions) are missing from the viral genome, the result is a cis defect which prevents encapsidation of genomic RNA. However, the resulting mutant is still capable of directing the synthesis of all virion proteins. A comprehensive review of lentiviruses, such as HIV, is provided, for example, in Field's Virology (Raven Publishers), eds. B. N. Fields et al., 1996.

[0412] This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patents and published patent applications cited throughout this application, as well as the Figures and the Sequence Listing, are incorporated herein by reference.

EXAMPLES

[0413] The following experimental procedures were used in the examples:

[0414] Mice, Cell Lines, Cytokines, Antibodies and Plasmids

[0415] BALB/c mice were obtained from Jackson Laboratories, DO11.10 TcR-transgenic mice (Jacobson, N. G., et al. 1995. J. Exp. Med. 181, 1755-1762), and MBP TcR-transgenic mice (Lafaille, J. J., 1994. Cell 78, 399-408.) have been described. Mice were used at 5-6 weeks of age. In addition, C57BL/6 (B6) and BALB/c mice (4-8 weeks old) were purchased from Taconic (Germantown, N.Y.). The generation and screening of T-bet deficient mice have been described (44, 46); and mice used were backcrossed at least six generations onto the B6 and BALB/c backgrounds.

[0416] Cell lines and primary cells were maintained in complete medium containing RPMI 1640 supplemented with 10% fetal calf serum (HyClone Laboratories), glutamine (2 mM), penicillin (50 units/ml), streptomycin (50 g/ml), Hepes (100 mM) and β-ME (50 μM). Jurkat is a human Th1 lymphoma, EL4 a mouse ThO thymoma, NK3.3 a human NK cell line (Ye, J., 1995. J. Leuko. Biol. 58, 225-233.; Kornbluth, J., 1982. J. Immunol. 129, 2831-2837), YT a human NK cell line (Yodoi, J., 1985. J. of Immuno. 134, 1623-1630), AE7 a mouse Th1 clone, D10 a mouse Th2 clone and M12 is a B cell lymphoma line. Recombinant IL-4 was obtained from DNAX, human rIL-2 was obtained from Chiron Corp., rIL-12 was obtained from Hoffman LaRoche, and rIL-18 was purchased from Peprotech, Inc. Monoclonal anti-IL-12, monoclonal anti-IFN-γ and monoclonal anti-IL-4 (11B11) were also used (Ohara, J. and Paul, W. E. 1985. Nature 315, 333-336). Both the T-bet polyclonal antisera, produced in rabbits, and the mAb were raised against full-length recombinant bacterially produced T-bet. The mAb was produced by fusion of spleen cells from mice to the SP2/O-Ag14 myeloma and is of the IgG1 subtype. Expression plasmids included c-Maf (pMex-maf)(Ho, I-C., et al. 1996. Cell 85, 973-983.). NFATp (Hodge, M. R., et al. 1996. Immunity 4, 1-20) and p65, the latter two cloned into the pCDNA vector.

[0417] CD4+ T Cell Purification and In vitro Cultures

[0418] CD4+ T cells were purified from lymph nodes (LN) by flow cytometry using PE-conjugated anti CD4 (RM4-4) (Pharmingen) and sorted using FACS (Mo Flo, Becton Dickenson) to 98-99% purity. For in vitro activation 2×10⁶/ml CD4+ cells were resuspended in complete medium and activated with plate-bound 1 μg/ml anti CD3 (2C11) and 2 g/ml anti CD28 (Pharmingen) for 3 days in the presence of 100 units/ml IL2. Cells were then split 1:4 in complete medium and cultured for 4 days in the presence of 100 units/ml IL2. On day 7 after primary stimulation, cells were harvested, washed twice and restimulated at 1×10⁶ cells/ml with 1 μg/ml plate-bound anti CD3 for 1, 3 and 6 hours. For Th1 and Th2 differentiation cultures, non-transgenic or DO11.10 LN and spleen cells were pooled, resuspended in 1×10⁶ cells/ml complete medium and cultured under Th1 (10 mg/ml anti IL4 [11B11], 10 ng/ml rIL12) or Th2 (10 mg/ml anti IFN-γ, 10 ng/ml IL4) conditions with 1 ug/ml plate-bound anti CD3. Cells were split 1:4 on day 3 with complete medium+100 u/ml IL2. On day 7, cells were restimulated with 1 g/ml anti CD3 for 4 hours and harvested for RNA preparation (Jacobson, N. G., et al. 1995). J. Exp. Med. 181, 1755-1762). Supernatants were taken at 24 hours to test for cytokines.

[0419] Purification and Isolation of Dendritic Cells and Macrophages

[0420] Recombinant mouse granulocyte/macrophage-colony stimulating factor (GM-CSF) used to generate bone marrow-derived DCs (bmDC) was produced as culture supernatant from a mouse macrophage cell line (J558L) transfected with the mouse GM-CSF gene (gift of Dr. I. Mellman). L-929 cells (gift of Dr. M. Starnbach) were used as the source of L-cell media to produce BM-derived macrophages

[0421] BmDCs were derived by a modification (47) that produces greater numbers of DCs. Briefly, BM cells were cultured in GM-CSF containing DMEM-10 media. At day 8, floating cells were collected and purified with CD11c⁺ magnetic beads (Miltenyi Biotec, Auburn Calif.) FACS analysis with Abs to FITC-I-A^(b) and PE-CD11c⁺ revealed >95% purity. Similarly, macrophages were derived from BM cells cultured in L-cell media (48). At day 8, adhesive cells were gently scraped off and purified with CD11b⁺ magnetic beads. FACS analysis with Abs to FITC-F4/80 and PE-CD14⁺ (Pharmigen, San Diego Calif.) revealed >95% macrophages.

[0422] Splenic DCs (spDC) and macrophages were isolated by collagenase treatment (49), and enriched by centrifugation in an Accudenz cell separation media (Accurate Chemical & Scientific Corp., San Diego, Calif.). T cells and NK cells were subsequently depleted using CD90 and NK1.1 magnetic beads, and DCs were then positively selected with CD11c⁺ magnetic beads. In some experiments, DCs were first positively selected with CD11c⁺ magnetic beads from collagenase treated spleen, and FACS sorted into subpopulations by staining with FITC-MHC II (I-E/I-A), PE-CD11c⁺, CyC-CD8⁺ or Cyc-CD4⁺ (Pharmingen, San Diego, Calif.). Macrophages were FACS sorted with Abs to PE-CD11b⁺ and FITC-F4/80, or FITC-CD11b⁺ and PE-CD14⁺. To generate activated peritoneal macrophages, 1 ml of 3% thioglycollagate (Difco, Irvine, Calif.) was injected intraperitoneal (i.p.) into young or aged mice; 3 to 5 days later, peritoneal exudates cells were collected, washed in PBS, and cultured in DMEM-10.

[0423] DC and Macrophage Stimulation

[0424] DCs and macrophages were cultured in DMEM-10 at a concentration of 1×10⁶/ml. Cells were stimulated with 10 ng/ml of recombinant mouse IL-12 or IL-18 (R&D sytems, Minneapolis, Minn.); 1-100 U/ml of rIFN-α/β (NIH, Bethesda, Md.); 20 ng/ml of IL-15 or IL-1 (Peprotech, Rocky Hill, N.J.); 1-100 ng/ml of IFN-γ (Peprotech, Rocky Hill, N.J.); 10 ng/ml of IL-21 (R&D systems); and LPS (Sigma-Aldrich, St. Louis, Mo.) at 100 ng/ml.

[0425] Northern and Western Blot Analysis

[0426] Total RNA was isolated from resting and stimulated cells using TRIZOL reagent (Gibco/BRL) and 10 μg of each sample separated on 1.2% agarose 6% formaldehyde gels, transferred onto Genescreen membrane (NEN) in 20× SSC overnight and covalently bound using a UV Stratalinker (Stratagene). Hybridization of blots was carried out at 42° C. as described (Hodge, M. R., et al. 1996. Immunity 4, 1-20) using the following cDNA probes labeled with 32P: T-bet, γ-actin. Nuclear and cytoplasmic extracts for western blot analysis were prepared from AE7, D10 and NK3.3 cells. Nuclei were isolated as described (Dolmetsch, R. E., et al. 1997. Nature 386, 855-858). Extracted proteins were separated by 8% PAGE followed by electrotransfer to nitrocellulose membranes and probed with a mAb specific for T-bet followed by horseradish peroxidase-conjugated goat anti-mouse IgG and enhanced chemiluminescence according to the instructions of the manufacturer (Amersham).

[0427] Transient Transfection Assays

[0428] EL4 and Jurkat cells were transfected using a Bio Rad electroporator (280V, 975 μF) using 5×10⁶ cells in 0.4 ml RPMI per transfection with 5 μg reporter plasmid and 5-10 μg expression plasmid. Luciferase assays were performed after 24 hrs with the luciferase activity in 20% of each sample measured as per instructions (Promega). The IFN-γ reporter-luciferase construct is derived from the plasmid pB9 which contains the entire human IFN-γ gene (P. Gray and D. V. Goeddel. 1982. Nature. 298:859). The pGL2 luciferase gene was inserted into the first exon of pB9. IL-2-promoter-reporter construct The IL-4 promoter reporter construct, IL-4Luc, contains 807 bp upstream of the murine IL-4 gene.

[0429] Retroviral Constructs and Transduction

[0430] The GFP-RV bicistronic vector has been described (Ouyang, W., et al. 1998. Immunity 9:745-755) as has the Phoenix-Eco packaging cell line (Kinoshita, S., et al. 1998. Cell 95, 595-604). The GFP-RV vector was constructed by inserting the encephalomyocarditis virus internal ribosomal entry sequence (IRES) and the GFP allele into the MSCV2.2 retroviral vector (Ouyang, W., et al. 1998. Immunity 9:745-755) or IL-2-MSCV vector. Both vectors express two cDNAs, T-bet and the cDNA encoding GFP, simultaneously using an IRES to initiate translation of each mRNA separately. Transfection of the packaging cell line and retroviral transductions of primary T cells were performed essentially as described (Ouyang, W., et al. 1998. Immunity 9:745-755).

[0431] Intracellular Cytokine Staining and FACS Analysis

[0432] Intracellular staining for cytokines was performed as described (Ouyang, W., et al. 1998. Immunity 9:745-755). Primary transgenic or non-transgenic T cells that had been infected with retrovirus for various time periods as indicated were restimulated with PMA (50 ng/ml and ionomycin (1 uM) for 2 hours and 10 ug/ml Brefeldin A added for an additional 2 hours.

[0433] Disease Characterization

[0434] Hematoxylin and cosin staining of formalin-fixed tissue sections, immunofluorescent studies on OCT-embedded frozen sections, flow cytometry of lymphoid cells, and assays for serum autoantibodies were performed as described⁷. Specific antibodies used in this study included R4-6A2 and XMG1.2 (anti-mouse IFN-γ), BVD4-1D11 and BVD6-24G2 (anti-mouse IL-4), MP5-20F3 and MP5-32C11 (anti-mouse IL-6), JES5-2A5 and SXC-1 (anti-mouse IL-10), MP1-22E9 and MP1-31G6 (anti-mouse GM-CSF), TN3-19.12 (anti-mouse TNF- ), rabbit anti-TNF-α, HM40-3 (anti-mouse CD40), 1D3 (anti-mouse CD19), and PE-R3-34 (rat IgG1, κ) (BD Pharmingen, San Diego, Calif.); PE-H106.771 (rat IgG1, κ anti-mouse IgG2a) (Southern Biotechnology Associates, Inc., Birmingham, Ala.); FITC-goat F(ab′)₂ anti-mouse IgG (Sigma, St. Louis, Mo.). Anti-DNA activity was determined by ELISA using high molecular weight mouse DNA (Sigma), and confirmed by immunofluorescence on Crithidia lucilliae kinetoplasts (Antibodies Incorporated, Davis, Calif.).

[0435] T Cell Assays

[0436] Naive CD4+ T cells were purified from spleen and lymph nodes by negative selection (R&D Systems, Minneapolis, Minn.) and stimulated for 48-72 hours in RPMI/10% with 1 μg/mL anti-murine CD28 (37.51) antibody and 1 μg/mL plate-bound anti-murine CD3 (145-2C11) antibody (BD Pharmingen). Cytokine production was evaluated in culture supernatants by ELISA (BD Pharmingen, San Diego, Calif.). Proliferation was measured by BrdU incorporation (Amersham Pharmacia Biotech, Piscataway, N.J.). Apoptosis was evaluated by exposing the cells for 24 hours to 20 μg/mL soluble anti-mouse CD3 and anti-mouse CD28, 5 μg/mL dexamethasone (Sigma), or 1200 J UV irradiation in a Stratalinker (Stratagene, La Jolla, Calif.), followed by evaluation by the CaspACE™ Assay System (Promega Corporation, Madison, Wis.).

[0437] Immunoglobulin Assays

[0438] For in vitro analyses, purified mature B cells were isolated from spleen and lymph nodes by magnetic CD43 depletion (Miltenyi Biotec, Auburn, Calif.) and stimulated in RPMI/10% with 25 μg/mL LPS (Sigma) supplemented with recombinant murine IL-4 at 10 ng/mL, IFN-γ at 100 ng/mL, human TGF-β1 at 1 ng/mL (PeproTech, Rocky Hill, N.J.), or murine IFN-γ at 100 U/mL (R&D Systems, Minneapolis, Minn.). For retroviral infection studies, purified CD43-depleted mature B cells were stimulated by 25 μg/mL LPS for 24 hours, followed by infection by a T-bet-GFP or control-GFP retrovirus². Quantification of serum immunoglobulin isotypes in serum or culture supernatants was performed as previously described. Germline and post-switch transcripts were determined by RT-PCR as described previously.

[0439] Real-Time PCR, ELISA, and Western Blot Analysis

[0440] RNA was isolated with Trizol (Sigma-Aldrich) from un-stimulated and stimulated DCs and macrophages. cDNA synthesis was performed with 1 ug of total RNA using oligo (dT) 15 primer, 20 nM of each dNTP, 0.1 M DTT, 1× first-stranded buffer, SuperScript II, and RNaseOUT (all from Invitrogen, Carlsbad, Calif.). Semiquantitative RT-PCR to determine the levels for T-bet, IFN-γ, TNF-α, IL-12 subunits p40 and p35, and other inflammatory cytokines, was performed as described by Overbergh et al (50). TaqMan universal PCR master mix was used for all reactions (AB Applied Biosystems, Branchburg, N.J.). Sequences of primers and TaqMan probe for most cytokines including β-actin are as described (51). Expression levels for the gene of interest are reported relative to β-actin abundance. Protein levels of IFN-γ and IL-12p40 were detected by ELISA from harvested supernantants of stimulated DCs and macrophages (Pharmigen). To detect the expression of T-bet protein, whole extracts were collected from DCs stimulated for different time periods and detected by immunoblot analysis as previously described (45).

Example 1 Cloning of a Novel Transcription Factor, T-Bet

[0441] Since the Th1-specific region of the IL-2 promoter had been well localized (Brombacher, F., et al. 1994. Int. Immunol. 6:189-197.; Rooney, J., et al. 1995. Mol. Cell. Biol. 15, 6299-6310; Lederer, J. A., et al. 1994. J. Immunol. 152, 77-86; Durand, D., et al. 1988. Mol. Cell. Biol. 8, 1715-1724; Hoyos, B., et al. 1989. Science 244, 457-450), a yeast one hybrid approach using an IL-2 promoter-reporter and a cDNA library made from the OF6 Th1 clone was chosen to identify Th1 specific transcription factors. To validate this approach, the Th2-specific region of the IL-4 promoter was expressed in yeast and demonstrated to be transactivated by the introduction of c-Maf, but not by several other transcription factors (eg NFAT). C-Maf transactivation did not occur when the c-Maf response element (MARE) was mutated. Thus, the yeast one hybrid approach was utilized.

[0442] The EGY48 yeast strain was stably integrated with the IL-2 promoter/histidine construct and transformed with a cDNA library made from an anti-CD3 activated Th1 cell clone, OF6. Of 5.6×10⁶ clones screened, 488 were positive in primary screening. Of the 210 clones tested during the secondary screen, 72 proved to be specific for the IL-2 promoter. To reduce the number of positive clones, we hybridized the yeast clone cDNA with cDNAs that were differentially expressed in Th1 and Th2 cell lines. These Th1-Th2 and Th2-Th1 cDNAs were made using the Clontech PCR select kit, radiolabeled and initially used in a pilot experiment to screen the 16 most strongly positive yeast clones. Of those 16 clones, 8 were positive with the Th1 (PL17) specific cDNA product probe and not with the Th2 (D10) specific cDNA product probe. Representational difference analysis (RDA; e.g., Lisitsyn. 1993. Science. 259:946; O'Neill and Sinclair. 1997. Nucleic Acids Res. 25:2681; Hubank and Schatz. 1994. Nucleic Acids Research. 22:5640; Welford et al. 1998. Nucleic Acids Research. 26:3059) with Th1-Th2 probe on 16 positive clones with control hybridization of the probe to IL-2, IFN-γ and IL-4 was performed. The specificity of the Th1 and Th2 subtracted cDNA probes is demonstrated by their detection of IL-2 and IFN-γ versus IL-4 respectively.

[0443] Restriction enzyme analyses and sequencing data revealed that all 8 of the clones were related. They fell into three groupings based on differences in the 5′ and 3′ untranslated regions, each of these categories representing an independent cDNA molecule. Comparing the sequence of these clones with the NCBI GenBank Sequence Database yielded homology with the T-box family of transcription factors. FIG. 1 shown the nucleotide and amino acid sequences of T-bet.

Example 2 T-Bet Shares a Region of Homology with the T-box Family Members T-Brain and Eomesodermin

[0444] Brachyury or T is the founding member of a family of transcription factors that share a 200 amino acid DNA-binding domain called the T-box (reviewed in (Smith, J. 1997. Current Opinion in Genetics & Development 7, 474-480; Papaioannou, and Silver. 1998. Bioessay. 20:9; Meisler, M. H. 1997. Mammalian Genome 8, 799-800.). The Brachyury (Greek for ‘short tail’) mutation was first described in 1927 in heterozygous mutant animals who had a short, slightly kinked tail (Herrmann, B. G., 1990. Nature 343, 617-622). There are now eight T-box genes in the mouse not including Brachyury. These include Tbx1-6, T-brain-1 (Tbr-1) and now, T-bet, each with a distinct and usually complex expression pattern. The T-box family of transcription factors is defined by homology of family members in the DNA binding domain. The T-bet DNA binding domain (residues 138-327 of murine T-bet) is most similar to the T-box domains of murine T-brain and Xenopus eomesodermin and thus places T-bet in the Tbr1 subfamily of the T-box gene family. The human homologue of the murine T-bet protein is approximately 88% identical to the mouse T-bet. FIG. 1A was derived using a Lipman-Pearson protein alignment (with G penalty set at 4 and gap length penalty set at 12. The similarity index was calculated to be 86.6; the gap number2, the gap length5, and the consensus length 535). T-bet shares a region of homology with the T-box family members T-brain and eomesodermin. The murine T-bet DNA binding domain is most similar to the T-box domains of murine T-brain and Xenopus eomesodermin. There is approximately 69% amino acid identity between the three T-box regions. T-bet bears no sequence homology to other T-box family members outside of the T-box domain.

Example 3 T-Bet Binds to and Transactivates Consensus T-Box Sites and has Functionally Important Domains that Map to Both 5′ and 3′ Regions

[0445] Recombinant T-bet protein binds to consensus T-box sites and to the T-bet site in the IL-2 promoter, and a complex present in nuclear extracts from anti-CD3-stimulated AE7 Th1 cells binds specifically to a consensus (GGGAATTTCACACCTAGGTGAAATTCC) T-box oligonucleotide probe. To test for activity of T-bet in T cells, the following experiments were performed. Jurkat Th1 cells were cotransfected with T-bet and a luciferase reporter construct. FIG. 2A shows the basal level (open bars) and the PMA (50 ng/ml) plus ionomycin (1 uM) induced (closed bars) promoter activity in Jurkat cells of a luciferase reporter construct containing a minimal thymidine kinase (TK) promoter with or without 4 copies of the consensus T-box site. Each reporter construct was co-transfected with empty pCDNA vector or pCDNA containing the full-length T-bet cDNA as indicated in the figure. The data shown are representative of three independent experiments. FIG. 2B shows Jurkat cells transiently transfected with the luciferase reporter construct containing the minimal TK promoter and multimerized consensus T-box sites and pCDNA vector containing the indicated regions of the T-bet cDNA diagrammed at the left of the bar graph. Luciferase activity was measured 24 hours post-transfection. The experiment was repeated three times with similar results. The basal level (open bars) and the PMA (50 ng/ml) plus ionomycin (1 uM) induced (closed bars) promoter activity obtained demonstrate that T-bet is active in T cells, and that its activity can be further increased upon stimulation.

Example 4 T-Bet Expression in T Cells is Restricted to the Th1 Subset and Regulated by Signals Transmitted via the TcR

[0446] T-bet was isolated from a Th1 cDNA library and a multiple organ Northern blot analysis revealed T-bet transcripts only in lung, thymus and in peripheral lymphoid organs.

[0447]FIG. 3A shows that T-bet is preferentially expressed in double negative (DN) thymocytes, not in double positive (DP) or single positive (SP) cells. Northern blot analysis of total cellular RNA isolated from Th1 cell clones (AE7 and D1.1) or Th2 clones (D10 and CDC35) that were treated with media or with plate-bound anti-CD3 (2C11) for 6 hours revealed T-bet transcripts only in the Th1 clones. Total cellular RNA was isolated from Th1 cell clones (AE7 and D1.1) or Th2 clones (D10 and CDC35) that were treated with media or with plate-bound anti-CD3 (2C11) for 6 hours. Total RNA was also isolated from M12 (B-cell lymphoma and EL4 (T-cell thymoma) treated with media or with PMA (50 ng/ml) and ionomycin (1 uM) for 6 hours. Northern blot analysis was performed with 10 ug of total RNA per lane using standard procedures and probed using the full-length T-bet cDNA. T-bet is preferentially expressed in Th1 clones. Further, the level of T-bet expression was augmented by signals transmitted via the TcR as evidenced by the induction of T-bet transcripts by anti-CD3. T-bet transcripts were not detected in M12, a B-cell lymphoma, in the Th1 lymphoma Jurkat or in EL4, a Th0-cell thymoma either when these cells were treated with media or with PMA (50 ng/ml) and ionomycin (1 uM) for 6 hours.

[0448] To determine protein levels of T-bet in primary T cells, DO11.10 TcR transgenic splenocytes were cultured under Th1 or Th2 polarizing conditions. At 72 hours the cells were expanded 3-fold in fresh medium with 200 U/ml IL-2. On day 7 after primary stimulation, nuclear and cytosolic extracts were prepared from resting or PMA/ionomycin activated (1 hr) bulk culture DO11.10 Th1 and Th2 cells. Nuclear extracts were also prepared from resting M12, EL4, Jurkat, NK3.3, and YT cells. As shown in FIG. 3C, among the cell lines, T-bet protein was present in YT cells only. FIG. 3C shows T-bet protein is restricted to Th1 cells and NK cells. Western blot analysis was performed on nuclear and cytosolic extracts prepared from resting or PMA/ionomycin activated (1 hr) bulk culture DO11.10 Th1 and Th2 cells as above. Briefly, D011.10 Tcr transgenic splenocytes were activated with OVA peptide (323-339) at 3×106 cells/ml in the presence of 10 ng/ml IL-12 and 10 ug/ml anti-IL-4 (11B11) to promote Th1 phenotype development, or 10 ng/ml IL-4 and 10 ug/ml anti-IFN-γ to promote Th2 phenotype development. At 72 hours the cells were expanded 3-fold in fresh medium with 200 U/ml IL-2. On day 7 after primary stimulation, nuclear and cytosolic extracts were prepared from resting or PMA/ionomycin activated (1 hr) bulk culture D011.10 Th1 and Th2 cells. Nuclear extracts were also prepared from resting M12 cells, EL4, Jurkat, NK3.3, and YT. 30 ug of nuclear and cytosolic extracts were separated by SDS-PAGE (8% gel), transferred to nitrocellulose, and probed with an anti T-bet antisera. In primary T cells, T-bet protein is selectively expressed in T cells driven along a Th1 but not a Th2 pathway, consistent with the Northern blot analysis of T cell clones and primary T cells shown above.

[0449] A monoclonal antibody (mAb) specific for T-bet allowed the direct visualization of T-bet protein by FACS analysis. FIG. 3D shows that T-bet can be visualized by FACS in activated AE7 Th1 cells. D10 (Th2) or AE7 (Th1) cells were treated with media or PMA (50 ng/ml) plus ionomycin (1 uM) for 2 hours and 2 uM monensin for an additional 3 hours. Cells were washed with PBS, fixed in 4% paraformaldehyde, permeabilized with 0.5% saponin, and stained with media (dashed line) or an IgG1 isotype control antibody (dotted line) or an affinity-purified anti-T-bet monoclonal antibody 3D10 (solid line) followed by goat anti-mouse IgG1-PE staining. Cells were analyzed by flow cytometry on a FACSCalibur. Mouse monoclonal antibodies were raised against full length bacterially produced T-bet. T-bet protein was not detectable in D10 cells, was present at low levels in unstimulated AE7 cells and was present at increased levels in stimulated AE7. Taken together, the experiments detailed here demonstrate that in T cells, T-bet is selectively expressed in Th1 cells where its level of expression is regulated by signals stemming from the TcR.

Example 5 T-Bet Expression Correlates with IFN-γ Induction in NK and B Cells

[0450] The Th1-limited expression of T-bet coupled with its isolation by virtue of binding to a T-box site in the IL-2 promoter suggested that T-bet might activate the transcription of the IL-2 gene. However, it was puzzling that two IL-2-producing cell lines, Jurkat and EL4, did not express T-bet, while the NK cell line YT, which produces IFN-γ but not IL-2, did express T-bet. Further, preliminary experiments did not demonstrate transactivation of the IL-2 gene by T-bet, despite the presence of an excellent T-box site in the IL-2 promoter. Other Th1-specific cytokines include IFN-γ, TNFα and LT. The expression of T-bet correlated well with the expression of IFN-γ. Further, a T-box site was found to be present in the third intron of the human IFN-γ gene. This was especially noteworthy since a Th1-specific DNaseI hypersensitivity site had recently been mapped to this region.

[0451] To examine the possibility that T-bet controlled the expression of the IFN-γ gene, the expression of T-bet and the expression of IFN-γ in cells other than Th1 cells was measured. IFN-γ is expressed in natural killer (NK) cells at low levels and is induced to high levels upon treatment with IL-2 and IL-12 (Kornbluth, J., et al. 1982. J. Immunol. 129:2831; Ye et al. 1995. J. Leuko. Biol. 58:225). Therefore, the NK3.3 cell line was treated for 24 h with IL-2, IL-12 and IL-2 plus IL-12, lysates prepared and western blot analysis performed with T-bet mAb as above. FIG. 4b demonstrates coordinate induction of T-bet protein and secretion of IFN-γ in NK3.3 cells. The NK3.3 cell line was treated for 24 h with reagents, IL-2, IL-12 and IL-2 plus IL-12, known to induce IFN-γ in NK cells, lysates prepared and western blot analysis performed with T-bet mAb as above. ELISA was performed on supernatants harvested from the cells.

[0452] B cells, which do not produce IFN-γ at baseline, can be driven to produce large amounts of IFN-γ upon treatment with anti-CD40 antibody and a combination of IL-12 and IL-18 (Yoshimoto, T., 1997. Proc. Natl. Acad. Sci. USA 94, 3948-3953). Purified B cells were treated for 72 h with anti-CD40 mAb, rIL-12 and rIL-18, RNA isolated and Northern blot performed using the T-bet cDNA as above. FIG. 4A shows induction of T-bet mRNA in B cells treated with this combination of reagents, and the induction of IFN-γ transcripts in these cells was confirmed. In conclusion, while neither cell type expresses T-bet constitutively, both NK3.3 cells and B cells can be induced to do so under conditions which also result in IFN-γ production. Thus, the pattern of expression of T-bet correlates well with the transcription of the IFN-γ gene.

Example 6 T-Bet Transactivates the IFN-γ Gene in Th Cells

[0453] Very little is yet known about the regulatory regions of the IFN-γ gene. In particular, the regions of the gene that direct its tissue-specific expression have not been identified in vitro or in vivo. It has been demonstrated that reporter constructs containing 500 bp or 3 kb of upstream sequence are expressed in both Th1 and Th2 cells (Young, H. A., 1994. J. of Immuno. 153, 3603-3610). ATF-2, NF B, AP-1 and Stat4 sites in the IFN-γ promoter or introns are thought to be functionally important, but clearly are not responsible for tissue-specific expression (Young, H. A., 1994. J. of Immuno. 153, 3603-3610; Sica, A., 1997. J. Biol. Chem. 272, 30412-30420; Penix, L., 1993. J. Exp. Med. 178, 1483-1496; Penix, L. A., 1996. J. Biol. Chem. 271, 31964-31972). Similarly, although Th1-preferential DNaseI hypersensitive sites have been noted both in the first and third introns, the relevant cis elements located in these introns have not been identified (Young, H. A., et al. 1994. J. of Immunol. 153, 3603-3610; Agarwal, S. and Rao, A. 1998. Immunity 9, 765-775). Therefore, a reporter construct containing the entire IFN-γ gene was utilized for these studies. The IFN-γ reporter gene used includes 3 kb of upstream sequence, the entire coding sequence with all three introns, and 1.5 kb of downstream (Xu, X., et al 1996. Science 273, 794-796).

[0454] The activity of a luciferase reporter construct containing 9 kb of the IFN-γ gene in the Jurkat human Th1 lymphoma and the mouse EL4 Th0 tyymoma was tested. Each reporter construct (10 ug) was co-transfected with empty pCDNA vector or pCDNA containing the full-length T-bet cDNA, c-Maf, NFATp or p65 (10 ug). The constructs also include the −400 to −40 IL-2 and IL-4 promoter luciferase reporters.

[0455] The Th0 mouse T cell thymoma EL4, which produces IL-2 and IL-4 but not IFN-γ was transfected with a T-bet cDNA expression plasmid and the IFN-γ-luciferase reporter (FIG. 5). Introduction of the T-bet expression plasmid resulted in (approximately 20-30 fold) transactivation of the IFN-γ gene compared to empty vector alone. This was in contrast to the absence of transactivation by two other factors, the Th2-specific transcription factor c-Maf and the Th non-selective transcription factor NFAT. Interestingly, although the NF B family member, p65, did not transactivate the IFN-γ reporter on its own, cotransfection of T-bet and p65 resulted in a synergistic activation.

[0456] Examination of the IL-2 promoter was also made using a region of the promoter known to be Th1-specific (Lederer, J. A., et al. 1994. J. Immunol. 152, 77-86). T-bet repressed the activity of the IL-2 promoter approximately 10 fold. This was especially apparent upon activation of the promoter by PMA and ionomycin. As before, substantial transactivation of the IFN-γ gene was noted. T-bet activity was specific for the IL-2 and IFN-γ genes since no effect on transactivation of an IL-4 promoter (FIG. 5) or a TNF-α promoter was present. These data demonstrate that T-bet specifically activates the transcription of the IFN-γ gene, and represses the transcription of the IL-2 gene.

[0457] To examine endogenous gene expression, EL4 cells were transiently transfected with T-bet or empty vector, and IFN-γ production measured by ELISA 48 hours after stimulation with PMA/ionomycin (FIG. 5). Consistent with the transactivation data shown above, ectopic expression of T-bet in EL4 cells led to measurable IFN-γ production while transfection with vector control did not result in detectable IFN-γ.

Example 7 Retroviral Gene Mediated Transfer of T-Bet into Primary Th Cells Results in Increased IFN-γ Production

[0458] The experiments described above argue strongly for a critical role of T-bet in controlling the transcription of the IFN-γ gene.

[0459] A bovine collagen-specific Th0 hybrid was transduced with retroviral constructs containing T-bet GFP or GFP only under the control of the TcR inducible IL-2 promoter. Transduced populations were FACS sorted on GFP twice, rested and then stimulated with anti-CD3 and supernatnats collected at 60 hours to measure cytokine production by ELISA. (FIG. 6). Control retroviral vectors which had not effect included anti-sense T-bet.

[0460] To further test whether T-bet is responsible for the tissue-specific expression of IFN-γ, retroviral gene mediated transfer of T-bet into primary T cells, both non-transgenic and TcR transgenic, was performed. Two different bicistronic retroviruses expressing both T-bet and GFP were used. The first expresses T-bet under the control of an IL-2 inducible promoter, and the second expresses T-bet under control of an MSCV LTR. Similar results were obtained with both constructs.

[0461] BALB/c CD4 T cells were infected after 36 hours of primary activation by anti-CD3 plus anti-CD28, harvested on day 7 and intracellular IFN-γ and IL-2 staining performed 5 hours after stimulation with PMA and ionomycin as described in Experimental Procedures. Data are shown as two-color plots showing GFP expression (FL1) versus intracellular cytokine (FL2) of events gated on expression of CD4. Primary T cells from MBP TcR transgenic mice were stimulated using MBP (Ac1-11) at 6 uM and infection performed on day 1 with IL-2/GFP and IL-2/T-bet/GFP. On day 7, cells were sorted for GFP expression, rested for 1 day and then intracellular cytokine analysis performed after a 5 hour stimulation with PMA and ionomycin.

[0462] Naive MBP-transgenic or non-transgenic BALB/c CD4 T cells were activated with MBP 1-11 and anti-CD3 under non-polarizing conditions and were infected with retrovirus on day 1 after primary activation as described (Ouyang, W., et al. 1998. Immunity 9:745-755). Cells were cultured for 7 days and then GFP expression measured to determine percentage of cells infected. GFP positive cells were sorted and cytokine production measured by intracellular staining after an additional 4 hours stimulation with PMA plus ionomycin.

[0463] Transduction of both MBP-TcR transgenic and non-transgenic T cells with T-bet resulted both in an impressive increase in the number of cells producing IFN-γ and in the amount of IFN-γ produced per cell as compared to cells transduced with GFP alone. (FIG. 7).

[0464] Naive Thp cells, early after stimulation, produce large amounts of IL-2, which is then gradually replaced in polarized Th cells by the effector cytokines IFN-γ and IL-4. Polarized Th1 cells do continue to produce IL-2 but at amounts considerably less than naïve Thp. Polarized Th2 cells shut off the production of IL-2. T-bet transduced Th cells produced somewhat less IL-2 than GFP/RV control transduced cells, consistent with the repression of IL-2 promoter transactivation by T-bet that we observed in EL4 cells. The repression of IL-2 by T-bet is consistent with a function for T-bet in driving lineage commitment from a naive precursor cell into a fully differentiated effector cell.

Example 8 T-Bet Activates IFN-γ and Represses IL-4 Production in Developing Th2 Cells

[0465] The experiments above demonstrate that T-bet can direct unskewed Th cells into the Th1 pathway. The T-bet could force Th cells to direct their genetic program along a Th1 pathway even in the presence of stimuli that would ordinarily drive them into the Th2 pathway was tested. In the experiments in FIG. 8, BALB/c CD4+ T cells were activated with anti-CD3 and anti-CD28 in the presence of rIL-4 and antibodies to IFN-γ and IL-12, retroviral infection performed at 36 hours, cells expanded with IL-2, GFP positive cells sorted on day 7 and cytokine production measured by intracellular staining after an additional 4 hours stimulation with PMA plus ionomycin. Transduction with GFP-RV alone resulted in a population that contained 13.4% IL-4-producing cells and 0.9% IFN-γ producers (FIG. 8). As expected, the Thp cells are not yet fully polarized at this time. Introduction of T-bet/GFP/RV produced a substantial shift of Thp into the Th1 pathway as evidenced by the large number of cells (50%) producing IFN-γ and the reduced number of cells producing IL-4 (3.5%), even under conditions (rIL-4 and anti-IL-12) that inhibit Th1 differentiation. Thus, T-bet can overcome the Th2-promoting signals delivered by cytokines to drive developing Th cells into the Th1 pathway.

Example 9 T-Bet Redirects Polarized Th2 Cells into the Th1 Pathway

[0466] It has been demonstrated that reversibility of Th1 and Th2 populations is lost after long-term stimulation under polarizing conditions. Reversibility is largely abrogated after one week and is completely lost after 3 weeks (Murphy, E., et al. 1996. J. Exp. Med. 183, 901-913.). To determine whether T-bet could redirect the commitment of a pure population of already polarized Th2 cells, CD4+ T cells were cultured as above and retroviral gene transduction performed at day 9 of culture. In Th cells cultured for 9 days under Th2 polarizing conditions, control GFP/RV-transduced cells are virtually all IL-4 and IL-5 producers (23% and 11%) with barely detectable IFN-γ producer cells (6%) (FIG. 9). Thus, as expected, almost complete polarization had occurred. Remarkably, introduction of T-bet into these fully polarized Th2 cells redirected or converted them into polarized Th1 cells as evidenced both by the induction of IFN-γ expression and the loss of IL-4 and IL-5 expression. This conversion occurred in the presence of exogenous IL-4. Fully 77% of T-bet-transduced Th2 cells now produced IFN-γ while the percentage of cells producing IL-4 and IL-5 has been reduced to 13% and 1% respectively. These T-bet-transduced cells are therefore not Th0 cells that produce both IFN-γ and IL-4. Therefore, T-bet has not simply induced IFN-γ expression in Th2 cells but has actually reprogrammed Th2 cells into the opposing Th1 subset.

Example 10 T-Bet also Redirects Polarized Tc2 Cells into the Tc1 Pathway

[0467] Although most attention has focused on the CD4+ T lymphocyte, it is apparent that cytotoxic CD8+ T cells also may also be divided into IFN-γ-producing (Tc1) and IL-4-producing (Tc2) subsets. The ability of T-bet to redirect fully polarized Tc2 cells into a Tc1 pathway was tested. Purified CD8+ T cells were therefore differentiated in culture under Tc2 polarizing conditions for 9 days to accomplish full differentiation. FIG. 10 demonstrates that T-bet transduced Tc2 cells, similar to T-bet transduced CD4 Th2 cells have been reprogrammed to produce IFN-γ (85% versus 15%) and to repress the production of IL-4 and IL-5 (3% versus 34% and 1% versus 45% respectively). Thus, T-bet can convert fully differentiated CD8+ Tc2 cells to Tc1 cells.

Example 11 T-Bet is Tyrosine Phosphorylated

[0468] To determine whether T-bet is a tyrosine phosphorylated protein, whole cell lysates from AE7 Th1 cells were prepared after incubation for 0, 5, 10, 30 minutes with pervanadate. Lysates were immunoprecipitated with anti-T-bet antiserum, separated by SDS-PAGE (8% gel), transferred to nitrocellulose, and probed with an anti-phosphotyrosine mAB 4G10. Following exposure, blots were stripped and reprobed with anti-T-bet antisera. As shown in FIG. 11, T-bet is clearly a tyrosine phosphorylated protein in T cells.

Example 12 Creation of a Dominant Negative T-Bet Molecule

[0469] Chimeric cDNA molecules were made with the T-bet DNA binding domain (residues 138-327) and the repressor domain of the Drosophila protein engrailed. The engrailed protein is a powerful, active repressor of transcription (Taylor, D., 1996. Genes Dev. 10, 2732; Li, J., Thurm, H., et al. 1997. Proc. Natl. Acad. Sci. USA 94, 10885). The T-bet-engrailed construct in vitro using a multimerized T-box consensus site/TK minimal promoter luciferase reporter construct. As shown in FIG. 12, T-bet/engrailed specifically and significantly represses the ability of wild type T-bet to transactivate a T-box reporter construct at a 5:1 ratio, and does not repress transactivation of an NFAT or NFkB reporter by NFATp and p65 expression constructs respectively.

Example 13 T-Bet is Required for Interferon-γ Production and Th1 Lineage Commitment

[0470] A. Generation of T-Bet Deficient Mice

[0471] To definitively address the role of T-bet in IFN-γ production and Th1 lineage commitment, T-bet deficient mice were generated. The T-bet gene was disrupted by homologous recombination by replacing the first exon, 500 bp of upstream sequence, 1 kb of intronic sequence with the neomycin resistance gene. Germline chimeric animals generated from the targeted TC1 embryonic stem cell clone produced heterozygous mice which were then intercrossed to obtain mice homozygous for the T-bet mutation (T-bet^(−/−)). T-bet deficient mice were born at the expected Mendelian ratios and were phenotypically normal and fertile. To confirm that the T-bet mutation inactivated the T-bet gene, total RNA or total protein lysates were isolated from resting or PMA/ionomycin activated CD4⁺ T cells from wild type littermate controls, and heterozygous or homozygous mutant mice. T-bet expression was not detected by Northern or Western blot analysis in T-bet^(−/−) CD4⁺ T cells and was present at a reduced level on T-bet^(+/−) heterozygotes.

[0472] Flow cytometric analysis of thymocytes, splenocytes and lymph node cells from littermate controls and T-bet^(−/−) mice revealed no abnormalities in expression of CD3, CD4, CD8, B220 nor in the composition of lymphocyte populations within each peripheral lymphoid organ. Thus, T-bet is not required for normal thymocyte maturation or mature T/B cell homing to peripheral organs.

[0473] B. T-bet Controls IFN-γ Production and Th1 Lineage Commitment

[0474] The cytokine production profiles from CD4⁺ T cells from T-bet deficient mice were examined. CD4⁺ T cells were purified from the lymph nodes of T-bet^(−/−), T-bet^(+/−) and T-bet^(+/+) mice to yield a population of 95% pure naïve CD4⁺/Me114⁺ T cells. A striking decrease in IFN-γ production by T-bet^(−/−) CD4⁺ T cells was observed as measured by ELISA 72 hrs after anti-CD3/CD28 stimulation as compared to wild type littermate control T-bet^(+/+) CD4⁺ T cells. A corresponding increase in IL-4 production was observed in T-bet^(−/−) CD4⁺ T cells. These results demonstrate that T-bet deficient cells produce Th2 type cytokines during a primary stimulation under neutral conditions (in which no cytokines or anti-cytokine antibodies were added).

[0475] To determine if this was an immediate effect on cytokine production or an effect on T helper cell differentiation, CD4⁺ T cells were purified from the lymph nodes of T-bet^(−/−), T-bet^(+/−) and T-bet^(+/+) mice and stimulated through the TCR under neutral conditions or under Th1 or Th2 inducing conditions to generate effector T helper cells. Upon restimulation with anti-CD3, cytokine production was measured by ELISA. T-bet^(−/−) CD4⁺ T cells produced dramatically less IFN-γ than the control T-bet^(+/+) CD4⁺ T cells with a concomitant increase in IL-4 and IL-5 production. This effect was seen even when the cells were stimulated in the presence of Th1 inducing conditions. Upon restimulation, these cells produced very low levels of IFN-γ and could not suppress production of IL-4 and IL-5. Thus, even under Th1 inducing conditions, T-bet^(−/−) CD4+ T cells default toward the Th2 lineage. These results were confirmed by ICC, an assay that allows for the examination of each IFN-γ producing cell, which showed a striking decrease in the number of IFN-γ producing cells in the absence of T-bet. We conclude that T-bet controls not only immediate cytokine production but also has a profound effect on T helper effector function.

[0476] Interestingly, heterozygous T-bet^(+/−) CD4⁺ T cells displayed an intermediate phenotype of cytokine production. It is possible that the absence of one allele of T-bet, with a corresponding decrease in T-bet protein, resulted in all CD4 T cells producing half as much IFN-γ as wild-type cells. Alternatively, there might be an exquisite sensitivity to threshold levels of T-bet with half as many cells producing wildtype levels of IFN-γ. To distinguish between these possibilities, ICC assays were performed. Cells were stimulated under Th1 inducing conditions for 7 days, then restimulated with PMA/ionomycin and analyzed for intracellular IFN-γ. This revealed that 85% of wildtype Th1 cells were IFN-γ producers while a striking decrease was observed in T-bet deficient Th1 cells (9%) and an intermediate phenotype observed in the heterozygous T cells (46%). Therefore the function of T-bet in controlling IFN-γ production is highly dosage sensitive, a finding that is consistent with the known function of other T-box family genes in which haploid insufficiency of Tbx3 and Tbx5 leads to the genetic disorders, Ulnar Mammary and Holt-Oram syndromes, respectively. Another possibility is monoallelic, rather than biallelic expression of T-bet as documented for certain cytokine genes (e.g. IL-2 and IL-4).

[0477] D. Conclusion

[0478] The analysis of the immune system in mice that lack T-bet, as described above, firmly establishes T-bet as a transcription factor that is required for Th1 lineage commitment. Further, it is clear that one mechanism by which this occurs is the control, of IFN-γ gene transcription by T-bet in vivo. Mice that lack T-bet do not develop a robust Th1 compartment as evidenced by the failure of CD4 T cells to produce the hallmark Th1 cytokine, IFN-γ even upon deliberate polarization. A large number of transcription factors have been implicated in the control of the IFN-γ gene. ATF-2, NFκB, AP-1, YY1, NF-AT and Stat sites in the IFN-γ promoter or introns are functionally important in vitro, but are not responsible for the tissue-specific expression of IFN-γ (Young et al., 1994; Sica et al., 1997; Penix et al , 1996; Xu et al., 1996; Sweetser et al., 1998), nor do they selectively control IFN-γ in vivo. Here we have demonstrated that T-bet is selectively required for IFN-γ production in CD4+ T cells and NK cells in vivo. Given the pathogenic role of Th1 cells in autoimmunity and cancer, and their protective role in asthma, these observations have clear implications for the treatment of human disease.

Example 14 T-Bet is Required for Interferon-γ Production and Lineage Commitment in CD4 and in Antigen Activated but not Anti-CD3 Activated CD8 T Cells

[0479] T-bet is expressed in both CD4 and CD8 T cells. To determine whether T-bet is involved with IFN-γ production in both CD4 and CD8 T cells, the following experiments were performed. Purified CD4 and CD8 T cells were stimulated for 72 hrs with plate bound anti-CD3, anti-CD28, rIL-12 and rIL-18, RNA prepared and northern blot analysis performed using T-bet, IFN-γ, and HPRT probes. CD8 T cells and CD4 T cells purified from T-bet^(−/−), T-bet^(+/−) and T-bet^(+/+) LN were stimulated with plate-bound anti-CD3 and anti-CD28 for 7 days. ICC analysis was performed after 5 hours stimulation with PMA (50 ng/ml) and ionomycin (1 uM). IFN-γ production was measured by ELISA 24 hrs after restimulation with anti-CD3/anti-CD28. CTL precursors from T-bet^(+/+) or ^(−/−) splenocytes were primed in vitro with Concanavalin A (5 ug/ml or plate bound anti-CD3/anti-CD28 and 100 U/ml hIL-2 for 5 days (32). On day 5 CD8 T cells (H-2^(b)) were purified by positive selection using MACS purification and incubated for 4 hours with ⁵¹Cr labeled P815 (H-2^(d)) allogeneic target cells at the indicated effector to target ratios.

[0480] The results of these experiments demonstrated that in contrast to CD4 T and NK cells, T-bet is not involved in controlling IFN-γ production in the other major subset of T cells, the cytotoxic CD8 T cell when this cell is stimulated via the T cell receptor and costimulatory CD28 receptor with antibodies to CD3 and CD28. However, as described in Example 28, T-bet does control the production of IFN-γ from antigen-activated CD8 cells.

Example 15 T-Bet Regulates IgG Class Switching and Pathogenic Autoantibody Production

[0481] Because of its role in Th1 responses, it is likely that T-bet would play a critical role in systemic autoimmune syndromes like lupus, which rely heavily upon Th1 T cells for pathogenesis. Lupus-prone T-bet-deficient mice were generated by intercrossing a T-bet-deficient line with the MRL/MpJ-Fas(CD95)^(lpr/lpr) murine lupus strain, generating animals of four genotypes, T-bet^(+/+)Fas^(+/+), T-bet^(−/−)Fas^(+/+), T-bet^(+/+)Fas^(lpr/lpr)(T-bet+lpr), and T-bet^(−/−)Fas ^(lpr/lpr)(T-bet-lpr). Flow cytometric analyses of tissues from adult 6-week old animals revealed that T-bet did not have a significant effect upon the proportional numbers of CD4+ or CD8+ T cells, or B220-positive B cells in spleen or lymph node. Upon aging, T-bet-lpr animals were protected from immune-complex renal disease, which was characterized by strikingly diminished glomerular, interstitial and perivascular inflammation as well as glomerular immune complex deposition. Also, they developed significantly less humoral autoimmunity as assessed by the fluorescent antinuclear antibody test and two tests for anti-DNA antibodies. Their sera contained some, albeit diminished, autoimmunity to DNA as assessed by ELISA, but were unable to recognize native, double-stranded DNA as assessed by Crithidia immunofluorescence, suggesting the presence of generalized (e.g., anti-ssDNA), but not matured (e.g., anti-dsDNA) autoimmunity in T-bet-lpr animals. Compared to T-bet+lpr animals, T-bet⁻lpr animals were relatively protected from glomerulonephritis-related mortality (survival of 57%, n=7 versus 100%, n=6, at 28 weeks, respectively).

[0482] Surprisingly, T-bet⁻lpr animals continued to develop other manifestations consistent with T-cell autoimmunity, including cutaneous, salivary gland, and hepatic infiltrates, as well as lymphoid organomegaly, often in excess of their T-bet⁺lpr littermates. These lymphoid infiltrates consisted mostly of T cells, as assessed by immunohistopathology. Such findings suggest that the Th1-dominant T cell autoimmunity in this model was largely intact in the absence T-bet. Although T-bet was required for the production of IFN-γ by naive CD4⁺ T cells from CD95-intact animals, T-bet⁻lpr T cells produced excess cytokines, including IFN-γ and IL-4, and demonstrated similar proliferative activity in an autologous mixed lymphocyte reaction, compared to their T-bet⁺lpr littermates.

[0483] Since pathogenic autoantibodies are necessary and sufficient to induce immune complex glomerulonephritis, and T-bet is induced in both human and murine B cells upon activation, it is likely that T-bet is directly required in B lymphocyte function. As assessed by serum levels, T-bet was required for the complete expression in these lupus-prone animals of hypergammaglobulinemia IgG2a, IgG2b and IgG3, a requirement amplified in Fas^(lpr/lpr) animals IgG2a levels, however, were severely diminished in T-bet-deficient sera from either Fas genotype. IgG2a immune deposits were significantly reduced in the kidneys of T-bet-lpr animals. Purified T-bet-deficient B cells were unable to complete class switching to IgG2a when stimulated in vitro, as assayed by secreted immunoglobulin. Class switching to IgG2b and IgG3 was significantly diminished, but nevertheless present in T-bet-deficient cells. These deficits appeared to occur at the transcriptional level, since in class-switching assays T-bet-deficient B cells were neither able to accumulate surface IgG2a nor generate germline or postswitch IgG2a transcripts. Conversely, T-bet-deficient B cells produced excess amounts of the Th2-related isotypes IgG1 and IgE. These deficits did not simply result from an unopposed effect of IL-4, because the addition of up to 10 μg/mL anti-mIL-4 antibodies to B cell cultures did not affect the IgG2a deficiency, or the IgG1/IgE excess. These observations suggest a profound role for T-bet in the regulation of IgG2a at the level of the germline transcript, and further implicate it in the regulation of IgG1 and IgE.

[0484] Further evidence that T-bet directly controls the transcription of IgG2a includes the following. Transfection of the murine pre-B cell lymphoma 18.81 with a T-bet expression plasmid induced endogenous IgG2a germline transcripts. In addition, transduction of primary T-bet-deficient B cells with a T-bet-expressing retrovirus confers the ability to generate IgG2a germline transcripts, as well as secreted IgG2a. Furthermore, purified B cells from a CMV-T-bet transgenic mouse line, which expresses T-bet under the control of the CMV early promoter, produced increased amounts of IgG2a when stimulated in vitro with LPS and rmIFN-γ compared to B cells from nontransgenic littermates (490±50 ng/mL vs. 1058±120 ng/mL, n=3). To determine if T-bet played a role in the IFN-γ signaling pathway, the CMV-T-bet transgenic line was crossed with an IFN-γ receptor (IFNγR)-deficient background T-bet was able to augment the production of IgG2a, this time in the absence of IFN-γ signaling. The proliferative capacity of T-bet deficient B cells, as well as their ability to upregulate several markers of B cell activation, including IFN-γ, IL-6, IL-10, and GM-CSF, was unaffected in vitro, further suggesting a direct role for T-bet in the regulation of IgG transcription, independent of B cell activation status.

[0485] T-bet therefore confers upon B lymphocytes the ability to class switch to IgG2a in response to IFN-γ. T-bet also plays a significant role in the regulation of other Ig isotypes, and thus, plays a major role in the regulation of pathogenic autoantibody production. Without being bound by one particular theory, given its role as a transcription factor, T-bet likely regulates class switching via control of germline transcripts, which have been strongly implicated as a prerequisite to isotype switch recombination. Alternatively, T-bet may participate in mediating accessibility of the IgG locus to transcriptional or recombinatorial factors, as it does for IFN-γ in CD4 T cells. In either scenario, T-bet serves as a mediator of signals to transactivate the classical IFN-γ-related immunoglobulin isotype IgG2a, yet inhibits the classical Th2-related isotypes IgG1 and IgE. While T-bet is capable of inducing germline transcripts in the absence of exogenous IFN-γ, complete wild-type-level production of IgG2a appears to require IFN-γ signaling, suggesting that T-bet cooperates with another factor in the IFNγR pathway, such as STAT1, or at least require signaling messages, such as tyrosine phosphorylation, e.g., activated by the IFNγR for complete activity.

[0486] The identification of T-bet as a regulator of IgG isotype class switching may prove helpful in future transcriptional analyses of the non-IL4-dependent IgG subclasses, whose study has been greatly hindered by their apparently very distant locus control regions. Although the present results demonstrate that T-bet can transactivate endogenous IgG2a transcripts in whole cells, it cannot transactivate a reporter construct consisting of 3 kB of putative IgG2a promoter upstream of the I exon, at least in 18.81 cells. Thus, the control region for IgG2a, at least as it relates to T-bet, may be quite distant. The present results are therefore of particular significance given the complete yet selective absence of IgG2a germline transcripts in the T-bet-deficient B cells. In comparison, several reported immunoglobulin isotype immunodeficiencies caused by other transcription factor knockouts involve multiple Ig isotypes and/or other developmental B cell defects. Thus, the present invention identifies T-bet as an isotype-specific participant in the class switch mechanism.

Example 16 T-Bet Regulates Mucosal T Cell Activation in Experimental Colitis and Crohn's Disease

[0487] Crohn's disease and ulcerative colitis are the two major forms of inflammatory bowel diseases (IBD) in humans. Whereas Crohn's disease is characterized by a transmural, granulomatous inflammation that can occur anywhere in the gastrointestinal tract, ulcerative colitis causes a more superficial, continuous inflammation that is restricted to the large bowel. Although the etiology of the diseases is unknown, it has been suggested that an activation of the mucosal immune system in response to bacterial antigens with consecutive pathologic cytokine production and activation of matrix metalloproteinases plays a key pathogenic role. In particular, cytokines produced by T lymphocytes appear to initiate and perpetuate chronic intestinal inflammation. Interestingly, cytokine production by lamina propria CD4⁺ T lymphocytes differs between Crohn's disease and ulcerative colitis. Whereas the former disease is associated with increased production of T helper 1 (Th1) type cytokines such as IFN-γ and TNF, the latter disease is associated with T cells producing large amounts of the Th2 type cytokine IL-5 while IFN-γ production is unaffected. In both Th1- and Th2-mediated inflammatory bowel disease, the immunosuppressive cytokine TGF-β, mainly secreted by Th3 cells and a unique population of regulatory T cells (Tr), provides a powerful protective effect.

[0488] A. Reciprocal Expression of GATA-3 and T-bet in Lamina Propria T Cells from Patients with Crohn's Disease

[0489] Since changes in cytokine production by lamina propria T cells have been implicated as a key phenomenon in the pathogenesis of inflammatory bowel diseases (IBD), a series of experiments on the expression of T-bet by purified lamina propria (LP) T cells in IBD patients was performed. Immunofluorescence double staining studies showed an accumulation of T-bet expressing LP T cells in patients with Crohn's disease (CD). In addition, it was found that T-bet was strongly expressed in both the cytoplasm and the nucleus of LP mononuclear cells in patients with Crohn's disease, while only a weak staining in perinuclear areas or no staining was observed in control patients and patients with ulcerative colitis. To verify increased expression of T-bet in patients with Crohn's disease, nuclear extracts of purified LP T cells from patients with Crohn's disease and control patients were isolated and expression of T-bet by EMSA and Western blot analysis was analyzed. Patients with Crohn's disease expressed higher amounts of nuclear T-bet compared with control patients.

[0490] The expression of GATA-3 in LP T cells from CD patients was also assessed. GATA-3 expression was downregulated in LP T cells from CD patients compared to control patients, as assessed by immunohistochemical double staining analysis for CD3 and GATA-3 on colon cryosections. These data are indicative of a reciprocal expression pattern of GATA-3 and T-bet in CD LP T cells that is associated with increased IFN-γ but decreased IL-4 and IL-5 production in this disease.

[0491] B. Induction of T-bet Expression in Th1—but not Th2-mediated Animal Models of Chronic Intestinal Inflammation

[0492] Nuclear proteins from T cell enriched lamina propria mononuclear cells (LPMC) in various animal colitis models were isolated and T-bet expression was assessed by EMSA and Western blot analysis. T-bet was found to be strongly expressed in T cell enriched LP cells in the TH1-mediated colitis model observed in SCID or RAG mice reconstituted with CD62L⁺ CD4⁺ T cells. Time course studies showed that increased T-bet expression in the colon occurred as early as 3 weeks after cell transfer before the onset of colitis. Maximum expression was noted 6 weeks after cell transfer when the mice started to develop colitis, although increased T-bet expression was also observed in the full-blown colonic inflammation seen at 12 weeks after T cell transfer. Furthermore, increased T-bet expression was consistently noted in two additional TH1-mediated animal models of chronic intestinal inflammation, namely colitis in IL-10 deficient mice and colitis induced by the hapten reagent 2,4,6,-trinitrobenzene sulfonic acid (TNBS). In contrast, unchanged or lower levels of T-bet were detected in T cell enriched LP cells in oxazolone colitis and TCRα^(−/−) μ^(−/−) associated colitis; two colitis models that are believed to be mediated by IL-4 producing T cells and Th2 cells, respectively. These findings indicate that T-bet is potentially a key regulator of the mucosal TH1/TH2 cytokine balance in experimental colitis in vivo.

[0493] C. Retroviral or Transgenic Overexpression of T-bet Induces an Early Onset of Severe CD62L⁺ CD4⁺ Th1 T Cell-Mediated Colitis in SCID Mice

[0494] To determine the potential regulatory role of T-bet in Th1-mediated colitis in vivo by transgenic or retroviral overexpression techniques, the colitogenic potential of T cells after infection with a T-bet retrovirus was analyzed. FACS-sorted GFP⁺ CD62L⁺ double positive CD4⁺ T cells that were retrovirally transduced with T-bet induced an earlier onset of severe colitis in SCID mice compared to SCID mice reconstituted with control transduced CD62L⁺ T cells, as assessed by weight loss curves. This phenotype demonstrates that overexpression of T-bet accelerates development of TH1-mediated chronic intestinal inflammation. It was further observed that transfer of CD62L⁺ CD4⁺ T cells from T-bet transgenic mice induced an earlier onset of colitis activity in SCID mice compared to T cells from wild-type littermates.

[0495] D. Mice Lacking T-bet (T-bet Knockout) are More Susceptible to Th2-Mediated Colitis

[0496] To determine the susceptibility of mice in which the T-bet gene has been inactivated by homologous recombination for T cell-mediated colitis, T-bet deficient mice that exhibited an altered susceptibility to Th2-mediated colitis using the oxazolone-induced colitis model that has previously been shown to be dependent on IL-4 production by T cells were ananlyzed. The T-bet knockout mice showed enhanced susceptibility to oxazolone-induced colitis compared to both wild-type littermates and heterozygous T-bet mice, based on by weight curve), macroscopic and histopathologic criteria. This was accompanied by a marked increase in IL-4 production by splenic CD3+ T cells, while IFN-γ production by these cells was not significantly changed.

[0497] To determine whether the observed increase in IL-4 production was responsible for the differences between wild-type and T-bet knockout mice, antibodies to IL-4 or control rat Ig to T-bet knockout mice after oxazolone sensitization were administered. Antibodies to IL-4 suppressed histologic colitis activity in oxazolone-treated T-bet knockout mice indicating that the protective role of T-bet in Th2-mediated colitis is due to its direct or indirect regulation of IL-4 production.

[0498] E. T-bet Deficiency Protects from Th1-Mediated Experimental Colitis in an Adoptive Transfer Model using CD62L⁺ CD4⁺ T Cells

[0499] The effects of T-bet deficiency in Th1-mediated colitis induced by transfer of CD4⁺ CD62L⁺ CD45Rb^(high) T cells in SCID and RAG knockout mice were assessed. Transfer of T-bet expressing CD4⁺ CD62L⁺ T cells from wild-type mice resulted in clinical and endoscopic signs of severe colitis. In contrast, transfer of T-bet^(−/−) CD4⁺ CD62L⁺ T cells failed to induce chronic diarrhea, weight loss, rectal prolapse and endoscopic signs of colitis. Furthermore, transfer of T-bet deficient T cells resulted in a markedly reduced colitis activity in SCID mice reconstituted with CD62L⁺ CD45Rb^(high) CD4⁺ T cells in three independent experiments, as assessed by macroscopic and histologic criteria. This protective effect of T-bet deficiency on CD62L⁺ CD4⁺ T cell-induced colitis was at least as pronounced as that seen upon transfer of STAT-1-deficient CD62L⁺ CD4⁺ T cells (histopathologic score: STAT-1^(−/−) reconstituted mice: 1.25+/−0.9 vs. T-bet^(−/−) reconstituted mice: 0.8+/−0.2). LP T cells from T-bet knockout T cell reconstituted mice produced less IFN-γ compared to LP cells from wild-type T cell reconstituted mice (336+/−24 pg/ml versus 1159+/−25 pg/ml) indicating that T-bet deficiency suppresses proinflammatory cytokine production by mucosal CD4⁺ T cells. Interestingly, CD4⁺ CD62L⁺ T cells from heterozygous T-bet mice showed a marked variability to induce colitis in three independent experiments, likely due to a threshold effect of T-bet expression in controlling cytokine gene expression and hence the colitogenic potential of T cells.

[0500] F. T-bet Controls the Mucosal Balance between IFN-γ and IL-4 Production by T Cell Enriched Lamina Propria Cells in the Absence of Colitogenic Stimuli

[0501] The structure of the lamina propria and cytokine production by lamina propria mononuclear cells (LPMC) in mice lacking T-bet was assessed. No macroscopic or histologic abnormalities in the small and large bowel of T-bet heterozygous and T-bet knockout mice in the absence of colitogenic stimuli was observed. To analyze cytokine production by T cell enriched LPMC from T-bet deficient mice and wild-type littermates, cells were stimulated by anti-CD3 plus anti-CD28 for 48 hours and cytokine production in culture supernatants was determined by ELISA. Two independent experiments demonstrated that T cell enriched LPMC from T-bet knockout mice secreted lower levels of IFN-γ than cells from wild-type littermates in the absence of colitogenic stimuli. In contrast, production of the Th2 type cytokines IL-4, IL-6 and IL-10 by T cell enriched LPMC was augmented in T-bet deficient animals compared to wild-type mice. In particular, IL-4 production by T-bet^(31 /−) and T-bet^(+/−) LPMC was increased compared to T-bet expressing LPMC from wild-type littermates (FIG. 7b). These changes in cytokine production were seen using LPMC from both the small and large bowel indicating that T-bet is a regulator of the mucosal Th1/Th2 cytokine balance in the entire gut immune system.

[0502] Whether increased Th2 cytokine production by LPMC in T-bet knockout mice was associated with evidence for activated IL-4 signaling in LP T cells was assessed next. There was increased GATA-3 expression in nuclear extracts from T cell enriched LPMC of T-bet deficient mice, as shown by both gel retardation assays and Western blot analysis, consistent with an increased presence of Th2 effector T cells in the mucosa of T-bet knockout mice.

[0503] G. T-bet Deficient Regulatory CD62L⁻ CD4⁺ T Cells Show Enhanced Protective Functions in Th1-Mediated Colitis and Exhibit Increased TGF-β Production and Signaling

[0504] To determine the effect of T-bet deficiency on TGF-β production and signaling in T cells, the T cell enriched LPMC in T-bet knockout mice were observed and shown to produce increased amounts of TGF-β compared to cells from wild-type littermates. This increased production of TGF-β in the absence of T-bet could be important for the regulatory function of T-bet in colitis, since TGF-β production by T cells has been recently suggested to play a key role in suppressing chronic intestinal inflammation. In intestinal inflammation, TGF-β is mainly produced by a unique population of regulatory CD25⁺ CD45RB^(low) CD62L⁻ CD4⁺ T cells that have been shown to suppress colitis activity in SCID mice when co-transferred with CD4⁺ CD62L⁺ T cells. Furthermore, at least in the spleen, IL-4 producing T cells have been shown to produce high amounts of TGF-β in secondary cultures.

[0505] Both splenic CD62L⁺ and CD62L⁻ CD4⁺ T cells from healthy mice expressed large amounts of nuclear T-bet as shown by Western blot analysis. Splenic CD25⁺ cells, however, showed lower amounts of nuclear T-bet expression. Furthermore, CD62L⁻ CD45RB^(low) CD4⁺ T cells from T-bet knockout mice showed decreased expression of Smad7, an inhibitory Smad protein that is induced by IFN-γ and suppresses TGF-β signaling in T cells, compared to cells from wild-type mice. Consistently, splenic T-bet^(−/−) CD62L⁻ CD4⁺ T cells exhibited increased nuclear Smad3 expression compared to T-bet expressing CD62L⁻ CD4⁺ T cells indicative of enhanced TGF-β signaling. Based on these findings the potential regulatory capacity of CD62L⁻ CD4⁺ T lymphocytes from wild-type, T-bet heterozygous and T-bet knockout mice to suppress colitis induced by T-bet expressing CD62L⁺ CD4⁺ T cells was analyzed. Cotransfer of regulatory CD62L⁻ CD4⁺ T cells plus naive CD62L⁺ CD4⁺ T cells from T-bet expressing wild-type mice led to less severe colitis compared to mice reconstituted with CD62L⁺ CD4⁺ T cells confirming a protective role for this T cell subset in vivo. Moreover, cotransfer of T-bet-deficient regulatory CD62L⁻ CD4⁺ T cells caused a more pronounced protective effect on CD62L⁺ CD4⁺ T cell-mediated colitis compared to regulatory CD62L⁻ cells from wild-type mice. This finding was associated with an increased production of TGF-β by lamina propria T cells from reconstituted mice and by an expansion of the number of regulatory CD4⁺ CD25⁺ T cells in the spleen of reconstituted mice.

[0506] H. T-bet Controls TGF-β Production and Signaling in Regulatory T Cells and TGF-β Inhibits T-bet Expression

[0507] Regulatory T cells producing IL-10 or TGF-β mediate protective effects in Th1-mediated colitis by suppressing the activity of T lymphocytes. To determine the if T-bet has a role in TGF-β production and signaling in regulatory T cells, the following studies were performed. Cells were cultured in the presence of antibodies to CD3 and CD28 with or without recombinant IL-4 and TGF-β (1 ng/ml). Cellular extracts were made after 48 hours and analyzed for the expression of T-bet and beta-actin by Western blot analysis. To determine whether TGF-β is produced by T cell enriched LPMC from wild-type (WILD TYPE), T-bet heterozygous (HET) and T-bet knockout (KNOCK OUT) mice in the absence of colitogenic stimuli, cells were stimulated with antibodies to CD3 plus CD28 and supernatants were analyzed by ELISA. To determine whether T-bet is expressed in splenic CD25⁺, CD62L⁺ and CD62L⁻ CD4⁺ T cells from healthy wild-type mice, cytoplasmic (CYT) and nuclear (NUC) extracts from these cells were isolated and analyzed for T-bet expression by Western blotting. To determine whether TGF-β-mediated signaling is increased in T-bet deficient CD62L⁻ CD4⁺ T cells, CD62L⁻ CD4⁺ T cells from wild-type and T-bet knockout mice were stimulated with anti-CD3 plus anti-CD28 and rIFN-γ for 12 hours followed by protein extraction and Western blot analysis. Cellular extracts were analyzed for Smad7 expression whereas nuclear extracts were analyzed for Smad3 levels. To measure the inflammation score of mice reconstituted with CD62L⁺ CD4,⁺ T cells from wild-type mice and CD62L⁻ CD4⁺ T cells from T-bet knockout mice (KNOCK OUT) and wild-type (WILD TYPE) control mice were measured.

[0508] FACS analysis of splenic CD4+ T cells from mice reconstituted with CD62L⁺ CD4⁺ T cells from wild-type mice plus CD62L⁻ CD4⁺ T cells from T-bet knockout mice (KNOCK OUT) or wild-type (WILD TYPE) control mice was also performed. Finally, TGF-β production by LPMC from the above reconstituted mice was measured by stimulating cells with antibodies to CD3 plus CD28 in serum free medium. Supernatants were collected after 3 days followed by analysis of supernatants by ELISA.

[0509] The foregoing studies demonstrate a regulatory role for T-bet in mucosal cytokine production. Specifically, the present invention demonstrates that CD62L⁻ CD4⁺ T cells from T-bet knockout mice exhibit a stronger protective effect on CD62L⁺ CD4⁺ T cell-induced colitis than the corresponding cell population from wild-type mice. This observation is related to differences in TGF-β production and signaling, as CD62L⁻ CD4⁺ T cells from T-bet deficient mice exhibited increased nuclear Smad3 expression. After binding of TGF-β to its receptor on T cells, Smad3 is interacts with the TGF-β receptor I followed by importin-1β and RanGTPase-mediated import of Smad3 into the nucleus where it controls expression of β target genes. IFN-γ has been previously shown to inhibit TGF-β signaling by a Jak1/STAT-1-mediated rapid activation of the synthesis of the inhibitory Smad-7 protein, which in turn can prevent the interaction of Smad3 with the TGF-β type I receptor. Furthermore, Smad7 can form a complex with the ubiquitin-ligase Smurf2 that targets the TGF-β receptor for degradation. Thus, the reduced production of IFN-γ by splenic CD4⁺ T cells and T cell enriched lamina propria cells in T-bet deficient animals causes reduced expression of Smad7 followed by increased TGF-β signaling via Smad3/4. In fact, CD62L⁻ CD4⁺ T cells from T-bet deficient mice express reduced levels of Smad7 compared to T cells from wild-type mice.

[0510] Since administration of neutralizing antibodies to TGF-β is known to suppress the protective capacity of CD62L⁻ CD4⁺ T cells on Th1-mediated colitis, the present invention demonstrates that the enhanced regulatory capacity of T-bet deficient CD62L⁻ CD4⁺ cells is due to increased TGF-β production and signaling. The enhanced TGF-β production of T-bet deficient T cells is likely augmented after T cell transfer, as TGF-β has been demonstrated to positively regulate its own production. The relevance of a defect in TGF-β1 expression or TGF-β-mediated signaling via Smad3 for the mucosal immune system has been shown by the observation that knockout mice for these proteins develop T cell-mediated chronic intestinal inflammation. TGF-β in turn downregulates T-bet expression in mucosal cells, demonstrating a reciprocal relationship between TGF-β and T-bet levels in T cells. We observed that treatment of activated T-cell enriched LPMCs with TGF-β but not IL-4 suppressed T-bet expression suggesting a reciprocal relationship between TGF-β and T-bet (FIG. 13).

[0511] In summary, the present invention identifies T-bet as a master switch for T cell-mediated chronic intestinal inflammation and the regulation of protective immune responses by TGF-β. T-bet controls Th1 and Th2 cytokine production in colitis and its levels are downregulated by TGF-β. Furthermore, downregulation of T-bet is associated with increased TGF-β levels due to failure of T-bet-mediated activation of Smad7. Moreover, TGF-β levels correlate with colitis in mice lacking T-bet. Thus, modulation of T-bet function is a valuable target for local therapeutic intervention in Th1-mediated chronic intestinal inflammation such as is observed in Crohn's disease.

Example 17 Mice Lacking T-Bet Spontaneously Develop Airway Changes Consistent with Human Asthma

[0512] Human asthma is associated with reversible airway obstruction, airway inflammation, airway hyperresponsiveness (AHR) and, in chronic asthma, airway remodeling. Murine models of asthma mimic many of the features of the human disease. In these models the production of IL4, IL-5 and IL-13 have been associated with the development of an asthma-like phenotype. In an adoptive transfer model, enhanced expression of IFNγ by Th1 cells in the airway protects against allergic disease, but the presence of Th1 cells does not attenuate Th2 cell-induced airway hyperreactivity and inflammation.

[0513] To determine whether T-bet was expressed in the lungs of normal individuals and in patients with allergic asthma, immunohistochemistry using a mAb to T-bet was performed. The results revealed expression of T-bet in thirteen normal control lungs, but very little expression in seven patients with allergic asthma. Double staining for CD4 and T-bet in consecutive sections showed that most of the cells expressing T-bet were CD4⁺ T cells. Thus, T-bet deficiency recapitulates many aspects of the asthmatic phenotype.

[0514] Naïve mice, i.e., neither antigen sensitized nor challenged, with a targeted deletion of T-bet were examined to ascertain if such animals would manifest various aspects of the induced asthma phenotype. Compared to wild type (wild type) mice, those either heterozygous (T-bet+/−) or homozygous for a targeted deletion of T-bet (T-bet−/−) exhibited greater airway responsiveness, as measured in unanesthetized animals by the enhanced pause response (Penh), following aerosol exposure to methacholine. These findings were confirmed in mice that had been sensitized by systemic exposure to ovalbumin but sham challenged with aerosol phosphate buffered saline (termed OVA/PBS), by the demonstration that both T-bet (+/−) and (−/−) mice manifested airway hyper-responsiveness, as compared to wild type mice, when the pulmonary resistance response resulting from intravenous infusion of methacholine, was used as the outcome indicator. Histopathologic analysis of the airways of T-bet (−/−) mice at baseline demonstrated peribronchial and perivenular infiltration with eosinophils and lymphocytes as compared to control wild type litermates. T-bet deficient mice had increased deposition of fibroblast-like cells beneath the basement membrane. Eosinophils were not present in the bronchoalveolar lavage fluid of T-bet deficient mice despite enhanced recovery of IL-5. T-bet +/− heterozygous mice, that have only a 50% reduction in T-bet protein, displayed a phenotype very similar to mice with a complete absence of T-bet.

[0515] In contrast to the spontaneous asthma observed in T-bet−/− and +/− animals, many murine models of asthma, depend on a protocol of priming and sensitization to allergen to elicit disease. Thus, OVA aerosol challenge of mice previously sensitized to OVA was tested to determine whether it would lead to enhanced airway responsiveness in T-bet deficient mice as it does in wild type mice. The pulmonary resistance response observed after intravenous infusion of methacholine in T-bet deficient mice sensitized to OVA and receiving aerosol challenge was similar to that observed in mice who did not receive aerosol OVA challenge. After OVA/OVA exposure, no differences were observed between wild type or T-bet deficient mice with respect to the infiltration of the airways with eosinophils or lymphocytes or in the cellular composition of the bronchoalveolar lavage fluid. Thus, mice with reduced or absent levels of T-bet display a spontaneous, non-allergen-induced asthma phenotype that is not further exacerbated with antigenic stimulation.

[0516] The thickness of the sub-epithelial collagen layer was evaluated in wild type and T-bet−/− and +/− deficient animals. In the wild type animals there was minimal deposition of collagen beneath the basement membrane, while in the T-bet deficient mice the sub-basement membrane collagen layer was significantly thicker than it was in wild type mice. In addition to a thickened collagen layer, there were increased numbers of bronchial myofibroblasts, as assessed by immunostaining for alpha-smooth muscle actin. These data indicate that the airways of T-bet deficient mice undergo remodeling similar to that observed in humans with chronic asthma.

[0517] Whether these structural changes in the airway were associated with a difference in the patterns of cytokine expression between wild type and T-bet deficient mice was examined TGF-beta, a potent stimulator of tissue fibrosis, TNFα and Il-4, another pro-inflammatory cytokine implicated in the chronic remodeling of the airways in asthma, were recovered in increased amounts from the BALF of mice homozygous for the T-bet targeted deletion. T-bet deficiency induced a selective alteration in patterns of cytokine expression as no significant changes were observed in IL-10 and IL-6 production. Although the physiological and histologic findings were similar in mice either hetero- or homozygous for the targeted deletion, only the homozygous mice exhibited an increased production of cytokines.

[0518] The identity of the cells in T-bet deficient mice responsible for airway hyperreactivity and airway inflammation was examined by adoptive transfer of spleen CD4+ cells from different groups of OVA sensitized mice into histocompatible SCID mice. To enhance the localization of the transferred T cells into the lungs of mice, the OVA aerosol was administered one day before adoptive transfer of the T cells. On the day following the adoptive transfer, OVA aerosol exposures were begun and continued for three days. Four days after cell transfer, lung mechanics were evaluated. Control SCID mice received an intraperitoneal infusion of saline rather than T cells suspended in saline. Recipients of wild type spleen CD4 cells had comparable airway responsiveness to wild type mice that received OVA sensitization but were not challenged. Mice that had been reconstituted with CD4 cells lacking T-bet showed increased airway hyperresponsiveness as compared to mice reconstituted with CD4 cells derived from wild type littermates and similar to that of OVA sensitized mice lacking T-bet. CD4 staining of BALF cells harvested after measurement of lung mechanics was performed to assure that CD4⁺ cells were recruited to the lung; the proportion of lymphocytes that were CD4 positive in wild type (+/+) mice was 38.9%+/−2.2; in CD4 T-bet (+/−) mice was 39.57%+/−6.48; and in T-bet (−/−) mice was 38.5%+/−5.48. In addition, the lungs of SCID mice reconstituted with CD4 cells derived from T-bet (−/−) mice exhibited increased IL-4, IL-5 and IL-13 in the BALF as compared to recipient mice reconstituted with spleen CD4+ cells derived from wild type mice, demonstrating that the airway hyperreactivity observed in T-bet (−/−) mice is T-cell mediated. Furthermore, treatment of T-bet knock out mice with antibodies to IL-13 abrogated airway hyperreactivity indicating that one mechanism by which T-bet acts is to regulate the production of IL-13.

[0519] The present invention demonstrates that targeted deletion of T-bet, in the absence of an induced inflammatory response, results in a physiological and inflammatory phenotype in murine airways similar to that created by allergen exposure in sensitized mice. In addition to acute inflammatory changes, T-bet deficient mice demonstrate airway remodeling consistent with asthma that is reminiscent of the human disease. Remarkably, this phenotype exists spontaneously and is full-blown, since, when sensitized and challenged with allergen, T-bet deficient mice fail to enhance either their physiological or pathologic responses.

Example 18 Mice Lacking T-Bet are Resistant to EAE Development

[0520] Mice lacking T-bet were evaluated in a murine model of EAE. Myelin oligodendrocyte glycoprotein (MOG) is able to generate an encephalitogenic T cell response in normal animals in the presence of pertussis toxin. T-bet^(−/−) and T-bet^(−/+) mice were immunized with a peptide derived from myelin oligodendrocyte glycoprotein (MOG 35-55) to induce EAE. Groups of mice were followed for up to 25 days to score for clinical disease as described (Bettelli et al., 1998. J. Immunol. 161: 3299-3306). Briefly, mice are injected s.c. in the flank with an emulsion containing 200 g of the peptide MOG₃₅₋₅₅, which is the encephalitogenic epitope in C57BL/6 (H-2^(b)) mice (24) and CFA supplemented with 400 ug of Mycobacterium tuberculosis H37 Ra (Difco Laboratories). Mice were observed daily and assessed for clinical signs of disease according to the following criteria: 0, no disease; 1, limp tail; 2, hind leg weakness or partial paralysis; 3, complete hind leg paralysis; 4, front and hind limb paralysis; 5, moribund state. Mean clinical score is calculated as follows: individual scores are added and divided by the total number of mice in each group for each day of observation; this includes the animals that do not develop any disease. Animals were sacrificed at the termination of the experiment or at the peak of disease. As shown in FIG. 14, T-bet ^(−/+) mice suffered from severe paralysis, the mean clinical score for this group of animals was approximately 3 at day 45. In contrast, T-bet^(−/−) mice did not develop paralysis; this group of animals had a mean clinical score of less than 1.

[0521] 2D2 MOG specific T cell receptor (TCR) transgenic mice were mated with T-bet^(+/+) and T-bet^(−/−) mice. Mice from each of the groups were immunized with pertussis toxin to induce EAE. As shown in FIG. 15, the animals lacking T-bet had a mean clinical score of less than 0.5 and were protected from EAE in this model. The role of another transcription factor acting upstream of T-bet was also tested in this model of EAE. Most IFN-γ responses are coupled to the Jak-Stat signaling pathway, in particular to the protein tyrosine kinases Jak1 and Jak2 and the transcription factor Stat1.

[0522] The proliferation of CD4⁺ cells from these mice was also examined. CD4⁺ cells were cultured with 0, 1, 10, or 100 ug/ml of MOG 35-55 peptide in the presence of irradiated spleen cells as antigen presenting cells using standard methods. ³H-thymidine uptake was used to measure proliferation of the cells. IFN-γ production by CD4 cells was measured by intracellular staining (Szabo et al. Cell. (2000 Mar. 17) 100(6):655-69).

[0523]FIG. 16 shows that the percentage of CD4⁺ cells staining positive for IFN-γ was 33% in 2D2 MOG×T-bet^(+/+) animals and 3% in 2D2 MOG×T-bet^(−/−) animals.

Example 19 Mice Lacking T-Bet Demonstrate Attenuated Arthritis

[0524] Rheumatoid arthritis (RA) is a form of arthritis in which the membranes or tissues lining the joints become inflamed (synovitis). Joint inflammation causes swelling and pain and, over time, may destroy the joint tissues and lead to disability. RA affects the hands, wrists, elbows, feet, ankles, knees, or neck. It usually affects both sides of the body at the same time. In unusual cases, rheumatoid arthritis may affect the eyes, lungs, heart, nerves, or blood vessels. Late stage RA can cause boutonniere deformity of the thumb, ulnar deviation of metacarpophalangeal joints and swan-neck deformity of fingers. To determine whether T-bet deficiency effects the development of RA, an animal model of RA was employed. 6-8 week old female Balb/c control and T-bet^(−/−) mice were injected with a anti-type II collagen monoclonal antibody cocktail (Terato et al Journal of Immunology 148, 2103-2108, 1992; Kagari et al, Journal of Immunology. 169:1459) by tail vein injection to induce Collagen Antibody-Induced Arthritis (CAIA). The mice were given an LPS injection (50 to 100 micrograms) intraperitoneally 72 hours later and the development of arthritis was evaluated on days 5 and 15. The bet deficient mice demonstrated attenuated arthritis compared to the wild-type controls.

Example 20 T-Bet Regulates the Generation of CD8 Effector/Memory Cells

[0525] To assess the role of T-bet in CD8 cell function, T-bet^(−/−) mice were mated to the TCR transgenic mouse OT-1, which recognizes the ovalbumin peptide 257-264 in the context of K^(b). In these mice virtually all T cells are CD8 cells and are specific for one peptide. A substantial decrease (approximately two thirds reduction) in numbers of CD8 cells in the absence of T-bet was observed. Impaired generation of the effector CD8 population was observed in T-bet^(−/−) mice as evidenced by the reduction in CD8⁺, CD44Hi, CD62Lhi, CD69Hi and Ly6CHi cells. FIG. 17 shows the results of FACS analysis performed on cells from wild-type and T-bet^(−/−) mice.

[0526] To determine if T-bet transcripts were expressed and induced in CD8 T cells as in CD4 T cells, RNA was isolated from purified CD8 cells activated for 72 hrs with plate-bound anti-CD3 and anti-CD28 in the presence or absence of IL-12 and IL-18 (Szabo et al. Cell. (2000 Mar. 17) 100(6):655-69). Northern blot analysis showed the coordinate induction of both T-bet and IFNγ RNA indicating that T-bet expression correlated with IFNγ production in CD8 cells. IFNγ production from cytotoxic CD8 cells is a key mechanism by which these cells combat viral infections; effector and memory CD8 cells produce large amounts of IFNγ.

[0527] To determine whether IFN-γ production was affected in T-bet deficient CD8 cells, CD8 T cells were purified from the lymph nodes of T-bet^(−/−), T-bet^(+/−) and T-bet^(+/+) mice and stimulated with plate-bound anti-CD3 and anti-CD28 for 7 days. On day 7 these cells were restimulated either with plate bound anti-CD3 for 24 hrs or PMA/ionomycin for 5 hours and IFNγ production was measured by ELISA or intracellular cytokine staining (ICCS). No difference in the level of IFNγ produced or in the number of IFNγ producing cells between the three genotypes was found. Thus, although retroviral transduction of T-bet into CD8⁺ Tc2 cells was found to convert them into Tc1 cells these data suggested that T-bet was not required for IFNγ gene transcription in these cells.

[0528] However, in subsequent experiments using a more physiological stimulus, the absence of T-bet was found to reduce IFN-γ production in CD8+ cells. Upon stimulation with antigen plus APCs, OT-1 TCR transgenic CD8+ cells produce IFN-γ. In the T-bet^(−/−) animals, however, IFN-γ production was almost completely eliminated (FIG. 18). Therefore, T-bet is required for IFN-γ production in CD8+ cells.

[0529] Naïve, effector and memory CD8 cells can be distinguished phenotypically by the expression of four markers, CD25, CD62L, CD69 and Ly-6C. Two cytokines, IL-7 and IL-15, control the generation and homeostasis of CD8 memory cells. Thus, IL-15 and IL-15R knock out mice have reduced numbers of CD8 cells and virtually lack CD44hi memory CD8 cells. In the absence of IL-15, IL-7 can maintain a memory response. However, the transcription factors that determine the fate of a CD8 cell, i.e., its response to extracellular stimuli such as cytokines, are unknown.

[0530] To search for a function for T-bet in CD8 cells, two different models of CD8 function were examined. In the first model, the role of T-bet in handling infection with lymphocytic choriomeningitis virus LCMV was examined. T-bet wild-type (WILD TYPE) or knock-out (KNOCK OUT) mice were infected with LCMV. At day 7 of the primary response, Tbet^(−/−) LCMV CD8 cells were isolated by Class I tetramer staining (gp120 antigen), and found to be present at equal numbers by tetramer staining (Altman et al. 1996. Science 274:94; McHeyzer-Williams et al. 1996. Immunol. Rev. 150:21) and unimpaired functionally as assessed by CTL lysis of LCMV-infected target cells and IFNγ production. However, by day 14, Tbet^(−/−) mice had a decrease in number of LCMV specific CD8 cells as measured by both tetramer staining and by intracellular cytokine staining for IFN-γ.

[0531] These results indicate an impaired CD8 memory response to LCMV in the absence of T-bet. In the LCMV model systems, a careful time course of the effector/memory response starting at day 8 and monitoring phenotypic markers, cell number, ICCS for cytokines and CTL activity must be performed. One possibility for the results obtained is that the lack of CD8 effector/memory could be a result of the deficiency of Th1 CD4 cells producing IL-2 and IFN-γ. Although MHC class II deficient mice have a normal CD8 LCMV CTL response, CD4 cells are important in LCMV infection in the immunocompetent host. In addition, T-bet actually represses IL-2 production, and CD8 cells from Tbet^(−/−) mice produce substantially more IL-2 than control CD8 cells.

[0532] In the second model, the T-bet knock out strain was mated to mice transgenic for the OT-1 TcR. In comparing the number and cytokine profile of OT1 transgenic CD8 cells from wild type and T-bet knock out mice, a substantial decrease in numbers of CD8 cells in the absence of T-bet was found, as well as a greatly increased production of IL-10 in response to the OVA peptide plus APC in vitro. Examining the phenotype of CD8 cells in this model has shown a substantial decrease in the generation of effector CD8 cells in the absence of T-bet and a dramatic increase in the levels of IL-10. In addition, the expression of the IL-15 receptor is not altered in freshly isolated OT1 CD8 T-bet^(−/−) cells.

Example 21 T-Bet Represses the Production of IL-10 in Effector CD8 Cells

[0533] One important function for T-bet in CD8 cells appears to be the control of the production of the immunosuppressive cytokine IL-10. CD8 cells that lack T-bet were found to produce substantially increased levels of IL-1 and IL-2 suggesting that T-bet is a repressor of IL-10 and IL-2 in CD8 cells (FIG. 36). IL-10 plays a key role in hampering the effective handling of intracellular pathogens such Mycobacterium, Francisella tularensis and Salmonella typhimurium because it opposes the macrophage-activating functions of IFN-γ and TNFα. IL-10 antagonizes IL-12 mediated protection against acute vaccinia virus infection and suppression of endogenous IL-10 in dendritic cells enhances antigen presentation for Th1 induction. Thus, compounds that enhance T-bet expression or activity should both increase IFN-γ and inhibit IL-10 production, tipping the balance in favor of a potent immune response to pathogens. The mechanism by which T-bet represses IL-10 or IL-2 production may be by direct regulation of the transcription of the IL-10 or the IL-2 gene or by regulation of genes that modulate the production of IL-10 or IL-2 in CD8 cells.

Example 22 T-Bet Regulates the Production of IFN-γ in NK Cells

[0534] T-bet also regulates IFN-γ production in cells of the innate immune system. For example, IFN-γ production is reduced in animals deficient in T-bet. DX5⁺ splenic NK cells were purified from T-bet^(−/−), T-bet^(+/−) and T-bet^(+/+) mice by positive selection with NACS purification (Szabo et al. 2002. Science. 295:338-42). IFN-γ production was measured by ELISA 72 hours after treatment with IL-12 alone or rIL-12 and rIL-18. Intracellular cytokine staining for IFN-γ was also performed. FIG. 19 shows that IFN-γ production was reduced in both T-bet^(−/+) and T-bet^(−/−) animals.

[0535] In addition to these effects on IFN-γ production, the generation of NK cells is also impaired in the absence of T-bet. The percentage of splenic NK cells in WILD TYPE and T-bet^(−/−) animals were compared. The percentage of DX5⁺ NK cells was reduced by 50% in the absence of T-bet (FIG. 20). In another experiment, the percentage of DX5⁺ NK cells was examined in RAG2^(−/−) animals and Rag2^(−/−)×T-bet^(−/−) animals. RAG2 is necessary for efficient V-to-DJ rearrangement during T and B cell development, therefore, RAG2^(−/−) animals are deficient in T and B cells. The percentage of DX5⁺ NK cells was also decreased in the Rag2^(−/−)×T-bet^(−/−) animals as compared to the RAG2^(−/−) animals (FIG. 20).

[0536] NK cytolytic activity was also examined. Diminished spontaneous tumor cell lysis was observed in T-bet^(−/−) NK cells. Unfractionated splenocytes were incubated for 4 hours with 51 Cr-labeled NK-sensitive YAC-1 target cells at the effector-to-target cell ratios indicated in left panel of FIG. 21. (Szabo et al. 2002. Science. 295:338-42). In the right panel, T-bet^(−/−) and T-bet^(+/+) mice were injected intraperitoneally with 100 ug of poly (I:C) 24 hours before splenocyte isolation. In another experiment, the effect of T-bet on the expression of lytic genes was assessed. DX5⁺ NK cells were isolated from the spleens of T-bet^(+/+) and T-bet^(−/−) animals and incubated in the presence of rIL-12 and rIL-18 for 6 hours. The abundance of mRNA encoding the lytic proteins perforin and granzyme B was determined using Beta-actin as a reference. Expression of these lytic genes was impaired in the absence of T-bet (FIG. 22).

Example 23 T-Bet Regulates the Production of IFN-γ in Dendritic Cells

[0537] Dendritic cells (DCs) are professional antigen presenting cells with an extraordinary capacity to activate naive T cells (Liu, Y. J., et al. (2001) Nat Immunol. 2:585; Mellman, I., et al. (2001) Cell 106:255; and Banchereau, J., et al. (2000) Ann. Rev. Immunol. 18:767). They are widely distributed in the lymphoid and non-lymphoid systems and much interest has been stimulated by their potent capacity to capture antigen in the lymph nodes and present it as diverse peptides to CD4 and CD8 cells to initiate a primary immune response. They have indeed been dubbed “Nature's adjuvants” and must be considered to be a vital component of any vaccination strategy since current vaccine strategies often generate weak immunity. When triggered by pathogens, the pattern-recognition receptors (Toll receptors) expressed on immature DCs leads them to mature to immunogenic DCs. Both human and mouse DCs are divided into subsets that subsume different functions in driving the expansion of T helper subsets. One mechanism by which DCs do this is the secretion of cytokines such as IL-12 and IL-10.

[0538] It has recently been discovered that dendritic cells also produce IFN-γ (Frucht, D. M., et al. (2001) Trends Immunol 22:556; Ohteki, T., et al. (1999) J.Exp.Med. 189:1981; Fukao, T., et al. (2000) Eur J Immunol 30:1453; Hochrein, H., et al. (2001) J Immunol 166:5448; Fukao, T., et al. (2001) J Immunol 166:4446; Fukao, T., et al. (2000) J Immunol 164:64; and Stober, D., et al. (2001) J Immunol 167:957). IFN-γ is a pleiotropic cytokine essential for both innate and adaptive immunity that acts by binding to a widely expressed IFN-γ receptor (Bach, E. A., et al. (1997) Annu Rev Immunol 15:563; Boehm, U., (1997) Annu Rev Immunol 15:749). Most IFN-γ responses are coupled to the Jak-Stat signaling pathway, in particular to the protein tyrosine kinases Jak1 and Jak2 and the transcription factor Stat1 (Leonard, W. J., et al. (1998) Ann.Rev.Immunol. 16:293.). Analysis of mice lacking IFN-γ, the IFN-γ receptor, or Stat1 reveals a profound disruption of both innate and adaptive immunity resulting in death from infection by microbial pathogens and viruses (Decker, T., (2002) J Clin Invest 109:1271; Dalton, D. K., (1993) Science 259:1739; Durbin, J. E., (1996) Cell 84:443; Huang, S., (1993) Science 259:1742; Meraz, M. A., (1996) Cell 84:431). In mice lacking a functional IFN-γ gene, disseminated tuberculosis occurred. Humans with inactivating mutations in components of the IFN-γ signaling pathway die at an early age from uncontrolled mycobacterial infections.

[0539] The cells that produce IFN-γ and respond to it reside in both the innate and adaptive immune systems. For example, this effector cytokine activates macrophages and renders dendritic cells more immunogenic, likely by upregulating MHC antigens, antigen-presenting capacity and cytokine secretion (Giacomini, E., et al. (2001) J Immunol 166:7033; Remoli, M. E., et al. (2002) J Immunol 169:366; Kinjo, Y., et al. (2002) J Immunol 169:323; McShane, H., et al. (2002) Infect Immun 70:1623). Uncovering the molecular mechanisms that regulate IFN-γ secretion at the sites of infection and of antigen presentation is thus an important task. To date, Stat4 is the only transcription factor known to control the production of IFN-γ in myeloid cells (Fukao, T., et al. (2001) J Immunol 166:4446; Frucht, D. M., et al. (2000) J. of Immuno. 164:4659).

[0540] To determine whether T-bet is expressed in dendritic cells at levels comparable to Th1 cells and is necessary for the optimal production of IFN-γ, the following studies were performed:

[0541] 1. Normal Development and Activation of Murine Dendritic Cells in Mice Lacking T-bet

[0542] Very few transcription factors have been implicated in the development and maturation of DCs (Ouaaz, F., et al. (2002) Immunity 16:257). Most notable among these are members of the NFκB family. Recent studies have demonstrated impaired development of both CD11c⁺CD8a⁺ and CD11c⁺CD8a⁻DCs in mice lacking both the RelA (p65) and p50 NFκB subunits. However, macrophage development and differentiation was unaffected in these mice, proving that the requirement for p50 and RelA in generation of DCs is specific and cell-autonomous (Ouaaz, F., et al. (2002) Immunity 16:257). Since T-bet is expressed in stem cells and progenitor cells from human bone-marrow and umbilical cord blood, it was possible that it might also be involved in the development, differentiation or activation of DCs.

[0543] DCs of myeloid origin can be most easily obtained by culturing bone-marrow (BM) in the presence of GM-CSF and stages of development can be monitored over time by assessing surface expression of MHC class II molecules and CD11c (Lutz, M. B., et al. (1999) J Immunol Methods 223:77: Inaba, K., et al. (1992) J Exp Med 176:1693). Precursor DCs (CD11c⁺MHC II^(lo)) are apparent at day 4, immature DCs (CD11c^(hi) MHC II⁺) days 4 to 8, and mature DCs (CD11c^(hi) MHC II^(hi)), days 8 to 10 followed by apoptosis. There was no significant difference in the yield of DCs at any stage of development in mice lacking T-bet, and similar proportions of precursor, immature and mature DCs, as determined by surface phenotype were obtained from T-bet^(−/−) and control BM (day 8 shown in FIG. 23A).

[0544] BM cultures containing GM-CSF provide a large population of CD11c⁺ and CD11b⁺ DCs that are derived from myeloid precursors. However, this population lacks the DC subpopulations that usually reside in the secondary lymphoid organs and are characterized by the surface expression of CD4⁺ and CD8α⁺ markers (Wu, L., et al. (1996) J Exp Med 184:903; Vremec, D., et al. (1997) J Immunol 159:565; Leenen, P. J., et al. (1998) J Immunol 160:2166; Kamath, A. T., et al. (2000) J Immunol 165:6762; Henri, S., et al. (2001) J Immunol 167:741. 20; Hochrein, H., et al. (2001) J Immunol 166:5448). We examined these DC subpopulations in spleen preparations from wild type and T-bet^(−/−) mice. FACS analysis revealed no obvious difference in DC composition based on staining with antibodies to CD11c⁺ and a combination of I-A^(b) (MHC class II), CD11b⁺, CD4⁺, and CD8α⁺ (FIG. 23B). Similar numbers of CD11c⁺ DCs were isolated from multiple independent preparations of spleen from wild and knock-out animals.

[0545] Microbial stimuli, proinflammatory cytokines, and interaction with CD40L-expressing T cells, can induce the maturation of DCs. Mature DCs are characterized by up-regulation of MHCII, co-stimulatory, and adhesion molecule expression. In order to test whether T-bet plays a role in DC maturation in vivo, mice were injected intraperitoneally with LPS for different time periods and DC maturation assessed by FACS analysis. Up-regulation of CD86 (B7-2) in T-bet^(−/−)DCs was normal compared to cells from wild-type mice (FIG. 23C). Similar results were obtained for the up-regulation of CD80 (B7-1), CD40, and MHC II.

[0546] These studies show that T-bet does not play a noticeable role in the development, differentiation or activation of DCs.

[0547] 2. T-bet Expression in Murine Dendritic Cells

[0548] T-bet expression is almost exclusively restricted to the hematopoietic system during mouse development with the only exception being the olfactory bulb (Faedo, A., et al. (2002) Mech Dev 116:157). T-bet is expressed in several blood lineages including progenitors/stem cells found in human bone marrow and cord blood (Faedo, A., et al. (2002) Mech Dev 116:157). In the adult animal, expression of T-bet is primarily evident in lymphoid organs. T-bet is also expressed in Th1 cells, CD8 cells, NK cells and B cells, and others have noted T-bet expression in human monocytes and myeloid DCs.

[0549] To examine the constitutive and regulated T-bet expression in mouse dendritic cells and macrophages, immature DCs of myeloid origin were obtained from BM cells cultured in the presence of GM-CSF. Such bone-marrow cultures typically yield DCs at a purity range between 70 to 90%. To further purify away DCs from contaminating macrophages or myeloid precursors, CD11c⁺ magnetic beads were used resulting in a population of >than 95% DCs. No T-bet mRNA was detected in unstimulated BM cells, or from cells isolated with CD11c⁺ magnetic beads at different days during development until day 8. At day 8, CD11c⁺ BM-derived DCs cells displayed a rapid up-regulation of T-bet mRNA after stimulation with IFN-γ (FIG. 23B). A comparable expression pattern for T-bet was obtained in BM-derived DCs obtained from the B6 strain and from the BALB/c strain.

[0550] In order to obtain pure populations of splenic DCs, spleen cells from C57B1/6 mice were FACS sorted with antibodies to CD11c⁺ and I-A^(b) (MHC class II) to avoid contamination with CD8 T cells and NK cells. Such sorted populations were >95% pure. Sorted DCs were cultured for various time periods in the presence or absence of recombinant IFN-γ, and RNA isolated for real-time PCR analysis. These experiments revealed low levels of T-bet expression in unstimulated DCs and a rapid up-regulation of T-bet transcript levels after treatment with IFN-γ (FIG. 24A). Similar to BM-derived DCs, T-bet mRNA expression peaked during the first hour, remained high up to 4 hours, and declined dramatically after 8 hours (FIG. 24B). Of note, the levels of T-bet transcripts in dendritic cells were very comparable to what has been observed in Th1 cells ranging between 10⁻³ to 10⁻² molecules of T-bet per 1 molecule of β-actin (FIG. 24A-B)

[0551] The expression of T-bet protein as assessed by western blot analysis of extracts prepared from splenic DCs untreated or treated with IFN-γ mirrored RNA expression with a rapid induction of T-bet protein beginning at 3 hours, peaking at 12 hours, and decreasing 24 hours after stimulation with IFN-γ (FIG. 24C). No difference was noted in T-bet expression between B6 and BALB/c strains. Three-color FACS sorting allowed the examination of T-bet expression in CD8α⁺ and CD8α⁻DC subpopulations. Both subsets up-regulated T-bet mRNA levels similarly after stimulation with IFN-γ. Other stimuli known to activate dendritic cells (e.g., LPS) or recently described to increase T-bet expression in NK cells (e.g., IL21 and IL15) did not induce T-bet expression.

[0552] These studies demonstrate that dendritic cells express T-bet and that this expression is controlled by IFN-γ in a positive feedback loop similar to what has been observed in T cells. These data confirm earlier observations on the ability of IFN-γ to control T-bet expression in human monocytes and myeloid dendritic cells and extend it to mouse myeloid DCs at different stages of development as well as to mature DCs from mouse spleen (Lighvani, A. A., et al. (2001) Proc. Natl. Acad. Sci. USA 98:15137). However, some important differences between species emerged. For example, we did not observe significant expression levels of T-bet mRNA or protein at 24 hours as reported for human myeloid DCs—the kinetics of T-bet induction being more rapid in mouse myeloid and splenic DCs. In addition, exquisite sensitivity to low dose IFN-γ was observed with maximal levels of T-bet obtained at 1 ng/ml. This is in contrast to human monocytes where T-bet mRNA levels increased proportionally with higher concentrations of IFN-γ (Lighvani, A. A., et al. (2001) Proc. Natl. Acad. Sci. USA 98:15137). Furthermore, T-bet expression was not detected in either peritoneal, splenic or bone marrow derived macrophages upon treatment with IFN-γ, or after phagocytosis of latex beads. These studies demonstrate that the production of IFN-γ from these cells is controlled by transcription factors other than T-bet such as Stat4 in macrophages of the BALB/c background (Frucht, D. M., et al. (2000) J. of Immuno. 164:4659; Lawless, V. A., et al. (2000) J. Immunol. 165:6803; Kuroda, E., et al. (2002) J. Immunol. 168:5477).

[0553] 3. T-bet is Essential for Optimal Production of IFN-γ by Dendritic Cells

[0554] Upon a 72 hour stimulation with IL12 and IL18, DCs secrete substantial amounts of IFN-γ ranging between 10 to 300 ng ml⁻¹ (Ohteki, T., et al. (1999) J.Exp.Med. 189:1981; Fukao, T., et al. (2000) Eur J Immunol 30:1453; Hochrein, H., et al. (2001) J Immunol 166:5448; Fukao, T., et al. (2001) J Immunol 166:4446; Fukao, T., et al. (2000) J Immunol 164:64; Stober, D., et al. (2001) J Immunol 167:957). To date, Stat4 is the only transcription factor known to control the production of IFN-γ in myeloid cells. In both DCs and macrophages, the IL12-dependent secretion of IFN-γ is severely diminished in the absence of Stat4 (Bach, E. A., et al. (1997) Annu Rev Immunol 15:563). In addition, Stat4^(−/ −) macrophages exhibited defective production of nitrate oxide in response to IL-12, and are susceptible to Toxoplasma gondii infection (Fukao, T., et al. (2001) J Immunol 166:4446). Since T-bet controls the transcription of the IFN-γ gene in CD4⁺ T cells, but not, for example in B cells, whether T-bet controls the transcritption of IFN-γ in DCs was studied.

[0555] A very marked impairment in IFN-γ secretion was observed in BM DCs derived from T-bet deficient B6 mice. Although IFN-γ production by BM derived DCs is typically lower than from splenic DCs, ranging from 100 to 5000 pg ml⁻¹ (Fukao, T., et al. (2001) J Immunol 166:4446; Fukao, T., et al. (2000) J Immunol 164:64; Stober, D., et al. (2001) J Immunol 167:957), T-bet^(−/−) BM DCs produced no detectable IFN-γ at all as measured by ELISA (FIG. 25A, left panel). BM-derived wild type B6 DCs produced levels that ranged from 100 to 500 pg ml⁻¹ (FIG. 25A, left panel). Unlike splenic DCs which die in culture after 48 to 72 h, BM-derived DCs survive for long enough periods of time to allow us to measure IFN-γ transcripts as well. Survival rates were similar in BM-derived DCs from T-bet and wild-type mice after stimulation for 72 hours. Real-time PCR analysis confirmed a very marked decrease (6 to 12 fold) in IFN-γ transcripts in T-bet^(−/−) BM-derived DCs cultured with IL-12 and IL-18 for 72 hours (FIG. 25A, right panel). Comparable results were obtained in BM derived DCs from T-bet^(−/−) mice on a BALB/c background.

[0556] Similarly, a significant reduction in IFN-γ secretion, ranging from 40 to 80% from six independent preparations of splenic DCs stimulated with IL-12, or IL-12 and IL-18, was observed in T-bet deficient as compared to control mice (FIG. 25A). Similar results were observed in DCs derived from T-bet^(−/−) mice on the BALB/c background. T-bet functions very early in Th differentiation in the naïve Th progenitor cell to regulate IFN-γ gene transcription. Optimal production of IFN-γ by murine dendritic cells has been reported to occur between 3 and 5 days (Ohteki, T., et al. (1999) J.Exp.Med. 189:1981; Fukao, T., et al. (2000) Eur J Immunol 30:1453; Hochrein, H., et al. (2001) J Immunol 166:5448; Fukao, T., et al. (2001) J Immunol 166:4446; Fukao, T., et al. (2000) J Immunol 164:64; Stober, D., et al. (2001) J Immunol 167:957). To investigate whether T-bet plays a role during the early production of IFN-γ by splenic DCs, a time course analysis of IFN-γ secretion during the first three days after stimulation with IL-12 alone, or in combination with IL-18, was performed and revealed an important role for T-bet (FIG. 25C). In the absence of T-bet, splenic DCs displayed a 40 to 45% reduction in IFN-γ production during the first 24 hours, which continued over the next 48 hours with a decrease in IFN-γ production that ranged between 60 to 70% (FIG. 25C). This impairment in IFN-γ production was also present in T-bet deficient DCs from BALB/c mice.

[0557] These studies demonstrate for the first time in the art that T-bet is expressed in murine DCs and that its expression is controlled by IFN-γ. Thus T-bet is essential for the optimal secretion of IFN-γ by this important cell type. This role is quite selective for IFN-γ in DCs as the expression of other DC cytokines such IL-12, p35 and p⁴⁰ subunits, TNFα, and IL-1 after stimulation with IL-12 and IL-18 or LPS were not affected by the absence of T-bet.

[0558] Furthermore, while it is clear that Stat4 is absolutely required for the initiation of IL-12-dependent production of IFN-γ in myeloid cells, T-bet also participates in the control of this cytokine. One possible mechanistic scenario is that upon the interaction of a pathogen with Toll receptor family members, the DC is stimulated to secrete IL-12 and IFN-γ, thereby activating both the Stat1 and Stat4 signaling pathways. Stat1 controls both the expression of T-bet and of Stat4 thus simultaneously maximizing the production of IFN-γ.

[0559] In conclusion, these studies demonstrate that T-bet influences the generation of Type I immunity not only by controlling Th1 lineage commitment in the adaptive immune system but also by a direct influence on the transcription of the IFN-γ gene in dendritic cells. T-bet is therefore a transcription factor that may be a molecular bridge between the innate and adaptive immune systems.

Example 24 The Role of T-Bet in Mouse Models of Mycobacterium tuberculosis

[0560] Susceptibility to Mycobeacterium tuberculosis and Francisella tularensis varies considerably in inbred mouse strains (ranging from highly susceptible to intermediate to relatively resistant). Transgenic mice overexpressing T-bet were produced and characterized on the C57BL6 background, and have been backcrossed with the T-bet-deficient strain several generations onto the relatively resistant strain, C57BL/6, to best assess its function in models of infection. The mechanism by which T-bet provides resistance to both avirulent and virulent bacterial strains was explored by taking advantage of T-bet overexpressor and deficient mice that lack various cell populations e.g., CD4 or CD8 T cells, NK and dendritic cells. The T-bet knock out and overexpressor strains were backcrossed extensively onto both C57BL/6 and BALB/c strains.

[0561] To test the function of T-bet in infection with Mycobacterium tuberculosis, two groups of mice, T-bet knock out and wildtype littermates, were infected intravenously with the standard dose of virulent MTB (100,000 CFU) and their survival was monitored. The results were as follows. Time to death (TTD) in days (±SD): T-bet knock out (4 mice)=41 (±0.8), wild type (3 mice)=106 (±36), p<0.02. For comparison, TTD of a very susceptible strain of mice (C3HeB/FeJ) in that experiment=26(±1.2) and TTD of HcB15 (another susceptible strain)=34 (±2.4). For further comparison, the most highly susceptible strain of mice yet identified, IFNγ knock out mice on the B6 background, usually died within 15 days under the same experimental conditions.

[0562] At day 41 after infection, organs of 3 T-bet knock out mice were harvested at the time of death or in a moribund state (one mouse) along with those of 1 wild type mouse (sacrificed), and histopathology, acid fast staining for bacteria and iNOS expression studies were carried out. A greater number of acid fast bacteria were found per macrophage in the T-bet knock out mice, however, neither pneumonia nor necrotic lesions often seen in the most susceptible strains of mice were observed.

[0563] In summary, the T-bet knock out mice were clearly more susceptible than their wild type littermates controls to infection with Mycobacterium tuberculosis. The degree of susceptibility conferred by the absence of T-bet is intermediate, in comparison to IFNγ deficient mice. The significant degree of protection retained as compared to the IFNγ knock out may be due to residual IFNγ production by T-bet^(−/−) CD8 cells.

Example 25 Phosphorylation of T-Bet by Tec Kinases

[0564] The T-bet protein is phosphorylated. The kinase which phosphorylates T-bet has been identified as a member of the Tec family of tyrosine kinases. ITK and Rlk/Txk are the predominant Tec family of tyrosine kinases expressed in T cells. FIG. 26 shows the conserved structure of Tec family members. The Tec family kinases have been shown to be important in cytokine secretion. Rlk/tkk is Thy specific and plays a role in the control of IFN-γ production. Itk−/− mice have reduced IL-4 production while rlk/itk−/− mice demonstrated reduced Th1 and Th2 cytokines. RIBP is an adapter protein that binds rlk and itk. RIBP−/− mice exhibit reduced IFN-γ and IL-2.

[0565] Both the ITK and Rlk/txk kinases have been found to phosphorylate T-bet in vitro. The predicted tyrosine phosphorylation sites of human T-bet are shown in FIG. 27. Modified forms of the T-bet protein were made and used as substrates in in vitro kinase assays (FIG. 28). Both ITK and Rlk phosphorylated N-terminal and C-terminal but not DNA-binding regions of T-bet in in vitro kinase assays (FIG. 29).

[0566] Further indicating the importance of Tec kinases, diminished tyrosine phosphorylation of T-bet has been observed in ITK knock-out animals. T-bet was immunoprecipitated from T cells from B6, Balb/C, ITK knock out and RLK knock out animals. Western blots of the immunoprecipitates were probed with either anti-phosphotyrosine antibodies or anti-T-bet antibodies. As shown in FIG. 30 although T-bet is present in T cells from ITK knock out animals, tyrosine phosphorylation of the molecule is reduced. In contrast, T-bet was hyperphosphorylated in Rlk knockout T cells indicating a role for Rlk in inhibiting T-bet tyrosine phosphorylation.

Example 26 Increased T_(R) Cells in the Absence of T-Bet

[0567] T regulatory (T_(R)) cells are essential for the induction of peripheral tolerance. Several types of T_(R) cells exist, including CD4(+) T cells which express CD25 constitutively and suppress immune responses via direct cell-to-cell interactions, and type 1 T regulatory (T_(R) 1) cells, which function via secretion of interleukin (IL)-10 and transforming growth factor (TGF)-beta. Suppression mediated by CD25(+)CD4(+) T cell clones is partially dependent on TGF-beta, but not on constitutive high expression of CD25. T_(R) cells are increased in the absence of T-bet. The percentage of CD4+/CD25+ T cells was determined by FACS analysis in T-bet +/+, T-bet +/−, and T-bet −/− mice. As shown in FIG. 31, T-bet +/+ animals have approximately 3% T_(R) cells, T-bet +/− animals have approximately 20% T_(R) cells and T-bet −/− animals have approximately 38% T_(R) cells.

Example 27 T-Bet Expression is Controlled through the IFN-γ Signaling Pathway

[0568] The following Materials and Methods were used in Example 26:

[0569] Mice, Antibodies and Cytokines

[0570] T-bet^(−/−) mice, backcrossed 5 generations onto the BALB/c background, were generated using techniques described herein. BALB/c, 129, STAT1^(−/−) and IFNγR1^(−/−) mice were purchased from Jackson laboratory.

[0571] Monoclonal anti-CD3 (2C11), anti-CD28, anti-IL4, anti-IFN-γ, anti-IL-12, and rmIFN-γ were all purchased from Pharmingen. Anti-IL-18, rmIL-18 were purchased from Peprotech.

[0572] CD4⁺ T Cell Purification and Th Differentiation

[0573] Cervical, axillary, inguinal and popliteal lymph nodes were isolated and passed through 40 μm filters. CD4⁺ T cells were purified by positive selection using MACS purification (Miltenyi Biotech). For in vitro activation 1×10⁶/ml T cells were resuspended in complete medium (RPMI 1640 supplemented with 10% fetal calf serum (HyClone Laboratories), Hepes (100 mM), L-glutamine (2 mM), non-essential amino acids, sodium pyruvate (1 mM), β-mercaptoethanol (50 μM), penicillin (50 units/ml), streptomycin (50 μg/ml) and stimulated with plate-bound 2 μg/ml anti-CD3 and 2 μg/ml anti-CD28 for 3 days in the presence of 100 U/ml rhIL-2. Cells were then split 1:4 in complete medium and cultured for 4 days in the presence of 100 U/ml rhIL2. To induce Th1 and Th2 differentiation as indicated in the figure legends the above cultures included (10 ng/ml rIL-12 and 10 μg/ml anti-IL4) for Th1 cell development or (10 ng/ml rIL4, 10 μg/ml anti-IFN-γ, and 10 μg/ml anti-IL-12) for Th2 cell development.

[0574] ELISA and Intracellular Cytokine Staining

[0575] On day 7 after primary stimulation, 1×10⁶ cells were restimulated with 2 g/ml plate bound anti-CD3. Supernatants were harvested after 24 hours for ELISA. Cytokines were captured during overnight incubation at 4° C. with 2 μg/ml plate bound anti-IFN-γ, anti-IL-4 and anti-IL-5 antibodies (Pharmingen), then sequentially labeled with secondary biotinylated antibodies (Pharmingen) and alkaline phosphatase conjugated avidin(Sigma). Following incubation in phosphatase substrate (Sigma), cytokine levels were measured against standards (Peprotech) at 405 nm. For intracellular cytokine staining, cells were restimulated with PMA (50 ng/ml) and ionomycin (1 μM) for 6 hours with the addition of monensin (3 μM) for the last 3 hours. Cells were then washed in PBS, fixed in 4% paraformadehyde, and permeabilized in 0.1% saponin/1% FBS/PBS. Staining was performed with PE-conjugated anti-IFN-γ (Pharmingen) and FITC-conjugated anti-CD4 and analyzed by flow cytometry using a FACS Calibur as described (Szabo, S. et al. 2000 Cell 100: 655-69).

[0576] Real Time Transcript Quantification

[0577] CD4⁺ T cells were isolated and stimulated as described above in the presence of indicated cytokines IL-12 (10 ng/ml) IFN-γ (500 U/ml) IL-4 (10 ng/ml) or cytokine neutralizing antibodies (10 μg/ml). Cells, 5×10⁶ per reaction, were stimulated in 2 ml medium and harvested at 3, 6 and 24 hours. Total RNA was isolated using RNeasy (Qiagen) and subjected to reverse transcription using the Superscript first strand synthesis system (Invitrogen). T-bet and IFN-γ transcripts were quantified using an ABI 7700 Sequence Detector, and plotted relative to the housekeeping gene GAPDH. Primers and probes used were as follows: IFN-γ forward 5′TCAAGTGGCATAGATGTGGAAGAA3′, IFN-γ reverse 5′TGGCTCTGCAGGATTTTCATG3′, IFN-γ probe 5′TCACCATCCTTTTGCCAGTTCCTCCAG3′, T-bet forward 5′CAACAACCCCTTTGCCAAAG3′, T-bet reverse 5′TCCCCCAAGCAGTTGACAGT3′, T-bet probe 5′CCGGGAGAACTTTGAGTCCATGTACGC3′, GAPDH forward 5′TTCACCACCATGGAGAAGGC3′, GAPDH reverse 5′GGCATGGACTGTGGTCATGA3′, GAPDH probe 5′TGCATCCTGCACCACCAACTGCTTAG3′.

[0578] (Cytokine, 11(4):305-312; Immunity, 14:205-215).

[0579] Northern and Western Blot Analysis

[0580] Total RNA was isolated from CD4+ T cells using RNeasy (Qiagen) and 10 g of each sample separated on 1.2% agarose 6% formaldehyde gels, transferred onto GeneScreen membrane (NEN) in 20× SSC overnight and covalently bound using a UV Stratalinker (Stratagene). Hybridization of blots was carried out at 42° C. as described (Hodge, M. et al. 1996. Immunity 4: 1-20; Hodge, M. R., et al. 1996 Science 274: 1903-1905) using the radiolabeled T-bet, HPRT or GAPDH cDNA probes. Whole cell extracts were prepared as described (Gouilleux et al., (1994) EMBO 13(18):4361-9). Extracts were separated by 10% PAGE followed by electrotransfer to nitrocellulose membranes and probed with polyclonal antisera specific for T-bet followed by horseradish peroxidase-conjugated goat anti-rabbit IgG and enhanced chemiluminescence according to the manufacturer's instructions (Amersham).

[0581] T-bet expression is controlled primarily through the IFN-γR/STAT1 signaling pathway, not the IL-12R/STAT4 pathway. This mode of signaling sets up a positive feedback loop between IFN-γ and T-bet during early TCR activation which propels the antigen activated Thp cell down the Th1 pathway. Thus, the balance between IL-4 and IFN-γ during initial TCR stimulation has a major influence on the fate of a T helper cell. IL-12, while required at later stages of primary Th1 differentiation, does not appear to contribute to the initial stage of Th1 lineage induction. Taken together, our data suggest that there are discrete phases of Th1 development in which STAT1, T-bet and STAT4 play distinct and critical roles. T-bet directs Th1 lineage commitment through a self-reinforcing feedback loop involving early IFN-γ production followed by proliferation and stabilization of committed Th1 cells by STAT4.

[0582] Several cytokines and cytokine receptors, such as IFN-γ, IL-18, and TCCR, have been implicated in alternative pathways of Th1 differentiation or in augmentation of IL-12 induced Th1 development (Okamura, 1995 Nature. 378:88; Schmitt, 1994. Eur. J. Immunol. 24:793; Robinson D, et al. (1997) Immunity 7: 571-81; Macatonia S E, et al. (1993). Int.Immunol. 5: 1119-28; Chen Q, et al. (2000) Nature 407: 916-20). IFN-γ plays an essential role during an immune response and exerts its effects by binding to the IFN-γ receptor, composed of two chains IFN-γR1 and R2, present on most cell types (Bach E A, et al. (1997) Annu Rev Immunol 15: 563-91; Boehm U, Klamp T, et al. (1997) Annu Rev Immunol 15: 749-95). However, the site and mechanism of IFN-γ's promotion of Th1 differentiation remains obscure. This Example shows that T-bet expression is controlled primarily through the IFN-γR/STAT1 signaling pathway, not the IL-12R/STAT4 pathway, with the initial source of IFN-γ originating from the antigen activated CD4 T cell itself. Thus T-bet controls Th1 lineage commitment through a self-reinforcing feedback loop involving early IFN-γ production.

[0583] Early T-bet Expression Requires IFN-γ

[0584] Several signaling pathways have been implicated in promoting Th1 differentiation and IFN-γ production. These include triggering of the T cell receptor by MHC: antigen complexes and the cytokines IL-12, IL-18 and IFN-γ. Given the central role of T-bet in Th1 differentiation we sought to determine which if any of these signals is responsible for inducing T-bet expression.

[0585] Purified CD4+ lymph node T cells from BALB/c mice were stimulated for 48 hrs with 2 μg/ml plate bound anti-CD3 and anti-CD28 for 72 hours. Where indicated IL-12 (20 ng/ml), IL-18 (20 ng/ml), IFN-γ (500 U/ml), anti-IFN-γ (10 μg/ml), anti-IL-12 (10 μg/ml), anti-IL-18 (10 μg/ml) were added. RNA was prepared and subjected to Northern blot analysis using T-bet, IFN-γ GATA3 and HPRT cDNAs as probes. This analysis revealed that signaling through the TCR/CD28 pathway alone appeared sufficient to induce T-bet expression with the inclusion of IL-12 slightly augmenting this expression. However, the inclusion of antibodies to IFN-γ in these CD4⁺ T cell cultures resulted in a dramatic loss of T-bet expression, while antibodies against both IL-12 and IL-18 failed to inhibit T-bet induction (FIG. 32). IFN-γ expression from these cells paralleled T-bet expression. In contrast to T-bet, the Th2 specific transcription factor GATA-3 was increased by anti-IFN-γ treatment and repressed by IL-12 treatment. These data suggest that the expression of T-bet, as well as IFN-γ during primary stimulation is primarily dependent on IFN-γ. The modest increase in T-bet following stimulation with IL-12 may be secondary to the capacity of IL-12 to augment IFN-γ expression (see below).

[0586] To assess the early kinetics of T-bet transcription, real-time PCR of T-bet and IFN-γ mRNA was performed. As before, CD4⁺ lymph node T cells were stimulated with anti-CD3/CD28 for 3, 6, and 24 hours in the presence of IFN-γ, IL-12, IL-4 or neutralizing antibodies against these cytokines. Consistent with the data above, T-bet transcripts were induced by signals involved in Th1 differentiation. Strikingly, cells stimulated in the presence of antibody IFN-γ failed to produce significant levels of T-bet. This inhibition was observed even in the presence of the Th1 promoting cytokine IL-12. Interestingly at these early time points (3 and 6 hours after stimulation) the induction of IFN-γ mRNA expression was unaffected by anti-IFN-γ treatment despite the inhibition of T-bet expression. Moreover, this early IFN-γ expression was unaffected by either Th1 or Th2 inducing conditions, a result consistent with recent studies by Grogen et al. (Immunity (2001) 14: 205-15).

[0587] However, by 24 hours of stimulation in the presence of anti-IFN-γ antibody, IFN-γ mRNA began to decrease and by 48 hours both IFN-γ and T-bet transcripts were absent (FIG. 32). Thus, the dependence on IFN-γ for T-bet expression and T-bet for sustained IFN-γ expression suggests that a self-reinforcing feedback mechanism may be occurring between IFN-γ and T-bet.

[0588] T-bet Expression is Downstream of Signals Emanating from the IFN-γ Receptor

[0589] The importance of STAT family members in cytokine signal transduction and the differentiation of CD4⁺ T helper cells has been well documented (Murphy K M, et al. (2000) Annu. Rev. Immunol. 18: 451-94; O'Garra A, et al. (2000) Trends in Cell Biology 10: 542-50). Mice lacking STAT4 and STAT6 fail to mount significant Th1 and Th2 responses, respectively (Kaplan M H, et al. (1996) Nature 382: 174-7; Thierfelder W E, et al. (1996) Nature 382: 171-4; Shimoda et al. (1996) Nature 380(6575):630-3; Takeda et al. (1996) Nature 380(6575) 627-30). In addition, IFN-γ tranduces signals through STAT1, which plays a critical role in the generation of Th1 mediated immune responses. Thus, experiments were conducted to definitively determine if these signaling molecules were involved in the coordination of T-bet and IFN-γ expression. CD4⁺ lymph node T cells were isolated from IFN-γ R^(−/−), STAT1^(−/−), and STAT4^(−/−) mice and stimulated with plate bound anti-CD3/CD28+IL-2 (100 U/ml) (neutral) or under Th1 (IL-12 and anti-IL-4) or Th2 (IL4, anti-IFN-γ, and anti-IL-12) inducing conditions for 72 h. RNA (on day 3) or whole cell lysates (on day 3 and day 6) were prepared and subjected to either Northern blot analysis using T-bet, IFN-γ and HPRT cDNAs as probes or were subjected to SDS-PAGE (10%) and subsequent Western blotting. T-bet protein was detected using an anti-T-bet polyclonal antiserum followed by HRP conjugated goat anti-rabbit IgG (Santa Cruz) and ECL substrate (Amersham). In wildtype cells, as expected, T-bet and IFN-γ mRNA expression were restricted to T cells stimulated under Th1 conditions. Interestingly, in all three deficient genotypes IFN-γ mRNA expression was dramatically reduced when these cells were stimulated under Th1 conditions. In these same Th1 conditions T-bet expression was markedly reduced in STAT1 and IFN-γ R1 deficient T cells yet STAT4 deficient cells exhibited T-bet levels comparable to wildtype controls (FIG. 33). The same pattern was observed when T-bet protein expression was examined by Western blot analysis following 3 days of stimulation. Only after 6 days in culture did STAT4^(−/−) T cells begin to show a reduction in T-bet expression. These data clearly demonstrate that signals emanating from the IFN-γ receptor via STAT1 are necessary for the induction of T-bet expression, while signaling through the STAT4 pathway is not required for this early T-bet induction. The late reduction in T-bet expression in STAT4 deficient T cells is likely due to reduced levels of IFN-γ in these cultures. The reduced IFN-γ levels in STAT4 deficient cells suggests that a key role for STAT4 may be to sustain high level IFN-γ production in the developing Th1 response.

[0590] Impaired IFN-γ Production in T-bet−/− and STAT1−/− CD4+ T Cells

[0591] Having established a role for IFN-γ and STAT1 in the induction of T-bet expression, the Th1 differentiation capacity and cytokine profiles of cells lacking T-bet versus those lacking either STAT1 or STAT4 was compared. Moreover, while numerous studies have demonstrated the integral role of STAT4 in Th1 development (Murphy K M, et al. (2000) Annu. Rev. Immunol. 18: 451-94), a similar analysis of STAT1 has been lacking. Primary cultures of CD4+ T-bet^(−/−), STAT1^(−/−) and STAT4^(−/−) CD4⁺ lymph node T cells were isolated and stimulated with plate bound anti-CD3/CD28+IL-2 (neutral) or with the addition of Th1 inducing conditions. Cultures were expanded on day 3 with additional IL-2. On day 7 cells were washed, restimulated and cytokine production was assayed by ICC and ELISA. For ICC, cells were restimulated with PMA/ionomycin for 6 hrs with the addition of monensin during the last 3 hrs. For ELISA, cells were restimulated with plate bound anti-CD3 for 24 hours and culture supernatants were analyzed for IFN-γ. C. Increased IL-4 and IL-5 production from T-bet deficient T cells. CD4+ T cells from T-bet^(−/−), STAT1^(−/−) and STAT4^(−/−) and wildtype controls were isolated and activated under neutral, Th1 or Th2 conditions. On day 7 cells were restimulated and assayed for IL-4 and IL-5 production by ELISA. A comparison of these three genotypes clearly illustrates the fundamental role of T-bet and STAT1 in IFN-γ production and Th1 development. Most dramatically, under neutral conditions, ICC staining showed very few IFN-γ producing cells in the T-bet^(−/−) and STAT1^(−/−) populations while there was no difference in the percentage of IFN-γ-positive cells in the STAT4^(−/−) T cells as compared to wild-type controls (FIG. 34). Following stimulation under Th1 skewing conditions, each deficiency exhibited a decreased percentage of IFN-γ-positive cells, with the greatest reductions observed in T-bet^(−/−) and STAT1^(−/−) T cells (FIG. 35A). ELISA measurement of IFN-γ levels in culture supernatants showed comparable results to the ICC staining.

[0592] Analysis of Th2 cytokine production in these cultures was performed to further characterize the developing Th phenotypes of T-bet^(−/−), STAT^(−/−) and STAT4^(−/−) T cells. Under Th2 conditions, each genotype produced IL-4 and IL-5 (as measured by ELISA) in quantities comparable to wildtype controls. T-bet deficient T cells produced markedly higher IL-4 and IL-5 under both neutral and Th1 conditions as compared to wildtype controls. Additionally, in neutral and Th1 conditions, STAT1 deficient T cells showed increased IL-4 production as compared to wildtype. In contrast, STAT4 deficient cells showed no difference in either IL-4 or IL-5 production as compared to wildtype cells in either neutral or Th1 conditions. Taken together, these studies demonstrate that an optimal Th1 response, characterized by abundant IFN-γ production and suppression of Th2 cytokines, requires the presence of both T-bet and STAT1.

[0593] IFN-γ was also measured in STAT4−/− and T-bet−/− double knock out animals. As above, FIG. 35B shows that Th1 cells from STAT4 and T-bet knock out animals exhibited reduced IFN-γ production, with the T-bet knock out showing the greatest decrease. The STAT4/T-bet double knock out, however, showed an even greater reduction in IFN-γ production.

[0594] These data show that there are discrete phases of Th1 cell development in which STAT1, T-bet and STAT4 have distinct roles. IFN-γ/STAT1 is the primary regulator of T-bet expression, not IL-12/STAT4. When IFN-γ was neutralized during primary stimulation, T-bet expression was lost and cells failed to fully commit to the Th1 lineage. These studies were confirmed in experiments using STAT1^(−/−) and IFNγR1^(−/−) T cells which showed that T-bet expression was severely diminished, as was subsequent production of IFN-γ.

[0595] Although Th1 development was greatly compromised in STAT4^(−/−) T cells, early expression of T-bet was not impaired. Initially, this observation seemed paradoxical given the central roles of both STAT4 and T-bet in Th1 differentiation. However, analysis of T-bet, STAT1 and STAT4 deficient T cells stimulated under neutral (without the addition of Th1 promoting stimuli) conditions could offer an explanation. While IFN-γ production was essentially absent in both STAT1^(−/−) and T-bet^(−/−) T cells, STAT4^(−/−) cells produced IFN-γ levels comparable to wildtype controls. This result suggests that STAT4 is not necessary for directly inducing IFN-γ production. Thus, the central role of STAT4 in Th1 development may be attributed to STAT4's ability to augment and stabilize the amount of IFN-γ produced during a Th1 response.

[0596] Locksley and colleagues have shown that immediately following TCR/CD28 engagement, naïve Thp cells express both IL-4 and IFN-γ transcripts, independent of STAT4 and STAT6 (Grogan J L, et al. (2001) Immunity 14: 205-15). This example corroborates this and demonstrates that initial IFN-γ expression is also independent of T-bet. Subsequently, within hours, the Thp cell enters a second, cytokine dependent, phase of commitment. Here, we find that T-bet expression is necessary to support Th1 development, and relies on signals emanating from the IFN-γR/STAT1 signaling pathway. During this secondary phase, while IFN-γ production is maintained, IL-4 expression is extinguished in developing Th1 cells (Grogan J L, et al. (2001) Immunity 14: 205-15)

[0597] Without wishing to be bound by any particular mechanism, T-bet may potentiate IFN-γ production at this stage, not by initiating chromatin remodeling of the IFN-γ allele, but perhaps by stabilizing the already open IFN-γ locus. T-bet may also induce expression of the IL-12Rα2 chain, allowing Th1 development to enter a third, IL-12/STAT4 dependent stage. Here IL-12 optimizes the level of IFN-γ produced and/or serves as a growth factor for committed Th1 cells (i.e. those expressing a functional IL-12R complex).

[0598] Taken together, these data suggest that this early cytokine expression may be the stochastic aspect of Th cell differentiation. Thus, while each Thp cell expresses both IL-4 and IFN-γ, they may not be expressed at the exact same time. During the initial burst of cytokine transcription, it may be arbitrary as to which cytokine gene is expressed first and which of the two alleles is expressed first.

[0599] This model proposes that the outcome of this first stochastic step plays an important role in directing the fate of an individual Thp cell due to a self-reinforcing feedback mechanism involving IFN-γ and T-bet or IL-4 and GATA3. For example, a naïve Thp cell is stimulated via the TCR/CD28 and may randomly initiate IFN-γ expression. The secreted IFN-γ then acts on the IFN-γR present on that naïve Thp cell to induce T-bet which in turns supports the expression of more IFN-γ followed by more T-bet. At some point the IL-4 gene is randomly expressed and the secreted IL-4 binds to the IL-4R expressed on that same naïve cell which induces GATA3 expression. However, at this point GATA3 may not be able to overcome the gradient of T-bet initially established by the first stochastic act of IFN-γ expression. At this stage T-bet may inhibit IL-4 and IL-5 expression by suppressing GATA3 expression. Additionally in the developing response the IL-12Rα2 chain is expressed allowing IL-12 to act as a growth factor for the developing Th1 cell and/or act to increase IFN-γ levels. Thus, early IFN-γ and T-bet act to initiate and potentiate Th1 development, followed by signals transduced by STAT4 that enhance and stabilize Th1 lineage commitment.

[0600] Nonetheless, our studies argue against a purely selective model. Under this hypothesis, Th cell development is a process solely determined by growth signals delivered by cytokines to T cells that have initially undergone a cytokine-independent stochastic process of Th1 or Th2 differentiation. If this model were to be correct, one would expect that T cells lacking STAT1 would retain the ability to produce IFN-γ. However, in neutral culture conditions IFN-γ producing STAT1^(−/−) cells are essentially absent. Moreover, IFN-γ historically is known for its anti-proliferative capacity and STAT1^(−/−) cells have increased growth rates compared to wildtype cells (Durbin J E, et al. (1996) Cell 84: 443-50; Meraz M A, et al. (1996) Cell 84: 431-42)

[0601] Thus one would predict based on the selection model that there should be more IFN-γ producing STAT1^(−/−) cells than wildtype cells. Even in Th1 culture conditions there is a severe reduction in the ability of the STAT1^(−/−) Th cells to produce IFN-γ and differentiate toward the Th1 phenotype. Thus, while these data suggest that the IL-12/STAT4 pathway is not involved in the initial promotion of Th1 differentiation, it appears that signals transduced by IFN-γ/STAT1, via an instructive mechanism, are required for the efficient generation of IFN-γ and the Th1 response.

[0602] Signaling through the IFN-γ receptor pathway appears to be the primary inducer of T-bet. T-bet transcripts were completely lacking in STAT1^(−/−) T cells stimulated under neutral conditions. TCR stimulation alone was not sufficient to induce T-bet expression nor did it induce T-bet autoregulation. This finding contrasts with prior studies that supported an autoregulatory mechanism for T-bet in experiments measuring endogenous T-bet transcripts when ectopic T-bet was retrovirally introduced into STAT4^(−/−) T cells (Mullen A C, et al. (2001) Science 292: 1907-10). However, retrovirally expressed T-bet has been shown to potently induce endogenous IFN-γ production (Szabo et al. (2000) Cell 100:655-69; Mullen A C, et al. (2001) Science 292: 1907-10) and the IFN-γ produced would then be able to bind IFN-γ receptors present on the STAT4^(−/−) T cells and induce endogenous T-bet. Thus, we find that an intact IFN-γ R1/STAT1 signaling pathway is essential to obtain high level T-bet expression. However, despite the striking reduction of T-bet transcripts in STAT1^(−/−) and IFNγR1^(−/−) T cells developing under Th1 conditions, a low level of T-bet transcripts remained. These results suggest that there are yet to be discovered IFN-γ independent signals/mechanisms that can induce T-bet and Th1 differentiation.

[0603] The data presented in combination with previous T-bet expression studies suggests the following model of early T-helper cell differentiation. Initial production of the signature Th1 and Th2 cytokines, IFN-γ and IL-4 respectively, are driven by TCR mediated signals. Commitment to either developmental pathway depends on the cytokine mediated induction of the transcription factors T-bet and GATA3 and subsequent stabilization of each lineage through multiple components, i.e. STATs.

[0604] Equivalents

[0605] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

1 4 1 1608 DNA Homo sapiens CDS (1)..(1605) 1 atg ggc atc gtg gag ccg ggt tgc gga gac atg ctg acg ggc acc gag 48 Met Gly Ile Val Glu Pro Gly Cys Gly Asp Met Leu Thr Gly Thr Glu 1 5 10 15 ccg atg ccg ggg agc gac gag ggc cgg gcg cct ggc gcc gac ccg cag 96 Pro Met Pro Gly Ser Asp Glu Gly Arg Ala Pro Gly Ala Asp Pro Gln 20 25 30 cac cgc tac ttc tac ccg gag ccg ggc gcg cag gac gcg gac gag cgt 144 His Arg Tyr Phe Tyr Pro Glu Pro Gly Ala Gln Asp Ala Asp Glu Arg 35 40 45 cgc ggg ggc ggc agc ctg ggg tct ccc tac ccg ggg ggc gcc ttg gtg 192 Arg Gly Gly Gly Ser Leu Gly Ser Pro Tyr Pro Gly Gly Ala Leu Val 50 55 60 ccc gcc ccg ccg agc cgc ttc ctt gga gcc tac gcc tac ccg ccg cga 240 Pro Ala Pro Pro Ser Arg Phe Leu Gly Ala Tyr Ala Tyr Pro Pro Arg 65 70 75 80 ccc cag gcg gcc ggc ttc ccc ggc gcg ggc gag tcc ttc ccg ccg ccc 288 Pro Gln Ala Ala Gly Phe Pro Gly Ala Gly Glu Ser Phe Pro Pro Pro 85 90 95 gcg gac gcc gag ggc tac cag ccg ggc gag ggc tac gcc gcc ccg gac 336 Ala Asp Ala Glu Gly Tyr Gln Pro Gly Glu Gly Tyr Ala Ala Pro Asp 100 105 110 ccg cgc gcc ggg ctc tac ccg ggg ccg cgt gag gac tac gcg cta ccc 384 Pro Arg Ala Gly Leu Tyr Pro Gly Pro Arg Glu Asp Tyr Ala Leu Pro 115 120 125 gcg gga ctg gag gtg tcg ggg aaa ctg agg gtc gcg ctc aac aac cac 432 Ala Gly Leu Glu Val Ser Gly Lys Leu Arg Val Ala Leu Asn Asn His 130 135 140 ctg ttg tgg tcc aag ttt aat cag cac cag aca gag atg atc atc acc 480 Leu Leu Trp Ser Lys Phe Asn Gln His Gln Thr Glu Met Ile Ile Thr 145 150 155 160 aag cag gga cgg cgg atg ttc cca ttc ctg tca ttt act gtg gcc ggg 528 Lys Gln Gly Arg Arg Met Phe Pro Phe Leu Ser Phe Thr Val Ala Gly 165 170 175 ctg gag ccc acc agc cac tac agg atg ttt gtg gac gtg gtc ttg gtg 576 Leu Glu Pro Thr Ser His Tyr Arg Met Phe Val Asp Val Val Leu Val 180 185 190 gac cag cac cac tgg cgg tac cag agc ggc aag tgg gtg cag tgt gga 624 Asp Gln His His Trp Arg Tyr Gln Ser Gly Lys Trp Val Gln Cys Gly 195 200 205 aag gcc gag ggc agc atg cca gga aac cgc ctg tac gtc cac ccg gac 672 Lys Ala Glu Gly Ser Met Pro Gly Asn Arg Leu Tyr Val His Pro Asp 210 215 220 tcc ccc aac aca gga gcg cac tgg atg cgc cag gaa gtt tca ttt ggg 720 Ser Pro Asn Thr Gly Ala His Trp Met Arg Gln Glu Val Ser Phe Gly 225 230 235 240 aaa cta aag ctc aca aac aac aag ggg gcg tcc aac aat gtg acc cag 768 Lys Leu Lys Leu Thr Asn Asn Lys Gly Ala Ser Asn Asn Val Thr Gln 245 250 255 atg att gtg ctc cag tcc ctc cat aag tac cag ccc cgg ctg cat atc 816 Met Ile Val Leu Gln Ser Leu His Lys Tyr Gln Pro Arg Leu His Ile 260 265 270 gtt gag gtg aac gac gga gag cca gag gca gcc tgc aac gct tcc aac 864 Val Glu Val Asn Asp Gly Glu Pro Glu Ala Ala Cys Asn Ala Ser Asn 275 280 285 acg cat atc ttt act ttc caa gaa acc cag ttc att gcc gtg act gcc 912 Thr His Ile Phe Thr Phe Gln Glu Thr Gln Phe Ile Ala Val Thr Ala 290 295 300 tac cag aat gcc gag att act cag ctg aaa att gat aat aac ccc ttt 960 Tyr Gln Asn Ala Glu Ile Thr Gln Leu Lys Ile Asp Asn Asn Pro Phe 305 310 315 320 gcc aaa gga ttc cgg gag aac ttt gag tcc atg tac aca tct gtt gac 1008 Ala Lys Gly Phe Arg Glu Asn Phe Glu Ser Met Tyr Thr Ser Val Asp 325 330 335 acc agc atc ccc tcc ccg cct gga ccc aac tgt caa ttc ctt ggg gga 1056 Thr Ser Ile Pro Ser Pro Pro Gly Pro Asn Cys Gln Phe Leu Gly Gly 340 345 350 gat cac tac tct cct ctc cta ccc aac cag tat cct gtt ccc agc cgc 1104 Asp His Tyr Ser Pro Leu Leu Pro Asn Gln Tyr Pro Val Pro Ser Arg 355 360 365 ttc tac ccc gac ctt cct ggc cag gcg aag gat gtg gtt ccc cag gct 1152 Phe Tyr Pro Asp Leu Pro Gly Gln Ala Lys Asp Val Val Pro Gln Ala 370 375 380 tac tgg ctg ggg gcc ccc cgg gac cac agc tat gag gct gag ttt cga 1200 Tyr Trp Leu Gly Ala Pro Arg Asp His Ser Tyr Glu Ala Glu Phe Arg 385 390 395 400 gca gtc agc atg aag cct gca ttc ttg ccc tct gcc cct ggg ccc acc 1248 Ala Val Ser Met Lys Pro Ala Phe Leu Pro Ser Ala Pro Gly Pro Thr 405 410 415 atg tcc tac tac cga ggc cag gag gtc ctg gca cct gga gct ggc tgg 1296 Met Ser Tyr Tyr Arg Gly Gln Glu Val Leu Ala Pro Gly Ala Gly Trp 420 425 430 cct gtg gca ccc cag tac cct ccc aag atg ggc ccg gcc agc tgg ttc 1344 Pro Val Ala Pro Gln Tyr Pro Pro Lys Met Gly Pro Ala Ser Trp Phe 435 440 445 cgc cct atg cgg act ctg ccc atg gaa ccc ggc cct gga ggc tca gag 1392 Arg Pro Met Arg Thr Leu Pro Met Glu Pro Gly Pro Gly Gly Ser Glu 450 455 460 gga cgg gga cca gag gac cag ggt ccc ccc ttg gtg tgg act gag att 1440 Gly Arg Gly Pro Glu Asp Gln Gly Pro Pro Leu Val Trp Thr Glu Ile 465 470 475 480 gcc ccc atc cgg ccg gaa tcc agt gat tca gga ctg ggc gaa gga gac 1488 Ala Pro Ile Arg Pro Glu Ser Ser Asp Ser Gly Leu Gly Glu Gly Asp 485 490 495 tct aag agg agg cgc gtg tcc ccc tat cct tcc agt ggt gac agc tcc 1536 Ser Lys Arg Arg Arg Val Ser Pro Tyr Pro Ser Ser Gly Asp Ser Ser 500 505 510 tcc cct gct ggg gcc cct tct cct ttt gat aag gaa gct gaa gga cag 1584 Ser Pro Ala Gly Ala Pro Ser Pro Phe Asp Lys Glu Ala Glu Gly Gln 515 520 525 ttt tat aac tat ttt ccc aac tga 1608 Phe Tyr Asn Tyr Phe Pro Asn 530 535 2 535 PRT Homo sapiens 2 Met Gly Ile Val Glu Pro Gly Cys Gly Asp Met Leu Thr Gly Thr Glu 1 5 10 15 Pro Met Pro Gly Ser Asp Glu Gly Arg Ala Pro Gly Ala Asp Pro Gln 20 25 30 His Arg Tyr Phe Tyr Pro Glu Pro Gly Ala Gln Asp Ala Asp Glu Arg 35 40 45 Arg Gly Gly Gly Ser Leu Gly Ser Pro Tyr Pro Gly Gly Ala Leu Val 50 55 60 Pro Ala Pro Pro Ser Arg Phe Leu Gly Ala Tyr Ala Tyr Pro Pro Arg 65 70 75 80 Pro Gln Ala Ala Gly Phe Pro Gly Ala Gly Glu Ser Phe Pro Pro Pro 85 90 95 Ala Asp Ala Glu Gly Tyr Gln Pro Gly Glu Gly Tyr Ala Ala Pro Asp 100 105 110 Pro Arg Ala Gly Leu Tyr Pro Gly Pro Arg Glu Asp Tyr Ala Leu Pro 115 120 125 Ala Gly Leu Glu Val Ser Gly Lys Leu Arg Val Ala Leu Asn Asn His 130 135 140 Leu Leu Trp Ser Lys Phe Asn Gln His Gln Thr Glu Met Ile Ile Thr 145 150 155 160 Lys Gln Gly Arg Arg Met Phe Pro Phe Leu Ser Phe Thr Val Ala Gly 165 170 175 Leu Glu Pro Thr Ser His Tyr Arg Met Phe Val Asp Val Val Leu Val 180 185 190 Asp Gln His His Trp Arg Tyr Gln Ser Gly Lys Trp Val Gln Cys Gly 195 200 205 Lys Ala Glu Gly Ser Met Pro Gly Asn Arg Leu Tyr Val His Pro Asp 210 215 220 Ser Pro Asn Thr Gly Ala His Trp Met Arg Gln Glu Val Ser Phe Gly 225 230 235 240 Lys Leu Lys Leu Thr Asn Asn Lys Gly Ala Ser Asn Asn Val Thr Gln 245 250 255 Met Ile Val Leu Gln Ser Leu His Lys Tyr Gln Pro Arg Leu His Ile 260 265 270 Val Glu Val Asn Asp Gly Glu Pro Glu Ala Ala Cys Asn Ala Ser Asn 275 280 285 Thr His Ile Phe Thr Phe Gln Glu Thr Gln Phe Ile Ala Val Thr Ala 290 295 300 Tyr Gln Asn Ala Glu Ile Thr Gln Leu Lys Ile Asp Asn Asn Pro Phe 305 310 315 320 Ala Lys Gly Phe Arg Glu Asn Phe Glu Ser Met Tyr Thr Ser Val Asp 325 330 335 Thr Ser Ile Pro Ser Pro Pro Gly Pro Asn Cys Gln Phe Leu Gly Gly 340 345 350 Asp His Tyr Ser Pro Leu Leu Pro Asn Gln Tyr Pro Val Pro Ser Arg 355 360 365 Phe Tyr Pro Asp Leu Pro Gly Gln Ala Lys Asp Val Val Pro Gln Ala 370 375 380 Tyr Trp Leu Gly Ala Pro Arg Asp His Ser Tyr Glu Ala Glu Phe Arg 385 390 395 400 Ala Val Ser Met Lys Pro Ala Phe Leu Pro Ser Ala Pro Gly Pro Thr 405 410 415 Met Ser Tyr Tyr Arg Gly Gln Glu Val Leu Ala Pro Gly Ala Gly Trp 420 425 430 Pro Val Ala Pro Gln Tyr Pro Pro Lys Met Gly Pro Ala Ser Trp Phe 435 440 445 Arg Pro Met Arg Thr Leu Pro Met Glu Pro Gly Pro Gly Gly Ser Glu 450 455 460 Gly Arg Gly Pro Glu Asp Gln Gly Pro Pro Leu Val Trp Thr Glu Ile 465 470 475 480 Ala Pro Ile Arg Pro Glu Ser Ser Asp Ser Gly Leu Gly Glu Gly Asp 485 490 495 Ser Lys Arg Arg Arg Val Ser Pro Tyr Pro Ser Ser Gly Asp Ser Ser 500 505 510 Ser Pro Ala Gly Ala Pro Ser Pro Phe Asp Lys Glu Ala Glu Gly Gln 515 520 525 Phe Tyr Asn Tyr Phe Pro Asn 530 535 3 1593 DNA Mus musculus CDS (1)..(1590) 3 atg ggc atc gtg gag ccg ggc tgc gga gac atg ctg acc ggc acc gag 48 Met Gly Ile Val Glu Pro Gly Cys Gly Asp Met Leu Thr Gly Thr Glu 1 5 10 15 ccg atg ccg agt gac gag ggc cgg ggg ccc gga gcg gac caa cag cat 96 Pro Met Pro Ser Asp Glu Gly Arg Gly Pro Gly Ala Asp Gln Gln His 20 25 30 cgt ttc ttc tat ccc gag ccg ggc gca cag gac ccg acc gat cgc cgc 144 Arg Phe Phe Tyr Pro Glu Pro Gly Ala Gln Asp Pro Thr Asp Arg Arg 35 40 45 gca ggt agc agc ctg ggg acg ccc tac tct ggg ggc gcc ctg gtg cct 192 Ala Gly Ser Ser Leu Gly Thr Pro Tyr Ser Gly Gly Ala Leu Val Pro 50 55 60 gcc gcg ccg ggt cgc ttc ctt gga tcc ttc gcc tac ccg ccc cgg gct 240 Ala Ala Pro Gly Arg Phe Leu Gly Ser Phe Ala Tyr Pro Pro Arg Ala 65 70 75 80 cag gtg gct ggc ttt ccc ggg cct ggc gag ttc ttc ccg ccg ccc gcg 288 Gln Val Ala Gly Phe Pro Gly Pro Gly Glu Phe Phe Pro Pro Pro Ala 85 90 95 ggt gcg gag ggc tac ccg ccc gtg gat ggc tac cct gcc cct gac ccg 336 Gly Ala Glu Gly Tyr Pro Pro Val Asp Gly Tyr Pro Ala Pro Asp Pro 100 105 110 cgc gcg ggg ctc tac cca ggg ccg cgc gag gac tac gca ttg ccc gcg 384 Arg Ala Gly Leu Tyr Pro Gly Pro Arg Glu Asp Tyr Ala Leu Pro Ala 115 120 125 ggg ttg gag gtg tct ggg aag ctg aga gtc gcg ctc agc aac cac ctg 432 Gly Leu Glu Val Ser Gly Lys Leu Arg Val Ala Leu Ser Asn His Leu 130 135 140 ttg tgg tcc aag ttc aac cag cac cag aca gag atg atc atc act aag 480 Leu Trp Ser Lys Phe Asn Gln His Gln Thr Glu Met Ile Ile Thr Lys 145 150 155 160 caa gga cgg cga atg ttc cca ttc ctg tcc ttc acc gtg gcc ggg ctg 528 Gln Gly Arg Arg Met Phe Pro Phe Leu Ser Phe Thr Val Ala Gly Leu 165 170 175 gag ccc aca agc cat tac agg atg ttt gtg gat gtg gtc ttg gtg gac 576 Glu Pro Thr Ser His Tyr Arg Met Phe Val Asp Val Val Leu Val Asp 180 185 190 cag cac cac tgg cgg tac cag agc ggc aag tgg gtg cag tgt gga aag 624 Gln His His Trp Arg Tyr Gln Ser Gly Lys Trp Val Gln Cys Gly Lys 195 200 205 gca gaa ggc agc atg cca ggg aac cgc tta tat gtc cac cca gac tcc 672 Ala Glu Gly Ser Met Pro Gly Asn Arg Leu Tyr Val His Pro Asp Ser 210 215 220 ccc aac acc gga gcc cac tgg atg cgc cag gaa gtt tca ttt ggg aag 720 Pro Asn Thr Gly Ala His Trp Met Arg Gln Glu Val Ser Phe Gly Lys 225 230 235 240 cta aag ctc acc aac aac aag ggg gct tcc aac aat gtg acc cag atg 768 Leu Lys Leu Thr Asn Asn Lys Gly Ala Ser Asn Asn Val Thr Gln Met 245 250 255 atc gtc ctg cag tct ctc cac aag tac cag ccc cgg ctg cac atc gtg 816 Ile Val Leu Gln Ser Leu His Lys Tyr Gln Pro Arg Leu His Ile Val 260 265 270 gag gtg aat gat gga gag cca gag gct gcc tgc agt gct tct aac aca 864 Glu Val Asn Asp Gly Glu Pro Glu Ala Ala Cys Ser Ala Ser Asn Thr 275 280 285 cac gtc ttt act ttc caa gag acc cag ttc att gca gtg act gcc tac 912 His Val Phe Thr Phe Gln Glu Thr Gln Phe Ile Ala Val Thr Ala Tyr 290 295 300 cag aac gca gag atc act cag ctg aaa atc gac aac aac ccc ttt gcc 960 Gln Asn Ala Glu Ile Thr Gln Leu Lys Ile Asp Asn Asn Pro Phe Ala 305 310 315 320 aaa gga ttc cgg gag aac ttt gag tcc atg tac gca tct gtt gat acg 1008 Lys Gly Phe Arg Glu Asn Phe Glu Ser Met Tyr Ala Ser Val Asp Thr 325 330 335 agt gtc ccc tcg cca cct gga ccc aac tgt caa ctg ctt ggg gga gac 1056 Ser Val Pro Ser Pro Pro Gly Pro Asn Cys Gln Leu Leu Gly Gly Asp 340 345 350 ccc ttc tca cct ctt cta tcc aac cag tat cct gtt ccc agc cgt ttc 1104 Pro Phe Ser Pro Leu Leu Ser Asn Gln Tyr Pro Val Pro Ser Arg Phe 355 360 365 tac ccc gac ctt cca ggc cag ccc aag gat atg atc tca cag cct tac 1152 Tyr Pro Asp Leu Pro Gly Gln Pro Lys Asp Met Ile Ser Gln Pro Tyr 370 375 380 tgg ctg ggg aca cct cgg gaa cac agt tat gaa gcg gag ttc cga gct 1200 Trp Leu Gly Thr Pro Arg Glu His Ser Tyr Glu Ala Glu Phe Arg Ala 385 390 395 400 gtg agc atg aag ccc aca ctc cta ccc tct gcc ccg ggg ccc act gtg 1248 Val Ser Met Lys Pro Thr Leu Leu Pro Ser Ala Pro Gly Pro Thr Val 405 410 415 ccc tac tac cgg ggc caa gac gtc ctg gcg cct gga gct ggt tgg ccc 1296 Pro Tyr Tyr Arg Gly Gln Asp Val Leu Ala Pro Gly Ala Gly Trp Pro 420 425 430 gtg gcc cct caa tac ccg ccc aag atg agc cca gct ggc tgg ttc cgg 1344 Val Ala Pro Gln Tyr Pro Pro Lys Met Ser Pro Ala Gly Trp Phe Arg 435 440 445 ccc atg cga act ctg ccc atg gac ccg ggc ctg gga tcc tca gag gaa 1392 Pro Met Arg Thr Leu Pro Met Asp Pro Gly Leu Gly Ser Ser Glu Glu 450 455 460 cag ggc tcc tcc ccc tcg ctg tgg cct gag gtc acc tcc ctc cag ccg 1440 Gln Gly Ser Ser Pro Ser Leu Trp Pro Glu Val Thr Ser Leu Gln Pro 465 470 475 480 gag ccc agc gac tca gga cta ggc gaa gga gac act aag agg agg agg 1488 Glu Pro Ser Asp Ser Gly Leu Gly Glu Gly Asp Thr Lys Arg Arg Arg 485 490 495 ata tcc ccc tat cct tcc agt ggc gac agc tcc tct ccc gct ggg gcc 1536 Ile Ser Pro Tyr Pro Ser Ser Gly Asp Ser Ser Ser Pro Ala Gly Ala 500 505 510 cct tct cct ttt gat aag gaa acc gaa ggc cag ttt tat aat tat ttt 1584 Pro Ser Pro Phe Asp Lys Glu Thr Glu Gly Gln Phe Tyr Asn Tyr Phe 515 520 525 ccc aac tga 1593 Pro Asn 530 4 530 PRT Mus musculus 4 Met Gly Ile Val Glu Pro Gly Cys Gly Asp Met Leu Thr Gly Thr Glu 1 5 10 15 Pro Met Pro Ser Asp Glu Gly Arg Gly Pro Gly Ala Asp Gln Gln His 20 25 30 Arg Phe Phe Tyr Pro Glu Pro Gly Ala Gln Asp Pro Thr Asp Arg Arg 35 40 45 Ala Gly Ser Ser Leu Gly Thr Pro Tyr Ser Gly Gly Ala Leu Val Pro 50 55 60 Ala Ala Pro Gly Arg Phe Leu Gly Ser Phe Ala Tyr Pro Pro Arg Ala 65 70 75 80 Gln Val Ala Gly Phe Pro Gly Pro Gly Glu Phe Phe Pro Pro Pro Ala 85 90 95 Gly Ala Glu Gly Tyr Pro Pro Val Asp Gly Tyr Pro Ala Pro Asp Pro 100 105 110 Arg Ala Gly Leu Tyr Pro Gly Pro Arg Glu Asp Tyr Ala Leu Pro Ala 115 120 125 Gly Leu Glu Val Ser Gly Lys Leu Arg Val Ala Leu Ser Asn His Leu 130 135 140 Leu Trp Ser Lys Phe Asn Gln His Gln Thr Glu Met Ile Ile Thr Lys 145 150 155 160 Gln Gly Arg Arg Met Phe Pro Phe Leu Ser Phe Thr Val Ala Gly Leu 165 170 175 Glu Pro Thr Ser His Tyr Arg Met Phe Val Asp Val Val Leu Val Asp 180 185 190 Gln His His Trp Arg Tyr Gln Ser Gly Lys Trp Val Gln Cys Gly Lys 195 200 205 Ala Glu Gly Ser Met Pro Gly Asn Arg Leu Tyr Val His Pro Asp Ser 210 215 220 Pro Asn Thr Gly Ala His Trp Met Arg Gln Glu Val Ser Phe Gly Lys 225 230 235 240 Leu Lys Leu Thr Asn Asn Lys Gly Ala Ser Asn Asn Val Thr Gln Met 245 250 255 Ile Val Leu Gln Ser Leu His Lys Tyr Gln Pro Arg Leu His Ile Val 260 265 270 Glu Val Asn Asp Gly Glu Pro Glu Ala Ala Cys Ser Ala Ser Asn Thr 275 280 285 His Val Phe Thr Phe Gln Glu Thr Gln Phe Ile Ala Val Thr Ala Tyr 290 295 300 Gln Asn Ala Glu Ile Thr Gln Leu Lys Ile Asp Asn Asn Pro Phe Ala 305 310 315 320 Lys Gly Phe Arg Glu Asn Phe Glu Ser Met Tyr Ala Ser Val Asp Thr 325 330 335 Ser Val Pro Ser Pro Pro Gly Pro Asn Cys Gln Leu Leu Gly Gly Asp 340 345 350 Pro Phe Ser Pro Leu Leu Ser Asn Gln Tyr Pro Val Pro Ser Arg Phe 355 360 365 Tyr Pro Asp Leu Pro Gly Gln Pro Lys Asp Met Ile Ser Gln Pro Tyr 370 375 380 Trp Leu Gly Thr Pro Arg Glu His Ser Tyr Glu Ala Glu Phe Arg Ala 385 390 395 400 Val Ser Met Lys Pro Thr Leu Leu Pro Ser Ala Pro Gly Pro Thr Val 405 410 415 Pro Tyr Tyr Arg Gly Gln Asp Val Leu Ala Pro Gly Ala Gly Trp Pro 420 425 430 Val Ala Pro Gln Tyr Pro Pro Lys Met Ser Pro Ala Gly Trp Phe Arg 435 440 445 Pro Met Arg Thr Leu Pro Met Asp Pro Gly Leu Gly Ser Ser Glu Glu 450 455 460 Gln Gly Ser Ser Pro Ser Leu Trp Pro Glu Val Thr Ser Leu Gln Pro 465 470 475 480 Glu Pro Ser Asp Ser Gly Leu Gly Glu Gly Asp Thr Lys Arg Arg Arg 485 490 495 Ile Ser Pro Tyr Pro Ser Ser Gly Asp Ser Ser Ser Pro Ala Gly Ala 500 505 510 Pro Ser Pro Phe Asp Lys Glu Thr Glu Gly Gln Phe Tyr Asn Tyr Phe 515 520 525 Pro Asn 530 

What is claimed is:
 1. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a T-bet polypeptide.
 2. The method of claim 1, wherein the nucleic acid molecule encodes the polypeptide shown in SEQ ID NO:2
 3. The method of claim 1, wherein the nucleic acid molecule encodes the polypeptide shown in SEQ ID NO:4
 4. The nucleic acid molecule of claim 1, which comprises the nucleotide sequence shown in SEQ ID NO:
 1. 5. The nucleic acid molecule of claim 4, which comprises the nucleotide sequence of SEQ ID NO:3.
 6. The nucleic acid molecule of claim 1, which has at least 70% nucleotide identity with at least about 700 contiguous nucleotides of SEQ ID NO:1.
 7. The nucleic acid molecule of claim 1, which has at least 70% nucleotide identity with at least about 500 contiguous nucleotides of SEQ ID NO:3.
 8. The nucleic acid molecule of claim 1, which has at least 90% nucleotide identity with at least about 700 contiguous nucleotides of SEQ ID NO:1.
 9. The nucleic acid molecule of claim 1, which has at least 90% nucleotide identity with at least about 500 contiguous nucleotides of SEQ ID NO:3.
 10. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide that modulates IFN-γ production in a cell, wherein the nucleotide sequence hybridizes to the complement of the nucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:3 in 6× SSC at 45° C., followed by one or more washes in 0.2× SSC, 0.1% SDS at 50-65° C.
 11. An isolated nucleic acid molecule comprising a nucleotide sequence that hybridizes under conditions of 6× SSC at 45° C., followed by one or more washes in 0.2× SSC, 0.1% SDS at 50-65° C. to at least nucleotides 138-327 of SEQ ID NO:1, or a complement thereof, wherein the nucleotide sequence detects a nucleotide sequence encoding a T-bet polypeptide.
 12. An isolated nucleic acid molecule which is antisense to the coding strand of the nucleic acid molecule of claim
 1. 13. An isolated nucleic acid molecule comprising a nucleotide sequence complementary to mRNA transcribed from a gene encoding a T-bet polypeptide.
 14. An isolated double stranded nucleic acid molecule comprising a first nucleotide sequence complementary to mRNA transcribed from a gene encoding a T-bet polypeptide and a second nucleic acid molecule complementary to the first nucleic acid molecule.
 15. The isolated nucleic acid of claim 13 or 14, wherein the nucleic acid molecule is between about 20-30 nucleotides in length.
 16. The isolated nucleic acid of claim 13 or 14, wherein the nucleic acid molecule is between about 22-25 nucleotides in length.
 17. The isolated nucleic acid of claim 13, wherein the nucleic acid molecule is double stranded.
 18. The isolated nucleic acid molecule of claim 13, wherein the nucleic acid molecule is single stranded.
 19. A vector comprising the nucleic acid molecule of claim
 1. 20. The vector of claim 19, which is an expression vector.
 21. A host cell containing the vector of claim
 20. 22. A method for producing a T-bet polypeptide comprising culturing the host cell of claim 10 in a suitable medium until a T-bet polypeptide is produced.
 23. The method of claim 22, further comprising isolating the T-bet polypeptide from the medium or the host cell.
 24. An isolated T-bet polypeptide.
 25. The polypeptide of claim 24, which comprises the amino acid sequence encoded by the nucleic acid sequence of SEQ ID NO:1.
 26. The polypeptide of claim 24, which comprises the amino acid sequence encoded by the nucleic acid sequence of SEQ ID NO:3.
 27. The polypeptide of claim 24, which comprises the amino acid sequence of SEQ ID NO:
 2. 28. The polypeptide of claim 24, which comprises the amino acid sequence of SEQ ID NO:
 4. 29. The polypeptide of claim 24, which has at least 70% amino acid identity with the polypeptide shown in SEQ ID NO:2 and binds to DNA.
 30. The polypeptide of claim 24, which has at least 70% amino acid identity with the polypeptide shown in SEQ ID NO:4 and binds to DNA.
 31. The polypeptide of claim 24, which has at least 90% amino acid identity with the polypeptide shown in SEQ ID NO:2.
 32. A fusion polypeptide comprising a T-bet polypeptide operatively linked to a polypeptide other than T-bet.
 33. The polypeptide of claim 32, wherein the polypeptide other than T-bet is the repressor domain of the Drosophila engrailed polypeptide.
 34. An antibody that specifically binds at least one mammalian T-bet polypeptide.
 35. The antibody of claim 34, wherein the antibody specifically binds human T-bet polypeptide
 36. The antibody of claim 34, wherein the antibody specifically binds both human and mouse T-bet polypeptide.
 37. The antibody of claim 34, which is a polyclonal antibody.
 38. The antibody of claim 34, which is a monoclonal antibody.
 39. The antibody of claim 34, which is coupled to a detectable substance.
 40. A method of producing an antibody that specifically binds to T-bet comprising: immunizing an animal with a T-bet polypeptide, or antigenic fragment thereof, such that antibodies are produced by B cells of the animal; isolating B cells of the animal; and fusing the B cells with myeloma cells to form immortal, hybridoma cells that secrete human monoclonal antibodies which specifically bind to T-bet.
 41. The method of claim 40, wherein the subject is a non-human transgenic animal having a genome comprising a human heavy chain transgene and a human light chain transgene.
 42. The method of claim 40, wherein the T-bet polypeptide, or a fragment thereof, comprises at least 8 amino acid residues of the amino acid sequence shown in SEQ ID NO: 2 or
 4. 43. An intrabody that specifically binds at least one mammalian T-bet polypeptide.
 44. The intrabody of claim 43, wherein the intrabody specifically binds human T-bet polypeptide.
 45. A composition comprising an agent that modulates T-bet and a pharmaceutically acceptable carrier.
 46. The composition of claim 45, wherein the agent is an agonist of T-bet.
 47. The composition of claim 45, wherein the agent is an antagonist of T-bet.
 48. An immunomodulatory composition comprising an agent that modulates the expression and/or activity of T-bet and an antigen
 49. The composition of claim 48, wherein the agent increases the expression and/or activity of T-bet
 50. The composition of claim 48, wherein the agent is a DNA molecule encoding a T-bet polypeptide
 51. The composition of claim 48, wherein the agent is a T-bet polypeptide
 52. The composition of claim 48, wherein the agent decreases the expression and/or activity of T-bet
 53. The composition of claim 52, wherein the agent is a DNA molecule encoding a dominant negative T-bet polypeptide
 54. A method for treating a condition or a disorder that would benefit from modulation of the expression and/or activity of T-bet in a subject comprising administering the immunomodulatory composition of claim
 40. 55. The method of claim 54, wherein the disorder is an autoimmune disorder
 56. A nonhuman transgenic animal that contains cells carrying a transgene encoding a T-bet polypeptide.
 57. The transgenic animal of claim 56, wherein the non-human animal is a mouse.
 58. A nonhuman animal comprising in its genome an exogenous DNA molecule that functionally disrupts a T-bet gene of the non-human animal, wherein the animal exhibits a phenotype characterized by decreased IFN-γ production, relative to a wild-type animal.
 59. The transgenic animal of claim 58, wherein the non-human animal is a mouse.
 60. A recombinant cell comprising an exogenous T-bet molecule or a portion thereof, and a reporter gene operably linked to a regulatory region responsive to T-bet such that upon activation of T-bet, transcription of the reporter gene occurs.
 61. A recombinant cell comprising a gene encoding an ecdysone receptor, an exogenous gene encoding a T-bet expression plasmid operatively linked to the ecdysone gene, and a reporter gene operatively linked to an IFN-γ promoter.
 62. A method for detecting the presence of T-bet in a biological sample comprising contacting the biological sample with an agent capable of detecting an indicator of T-bet activity or expression such that the presence of T-bet is detected in the biological sample.
 63. A method for modulating expression in a cell of a gene whose transcription is regulated by T-bet, comprising contacting the cell with an agent that modulates the expression or activity of T-bet such that expression of the gene is altered.
 64. The method of claim 63, wherein the expression of T-bet is selectively modulated.
 65. The method of claim 63, wherein the agent increases the expression and/or activity of T-bet
 66. The method of claim 63, wherein herein the agent decreases the expression and/or activity of T-bet
 67. The method of claim 63, wherein the step of contacting occurs in vivo.
 68. The method of claim 63, wherein the step of contacting occurs in vitro.
 69. The method of claim 63, wherein the cell is a T cell.
 70. The method of claim 69, wherein the cell is selected from the group consisting of: a lamina propria T cell, a CD8+ cell, and a CD4+ cell.
 71. The method of claim 63, wherein the cell is a B cell.
 72. The method of claim 63, wherein the cell is selected from the group consisting of a dendritic cell and an NK cell.
 73. The method of claim 63, wherein the cell is a mammalian cell.
 74. The method of claim 63, wherein the cell is a human cell.
 75. The method of claim 63, wherein the gene is a cytokine gene.
 76. The method of claim 63, wherein the cytokine gene is selected from IL-2, IFN-γ, IL-4, IL-5, TNFα, TGF-β, LT(lymphotoxin), and IL-10.
 77. The method of claim 63, wherein the gene is a cytokine receptor gene
 78. A method for modulating the effects of at least one external influence on a cell, wherein the external influence modulates T-bet expression and/or activity, the method comprising contacting a cell with an agent that modulates T-bet expression and/or activity in the cell such that T-bet mediated effects of at least one external influence is modulated.
 79. The method of claim 78, wherein the at least one external influence is a cytokine
 80. The method of claim 78, wherein the cell is present in a subject suffering from a disorder that would benefit from modulation of T-bet expression and/or activity.
 81. The method of claim 78, wherein the external influence is a cytokine the agent increases the expression and/or activity of T-bet.
 82. The method of claim 78, wherein the external influence is a cytokine the agent decreases the expression and/or activity of T-bet
 83. The method of claim 78, wherein the cell is a T cell.
 84. The method of claim 78, wherein the cell is selected from the group consisting of: a lamina propria T cell, a CD8+ cell, and a CD4+ cell.
 85. The method of claim 78, wherein the cell is a B cell.
 86. The method of claim 78, wherein the cell is selected from the group consisting of a dendritic cell and an NK cell.
 87. The method of claim 78, wherein the cell is a mammalian cell.
 88. The method of claim 78, wherein the cell is a human cell.
 89. The method of claim 78, wherein the agent directly modulates T-bet expression and/or activity
 90. The method of claim 78, wherein the agent indirectly modulates T-bet expression and/or activity
 91. The method of modulating the expression and/or activity of T-bet, comprising contacting a cell with an agent that modulates TGF-β-mediated signaling.
 92. The method of claim 91, wherein TGF-β-mediated signaling is increased and T-bet expression and/or activity is decreased.
 93. The method of claim 92, wherein the method is performed in a subject that would benefit from reduced IFN-γ production by cells of the innate and/or adaptive immune system.
 94. The method of claim 91, wherein TGF-β-mediated signaling is decreased and T-bet expression and/or activity is increased.
 95. The method of claim 94, wherein the method is performed in a subject that would benefit from increased IFN-γ production by cells of the innate and/or adaptive immune system.
 96. The method of modulating the expression and/or activity of T-bet, comprising contacting a cell with an agent that modulates STAT1-mediated signaling.
 97. The method of claim 96, wherein STAT1-mediated signaling is increased and T-bet expression and/or activity is increased.
 98. The method of claim 96, wherein the method is performed in a subject that would benefit from increased IFN-γ production by cells of the innate and/or adaptive immune system.
 99. The method of claim 96, wherein STAT1 mediated signaling is decreased and T-bet expression and/or activity is decreased.
 100. The method of claim 99, wherein the method is performed in a subject that would benefit from decreased IFN-γ production by cells of the innate and/or adaptive immune system.
 101. A method of modulating the interaction between T-bet and a molecule with which T bet interacts comprising contacting a cell with an agent that modulates T-bet expression and/or activity such that the Interaction between T-bet and a Molecule with which T-bet interacts is modulated
 102. The method of claim 101, wherein the molecule with which T-bet interacts is selected from the group consisting of: a T-bet responsive DNA element, a cytokine promoter, and a Tec kinase.
 103. The method of claim 101, wherein the method is performed in a subject that would benefit from modulation of IFN-γ production by cells of the innate and/or adaptive immune system.
 104. A method for reducing the level of expression of genes which are activated by extracellular influences which induce T-bet mediated intracellular signaling in a cell, the method comprising contacting a cell with an agent that reduces T-bet activity in the cell such that expression of the genes is reduced.
 105. The method of claim 104, wherein the cell is a T cell.
 106. The method of claim 105, wherein the cell is a CD4+ cell or a CD8+ cell.
 107. The method of claim 104, wherein the cell is selected from the group consisting of: a B cell, an NK cell, and a dendritic cell.
 108. The method of claim 104, wherein the gene is a cytokine gene.
 109. The method of claim 104, wherein the gene is IFN-γ.
 110. A method for increasing the level of expression of genes which are activated by extracellular influences which induce T-bet mediated intracellular signaling in a cell, the method comprising contacting a cell with an agent that increases T-bet activity in the cell such that expression of the genes is increased.
 111. The method of claim 110, wherein the cell is a T cell.
 112. The method of claim 111, wherein the cell is a CD4+ cell or a CD8+ cell.
 113. The method of claim 110, wherein the cell is selected from the group consisting of: a B cell, an NK cell, and a dendritic cell.
 114. The method of claim 110, wherein the gene is a cytokine gene.
 115. The method of claim 114, wherein the gene is IFN-γ.
 116. A method for modulating T-bet expression and/or activity in a cell comprising contacting the cell with an agent that modulates T-bet expression and/or activity such that T-bet expression and/or activity in the cell is modulated.
 117. The method of claim 116, wherein the agent increases the activity of T-bet
 118. The method of claim 116, wherein the agent decreases the activity of T-bet
 119. The method of claim 116, wherein the agent increases the expression of T-bet.
 120. The method of claim 116, wherein the agent decreases the expression of T-bet
 121. A method for modulating the production of at least one cytokine by a cell comprising contacting the cell with an agent that modulates T-bet expression and/or activity such that cytokine production in the cell is modulated.
 122. The method of claim 121, wherein the cell is selected from the group consisting of: a T cell, a B cell, an NK cell, and a dendritic cell.
 123. The method of claim 121, wherein the at least one cytokine is a Th1 cytokine.
 124. The method of claim 123, wherein the cytokine is IFN-γ.
 125. The method of claim 123, wherein the at least one cytokine is a Th2 cytokine.
 126. The method of claim 123, wherein the pattern of cytokines produced by the cell is altered.
 127. A method of modulating an immune response in a subject comprising administering an agent that modulates T-bet to the subject such that the immune response is modulated.
 128. The method of claim 127, wherein a humoral immune response is modulated
 129. The method of claim 127, wherein a cellular immune response is modulated
 130. A method of modulating IFN-γ production by a cell comprising contacting a cell with an agent that modulates T-bet expression and/or activity such that IFN-γ production is modulated
 131. The method of claim 130, wherein the cell is a T cell.
 132. The method of claim 130, wherein the cell is selected from the group consisting of: a B cell, an NK cell, and a dendritic cell.
 133. The method of claim 130, wherein the expression and/or activity of T-bet is increased, thereby increasing the production of IFN-γ.
 134. The method of claim 130, wherein the expression and/or activity of T-bet is decreased, thereby decreasing the production of IFN-γ.
 135. A method of modulating signaling via the Jak1/STAT-1 pathway in a cell comprising contacting a cell with an agent that modulates T-bet expression and/or activity such that signaling via the Jak1/STAT-1 pathway is modulated
 136. A method of modulating the IgG class switching in a cell comprising contacting a cell with an agent that modulates T-bet expression and/or activity such IgG Class Switching is modulated
 137. A method of modulating B lymphocyte function comprising contacting a cell with an agent that modulates T-bet expression and/or activity such B lymphocyte function is modulated.
 138. A method of modulating TGF-β-mediated signaling in a cell comprising contacting a cell with an agent that modulates the activity or expression of T-bet such that TGF-β-mediated signaling is modulated.
 139. The method of claim 138, herein the activity or expression of T-bet is decreased in the cell and TGF-β-mediated signaling is increased
 140. The method of claim 138, wherein the activity or expression of T-bet is increased in the cell and TGF-β-mediated signaling is decreased.
 141. A method of modulating the generation of CD8+ effector memory cells comprising contacting a CD8+ T cell with an agent that modulates the expression and/or activity of T-bet to thereby modulate the production of CD8+ effector memory cells.
 142. The method of claim 141, wherein the expression and/or activity of T-bet is increased, thereby increasing the generation of CD8 effector memory cells.
 143. The method of claim 141, wherein the expression and/or activity of T-bet is decreased, thereby decreasing the generation of CD8 effector memory cells.
 144. A method of treating a disorder that would benefit from modulation of a CD8+ T cell response comprising contacting a CD8+ T cell with an agent that modulates the expression and/or activity of T-bet to thereby treat a disorder that would benefit from modulation of a CD8+ T cell response.
 145. The method of claim 144, wherein the expression and/or activity of T-bet is increased, thereby increasing the activity of CD8 cells.
 146. The method of claim 144, wherein the disorder is a viral infection
 147. The method of claim 144, wherein the disorder is cancer.
 148. The method of claim 144, wherein the expression and/or activity of T-bet is decreased, thereby decreasing the activity of CD8+ cells.
 149. A method of modulating the production of IL-10 in a CD8+ cell comprising contacting a CD8+ T cell with an agent that modulates the expression and/or activity of T-bet to thereby modulate the production of IL-10 in a CD8+ T cell.
 150. The method of claim 149, wherein the expression and/or activity of T-bet is increased, thereby decreasing the production of IL-10
 151. The method of claim 149, wherein the expression and/or activity of T-bet is decreased, thereby increasing the production of IL-10.
 152. A method of modulating the cytolytic activity of a CD8+ cell comprising contacting a CD8+ T cell with an agent that modulates the expression and/or activity of T-bet to thereby modulate the cytolytic activity of a CD8+ cell.
 153. A method of modulating the production of IFN-γ in an NK cell comprising contacting an NK cell with an agent that modulates the expression and/or activity of T-bet to thereby modulate the production of IFN-γ in an NK cell.
 154. The method of claim 153, wherein the expression and/or activity of T-bet is increased, thereby increasing the production of IFN-γ.
 155. The method of claim 153, wherein the expression and/or activity of T-bet is decreased, thereby decreasing the production of IFN-γ.
 156. A method of modulating the generation of NK cells comprising contacting an NK cell with an agent that modulates the expression and/or activity of T-bet to thereby modulate the cytolytic activity of an NK cell.
 157. The method of claim 156, wherein the expression and/or activity of T-bet is increased, thereby increasing the generation of NK cells.
 158. The method of claim 156, wherein the expression and/or activity of T-bet is decreased, thereby decreasing the generation of NK cells.
 159. A method of modulating NK cell cytolytic activity comprising contacting an NK cell with an agent that modulates the expression and/or activity of T-bet to thereby modulate NK cell cytolytic activity.
 160. The method of claim 159, wherein the agent increases the expression and/or activity of T-bet and NK cell cytolytic activity is increased
 161. The method of claim 159, wherein the agent decreases the expression and/or activity of T-bet and NK cell activity is decreased.
 162. The method of claim 161, wherein the expression of granzyme b is decreased.
 163. The method of claim 161, wherein the agent decreases the expression of perforin
 164. A method of modulating the production of IFN-γ in a dendritic cell comprising contacting an NK cell with an agent that modulates the expression and/or activity of T-bet to thereby modulate the production of IFN-γ in a dendritic cell.
 165. The method of claim 164, wherein the expression and/or activity of T-bet is increased, thereby increasing the production of IFN-γ.
 166. The method of claim 164, wherein the expression and/or activity of T-bet is decreased, thereby decreasing the production of IFN-γ.
 167. A method of modulating the production of IFN-γ at the site of antigen presentation to a naive T cell in vivo, comprising administering an agent that modulates the expression and/or activity of T-bet to a subject to thereby modulate the production of IFN-γ at the site of antigen presentation to a naive T cell.
 168. The method of claim 167, further comprising administering an antigen to the subject.
 169. A method of modulating the induction of tolerance in peripheral T cells, comprising administering an agent that modulates the expression and/or activity of T-bet to a subject to thereby modulate the induction of tolerance in peripheral T cells.
 170. The method of claim 169, wherein the number or percentage of Tr cells in the subject is modulated
 171. The method of claim 169, wherein the activity or expression of T-bet is increased and peripheral tolerance is increased.
 172. The method of 169, wherein the activity or expression of T-bet is decreased and peripheral tolerance is decreased.
 173. A method of treating or preventing a disorder that would benefit from treatment with an agent that modulates the expression and/or activity of T-bet comprising administering to a subject with said disorder an agent that modulates the expression and/or activity of T-bet.
 174. A method of treating or preventing a disorder that would benefit from treatment with an agent that modulates the expression of T-bet comprising administering to a subject with said disorder an agent that modulates the expression of T-bet.
 175. The methods of any of claims 173-174, wherein the disorder is an autoimmune disease.
 176. The method of claim 175, wherein the autoimmune disease is selected from the group consisting of: diabetes mellitus, rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, psoriatic arthritis, multiple sclerosis, myasthenia gravis, systemic lupus erythematosis, autoimmune thyroiditis, atopic dermatitis and eczematous dermatitis, psoriasis, Sjögren's Syndrome, alopecia areata, allergic responses due to arthropod bite reactions, Crohn's disease, aphthous ulcer, iritis, conjunctivitis, keratoconjunctivitis, ulcerative colitis, allergic asthma, cutaneous lupus erythematosus, scleroderma, vaginitis, proctitis, compound eruptions, leprosy reversal reactions, erythema nodosum leprosum, autoimmune uveitis, allergic encephalomyelitis, acute necrotizing hemorrhagic encephalopathy, idiopathic bilateral progressive sensorineural hearing loss, aplastic anemia, pure red cell anemia, idiopathic thrombocytopenia, polychondritis, Wegener's granulomatosis, chronic active hepatitis, Stevens-Johnson syndrome, idiopathic sprue, lichen planus, Crohn's disease, Graves ophthalmopathy, sarcoidosis, primary biliary cirrhosis, uveitis posterior, experimental allergic encephalomyelitis (EAE), inflammatory bowel disease and interstitial lung fibrosis.
 177. The method of claim 175, wherein the autoimmune disease is mediated by Th1 cells.
 178. The method of claim 175, wherein the autoimmune disease is mediated by Th2 cells.
 179. The method of claim 175, wherein the autoimmune disease is Crohn's disease.
 180. The method of claim 175, wherein the autoimmune disease is multiple sclerosis
 181. The method of claim 175, wherein the autoimmune disease is ulcerative colitis.
 182. The methods of any of claims 173-174, wherein the disorder is asthma.
 183. The method of claim 175, wherein the autoimmune disease is rheumatoid arthritis.
 184. A method of treating or preventing an infectious disease that would benefit from treatment with an agent that modulates the expression and/or activity of T-bet comprising administering to a subject with said infectious disease an agent that modulates the expression and/or activity of T-bet.
 185. The method of claim 184, wherein the infectious disease is caused by a bacterium.
 186. The method of claim 184, wherein the infectious disease is caused by a virus.
 187. A method of treating multiple sclerosis comprising administering an agent that reduces the expression and/or activity of T-bet to a subject such that multiple sclerosis is treated.
 188. A method of treating rheumatoid arthritis comprising administering an agent that reduces the expression and/or activity of T-bet to a subject such that rheumatoid arthritis is treated.
 189. A method for identifying a compound that modulates the expression and/or activity of a T-bet polypeptide, comprising providing an indicator composition that comprises a T-bet polypeptide; contacting the indicator composition with a test compound; and determining the effect of the test compound on the expression and/or activity of the T-bet polypeptide in the indicator composition to thereby identify a compound that modulates the expression and/or activity of a T-bet polypeptide.
 190. The method of claim 189, wherein: the indicator composition comprises a T-bet polypeptide and a DNA molecule to which the T-bet polypeptide binds; and the effect of the test compound on the expression and/or activity of the T-bet polypeptide is determined by evaluating the binding of the T-bet polypeptide to the DNA molecule in the presence and absence of the test compound.
 191. The method of claim 189, wherein: the indicator composition is a cell comprising a T-bet polypeptide and a reporter gene responsive to the T-bet polypeptide; and the effect of the test compound on the expression and/or activity of the T-bet polypeptide is determined by evaluating the expression of the reporter gene in the presence and absence of the test compound.
 192. The method of claim 191, further comprising determining the effect of the test compound on an immune response to thereby identify a compound that modulates an immune response.
 193. The method of claim 189, wherein the expression and/or activity of T-bet is enhanced.
 194. The method of claim 189, wherein the expression and/or activity of T-bet is inhibited.
 195. The method of claim 189, wherein the activity of T-bet is IFN-γ production.
 196. The method of claim 189, wherein the activity of T-bet is transcription of IgG2a.
 197. The method of claim 189, wherein the step of contacting occurs in vivo. 198 The method of claim 189 wherein the step of contacting occurs in vitro. 199 The method of claim 189 wherein the test compound is selected from the group comprised of: a T-bet nucleic acid molecule, a T-bet peptide, a small molecule T-bet agonist and a small molecule T-bet antagonist.
 200. The method of claim 189, wherein the test compound is selected from a group comprised of: an intracellular antibody, a nucleic acid molecule that is antisense to a T-bet molecule, a dominant negative T-bet molecule, a small molecule T-bet agonist and a small molecule T-bet antagonist.
 201. The method of claim 189, wherein the cell is selected from the group consisting of: a T cell, a B cell, and a macrophage.
 202. The method of claim 201, wherein the cell is a Th1 cell.
 203. The method of claim 189, wherein the indicator composition is a cell that expresses T-bet polypeptide.
 204. The method of claim 203, wherein the cell has been engineered to express the T-bet polypeptide by introducing into the cell an expression vector encoding the T-bet polypeptide.
 205. The method of claim 203, wherein the indicator composition is a cell free composition.
 206. The method of claim 189, wherein the indicator composition is a cell that expresses a T-bet polypeptide and a target molecule, and the ability of the test compound to modulate the interaction of the T-bet polypeptide with a target molecule is monitored.
 207. The method of claim 189, wherein the indicator composition comprises an indicator cell, wherein the indicator cell comprises a T-bet polypeptide and a reporter gene responsive to the T-bet polypeptide.
 208. The method of claim 207, wherein said indicator cell contains: a recombinant expression vector encoding the T-bet polypeptide; and a vector comprising a T-bet responsive regulatory element operatively linked a reporter gene; and said method comprises: a) contacting the indicator cell with a test compound; b) determining the level of expression of the reporter gene in the indicator cell in the presence of the test compound; and c) comparing the level of expression of the reporter gene in the indicator cell in the presence of the test compound with the level of expression of the reporter gene in the indicator cell in the absence of the test compound to thereby select a compound of interest that modulates the expression and/or activity of T-bet polypeptide.
 209. A method of identifying a compound that modulates a signal transduction pathway involving T-bet comprising: a) contacting cells deficient in T-bet with a test compound; and b) determining the effect of the test compound on an expression and/or activity of T-bet, the test compound being identified as a modulator of the expression and/or activity of a signal transduction pathway involving T-bet based on the ability of the test compound to modulate a signal transduction pathway involving T-bet in the cells deficient in T-bet.
 210. The method of claim 203, wherein the cells deficient in T-bet are in a non-human T-bet deficient animal and the cells are contacted with the test compound by administering the test compound to the non-human T-bet deficient animal.
 211. A method of identifying compounds useful in modulating TGF-β-mediated signaling comprising, a) providing an indicator composition comprising T-bet polypeptide; b) contacting the indicator composition with each member of a library of test compounds; c) selecting from the library of test compounds a compound of interest that modulates the expression and/or activity of T-bet polypeptide to thereby identify a compound that modulates TGF-β-mediated signaling.
 212. The method of claim 205, wherein T-bet activity is measured by measuring cytokine production.
 213. The method of claim 205, wherein T-bet activity is measured by measuring the expression of Smad7.
 214. The method of claim 211, wherein T-bet activity is measured by measuring TGF-β-mediated signaling.
 215. The method of claim 211, wherein the amount of TGF-β is measured.
 216. A method of identifying compounds useful in modulating the Jak1/STAT-1 pathway comprising, a) providing an indicator composition comprising T-bet polypeptide; b) contacting the indicator composition with each member of a library of test compounds; c) selecting from the library of test compounds a compound of interest that modulates the expression and/or activity of T-bet polypeptide to thereby identify a compound that modulates the Jak1/STAT-1 pathway.
 217. A method of identifying compounds useful in modulating T cell lineage commitment comprising, a) providing an indicator composition comprising T-bet polypeptide; b) contacting the indicator composition with each member of a library of test compounds; c) selecting from the library of test compounds a compound of interest that modulates the activity or expression of T-bet polypeptide to thereby identify a compound that modulates T cell lineage commitment.
 218. The method of claim 217, wherein commitment of T cells to Th1 lineage is measured.
 219. The method of claim 217, wherein commitment of T cells to Th2 lineage is measured.
 220. The method of claim 217, wherein the compound increases commitment of T cells to Th1 lineage.
 221. The method of claim 217, wherein the compound decreases commitment of T cells to Th2 lineage.
 222. The method of claim 217, wherein the compound increases commitment of T cells to Th2 lineage.
 223. The method of claim 217, wherein the compound decreases commitment of T cells to Th1 lineage.
 224. The method of claim 217, wherein the activity of T-bet is measured by measuring cytokine production.
 225. The method of claim 224, wherein the cytokine is selected from the group consisting of IL-2, IFNγ, IL-4, IL-5, TNFα, TGF-β, LT(lymphotoxin), and IL-10.
 226. The method of claim 217, wherein the indicator composition is a cell that expresses T-bet polypeptide.
 227. The method of claim 226, wherein the cell is committed to a T cell lineage.
 228. The method of claim 226, wherein the cell is not yet committed to a T cell lineage.
 229. A method of identifying compounds useful in modulating the production of at least one cytokine comprising, a) providing an indicator composition comprising T-bet polypeptide; b) contacting the indicator composition with each member of a library of test compounds; c) selecting from the library of test compounds a compound of interest that modulates the expression and/or activity of T-bet polypeptide to thereby identify a compound that modulates the production of at least one cytokine.
 230. The method of claim 229, wherein the production of at least one cytokine is measured.
 231. The method of claim 229, wherein the production of more than one cytokine is measured.
 232. The method of claim 229, wherein the pattern of cytokines produced is measured.
 233. The method of claim 229, wherein the cell is selected from the group consisting of: a T cell, a B cell, and an NK cell.
 234. A method of identifying compounds useful in modulating the production of IFN-γ comprising, a) providing an indicator composition comprising T-bet polypeptide; b) contacting the indicator composition with each member of a library of test compounds; c) selecting from the library of test compounds a compound of interest that modulates the expression and/or activity of T-bet polypeptide to thereby identify a compound that modulates the production of IFN-γ.
 235. The method of claim 234, wherein the indicator composition is a cell that expresses T-bet polypeptide.
 236. The method of claim 235, wherein the cell is selected from the group consisting of: a T cell, a B cell, and an NK cell.
 237. The method of claim 235, wherein the cell has been engineered to express the T-bet polypeptide by introducing into the cell an expression vector encoding the T-bet polypeptide.
 238. The method of claim 234, wherein the indicator composition is a cell free composition.
 239. The method of claim 234, wherein the indicator composition is a cell that expresses a T-bet polypeptide and a target molecule, and the ability of the test compound to modulate the interaction of the T-bet polypeptide with a target molecule is monitored.
 240. The method of claim 234, wherein the indicator composition comprises an indicator cell, wherein the indicator cell comprises a T-bet polypeptide and a reporter gene responsive to the T-bet polypeptide.
 241. The method of claim 234, wherein said indicator cell contains: a recombinant expression vector encoding the T-bet polypeptide; and a vector comprising a T-bet responsive regulatory element operatively linked a reporter gene; and said method comprises: a) contacting the indicator cell with a test compound; b) determining the level of expression of the reporter gene in the indicator cell in the presence of the test compound; and c) comparing the level of expression of the reporter gene in the indicator cell in the presence of the test compound with the level of expression of the reporter gene in the indicator cell in the absence of the test compound to thereby select a compound of interest that modulates the expression and/or activity of T-bet polypeptide.
 242. A method of identifying a compound that modulates the production of IFN-γ comprising: a) contacting cells deficient in T-bet with a test compound; and b) determining the effect of the test compound on the production of IFN-γ the test compound being identified as a modulator of the production of IFN-γ based on the ability of the test compound to modulate the production of IFN-γ in the cells deficient in T-bet.
 243. A method of identifying compounds useful in modulating IFN-γ production comprising, a) providing an indicator composition comprising T-bet polypeptide; b) contacting the indicator composition with each member of a library of test compounds; c) selecting from the library of test compounds a compound of interest that modulates the interaction between T-bet and a Tec kinase to thereby identify compounds useful in modulating IFN-γ production.
 244. A method of identifying compounds useful in modulating IL-4 production comprising, a) providing an indicator composition comprising T-bet polypeptide; b) contacting the indicator composition with each member of a library of test compounds; c) selecting from the library of test compounds a compound of interest that modulates the interaction between T-bet and a Tec kinase to thereby identify compounds useful in modulating IL-4 production.
 245. A method of identifying compounds useful in modulating IgG class switching comprising, a) providing an indicator composition comprising T-bet polypeptide; b) contacting the indicator composition with each member of a library of test compounds; c) selecting from the library of test compounds a compound of interest that modulates the expression and/or activity of T-bet polypeptide; and d) determining the effect of the compound of interest on IgG class switching to thereby identify a compound that modulates the production of IgG class switching.
 246. The method of claim 238, wherein the activity of T-bet is measured by measuring IgG2a production.
 247. The method of claim 238, wherein T-bet activity is measured by measuring IgG1 production.
 248. The method of claim 238, wherein T-bet activity is measured by measuring IgE production.
 249. A method of identifying compounds useful in modulating B lymphocyte function comprising, a) providing an indicator composition comprising T-bet polypeptide; b) contacting the indicator composition with each member of a library of test compounds; c) selecting from the library of test compounds a compound of interest that modulates the expression and/or activity of T-bet polypeptide; and d) determining the effect of the compound of interest on B lymphocyte function to thereby identify a compound that modulates B lymphocyte function.
 250. The method of claim 249, wherein the activity of T-bet is measured by measuring cytokine production.
 251. The method of claim 249, wherein the activity of T-bet is measured by measuring production of pathogenic autoantibodies.
 252. A method of identifying compounds useful in modulating an autoimmune disease comprising, a) providing an indicator composition comprising T-bet polypeptide; b) contacting the indicator composition with each member of a library of test compounds; c) selecting from the library of test compounds a compound of interest that modulates the expression and/or activity of T-bet polypeptide to thereby identify a compound that modulates an autoimmune disease.
 253. A method for modulating the expression and/or activity of T-bet comprising contacting a cell with an agent that modulates a post-translational modification of T-bet such that the expression and/or activity of T-bet is modulated.
 254. The method of claim 253, wherein the post-translational modification is selected from the group consisting of phosphorylation, glycosylation and ubiquitination.
 255. A method of diagnosing a subject for a disorder associated with aberrant immune cell activation comprising: detecting expression of T-bet in immune cells of a subject suspected of having said disorder; comparing expression of T-bet in immune cells of said subject to a control that is not associated with aberrant immune cell activation; and diagnosing the subject for a disorder based on a change in expression of T-bet in immune cells of the subject as compared to the control.
 256. The method of claim 249, wherein the disorder is an autoimmune disease. 